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Abstract 
Cytokine based therapies can be targeted to the sites of active inflammation by modifying a given 
cytokine as a LAP-cytokine. IL-17A has been shown to directly contribute to pathogenesis of 
rheumatoid arthritis (RA). IL-17F, another member of the IL-17 cytokines family shares structural 
homology, receptor binding and biological properties with IL-17A but is 30-100 times less potent 
than IL-17A. (H161R) IL-17F mutant, a natural variant of IL-17F was shown to be protective against 
asthma in Japanese population. In vitro, IL-17F mutant competitively inhibited wild-type IL-17F and 
lacked the ability to activate downstream signaling pathways. I hypothesized that (H161R) IL-17F 
mutant is an additional inhibitor of IL-17A and if modified as LAP-IL-17F mutant, would be an 
effective targeted therapy for RA. 
(H161R) IL-17F mutant was created by substituting nucleotide A at position 485 in the wild type IL-
17F by G. In vitro assays showed that the IL-17F mutant could bind to IL-17RC but lacked the ability 
to stimulate IL-6 secretion in HFFF2, 3T3 and HeLa cells and phosphorylate ERK1/2 in HeLa cells. IL-
17F mutant also inhibited IL-17A induced secretion of IL-6 in all these cell lines. 
In order to assess in vivo therapeutic efficacy of LAP-IL-17F mutant in collagen induced arthritis mice, 
three mouse analogues of human IL-17F mutant were developed. Of these, (Q158R) IL-17F mutant 
displayed IL-17 agonistic properties, (H157R) IL-17F mutant could not be expressed in vitro and the 
truncated IL-17F mutant could not bind to mouse IL-17RC.  
Investigation of in vivo expression and pharmacokinetics of intravenous hydrodynamically delivered 
human full-length and LAP-IL-17 plasmid DNAs in naïve SCID and C57BL/6 mice showed that human 
IL-17 transgene expression was detectable in mouse serum at 48 hours post-delivery. The transgene 
expression however declined rapidly over the next two weeks. The local expression of transgene in 
C57BL/6 airpouch lavage fluid was less than 5% of its systemic levels.  
Taken together, the findings of the study warrant an investigation of in vivo therapeutic efficacy of 
human (H161F) IL-17F mutant in a suitable preclinical RA model, such as RA synovium/SCID mice. 
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1.1 Rheumatoid arthritis 
RA is a systemic autoimmune disease characterised by chronic synovial inflammation, cartilage 
damage and bone destruction. It is the most common inflammatory arthritis that affects adults with 
a remarkably consistent worldwide prevalence of approximately 1%. RA usually affects people in 
their fourth and fifth decades and women are three times more commonly affected than men. RA 
classically presents as symmetrical polyarthritis affecting both the small and large joints of upper and 
lower extremities. The arthritis although principally affects synovial joints, is truly a systemic disease 
and may affect many other organ systems (Fig. 1.1). Some of the extra-articular manifestations of RA 
include fever, anorexia, weight loss, fatigue, subcutaneous nodules, dry eyes, lung fibrosis, pleuritis, 
pericarditis and vasculitis. RA is associated with an increased prevalence of co-morbid conditions 
such as cardiovascular disease, infections and lymphoproliferative disorders (1). RA patients are at 
risk of premature mortality and the life expectancy of the patients is shortened by 3-10 years (2). 
  
 
 
 
Figure 1.1 Clinical manifestations of RA. RA characteristically affects small and large joints in a 
symmetrical distribution. Although predominantly affecting joints, RA is truly a systemic disease 
and can involve many other organ systems. The extra-articular manifestations of RA include 
fatigue, weight loss, anaemia, dryness of eyes or mouth, pleural and pericardial effusions, 
pulmonary nodules, fibrosis, lymphadenopathy, splenomegaly and small vessel vasculitis. 
24 
 
RA is diagnosed clinically on the basis of clinical features of inflammatory arthritis that affects three 
or more joint and is of more than 6 weeks duration in association with radiology and blood findings. 
Using the most recent American College of Rheumatology and the European League Against 
Rheumatism (ACR/EULAR) classification criteria, last revised in 2010 (Table 1.1), a definite diagnosis 
of RA is established if the combined score  in four individual domains (the number and site of joints  
involved, positivity of rheumatoid factor (RF) or anti-citrullinated peptide antibody (ACPA), raised 
erythrocyte sedimentation rate or C-reactive protein and symptom duration of at least six weeks)  in 
the absence of an alternative diagnosis is 6 (from the  maximum possible of 10). 
Although the course of RA is variable, most patients suffer a progressive disease. The overall 
outcome of RA is dependent upon the degree of disease activity, joint damage, the physical  
function and psychological health of the patient and the presence of comorbid illness. Much of the 
joint damage that ultimately results in disability begins early in the course of the disease. Two thirds 
of patients with RA of less than two years duration have joint erosions on plain radiographs of the 
hands. The key to prevent serious disease outcomes is instituting disease modifying anti-rheumatic 
drug (DMARD) therapy as soon as possible. With such a shift in the strategy, the goal of treatment 
now is to achieve remission or at least the lowest possible level of disease activity.  
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Table 1.1 2010 ACR/EULAR classification criteria for RA 
     Domain Score 
A Joint involvement* 
 Large joints 
 1 0 
 2-10 1 
 Small joints 
 1-3 2 
 3-10 3 
 >10 joints (at least 1 small joint) 5 
B Serology ** 
 RF/ACPA negative 0 
 RF/ACPA low positive 2 
 RF/ACPA high positive 3 
C Acute phase reactants 
 CRP/ESR normal 0 
 CRP/ESR abnormal 1 
D Duration of symptoms 
 < 6 weeks 0 
  6 weeks 1 
 
The criteria are aimed at classification of newly presenting patients. The scores in categories A-D are 
added; the patient is classified to have definite RA if the total score is 6. * Joint involvement refers 
to any swollen or tender joint on examination, which may be confirmed by radiology evidence of 
synovitis; **At least one test result is needed. ACR, American College of Rheumatology; EULAR, 
European League Against Rheumatism; RF, rheumatoid factor; ACPA, anti-citrullinated protein 
antibody; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. 
 
 
 
 
1.1.1 Pathogenesis of RA 
RA is not just a single disease, instead a common end result of activation of different pathways, 
depending on the genetic makeup of the patient, leading to autoreactivity and chronic synovial 
inflammation. Exogenous or endogenous environmental triggers cause repeated activation of innate 
immunity, which leads to gradually increasing. The exact trigger or the cause of RA is not known. 
Amongst the genetic factors, RA is strongly linked to the major histocompatibility class II antigens 
HLA-DRB1*0404 and HLADRB1*0401(3, 4); HLA alleles that contain the shared epitope (QKRAA) 
particularly confer susceptibility to RA (4). Likewise PTPN22, STAT4, CTLA4, TRAF1-C5, c-REL, which 
aggregate around immune regulatory functions are the other identified risk alleles (5-9). These single 
nucleotide polymorphisms increase the risk for RF or ACPA positive disease whereas HLA-DRB1*03, 
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interferon regulatory factor 5 and C-type lectin domain family 4 member A, some of the less 
established genetic risk factors are associated with ACPA negative RA (10-12). 
Of the environmental stimuli, the best defined is smoking, which in association with susceptible HLA-
DRB1 alleles, synergistically increases the risk of having ACPA and RA (13, 14). Although no causative 
infectious agent has ever been isolated from RA patients, infections such as Parvovirus, Rubella, 
Epstein Barr virus, Cytomegalovirus, Proteus species, Escherichia coli and Borrelia Burgdorferi have 
been associated with arthritis (15). Porphyromonas gingivalis, the predominnat pathogenic organism 
in chronic periodontitis expresses the enzyme, peptidyl arginine deiminase, type IV (PADI 4), which is 
capable of promoting citrullination of mammalian proteins (16). Endogenous antigens such as 
human cartilage glycoprotein 39 and heavy-chain-binding protein have also been ascribed as 
possible triggers RA (17). Although RF and ACPA are often positive even before the onset of RA, a 
pathogenic role for these has not been established.  
Whatever the trigger, very early during the course of RA, the synovium undergoes hyperplasia, 
neoangiogenesis and cellular infiltration. Once initiated, the chronic synovial inflammation is self-
perpetuated and propagated via activated resident (macropahges, fibroblasts, endothelial cells) and 
infiltrated cells (T lymphocytes, B lymphocytes, monocytes, plasma cells, mast cells and dendritic 
cells), which in turn secrete cytokines, chemokines, growth factors, matrix degrading enzymes, PGE2 
and NO. The hyperplastic synovium ultimately expands and forms finger-like projections termed 
pannus, which invades and destroys the adjacent cartilage and bone resulting in the characteristic 
joint damage of RA (18). Once initiated, the chronic synovial inflammation in RA is self-perpetuated. 
Distinct mechanisms regulate inflammation and destruction of matrix, cartilage and bone. 
 
1.1.1a Cellular mediators of inflammation and joint damage (Fig. 1.2) 
Macrophages are central effectors of synovitis. The rheumatoid synovium is predominantly 
infiltrated by monocytes and macrophages. Clinically effective biologic agents consistently reduce 
macrophage infiltration in the synovium (19). Macrophages are responsible for antigen presentation, 
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phagocytosis, production of various cytokines (TNF-α, and IL-1, 6, 12, 15, 18, and 23), prostanoids 
and matrix-degrading enzymes, release of reactive oxygen and nitrogen intermediates, stimulation 
of angiogenesis and maturation of osteoclasts (20, 21). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Cellular mediators of inflammation and joint damage in RA. RA synovitis is characterised 
by activated resident and infiltrated cells which secrete cytokines, chemokines, growth factors, 
matrix degrading enzymes, prostaglandins, nitric oxide , thus playing a crucial role in the propagation 
and maintenance of self-perpetuating chronic synovitis accompanied by matrix, cartilage and bone 
damage. 
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Fibroblasts are the other principal cells in RA synovium and mainly involved in effecting the 
destructive response. Fibroblasts in RA synovium demonstrate properties of anchorage 
independence, loss of contact inhibition, inability to undergo apoptosis, invade cartilage and 
stimulate differentiation and activation of osteoclasts (22-26). Additionally, RA synovial fibroblasts 
promote expression of proinflammatory cytokines, chemokines, adhesion molecules and MMPs and 
directly contribute to the chronic synovial inflammation (27).  
T cells constitute approximately 50% or more of RA synovial cells, the majority of which are memory 
type Th1 and Th17 CD4+ cells. T cell activated by the inciting and other autoantigens in association 
with costimulatory molecules initiate a pathogenic chronic synovial immune response. Antigen-
activated CD4+ T cells stimulate monocytes, macrophages and synovial fibroblasts cells to produce 
cytokines and matrix-degrading enzymes, activate B cells to produce autoantibodies, and express 
ligands that stimulate osteoclastogenesis. T cell activation in RA can also take place without specific 
antigen and results in self-perpetuating cycles of T cell proliferation sufficient to sustain 
autoimmunity (28). Although T cells modulate synovial inflammatory responses, a direct role of T 
cells has not been confirmed in RA (29-31). Abatacept or CTLA4-Ig, which restricts T cell activation 
via inhibition of T cell costimulation has proven to be effective in the treatment of RA. 
B cells have a multifaceted role in the pathogenesis of RA having the ability to maintain synovial 
ectopic germinal centres, to mediate pathological immune responses and to drive the humoral 
autoimmune process. B cells in RA produce RF, APCA, anti-nuclear antibody and also specific 
autoantibodies against collagen II, human cartilage gp39, matrix components in cartilage and 
cartilage link protein. These cells exhibit an increased expression of IL-1β, IL-6, IL-7, IFN-γ and G-CSF, 
and have been recently identified to have novel functions such as participation in angiogenesis (32). 
Rheumatoid B cells show evidence of inappropriate proliferation, oligoclonality, autoreactivity and 
self-perpetuation. Although the naïve B cells can be activated in a T cell-dependent or independent 
manner, they themselves are crucial in T cell activation (33).  
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Neutrophils contribute to synovitis by synthesizing prostaglandins, proteases, and reactive oxygen 
intermediates (34). Mast cells are activated at the very onset of RA and secrete cytokines such as 
TNF-α, IL-1β and IL-17, chemokines and produce high levels of vasoactive amines and  
proteases (35, 36). The activated macrophages, lymphocytes and fibroblasts, and their products 
stimulate angiogenesis. Endothelial cells in the synovium are activated and express adhesion 
molecules such as E-selectin, P-selectin, LFA-1, ICAM-1, VLA-4, and 4β7. The adhesion molecules, in 
association with IL-8 promote the recruitment of inflammatory cells into the joint. Anti-ICAM-1, an 
anti-adhesion molecule therapy, prevented synovial inflammation and disease development in 
animal models and humans (37).  
 
1.1.1b Soluble mediators of inflammation and joint damage 
The cells in RA synovium secrete numerous cytokines, chemokines, growth factors and other 
mediators of inflammation (20, 38). Of these, cytokines particularly TNF, IL-1, IL-6 and IL-17 are 
fundamental to both chronic inflammatory and the destructive phases of RA; their role in RA 
pathogenesis is summarised in Table 1.2. 
IL-6 drives local leukocyte activation and autoantibody production, mediates systemic effects that 
promote acute phase responses, inhibits bone formation and stimulates bone resorption (39, 40). Its 
critical role in RA is demonstrated by the positive outcomes in the patients after treatment with IL-6 
receptor inhibiting antibody (41). 
TNF-α plays the most important role in mediating and sustaining the chronic inflammatory response 
in RA. It activates expression of other cytokines, chemokines and endothelial cell adhesion molecules 
and promotes protection of synovial fibroblasts, angiogenesis and suppression of regulatory T cells 
(42, 43). The significance of TNF- in the pathogenesis of RA is evidenced by the fact that the TNF 
inhibitors are the most widely used biologics in the treatment of RA. 
IL-1 promotes activation of leukocytes, endothelial cells, chondrocytes, and osteoclasts (44, 45). 
However, benefits of IL-1 inhibition in the treatment of RA have only been modest (46).  
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Despite substantial lymphocytic infiltration, activated T cells secreted cytokines such as IFN-γ, IL-2 
and IL-4 except IL-17 are sparsely expressed in RA (47).   
Proinflammatory cytokines such as IL-7, IL-15, IL-18, IL-21, IL-23, IL-33 (48-55) are also upregulated in 
RA and play a role in the pathogenesis. Other proinflammatory cytokines such as IL-20, IL-22, IL-32, 
TNF-like weak inducer of apoptosis (TWEAK) and macrophage chemoattractant protein (MCP)-1 (56-
61) also contribute to the pathogenesis of RA.  
Inflammatory enzymes such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (Cox-2) 
are upregulated in RA and their inhibition reduces pain and inflammation in arthritic joints (62-66). 
Enzymatic factors such as matrix metalloproteasaes (MMPs), cathepsins, aggrecanases-1 and 2 (also 
called ADAMTS-4 and -5 respectively) (67-70) are overexpressed in RA and are predominantly 
responsible for inducing cartilage damage. Endogenous enzyme inhibitors such as TIMPs fail to 
reverse this destructive cascade due to their lower expression levels. 
Synovial cytokines, particularly macrophage colony stimulating factor (M-CSF) and receptor activator 
of NF-κB ligand (RANKL) promote osteoclast differentiation and invasion of the periosteal surface 
adjacent to articular cartilage (71). Cytokine-induced mediators such as dickkopf-1 and frizzled-
related protein 1 potently inhibit the differentiation of mesenchymal precursors into chondroblasts 
and osteoblasts (72).  
Although multiple anti-inflammatory molecules such as IL-10 (73), TGF-β (74), soluble p55 and p75 
TNFR (75-77) and IL-1 receptor antagonist (IL-1ra) are also upregulated in RA, their levels are 
insufficient to counterregulate the on-going chronic synovial inflammation. In RA, the cytokine 
homeostasis is imbalanced in favour of more pro-inflammatory than anti-inflammatory cytokines 
(42).  
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Table 1.2 Soluble protein mediators of inflammation and joint damage in RA 
Mediator                    Role played in the pathogenesis of RA 
 
Cytokines 
IL-6 Activates leukocytes and osteoclasts, promotes B-lymphocyte differentiation, 
mediates acute-phase response 
TNF- Activates leukocytes, endothelial cells, and synovial fibroblasts; induces production 
of cytokines, chemokines, adhesion molecules, and matrix enzymes; suppresses 
regulatory T-cell function; activates osteoclasts; and promotes resorption of 
cartilage and bone  
IL-1β Activates leukocytes, endothelial cells, and synovial fibroblasts; induces matrix 
enzyme production by chondrocytes; activate osteoclasts 
IL-17 Activates synovial fibroblasts, chondrocytes, and osteoclasts; stimulates secretion of 
cytokines, chemokines, growth factors, and matrix enzymes; suppresses regulatory 
T-cell function; and promotes resorption of cartilage and bone  
IL-21 Activates Th17 and B cell subsets 
IL-23 Expands Th17 cells 
IL-7 and 
IL -15 
Activate T and NK cells; promote and maintain memory T cells, and survival and 
activation of neutrophils and B cells; promote TNF production; drive activation of 
Th17 cells 
IL-18 Activates Th1, NK cells and neutrophils 
IL-32 Stimulates cytokine production by various leukocytes, promotes differentiation of 
osteoclasts 
IL-33 Activates mast cells and neutrophils 
 
Growth and differentiation factors 
GM- and 
M-CSF 
Enhance differentiation of granulocyte and myeloid-lineage cells in the bone marrow 
and synovium 
RANKL Promotes maturation and activation of osteoclasts 
BLyS and 
APRIL 
Activate B cells, promote maturation of B cells and production of autoantibodies 
 
Enzymatic factors 
MMPs Promote disassembly of the type II collagen network, degrade collagenous cartilage 
matrix 
Aggrecanases Degrade aggrecan 
Cathepsins Promote proteolysis of collagen in non-triple helical region, degradation of matrix, 
activation of other enzymes and amplification of destructive process 
 
GM-CSF granulocyte-macrophage colony-stimulating factor; M-CSF, macrophage colony-stimulating 
factor; BLyS, B-lymphocyte stimulator; APRIL, a proliferation-inducing ligand; RANKL, receptor 
activator of NF-B ligand; MMPs, matrix metalloproteases; Th1, type 1 helper T cells; NK cells, 
natural killer cells. 
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1.1.2 Current therapies for RA  
Patients are best managed using a multidisciplinary team approach and an early institution of 
DMARD therapy. The National Institute of Clinical Excellence (NICE) recommends use of combination 
DMARDs plus short-term glucocorticoids as soon as possible after the onset of RA. The treatment is 
escalated rapidly until an adequate disease control is achieved; biologics introduced if necessary. 
Patients receive additional analgesics, NSAIDs/COX2 inhibitors and intra-articular steroid injections 
as needed. RA disease activity is monitored using CRP and DAS 28, a composite disease activity 
score. The goal of therapy is to achieve total remission if possible or an acceptable ‘low-disease-
activity’ status. 
A number of therapies, both biologic and non-biologic as outlined below are effective in the 
treatment of RA yet atleast one third of patients remain unresponsive to the currently available 
therapies. Introduction of anti-TNFs, the first biologics in the treatment of RA two decades ago, 
almost revolutionised the management of RA but systemic side-effects such as increased risk of 
infections still remain major concerns. Since the advent of anti-TNFs, similar biologics targeting other 
cytokines or cell molecules such as IL-6, CD20 and CTLA-IgG have been developed and successfully 
used to treat RA. All these therapies are however based on the principle of inhibiting a 
proinflamamtory cytokine or downregulating B or T cells, either via use of monoclonal antibodies or 
receptor blockers. This approach results in non-selective inhibition of targeted cytokine or immune 
cell, which is also required for normal immune regulatory functions such as host defence against 
microbial infection. There is therefore still an unmet need for better and safer therapies in RA.  
Generalised immune suppression, the major limitation of currently available highly efficacious 
biologic therapies can be avoided if such a therapy is targeted to the actively inflamed RA joints, the 
actual site of pathology. Latent cytokines by allowing targeting of therapeutic biological activity of a 
given cytokine to disease sites where MMPs are overexpressed, such as actively inflamed joints in RA 
offer such an opportunity A cytokine if covalently fused to latency-asscoaited peptide (LAP) of TGF-β 
via a MMP-sensitive linker is unable to interact with its receptor and therefore becomes biologically 
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latent. The biological activity of a latent cytokine however can be released by the action of MMP, 
which is able to cleave the linker between LAP and a given cytokine, thus freeing the cytokine to 
exert its therapeutic actions. The latent cytokine approach was first pioneered in our laboratory 
using IFN-β and since then has been validated for a number of other cytokines and small moelcules. 
LAP-IFN-β was superior to naïve IFN-β in ameliorating CIA in mice and had a significantly prolonged 
half life in vivo. LAP-MSH- was more efficacious than naïve MSH- in a mouse peritonitis model.  
IL-17A (or IL-17), the prototype effector cytokine of Th17 cells, the recently discovered independent 
T helper cell lineage plays an important role in the pathogenesis of RA. Phase 1/2 clinical trials of 
inhibition of IL-17 in RA have demonstrated therapeutic efficacy without notable side-effects, thus 
confirming its previously reported beneficial effects in experimental arthritis. Exogenous 
admisnitration of IL-17 exacerbated arthritis whereas its neutralisation suppressed experimental 
arthritis. In vitro and in vivo preclinical studies have demonstrated that IL-17 works both in synergy 
as well as independently of TNF- and IL-1β in mediating joint inflammation and joint damage in 
inflammatory arthritis. A combined blockage of IL-17 and TNF- and IL-1β is therapeutically more 
efficacious in experimental arthritis than TNF- or IL-1β alone. Inhibition of IL-17 for the treatment 
of RA therefore is likely to be effective as an independent therapy as well as an adjunct to TNF- and 
IL-1β. Moreover, a given IL-17 antagonist if by using LAP cytokine approach is modified as latent IL-
17 antagonist would offer a highly efficacious therapy for RA, which would be targeted to the active 
arthritic joints and devoid of the side-effects ofgeneralised immune suppression and increased risk 
of infections. 
The therapies both non-biologics and biologics that are in the current use to treat RA are in brief 
described below. 
1.1.2a Non-biologic DMARDs 
Methotrexate  
MTX is the preferred first-line DMARD and often the ‘anchor drug’ for the most RA patients (78-80). 
MTX is the most effective and the best tolerated DMARD in the long-term and results in the 
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enhancement of therapeutic efficacy of other DMARDs (both non-biologic and biologic) when 
combined together (81-83).  
Sulfasalazine 
Sulfasalazine alone or in combination with Hydroxychloroquine is generally used in patients who are 
poor candidates for MTX or who lack poor prognostic factors (RF or ACPA positivity, extra-articular 
manifestations, radiographic erosions and functional limitations). 
Hydroxychloroquine 
Hydroxychloroquine may be appropriate for some patients with RA, particularly those who lack poor 
prognostic features and are at the milder end of the spectrum of disease activity. 
Leflunomide 
Leflunomide is effective for the treatment of early, moderate to severely active RA, regardless of the 
presence or absence of poor prognostic factors (84). Leflunomide is most commonly used in 
combination with MTX in patients who have an inadequate response to MTX but are not candidates 
for triple therapy with MTX, Hydroxychloroquine and Sulfasalazine. 
Glucocorticoids  
Short-term treatment with glucocorticoids is indicated as part of initial DMARD combination therapy 
and treatment of flares. Long-term treatment with glucocorticoids is used only when all other 
treatments have been offered and have failed. Both intra-articular and oral glucocorticoids are used 
depending on the clinical indication (85, 86). 
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Table 1.3 Non-biologic DMARDs 
Agent Usual dose Mechanism  of action Side-effects 
 
Methotrexate 7.5 – 20mg 
per week 
Blockage of tetrahydrofolate dependent cell 
metabolism via Inhibition of dihydrofolate reductase; 
accumulation of adenosine; induction  
of apoptosis and inhibition of immune/inflammatory 
cell proliferation; inhibition of IL-1, IL-6 and TNF- 
production 
 
Oral ulcers, bone marrow suppression, GI 
intolerance, hepatotoxicity, hypersensitivity 
pneumonitis, pulmonary fibrosis, alopecia, rash, 
dermatitis, lymphoproliferative disorders 
Sulfasalazine 1gm BD Inhibition of IL-8, MCP-1, TNF-, NF-B; increased 
production of adenosine; inhibition of osteoclast 
formation; apoptosis of macrophages; suppression of B 
cell function 
 
GI intolerance, headache, anorexia, hepatic 
toxicity, hematologic toxicity, haemolytic 
anaemia, DRESS syndrome** 
Hydroxychloroquine* 200mg BD Blockage of TLR9 and B cell antigen receptor 
costimulation; inhibition of TLR signaling; decreased 
inflammatory mediators and lymphocyte proliferation 
secondary to lysosomotropic actions; inhibition of TNF-
, phospholipase, metalloproteinase; blockage of 
superoxide release; antagonism of PG 
 
GI intolerance, skin rash, headache, light 
headedness, tinnitus, toxic neuropathy, skeletal 
myopathy, cardiomyopathy, corneal deposits, 
retinopathy. 
 
Leflunomide 20mg OD Reduced synthesis of rUMP via inhibition of dihydro-
orotate dehydrogenase; inhibition of memory T cells, 
dendritic cells; inhibition of leukocyte adhesion to 
endothelial cells and synovial infiltration of lymphocytes 
and macrophages; blocking of NF-B and JAK1 and JAK3 
signaling 
 
Diarrhoea, hypertension, hyperkalemia, 
hepatotoxicity, leukopenia, interstitial lung 
disease, peripheral neuropathy 
 
* Hydroxychloroquine is one of the safest DMARDs. Serious side-effects are rare. ** DRESS syndrome, drug rash with eosinophilia and systemic symptoms.
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1.1.2b Biologic DMARDs 
Biological agents represent a major advance for the treatment of patients who have inadequate 
response to non-biologic DMARDs.  
Biologic DMARDs are produced using recombinant DNA technology, and target cytokines or their 
receptors or are directed against other cell surface molecules. The current NICE approved biologics 
for the treatment of RA are listed in the Table 1.4 and include TNF inhibitors (Etanercept, Infliximab, 
Adalimumab, Certolizumab and Golimumab), T cell co-stimulation inhibitor (Abatacept), IL-6 
inhibitor (Tocilizumab) and B cell depleting agent (Rituximab).  
TNF inhibitors  
TNF antagonists have held to their place as the biologics of choice since being introduced two 
decades ago as the first biological therapy for RA. Targeting TNF by means of either monoclonal 
antibodies or TNF receptor-IgG fusion protein proved to be extremely effective in control of RA (87). 
The unprecedented success of TNF inhibiting biologics has translated into the development and 
availability of similar therapies targeting other mediators of inflammation. 
It has been well established that combination of an anti-TNF agent and MTX reduces disease activity 
to a greater extent and slows radiographic progression further than achieved by monotherapy with 
either of the agents (83). 
Etanercept is a soluble p75 TNF receptor fusion protein that consists of two p75 TNF receptor 
extracellular domains bound to the Fc portion of immunogloubulin G1 (IgG1). It is capable of also 
binding lymphotoxin. 
Infliximab is a mouse chimeric monoclonal antibody directed against TNF. Within infliximab, the VL 
and VH domains of the antigen-binding portion of the molecule are murine, and the constant Fc 
domain is human IgG1.  
Adalimumab is a recombinant fully human monoclonal antibody and therefore associated with a 
lower risk of anti-drug antibody formation compared with chimeric or humanised anti-TNF 
preparations. 
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Certolizumab pegol is a Fab’ fragment of a humanised IgG1 monoclonal anti-TNF antibody that is 
chemically linked to polyethylene glycol. It neutralizes membrane-associated and soluble TNF-. In 
contrast to other anti-TNFs, Certolizumab does not contain an Fc portion and therefore does not 
induce complement activation, antibody-dependent cellular cytotoxicity or apoptosis. 
Golimumab is a human monoclonal antibody that binds to both the soluble and transmembrane 
bioactive forms of human TNF-.  
IL-1 inhibitors 
By comparison to the TNF inhibitors, inhibition of IL-1 had a smaller impact on RA. Anakinra, a 
recombinant human IL-1Ra differs from the native human protein in that it is not glycosylated and 
has an additional N-terminal methionine. The effects of Anakinra were only modest in most RA 
patients (46) whereas effectiveness of other IL-1 inhibitors such as Rilonacept, an IL-1R fusion 
protein and Canakinumab, an IL-1β monoclonal antibody in RA has not been established. 
IL-6 inhibitor 
Tocilizumab is a humanized anti-human IL-6 receptor antibody having complementarity determining 
regions of a mouse anti-human IL-6 receptor monoclonal antibody grafted onto human IgG1. 
Tocilizumab competes for both the membrane-bound and soluble forms of human IL-6 receptor, 
thereby inhibiting the binding of the native IL-6 to its receptor and interfering with its effects. 
Abatacept 
Abatacept (also called CTLA4-Ig) is a soluble fusion protein comprising CTLA-4 and the Fc portion of 
IgG1. It prevents activation of T cells by competing with CD28 to bind to its counter-receptor, 
CD80/CD86, due to its higher affinity for CD80/CD86. Abatacept was initially available only for 
intravenous use but can also be administered subcutaneously (88).  
Rituximab 
Rituximab is a B cell mouse chimeric monoclonal anti-CD20 antibody. Rituximab causes B cell 
depletion through antibody dependent mechanisms (89), which include Fc receptor gamma-
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mediated antibody-dependent cytotoxicity, antibody-dependent complement mediated cell lysis, 
growth arrest and B cell apoptosis. Rituximab is given in combination with MTX (90). 
 
Table 1.4 Biologic DMARDs 
Agent Target Structure Usual dose Half-life 
Infliximab TNF- Chimeric monoclonal antibody IV – 3mg/kg in 
combination with MTX at 
0, 2, 4 weeks, thereafter 
every 8 weeks 
 
9 days 
Etanercept TNF- TNFRII-IgG fusion protein SC – 50mg/week with or 
without MTX 
 
4 days 
Adalimumab TNF- Human monoclonal antibody SC – 40mg/every 
fortnight with or without 
MTX 
 
14 days 
Certolizumab TNF- Pegylated humanised Fab’ 
fragment of monoclonal 
antibody 
SC – 400mg at 0, 2, 4 
weeks, thereafter 200mg 
every fortnight 
 
14 days 
Golimumab TNF- Human monoclonal antibody SC – 50mg every 4 weeks 
in combination with MTX  
 
14 days 
Anakinra IL-1 IL-1 receptor antagonist SC – 100mg/day 
 
4-6 
hours 
Abatacept T cell  CTLA4-IgG fusion protein IV – 500mg, 750mg or 
1gm for body weight 60, 
60-100 and >100kg at 0, 
2, 4 weeks, thereafter 
every 4 weeks 
SC – weight-based iv 
loading dose, thereafter 
125mg SC/week 
 
14 days 
Tocilizumab IL-6 Humanised IL-6 receptor 
antibody 
IV – 8mg/kg every 4 
weeks 
 
14 days 
Rituximab B cell Chimeric anti-CD20 antibody IV – 1gm infusion 
separated by 2 weeks, 
not to be repeated 
sooner than 16 weeks 
7 days 
TNF-, tumour necrosis factor-; MTX, methotrexate; SC, subcutaneous; IV, intravenous. 
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1.1.2c Targeting intracellular signaling pathways in RA 
Recent evidence suggests hierarchal importance of JAK pathways amongst the intracellular signalling 
pathways in the pathogenesis of RA. Tofacitinib, a JAK 3 and 1 inhibitor in phase 2 clinical trials 
demonstrated an acceptable safety and therapeutic efficacy, which was equivalent to the current 
biologics (91, 92). Inhibition of spleen tyrosine kinase by Fostamatinib, is effective in some 
subgroups of RA patients (93, 94). In contrast, despite a strong preclinical rationale, the targeting of 
p38 mitogen-activated protein kinase has been disappointing in clinical settings. 
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1.2 IL-17 family of cytokines 
IL-17 which was identified in 1995 lacked sequence similarity with any other known family of 
cytokines and was therefore classified as a new family of cytokines. The IL-17 family now includes 6 
members, IL-17A to IL-17F (Table 1.5). Amongst these IL-17A and IL-17F are best characterised and 
shown to play a role in host defence and autoimmunity.   
1.2.1 IL-17A  
IL-17A, also termed IL-17 is the prototype IL-17 cytokine. IL-17A is produced mainly by activated 
peripheral CD4+ T lymphocytes (95, 96) but also other cells such as CD8+ T lymphocytes (97), δ+T 
cells (98), natural killer T (NKT) cells , natural killer (NK) cells (99) , dendritic cells (100), mast cells 
(36) lymphoid-tissue inducer (LTi)-like cells, paneth cells and neutrophils (101). Human IL-17 mRNA is 
detected in neutrophils, eosinophils and monocytes (102, 103).  
IL-17 mediates predominantly proinflammatory and hematopoietic responses. IL-17A stimulates 
secretion of TNF-, IL-1, IL-6, IL-8, G-CSF, ICAM-1 and PGE2 from fibroblast, endothelial, epithelial 
and macrophage cells (96, 104-107). IL-17 mediates activation of neutrophils through promotion of 
granulopoiesis (108, 109) and expression of ELR-positive CXC chemokines CXCL1/KC/GRO and 
CXCL5/LIX in mice (110-113) and IL-8 in humans (96). The action of IL-17 is synergistic to both IL-1β 
and TNF- (114-116).  
IL-17 plays a critical role in host defence against extracelluar pathogens in epithelial and mucosal 
tissues such as the skin, lung and intestine.  IL-17R signalling is required for host defence against  
extracellular bacterial and fungal infection in the skin and lung (117). Th17 cell differentiation is 
promoted in response to muramyldipeptides from bacterial cell walls and β-glucans in zymosans and 
fungi (118). IL-17 promotes expression of various anti-microbial genes including acute phase 
reactant protein lipocalin 2/24p3 (119) and molecules with direct antimicrobial activity, such as β-
defensins, mucins and calgranulins (120-122). 
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IL-17A plays an important role in the initiation and/or maintenance of an inflammatory response in 
autoimmune conditions such as RA, multiple sclerosis, psoriasis and inflammatory bowel disease 
(123-126).  
Regulatory effects of IL-17A 
Although identified as a predominantly proinflammatory cytokine, IL-17A has also been shown to 
exert protective effects. In asthma, IL-17A although is required for antigen-sensitization, it plays a 
protective role in the effector phase of the disease (127).  
In GVHD, the weight loss and diarrhoea is accentuated in the absence of IL-17A, mainly due to 
increase in IFN-γ (128). In the dextran sodium sulfate-induced colitis model, IL-17A plays a protective 
role against epithelial ulceration, mainly due to decreased IFN-γ and osteopontin (129) in contrast to 
pathogenic IL-17F, which contributes to excessive tissue damage and wasting disease (130).  
 
 
Figure 1.3 Biological functions of IL-17. IL-17 mediates tissue inflammation and damage, leads to 
autoimmunity and protects the host against infections by inducing secretion of inflammatory 
cytokines, MMPs, RANKL, chemokines and growth factors in cell of target tissues, promoting the 
survival and expansion of B-cells and the differentiation of B-cells into antibody-producing plasma 
cells and acting directly on epithelial cells of peripheral tissues to promote release of peptides with 
antibacterial properties such as defensins, regenerating proteins and S100 proteins. 
 
 
IL-17 
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Table 1.5 IL-17 cytokine family 
Family 
member 
Size 
(aa) 
% Homology  
(to IL-17A) 
% Homology 
(mouse/human) 
Produced by Receptor 
complex 
Receptor Main functions 
IL-17A 155 100 62 Th17 cells, CD8+T cells, 
δ T cells, NK cells, NKT 
cells, LTi cells 
 
IL-17RA/RC Prefer IL-17RA 
to IL-17RC 
 
Promote autoimmune diseases 
and protect against extracellular 
bacterial and fungal infection 
IL-17F 163 55 77 T cells, innate immune 
cells, epithelial cells 
 
IL-17RA/RC Prefer IL-17RC 
to IL-17RA 
 
Drive inflammation and 
autoimmunity, neutrophil 
recruitment 
IL-17B 180 29 88 Cells of gastrointestinal 
tract, pancreas and 
neurons 
 
 
_ 
 
 
IL-17RB 
 
Activate TNF- and IL-1β release 
in THP-1 cells 
IL-17C 197 23 83 Cells of prostate, foetal 
kidney 
 
 
_ 
IL-17RE Activate TNF- and IL-1β release 
in THP-1 cells 
IL-17D 202 25 78 Cells of muscles, brain, 
heart, lung, pancreas, 
adipose tissue 
 
 
_ 
Unknown 
 
Promote proinflammatory gene 
profile in endothelial cells 
IL-17E 161 17 81 Th2 cells, mast cells, 
alveolar macrophages, 
eosinophils, epithelial 
cells, brain capillary 
endothelial cells 
IL-17RB/RA Prefer IL-17RB 
to IL-17RA 
Promote type 2 immune 
response and inhibit 
autoimmune diseases 
 
aa, amino acid; Adapted from Alcorn JF et al. Annu Rev Physiol 2010; 72:495-516 and Zhang X et al. Protein Cell 2011; 2: 26–40 
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1.2.2 IL-17F 
Amongst all IL-17 family members, IL-17F is most closely related to IL-17A sharing 55% structural 
homology, receptor binding and biological functions. The Il-17f and Il-17a genes are co-localised at 
6p12 into a tail-to-tail orientation, only 50kb apart (GenBank accession no. AL391221), which points 
towards a potential gene duplication event.  
Two different but functionally similar isoforms of human IL-17F have been identified (the longer and 
the shorter isoform) (131). The full-length IL-17F contains 163 amino acid residues and like IL-17A is 
secreted as a disulfide-linked homodimeric glycoprotein. The crystallographic structure of IL-17F 
revealed a cystine knot fold, which is similar to neurotrophin growth factors (132). 
IL-17F has a much wider expression than IL-17A suggesting that IL-17F has more biological functions. 
Rapid scan gene expression panel showed a strong expression of IL-17F in liver, lung, spleen, 
placenta, adrenal gland, ovary, and foetal liver. In addition, IL-17F expression was upregulated in 
activated PBMCs, activated Th0, Th1, and Th2 cells, activated basophils, activated mast cells, and 
activated peripheral blood CD4+ T but not CD8+ T cells and monocytes. In contrast, IL-17a gene 
expression is increased only in activated peripheral blood CD4+ T cells, Th0 clones and PBMCs.  
IL-17F is generally co-expressed with IL-17A in naive T cells under Th17 polarising conditions. The 
possibility of differential ratios of these two cytokines in different T cell states or in different tissues 
has been suggested (130). 
Like IL-17A, IL-17F induces many proinflammatory cytokines and chemokines. It induces TGF-β, IL-2 
in endothelial cells (133); ICAM-1, GM-CSF in airway bronchial epithelial cells (131, 134); and IL-6 and 
CXCL-1 in fibroblasts and epithelial cells (130). In lung fibroblasts, IL-17F induces CCL2, CCL7, TSLP 
and MMP-13 (130). IL-17F by stabilising mRNA transcript synergises with other cytokines (135). In 
combination with TNF-α, IL-17F induces G-CSF expression in human bronchial epithelial cells (136) 
and, together with IL-22, IL-17F induces antimicrobial-peptides, hBD-2, S100A7, S100A8 and S100A9 
(121). 
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IL-17F along with IL-17A is required for host defence to extracellular bacteria and fungi in skin and 
mucoepithelial tissues (137, 138). IL-17F, however, plays a less important role than IL-17A in 
systemic infection of C. albicans. It was shown that only Il17a-/-mice but not Il17f-/-mice, showed 
increased susceptibility to candidial infection (139).  
Studies in Il17a-/- mice and Il17f-/-mice indicated that in comparison to IL-17A, IL-17F plays a minor 
role in driving autoimmunity (130, 138). In experimental autoimmune encephalitis (EAE) while both 
the IL-17A and IL-17F contributed to the chronic inflammatory phase, IL-17A was more important 
initiating factor than IL-17F. 
IL-17F also may function differently than IL-17A in mediating allergy and autoimmunity.  IL-17F is 
more important than IL-17A in allergen-mediated immune response (130). Mice deficient in IL-17F, 
but not IL-17A show defective airway neutrophilia in response to allergen challenge. A sustained 
expression of IL-17F mediates tissue infiltration by lymphocytes and macrophages, and mucus 
hyperplasia in asthma suggestive of a regulatory rather than a pathogenic role for IL-17F in this 
condition (127, 130, 140). In the dextran sulfate sodium (DSS)-induced colitis model, IL-17F played a 
pathogenic as role as opposed to IL-17A, which plays a protective role (129, 130). 
Hymowitz et al. demonstrated that, in vitro, IL-17F induced cartilage matrix release and inhibited 
new cartilage matrix synthesis with an efficiency that was comparable to IL-17A (132). In vivo studies 
in IL-17F-deficient mice however, showed that the development of arthritis in Il17f-/-IL-1ra-/-mice 
was partially suppressed whereas CIA developed normally in the Il17f-/-mice (138). These findings 
suggest that IL-17F, although contributing to the development of arthritis in IL-1 receptor 
antagonist-deficient mice, is not required for CIA.  
 
1.2.3 IL-17A/F heterodimer 
As activated T cells from both mouse and humans co-express IL-17F and IL-17A (107, 133, 141), 
existence of IL-17A/IL-17F heterodimer appeared to be a strong possibility, which has now been 
confirmed (142, 143). While mouse Th17 cells secrete all the three isoforms IL-17A, IL-17F and IL-
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17A/F (142, 144), human CD4+T cells expressed IL-17A/F heterodimer and IL-17F homodimer but 
almost no IL-17A homodimer (143). In vitro functions of the IL-17A/F heterodimer are similar to IL-
17A and IL-17F (144). The activity of the IL-17A/F heterodimer was reported to be intermediate of IL-
17A and -17F by Wright et al. (143), whereas nearly equal to IL-17A homodimers but greater than IL-
17F by Liang et al. (144). 
 
1.2.4 Other IL-17 cytokine family members 
1.2.4a IL-17B and IL-17C 
IL-17B and IL-17C share 20-25% sequence identity with IL-17A. The absence of AU-rich repeats in IL-
17B resulting in a translation product of more stable message points towards the possibility of  a 
constitutive serum presence of the protein (145). IL-17C was detectable in CD4+ T cells in CIA mice, 
which suggests that besides IL-17A and IL-17F, expression of IL-17C also takes place at inflammatory 
sites. IL-17C-induced neutrophil responses were comparable to IL-17A and IL-17F (146) whereas the 
potency of IL-17B in inducing PMN infiltration was  about 10 times less than IL-17A (147). A study by 
Yamaguchi et al. demonstrated that IL-17B and IL-17C but not IL-17A is directly associated with in 
vivo production of TNF- (148). 
 
1.2.4b IL-17D 
IL-17D, similar to IL-17A and IL-17F, stimulates the production of IL-6, IL-8, and GM-CSF in 
endothelial cells. However, it inhibits the haematopoiesis of myeloid progenitor cells (149).  
 
1.2.4c IL-17E 
Human IL-17E, also called IL-25, is a 177 amino acid residues precursor protein (150). IL-17E 
promotes the expression of the prototypical Th2 genes (146, 151, 152) and appears to be an 
important mediator of allergic diseases.  
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1.2.5 (H161R) IL-17F mutant  
(H161R) IL-17F mutant is a natural variant of IL-17F, a result of substitution of Histidine by Arginine 
at amino acid 161 in the third exon. Homozygotes of the (H161R) IL-17F mutant were protected from 
asthma in a Japanese population (OR 0.06, 95% CI 0.01-0.43, p = 0.0039) (153). In vitro studies 
revealed that the (H161R) IL-17F mutant was a competitive inhibitor of the wild-type IL-17F and 
lacked the ability to activate upstream signaling pathways and induction of cytokine and chemokine 
secretion in bronchial epithelial cells. Studies in Chinese and European American populations, 
however, failed to find a similar association between asthma and the IL-17F mutant (154, 155). On 
the contrary, in a Chinese subpopulation of male asthma patients, the mutant allele was associated 
with increased risk of susceptibility to the disease. The lack of association in the European American 
population may be related to a much lower frequency of the mutant, which was only 4.5% as 
compared to 11.4% in Japanese population.  
The association of the (H161R) IL-17F mutant with the risk of susceptibility to various other diseases 
has been summarised in Table 1.6. In keeping with the observations in asthma, the (H161R) IL-17F 
mutant was inversely associated with susceptibility to idiopathic thrombocytopenic purpura (ITP) in 
Japanese; ulcerative colitis in Japanese and Chinese, albeit weakly but not in Caucasian population 
(156-159). In the Japanese population, there was no association between the mutant and overall 
susceptibility to psoriasis vulgaris, functional dyspepsia or gastric carcinoma (160-162).  
Similar to Japanese asthmatic patients, the (H161R) IL-17F mutant was protective against chronic 
fatigue syndrome in Europeans and Behcet’s disease in the Korean population (163, 164) 
whereas, studies in Chinese Han population showed that (H161R) IL-17F mutant was not a major 
contributor to the pathogenesis of myocardial infarction in men and it did not increase the 
susceptibility to breast carcinoma in women (165, 166). 
Paradowska-Gorycka et al. investigated association between (H161R) IL-17F polymorphism in 220 
Polish patients with RA and 106 healthy subjects and reported that, although the (H161R) IL-17F 
mutant did not increase the overall susceptibility to RA, it was associated with a higher number of 
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tender joints, higher DAS 28 and higher HAQ score implying that (H161R) IL-17F polymorphism might 
be associated with an increased disease activity in RA (167). 
 
Table 1.6 Association of (H161R IL-17F) mutant with the risk of susceptibility to various diseases 
Disease Population Disease 
Association 
OR Reference 
Asthma 
 
Asthma 
 
Asthma 
 
Japanese Inverse 
 
CC - 0.06(0.01-0.43), p=0.039 
TC - 1.32 (0.95-1.84), p= 0.08 
137 
Chinese 
male 
Direct 1.58 (106-236), p=0.0148 138 
White women None _ 139 
     
UC 
 
UC 
Chinese Weak 
Inverse 
TC - 0.96(0.94-0.96) 140 
Japanese 
 
Inverse  TT- 1.81(1.01-3.23), p=0.045  
 
141 
IBD 
(UC+CD) 
 
Caucasian None _ 142 
ITP Japanese Inverse TC/CC-0.48(0.27-0.84), p=0.016 143 
     
Ca-breast Chinese han 
women 
 
 
None _ 150 
FD Japanese None _ 144 
Ca-stomach Japanese None _ 145 
     
Behcet’s 
Disease 
Korean Inverse CC - 0% vs 8.3%, p<0.001 
TC - 9.6% vs 1.3%, p<0.001 
 
148 
CFS European Inverse TC/CC - 8.9% vs 28.5%,  
OR 4.05, p=0.0018 
147 
     
Psoriasis 
Vulgaris 
Japanese None _ 146 
     
MI Chinese Han None _ 149 
     
RA Polish None _ 151 
 
OR, odds ratio; CFS, chronic fatigue syndrome, IBD, inflammatory bowel disease; UC, ulcerative 
colitis; CD, Crohn’s disease; RA, rheumatoid arthritis; MI, myocardial infarction; FD, functional 
dyspepsia; ITP, idiopathic thrombocytopenic purpura. 
 
 
48 
 
1.2.6 IL-17 receptor family  
The IL-17 receptor family comprises five receptor subunits, IL-17RA to IL-17RE (Table 1.7). The genes 
encoding human receptors cluster on chromosome 3, except IL-17RA which is located on  
chromosome 22. All the receptor subunits are single transmembrane domain proteins and contain 
certain conserved structural motifs, an extracellular fibronectin III-like domain and a cytoplasmic 
similar expression of fibroblast (SEF)/IL-17R (SEFIR) domain (168). In addition, IL-17RA also contains 
two extra domains, a TILL [TIR (Toll/IL-1R) like loop] domain close behind the SEFIR domain and a 
Distal domain in the C-terminus. IL-17RA is a common subunit that forms heterodimeric complexes 
with other IL-17 receptors. 
1.2.6a IL-17RA  
IL-17RA mRNA is expressed in virtually all cells and tissues tested. The ubiquitous expression of IL-
17RA is consistent with its wide range of effects (169). The expression of IL-17RA is particularly high 
in hematopoietic tissues (95, 138). In contrast to most cytokines receptors, high levels of IL-17RA 
seem to be required for an effective response (119, 170). As the signaling strength of IL-17A 
correlates with cell surface expression levels of IL-17RA, a dynamic regulation of IL-17RA seems to be 
biologically important. IL-15 and IL-21 upregulate its expression while phosphoinositide 3 kinase 
(PI3K) limits the expression of IL-17RA in T cells (171, 172). The surface expression of IL-17RA rapidly 
decreases after it binds to IL-17A due to receptor internalisation. IL-17RA might therefore also limit 
the signalling by clearing itself from the inflammatory milieu (171). IL-17RA binds to IL-17A with a 
strong affinity (95), and although weakly to IL-17F, is necessary for signal transduction mediated by 
IL-17A, IL- 17F and IL-17A/F heterodimer.  
IL-17RA complex formation  
IL-17RA forms heteroreceptor complexes with other IL-17 receptors. It pairs with IL-17RC to induce 
responses to IL-17A and IL-17F (173). IL-17RA couples with IL-17RB to form IL-17A/B receptor 
complex (174) and forms a receptor complex with IL-17RD (175). However, no ligand for an IL-
17RA/IL-17RD receptor complex has yet been identified.   
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Studies using fluorescence resonance energy transfer (FRET) showed that formation of IL-17RA 
complexes is independent of its ligands (176-178). It is not known whether IL-17RC is pre-assembled 
with IL-17RA to any degree (173). It seems that IL-17RA dimers either dissociate after ligand binding 
and are replaced by IL-17RA/IL-17RC heterodimers or IL-17RC might be recruited to the IL-17RA 
dimer to create a trimer or a multimer. Like TNFR, IL-17RA also contains a fibronectin III-like pre-
ligand assembly domain (PLAD) (176).  
The crystallographic structure of IL-17RA bound to IL-17F showed that it binds to IL-17F in 1:2 
stoichiometry. IL-17RA forms an extensive binding interface with IL-17F with the major interaction 
taking place at three different sites (179). At the sites 1 and 2, IL-17RA D1 binds with strands 2 and 3 
of IL-17F whereas site 3 is formed between the IL-17RA D2 F G loop (Cys259–Arg265) and the C-
terminal regions of strands 3 and 4 of IL-17F chain A, and the N-terminal extension of IL-17F chain B. 
Site 3 is rich in charged interactions with nine potential hydrogen bonds and a salt bridge. Once IL-17 
is engaged by two fibronectin-type domains of IL-17RA, binding of the first receptor to IL-17 
modulates its affinity and specificity of the second receptor-binding event to promote a 
heterodimeric rather than homodimeric complex formation. 
IL-17RA as a common receptor 
IL-17RA is able to associate with other IL-17 family members and seems to act as a shared receptor, 
analogous to those in class I cytokine receptor complexes. IL-17RA is used as a common signaling 
subunit by at least four ligands. IL-17RA binds both IL-17A and IL-17F, and also IL-17E/IL-17RB 
receptor complex, and was shown to associate with IL-17RD to form IL-17RA/RD receptor complex. 
Mapping of the residues conserved among the IL-17 family members onto the IL-17RA-IL-17F 
complex showed that IL-17RA appears to use a strategy of cross-reactivity based on a subset of 
conserved and distinct binding sites amongst the several IL-17 family members. IL-17RA contacts the 
conserved residues with the N-terminal region of the D1 domain and the D2 FG loop domain 
whereas the IL-17RA C′–C loop interacts mainly with IL-17 residues that differ around the receptor-
binding pocket.  
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Table 1.7 IL-17 receptor family 
Family 
member 
Size 
(aa) 
% Homology 
(to IL-17RA) 
% Homology 
(mouse/human) 
Distribution Ligand Binding bias Main functions 
IL-17RA 818 100 69 Ubiquitous, high 
levels in 
haematopoietic 
tissues 
 
IL-17A, IL-17F, 
IL-17E 
Prefer IL-17A 
to IL-17F 
Necessary for signal 
transduction by IL-17A, IL-17F, 
IL-17E 
IL-17RC 791 22 68 Non haematopoietic 
tissues such as colon, 
small intestine, lung, 
prostate 
 
IL-17A, IL-17F Prefer IL-17F  
To IL-17A 
Complexes with IL-17RA to 
mediate IL-17 signaling 
IL-17RB 502 19.2 76 Th2 cells, various 
endocrine tissues, 
kidney, liver 
 
IL-17B, IL-17E Prefer IL-17B 
to IL-17E 
Pairs with IL-17RA to form a 
functional receptor complex for 
IL-17E 
IL-17RD 739 _ _ Kidney, heart, small 
intestine, colon, 
skeletal muscles, 
brain, lung, spleen 
 
IL-17A?,  
FGF? 
Interaction 
with IL-17RA  
Mediate IL-17 signaling, inhibit 
FGF signaling and facilitate EGF 
signaling 
IL-17RE 667 _ _ 
 
NA IL-17C Prefer IL-17C Might promote proliferation 
 
IL-17R, Interleukin-17 receptor; FGF; fibroblast growth factor; FGF-R, fibroblast growth factor receptor; EGF, epidermal growth factor; NKT, natural killer T; 
LTi, lymphoid tissue inducer; THP-1 cells, a human leukemia monocytic cell line; Th, T helper. 
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1.2.6b IL-17RC 
IL-17 receptor C (IL-17 RC, also known as IL-17 RL and IL-17R hom) contains 791 amino acids. The 
gene for human IL-17RC contains 19 exons and more than 90 splice isoforms of IL-17RC have been 
identified in human prostate cancer lines (180). The full length IL-17RC isoform occurs 10% of the 
time, while the three most common isoforms, as a group, occur about 50% of the time. Alternative 
splicing of IL-17RC appears to regulate ligand specificity. There is a ligand preference of IL-17RC 
splice isoforms as certain forms bind preferentially to IL-17A or IL-17F. Moreover, some isoforms do 
not bind either cytokine, suggesting that there might be additional ligands for this receptor subunit 
(181).  
IL-17RC contains a SEFIR domain but not an obvious TILL domain.  IL-17RC cannot induce signaling in 
the absence of IL-17RA and is required for both IL-17A- and IL-17F-mediated signaling. In humans, IL-
17RA binds with extremely low affinity to IL-17F but IL-17RC binds to IL-17F with an affinity higher 
than IL-17A (181). Soluble IL-17RA can efficiently block IL-17A-dependent but not IL-17F-dependent 
responses in human cells, providing an opportunity to selectively target individual cytokines (181). In 
mice, IL-17RA binds both IL-17A and IL-17F, whereas IL-17RC binds strongly only to IL-17F. These 
species dependent differences in receptor binding are important in evaluating IL-17-specific 
therapeutics in pre-clinical models. There is also species-dependent interaction between the IL-17R 
subunits. Only mouse IL-17RA can reconstitute IL-17A-dependent signaling in mouse Il17ra-/-
fibroblasts and co-operation of human but not mouse IL-17RC with human IL-17RA could induce 
signaling by human IL-17 in these cells (173). 
IL-17RA and IL-17RC subunits have reciprocal expression patterns, which indicate tissue-dependent 
activities (138, 181). In contrast to IL-17RA, expression of IL-17RC is low in haematopoietic tissues 
whereas seen predominantly in non-iimune cells such as prostate, liver, kidney, thyroid and joints 
(181, 182). Therefore cells with high IL-17RC expression could be highly responsive to IL-17F, 
whereas those with low IL-17RC expression and high IL-17RA expression might respond better to IL-
17A.  
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1.2.6c Other IL-17 receptors 
Recent evidence suggests that IL-17RB pairs with IL-17RA to form a functional receptor complex 
(174). IL-17 RB binds strongly to IL-17E (150), weakly to IL-17B and does not bind IL-17A, IL-17C and 
IL-17F.  
IL-17RD seems to be the most evolutionary ancient member of the IL-17R family (183). IL-17RD can 
interact with IL-17RA, although the biological importance of this association remains unclear (175).  
IL-17RD has no known ligand. 
IL-17RE is highly spliced; six isoforms have been identified in EST databases. Recent studies suggest 
that its ligand is IL-17C (184). 
 
1.2.7 IL-17-induced signaling pathways 
Both IL-17A and IL-17F bind to the IL-17RA and IL-17RC heterodimeric complex to transduce 
downstream signaling. IL-17 activates many common downstream signaling pathways including 
nuclear factor kappa light enhancer of activated B cells (NF-κB), mitogen-activated protein kinases 
(MAPKs), c-Jun N-terminal kinase (JNK), p38 and extracellular-signal regulated kinase (ERK), 
CCAAT/enhancer-binding proteins (C/EBPs), phosphoinositide 3-kinase /Janus kinase (PI3K/JAK) and 
signal transducer and activator of transcription (JAK/STAT) (Fig. 1.4). In addition, IL-17 stabilizes 
mRNA of some proinflammatory cytokines and chemokines induced by TNF- (185-188). 
The IL-17R family members encode a novel, conserved signalling motif termed: similar expression of 
fibroblast (SEF)/IL-17R (SEFIR) domain (168). The SEFIR domains of both IL-17RA and IL-17RC are 
required to activate NF-B, MAPK, and C/EBP pathways in response to IL-17A or IL-17F (189, 190).  
TRAF6, an adaptor and E3 ubiquitin ligase is essential for IL-17A signaling (191). A cytoplasmic 
protein, Act1, also known as CIKS (connection to IκB kinase and stress-activated kinase) contains 
both SEFIR (192, 193) and a TRAF6 binding motif (194). Act1 directly associates with IL-17RA and IL-
17RC via interaction with each SEFIR domain, resulting in the recruitment of TRAF6 and TGFβ-
activated kinase 1 (TAK1) to activate NF-B. In addition to NF-B activation, Act1 also mediates IL-
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17-induced MAPK activation and C/EBP induction pathways. One report has shown that IL-17 can 
activate the JAK1/2 and PI3K pathway, which co-ordinates with the NF-B-activating pathway of 
Act1/TRAF6/TAK1 (195). 
CXCL1 mRNA stabilization in response to IL-17A is dependent on Act1, but not TRAF6. Recently, 
inhibitor of B kinase I (IKKi) was shown to be important for IL-17-induced phosphorylation of Act1, 
which is critical for the formation of the Act1–TRAF2–TRAF5 signal complex required to mediate IL-
17-induced mRNA stability through dissociation of alternative splicing factor (ASF) from mRNA (186, 
187).  
IL-17R signaling activates ERK to phosphorylate Thr188 of C/EBPβ, which is required for Thr179 
phosphorylation of C/EBPβ by GSK3β (glycogen synthase kinase 3β). The dual phosphorylation of 
C/EBPβ inactivates itself, resulting in the suppression of IL-17-mediated downstream gene induction. 
TRAF3 in association with Act1 negatively regulates IL-17A-mediated NF-B and MAPK activation. 
(196, 197). A recent study showed that persistent stimulation with IL-17 resulted in β transducin 
repeat-containing protein (β- TrCP)-mediated ubiquitination of Act1 for its subsequent degradation, 
and consequently desensitization of IL-17R signaling for the prevention of persistent  
inflammation (198). 
At the downstream of the C-terminus of the IL-17RA, motif TIR-like loop (TILL) (170) bears homology 
to TIR (Toll/IL-1R) domain of the Toll-like receptor (TLR). The TILL domain is vital for signal 
transduction by IL-17. Mutations specific to this region, abrogate all IL-17-induced responses. 
Despite its similarity with TIR domain, IL-17 does not utilize myeloid differentiation primary response 
protein 88 (MyD88), TIR domain-containing adaptor inducing IFN-β (TRIF), IL-1R-associated kinase 4 
(IRAK4) or IRAK1 for cytokine induction (170, 196, 199).  
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Figure 1.4 IL-17-induced signaling pathways. (a) Both IL-17A and IL-17F bind to a heteroreceptor 
complex composed of IL-17RA and IL-17RC to transduce downstream signaling. Both IL-17RA and IL-
17RC encode SEFIR domains whereas IL-17RA also encodes additional TILL and distal units. IL-17RA 
and IL-17RC interact with SEFIR domain-containing adaptor Act1, which in turn recruits TRAF6 
required for the activation of the NF-B, MAPK pathways and induction of C/EBP. The TILL domain of 
IL-17RA is important for inducible phosphorylation of C/EBPβ on threonine 179, which is mediated 
by GSK3. IL-17 probably also activates the JAK/PI3K pathway. IL-17 mediates TRAF6 independent 
mRNA stability by formation of another complex Act1–IKKi–TRAF2–TRAF5–SF2 (ASF). In contrast, 
TRAF3 negatively regulates IL-17R by interfering with the formation of the IL-17R–Act1–TRAF6 
complex. TNFR 6, TNFR associated factor 6; IKKi, IB kinase i; SF2(ASF), splicing factor 2 (alternative 
splicing factor); C/EBP, CCAAT enhancer binding protein; GSK3, glycogen synthase kinase 3; CBAD, C-
enhancer binding protein activation domain; NF-B, nuclear factor kappa light chain enhancer of 
activated B cells; MAPK, mitogen activated protein kinase; PI3K/JAK, phosphoinositide 3 
kinase/Janus kinase; FN, fibronectin III-like domain; SEFIR, similar expression of fibroblast/IL-17R; 
TILL, Toll/IL-1R (TIR)-like loop. 
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1.3 Th17 cells 
Th17 cells are a subset of CD4+ effector T cells that are different from Th1 and Th2 cells (200). Th1 
cells mainly produce IFN-γ and are involved in immunity against intracellular pathogens while Th2 
cells produce IL-4, IL-10 and IL-13 and are responsible for immunity against parasites and mediation 
of allergic responses. In contrast to Th1 and Th2 cells, Th17 cells preferentially secrete IL-17A, IL-17F, 
IL-21, IL-22 and IL-26 (201-203). In healthy individuals, approximately 1% circulating CD4+ T cells 
produce IL-17. Th17 cells play a role in defence against extracellular pathogens (137, 204, 205) and 
along with Th1 cells are implicated in autoimmune diseases. More recently, a regulatory role of Th17 
cells in the form of protection against tissue damage during inflammation has been identified. 
Evidence now suggests that depending on the microenvironment of various diseases, naïve CD4+ T 
cells can differentiate into either proinflammatory or protective Th17 cells to mediate a diverse set 
of responses in infection, autoimmunity and immunodeficiency. 
 
1.3.1 Differentiation of Th17 cells 
TGF-β and IL-6 are critical for mouse Th17 cell differentiation (204, 206, 207). IL-21, IL-23, IL-1β and 
TNF- provide additional amplificatory signals (204, 206-210). However, IL-6 signaling was 
dispensable for the induction of pathogenic Th17 cells and induction of EAE in mice lacking Treg cells 
(211) and more recently, a TGF-β independent differentiation of naïve murine T cells was 
demonstrated in the presence of IL-6, IL-1β1 and IL-23 (212).  
Production of IL-17 in humans is dependent on IL-23, IL-1, IL-1β, IL-6 and TGF-β. The combined 
activity of IL-1β and IL-23 (or IL-6) is critical in the development of Th17 cells (212, 213). In the 
absence of IL-1, IL-23 and IL-6 are unable to induce IL-17. It was demonstrated that human IL-17A-
producing cells originated from CD161+CD4+ T cell precursors from human umbilical cord blood 
(UBC) and post-natal thymus in the presence of both IL-1β and IL-23 but no other cytokine(s) 
including  TGF-β, IL-6 and IL-21 (214, 215). The CD161+CD4+ T cell expressed both IL-23R and RORC. 
IL-23 is required for optimum expansion and activation but not for the differentiation of naive Th17 
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cells (216-218). In vitro, IL-6 in conjunction with T cell antigen receptor activation induces the 
expression of IL-21 in naive CD4+ T cells, which together with TGF-β, independently of IL-6 can 
induce expression of IL-17 in mice and humans. In contrast, in vivo the absence of IL-21 signaling has 
little effect on Th17 cell differentiation (208, 219-221).  
In initial studies, differentiation of human Th17 cells was shown to be both, TGF-β-independent 
(222-225) or dependent (226-228). A few earlier reports even indicated that TGF-β actually inhibited 
Th17 cells (222, 223, 225, 229, 230). In T-bet and STAT6-deficient T cells, IL-6 alone, even in the 
absence of TGF-β can induce IL-17 production (231). Santarlasci et al. showed that addition of TGF-β 
to IL-1β and IL-23 increased the relative proportions of CD161+ T cells that differentiate into Th17 
cells by inhibiting T-bet expression and Th1 development (232). Ichiyama et al. demonstrated that 
TGF-β JNK c-Jun signaling strongly suppressed T Box factor Eomesodermim (Eomes) expression 
which directs T cell differentiation to Th1 cells and suppresses Th17 development (233). Taken 
together, all these findings suggest an indirect role of TGF-β in the regulation of Th17 by supressing 
Th1 and Th2 cell differentiation. It is yet unknown whether human Th17 cells also produce TGF-β. 
The cytokine environment at the time of differentiating Th17 cells determines the pathogenicity of 
cells (Fig. 1.5). Th17 cells can differentiate in the presence of IL-1β and IL-6 in combination with TGF-
β or alternatively in combination with IL-23 in the absence of TGF-β. The IL-23-differentiated Th17 
cells express T-bet, CXCR3, IL-18R1 in addition to IL-17 and could turn into IL-17/IFN- double 
producing cells. On the other hand, the TGF-β-differentiated Th17 cells express IL-17 along with AhR, 
CCL20, IL-9 and IL-10. The IL-23 differentiated but not the TGF-β differentiated Th17 cells therefore 
are pathogenic (234, 235). The former subset of Th17 cells often represent a mixed Th1- and Th17-
mediated pathology and seem more relevant in terms of autoimmune diseases. In contrast, the Th17 
cell population generated in environments with high TGF-β have limited pathogenic potentials but 
would be useful in host defence (236-238).  
Interestingly, in vitro TGF-β also induces differentiation of Tregs, cells having properties reciprocal to 
Th17 cells (239). At lower concentration, together with IL-6 or IL-21 and in the presence of IL-23, 
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TGF-β induces IL-23R and promotes Th17 differentiation and expansion. In contrast, at higher 
concentrations, TGF-β inhibits IL-23R, IL-22 and IL-17 expression and favours induction of FoxP3 and 
Treg differentiation.  
Th17 cells also produce IL-22. In vitro, IL-22 production was shown to be induced in both Th1 and 
Th17 conditions, but IL-6 and TGF-β inhibited rather than enhanced IL-22 production in Th17 
conditions (226, 240).  
 
 
 
 
 
 
 
 
 
Figure 1.5 Differentiation of pathogenic versus non-pathogenic Th17 cells. Depending on the 
microenvironment of diseases, naïve T cells can differentiate into either pathogenic or non-
pathogenic cells. The naïve T cells can differentiate in the presence of IL-1β and IL-6 in combination of 
TGF-β or alternatively with IL-23 in the absence of TGF-β. The T cells generated in the presence of 
TGF-β express IL-9 and IL-10 in addition to IL-17 and are therefore involved in host defense but have 
limited role in pathogenicity. In contrast, IL-23 generated Th17 cells express T-bet, CXCR3, IL-18R1 and 
IL-33 along with IL-17 and can turn into IL-17/IFN- cells. This subset ofTh17 cells are therefore 
pathogenic in nature. 
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1.3.2 Th17 transcriptional regulatory networks  
Like other Th lineages, differentiation of Th17 cells is regulated by a complex network of 
transcription factors which interact with each other at genetic and protein levels (Fig. 1.6). 
RORγt/STAT3 are the key master regulator and the signal transducer and activator of transcription 
(STAT) proteins that are required for the differentiation of Th17 cells. STAT3 activated by IL-6, IL-21 
and IL-23, in conjunction with TCR related transcription factors such as nuclear factor of activated T 
cells (NFAT) and B-cell activating transcription factor (BATF), induces the expression of RORt. Both 
RORγt and STAT3 bind to multiple sites in the Il17a/Il17f locus including the promoters of these 
cytokines. The transcription of Th17 is negatively regulated by STAT5, eomesodermin (Eomes), 
vitamin D receptor (VDR) and RA (retinoic acid). 
 
 
 
 
 
 
 
Figure 1.6 Th17 transcriptional regulatory network. IL-6, IL-21 and IL-23 activate STAT3, which in 
turn is required for the induction of RORt, the Th17 lineage marker. STAT3 is suppressed by 
STAT5. ROR, another ROR family member is also unregulated during Th17 differentiation. RUNX1 
and AhR synergise with RORt to enhance IL-17 expression while Fox p3, Eomes and RA suppress 
its activity. The expression of Fox p3 is enhanced by VDR and RA whereas RUNX1 is suppressed by 
both Foxp3 and VDR. Transcription factors IRF-4, cMaf, IkBζ, NFAT and BATF directly bind to il-17 
gene to increase the expression of IL-17.  
RORt,retinoic acid receptor-related orphan receptor gamma 2; ROR, retinoic acid receptor-
related orphan receptor alpha; STAT 3; signal transducer and activator of transcription 3; IRF-4, 
interferon-regulatory factor-4; RUNX 1, runt related transcription factor 1; NFAT, nuclear  factor for 
activated T cells; BATF, B cell activating factor; IκBζ, inhibitor kappa B zeta; AhR, aryl hydrocarbon 
receptor;  VDR, vitamin D receptor; RA, retinoic acid; Ets-1, erythroblastosis virus E26 oncogene  
homolog 1; Eomes, eomesoderm; gfi1, growth factor independent 1; NR2F6, nuclear receptor 
subfamily 2 group F member 6; IBP, IRF-4 binding protein. 
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1.3.2a Positive regulators of Th17 transcription 
il17a is a direct target gene for RORγt (241-245). Forced expression of RORγt is sufficient to induce 
IL-17 expression in the absence of any exogenous cytokines. RORγt-deficient mice develop less 
severe autoimmune diseases and lack Th17 cells in the inflammatory tissues (246, 247). Another ROR 
family member, ROR is also upregulated during in vitro Th17 cell differentiation (241). Although 
forced expression of ROR is sufficient to induce IL-17, ROR deficiency only selectively impairs IL-
17A but not IL-17F expression (241). Both RORγt activity and Th17 differentiation, are suppressed by 
Foxp3 (199, 239, 242, 248, 249).  
STAT3 plays an essential role in the differentiation of Th17 cells (208, 210, 250-253). It is activated by 
IL-6 and IL-23 and binds directly to il17a promoter (251), Il17 locus itself, Il21, and Il23r and CCR6 
(212, 254, 255). In addition, STAT3 binds to genes encoding transcription factors that are important 
for Th17 differentiation such as Rorc, Irf4, Batf and Nfibiz (254). STAT3 is required for induction of 
RORγt by cytokines and acts together with RORγt to induce maximal IL-17 expression (208).  
Runt related transcription factor 1 (RUNX1), a transcription factor upregulated during TCR 
stimulation, is also required for differentiation of Th17 cells (242, 256). Binding of RORγt and RUNX1 
together to the il17a locus leads to increased expression of IL-17. Foxp3 inhibits not only RORγt but 
also RUNX1 activity (242).  
Interferon-regulatory factor-4 (IRF-4), a transcription factor previously shown to be important for 
Th2 cell differentiation, is essential also for Th17 differentiation. IRF-4 regulates expression of IL-21 
and IL-23R. IRF-4 deficient T cells show impaired induction of RORγt and ROR and increased 
expression of Foxp3 (257, 258).  
Nuclear factor of activated T cells (NFAT) has been identified as a central regulator of T cell-mediated 
IL-17 gene transcription. Two crucial NFAT sites have been identified in the IL-17a but not in the IL-
17f proximal promoter. Inhibition of NFAT activation causes a defect in IL-17A transcription (259, 
260). 
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Activator protein-1 (AP-1 protein) transcription factor, B-cell activating transcription factor (BATF) 
also plays a critical role in Th17 differentiation. BATF binds conserved intergenic elements in the 
Il17a/Il17f locus and Il17, Il21 and Il22 promoters. Batf-/-T cells fail to induce RORt (246) and IL-21. 
Batf-/- mice have a defect in Th17 differentiation but a normal Th1 and Th2 differentiation. 
Th17 cells also express transcription factor proto-oncogene musculoaponeurotic fibrosarcoma 
oncogene homolog (c-Maf). Lack of c-Maf resulted in a defect in IL-21 production, IL-23R expression 
and fewer Th17 cells (261). 
Inhibitor kappa B zeta (IκBζ) encoded by the Nfkbiz gene, has recently been shown to be required for 
Th17 cell development (262). It may act by binding directly to the regulatory region of the IL-17 gene 
and synergising with RORγt or RORα. Nfkbiz-/- mice have a defect in Th17 development. 
Aryl hydrocarbon receptor (AhR) a cytosolic  transcription factor (263) is also involved in Th17 cell 
differentiation creating a link between environmental pollution and inflammation. AhR is required 
for IL-22 and, to lesser extent, IL-17 expression in Th17-polarizing conditions in the presence of 
either dioxin or FICZ (264). AhR co-operates with RORγt to induce maximal amounts of IL-17 and IL-
22 and inhibits TGF-β-induced expression of Foxp3.  
1.3.2b Negative regulators of Th17 transcription 
IL-2-induced STAT5 is known to inhibit Th17 differentiation potently (265). It displaces STAT3 by 
directly binding to essentially the same elements in promoter and enhancer on Il17 gene as STAT3. 
The balance of activation of STAT3 and STAT5 transcription factors, therefore determines the 
outcome fate of T cells. 
Eomesodermin (Eomes) substantially inhibits RORγt and IL-17A expression by directly binding to Rorc 
and Il17a promoters and also enhancing Ifng promoter activity (233). 
IRF-4 binding protein (IBP) sequesters IRF-4 to prevent it from targeting the transcriptional 
regulatory regions of il-17 and il-21genes (266). 
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The nuclear orphan receptor NR2F6 directly interferes with the transcriptional activity of the NFAT 
dependent IL-17A cytokine promoter (267). Growth factor independent 1 (Gfi1) inhibits RORγt 
activity (268). 
1,25(OH)2D3 via vitamin D receptor (VDR) transcriptionally represses IL-17A expression through 
multiple mechanisms which include blockage of NFAT, recruitment of histone deacetylase (HDAC), 
sequestration of Runx1 and a direct induction of Foxp3 (269).  
Retinoic acid inhibits Th17 differentiation by down regulating the expression of RORγt, and 
enhancing the expression of Foxp3 (270).  
Erythroblastosis virus E26 oncogene homolog 1 (Ets-1) is a negative regulator of Th17 differentiation 
(271). However, Ets-1 does not bind to the Il17 promoter. Ets-1-deficient T cells make less IL-2 and 
have impaired responsiveness in terms of IL-2- mediated inhibition of Th17 differentiation.  
 
1.3.2c Epigenetic control of IL-17 expression 
The possibility of an epigenetic regulation of IL-17 expression was raised by an initial observation 
that the promoters of Il17 and Il17F genes in Th17 cells, but not in Th1 or Th2 cells were histone H3 
acetylated and K4 trimethylated (272). Subsequently eight conserved non-coding sequences (CNS) in 
the Il17/Il17f gene locus were identified to be histone H3 acetylated. It was further shown that 
CNS2, the best studied CNS, could be induced by TGFβ and IL-6 and both RORα and RORγt could bind 
to the ROR response elements (RORE) sites in this region (241). In keeping in with these findings, 
more recently, RUNX1 factor was shown to cooperate with RORγt in activating this element (242). 
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1.3.3 Plasticity, instability and heterogeneity of Th17 cells 
Th17 cells are not terminally differentiated and can be readily converted to other Th effector 
lineages. It has been suggested that Th17 cells-derived Th17/Th1 or Th1 cells than rather Th17 
themselves play a pathogenic role in chronic inflammatory disorders (273, 274). 
 
1.3.3a Th17/Treg cells 
IL-17+ Foxp3+ T cells can be detected in vitro and in vivo in both mice and humans (275, 276). IL-
17+Foxp3+ T cells also express CD25 and RORγt (277). However, it is not known whether these IL-
17+Foxp3+ T cells originate from Th17 or Treg cells (278). Exposure of antigen activated naive CD4+ T 
cells to TGF-β results in transcriptional up regulation of both Foxp3 and RORγt. The double positive 
Foxp3+ RORγt+ T cells are probably a transient population that can differentiate into Treg or Th17 
cells. The balance of TGF- and IL-6 seems to determine the differentiation of Treg/Th17 cells (278-
280).  
The numbers of Treg and Th17 cells are inversely associated in autoimmune diseases suggesting a 
dynamic interaction between Treg and Th17 cells (281). Foxp3 expressing Tregs under appropriate 
conditions can express RORt and, develop capacity to secrete IL-17 or INF-γ (275, 278-280, 282-
284). IL-17-secreting Foxp3+ Tregs may either retain or lose their suppressive function. The 
conversion of human Foxp3+ Tregs into IL-17 producing cells is enhanced in the presence of IL-1 
alone or in combination with IL-23 or IL-6 (275, 285) or in the presence of IL-2, IL-21 and IL-6 (278). It 
is therefore plausible that reduced numbers of Foxp3 Tregs in patients with autoimmune diseases 
may occur due to enhanced conversion of these cells into IL-17 secreting cells in the context of an 
inflammatory environment.  
 
1.3.3b Th17/Th1 cells 
Recent evidence suggests that Th17 and Th1 cells might be phenotypically, developmentally and 
functionally linked in autoimmune diseases. Like Th1, polarized Th17 cells have the capacity to cause 
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autoimmune diseases although the disease induced by each cell type is distinct in terms of 
inflammatory infiltrate and preferential tissue location (213, 286-289).  
IFN+IL-17+ double positive T cells are detectable in both human and mouse inflamed tissues (213, 
290, 291). It is possible that IFN+IL-17+ T cells can develop from Th1 and/or Th17 cells (292).  
The Th1 signature cytokine, IFN-γ, can be expressed by primary Th17 cells in Th17-polarized mouse 
cells. Th17 cells after multiple rounds of culture in vitro begin to produce IFN- whereas after 
transfer in vivo, quickly acquire the ability to produce IFN- and lose their ability to produce IL-17 
(293, 294). In mouse models, under lymphopenic conditions, Th17 cells can re-differentiate into Th1 
cells (235). Using the IL-17A reporter mouse model, it was shown that during EAE, a substantial 
proportion of IFN-+T cells was derived from previous IL-17 producing cells (295).  
 
1.3.3c Th17/ Th2 cells 
A novel subset of effector T lymphocytes that co-express GATA3 and RORc and that produce both IL-
17A and IL-4 has recently been described in both mice and humans (296, 297). Th17/Th2 cells could 
be produced from either Th17 or Th2 cells. In the presence of an IL-4-rich microenvironment, Th17 
lymphocytes could switch toward the Th17/Th2 phenotype whereas, in vitro, classical mice Th2 
memory cells could be induced into Th17 cells in the presence of IL-1β, IL-6, and IL-21. 
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1.4 Targeting IL-17 for the treatment of RA  
IL-17 plays a direct role in the pathogenesis of RA (298). The expression of IL-17A, IL-17F, IL-17RA 
and IL-17RC is augmented in the rheumatoid joint and the levels of IL-17A and IL-17F increased in RA 
synovial fluid (SF) (299). Serum levels of IL-17 are significantly raised even before the onset of clinical 
RA (300, 301). IL-17A but not IFN- was transiently elevated in SF of RA patients having disease 
duration less than 3 months suggesting that IL-17 is an important T cell cytokine during early RA 
(302). The presence of IL-17 in early synovitis SF predicted development of RA and synovial IL-
17mRNA expression in early RA predicted progressive joint damage (301, 303).  
Development of a cytokine environment that favours Th17 cell generation is an early event in the 
pathogenesis of RA.  IL-17A is predominantly produced in rheumatoid joint by activated CD4+ T cells, 
though  other cells such as γδT cells, NKT cells, CD8+T cells, fibroblasts, cells in the subchondral lining 
and osteoblasts also produce IL-17 (304, 305). Heuber et al. reported unexpected finding of 
predominant production of IL-17A in inflamed RA synovial tissue by mast cells rather than Th17 cells 
(36). Th17 cells migrate to inflamed joints in response to CCL20 (306) and are activated and 
expanded via cell contact (307) and cytokines, IL-1β, IL-6, IL-21 and IL-23 (51, 308-312). 
The data now available supports the suggestion that Th17 cells play an important role in driving 
innate immune inflammation to chronic autoimmune inflammation in RA. Synovial hyperplasia, 
which occurs at the earliest stages of RA is characterised by the innate immunity cytokine complex 
of TNF-, IL-1β, IL-6, IL-8, IL-15, IL-18 and GM-CSF. The cross-talk between Th17 and RA synoviocytes 
results in reciprocal activation of both these cells. Th17 promotes uncontrolled growth and 
invasiveness of RA synoviocytes, which in turn promotes uncontrolled production of IL-6 and IL-15 
(313, 314). A persistent stimulation of T lymphocytes by IL-6, IL-15 and TNF- results in the down 
regulation of TCRζ and CD28 expression on synovial T cells (315-318), which in RA signifies transition 
from antigen-driven to cytokine-driven activation of T cells and conversion from regulatory to 
inflammatory cytokine production.  
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IL-17 directly supports both the chronic inflammatory and destructive phase of RA. IL-17 acts as an 
important effector of chronic synovial inflammation by inducing secretion of other mediators of 
inflammation, growth factors, adhesion molecules and matrix degrading enzymes (106, 107, 306, 
319-322). In vitro, IL-17 inhibits both proteoglycan and collagen synthesis, and promotes cartilage 
destruction (323). IL-17, by increasing the expression of receptor activator of NF-B ligand (RANKL) 
and inhibiting osteoprotegerin supports downstream bone destruction (323-328). The 
proinflammatory and tissue destructive actions of IL-17 are synergistic to TNF- and IL-1β (115). 
Exogenous administration of IL-17 exacerbates the onset and severity of experimental arthritis, 
whereas its neutralisation suppresses disease (327, 329-332). T cells from IL-17 deficient mice 
showed decreased sensitization to collagen and reduced levels of anti-collagen II antibodies 
indicating modulation of both cellular and humoral immunity in CIA by IL-17. Inhibition of IL-17 both 
before and after the onset of arthritis resulted in suppression of synovial inflammation implying that 
IL-17 contributes to the initiation as well as the effector phase of arthritis (331, 333). Mice deficient 
in inducible costimulator (ICOS), which is associated with reduced production of IL-17A but a normal 
Th1 response, were protected against CIA (334). Vaccinating mice with an IL-17-conjugated virus-like 
particle resulted in high levels of anti-IL-17 antibodies and a lower incidence and severity of CIA 
(335). Local overexpression of IL-17 enhanced inflammation and erosions in streptococcal cell wall-
induced arthritis in both normal and IL-1β-deficient mice, supporting an IL-1-independent role of IL-
17 (332). Ex vivo blockage of IL-17A in synergy with TNF- and IL-1β was more effective in controlling 
synovial inflammation and bone resorption (116). A study in TNF--deficient mice demonstrated 
that although TNF- is required in IL-17-induced joint pathology under naive conditions (336), TNF- 
dependency of IL-17 is lost under arthritic conditions (336). Notley et al. first reported an 
unexpected finding of increased number of pathogenic Th1 and Th17 cells in lymph nodes of CIA 
mice after TNF blockade despite diminished accumulation of Th1/Th17 cells in the joint (337). In 
keeping with results in murine arthritis, Bose et al. showed enhanced expression of activation 
markers and proliferative response to TCR stimulation of peripheral blood CD4+ T cells from patients 
66 
 
of psoriasis and IBD, which occurred concurrently with down regulation of Th7/Th1 cytokines and 
inflammatory genes in tissue biopsies (338). Moreover, the peripheral CD4+ T cells hyperactivity in 
these patients did not interfere with responsiveness to anti-TNF therapy. 
Phase I/II trials of treatment with anti-IL-17 antibodies have reported beneficial therapeutic effects 
with no notable side-effects (339-341). 
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1.5 Targeted therapies 
Inhibition of TNF by either monoclonal antibodies or receptor fusion protein in RA has demonstrated 
outstanding efficacy but unwanted systemic side effects due to the pleiotropic activities of cytokines 
still remain an issue. These limitations could be overcome by the use of therapies that can target 
their therapeutic effects to the active disease sites. Immunocytokines and latent cytokines are 
examples of targeted therapies that have been developed with the aim of localising therapeutic 
cytokines in this way. 
1.5.1 Immunocytokines 
An immunocytokine consist of an antigen-specific monoclonal antibody (mAb) and a cytokine, fused 
into a single molecule in a way that the independent functions of antibody and cytokines are not 
disturbed. The targeting properties of an immunocytokine mAb enables directing the cytokine to the 
specific pathology site in order to achieve an effective local concentration in the desired 
microenvironment, thus minimising the risk of toxicity that could result from the systemic 
administration of the cytokine. In addition, the large size and inherent stability of the mAb in the 
complex increases the half-life of the cytokine. 
During the past years, several immunocytokines have been developed including mAbs fused to 
cytokines such as TNF-α, IL-2 and GM-CSF (342-345). Amongst these, Ab-IL-2 fusion proteins are the 
best characterised. The Ab-IL-2 uses the mAb component to recognize and bind to the tumour, 
whereas the IL-2 portion activates cells expressing IL-2 receptors, such as CD8+T cells and NK cells, 
inducing the destruction of the tumour cell (346, 347). Dario Nari’s group has reported therapeutic 
efficacy of IL-10 conjugated to the specific components of extracellular matrix in CIA mice. IL-10 
when fused to L19, a monoclonal antibody against tenascin C, a specific marker for angiogenesis or 
F8, a monoclonal antibody to extracellular domain A of fibronectin was effective in inhibiting 
progression of arthritis in established CIA (348, 349). Hughes et al. in our laboratory have 
demonstrated that anti-ROS modified CII scFv fused to soluble murine TNF receptor II-Fc fusion 
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protein (mTNFRII-Fc) resulted in significantly reduced inflammation in CIA mice as compared to 
mTNFRII-Fc alone or mTNFRII-Fc fused to an irrelevant scFv (350). 
 
1.5.2 Latent cytokine  
TGF-β, unlike most cytokines is secreted as latent cytokine. TGF-β is produced with an N-terminal 
region, termed latency associated peptide (LAP). Following disulfide bonding, the LAP serves as a 
shell that protects C-terminal region, which is the active TGF-β cytokine (351). The non-covalently 
bound active TGF-β is released from this structure by several mechanisms, including the proteolytic 
cleavage of LAP, changes in pH or heat (352). For the purpose of targeted therapy, a cytokine can be 
modified as latent cytokine (Fig. 1.11) by covalently binding the cytokine to the LAP of TGF-β via a 
MMP sensitive linker (353). This allows formation of a protective shell of LAP around the cytokine, 
which in turn prevents the interaction of the cytokine with its receptor. The biological activity of a 
LAP cytokine nonetheless can be released by MMP, which free ups the biologically active cytokine by 
cleaving the MMP-sensitive linker. Due to the overexpression and localised abundance of MMPs 
within actively inflamed tissues, therapeutic effects of a LAP-cytokine can be targeted to the actual 
disease sites. Using this approach, LAP- IFN-β was the first cytokine that was modified as a latent 
cytokine in our laboratory. In vitro LAP- IFN-β did not bind to its cellular receptors and in vivo the 
half-life of LAP-IFN-β was 37-times higher and therapeutic efficacy in CIA mice superior to naïve IFN-
β (354). Additional therapeutic agents that were made latent include short anti-inflammatory 
peptides such as - and -MSH and vasoactive intestinal peptide (VIP) (355). 
Latent cytokines can be used in a number of disease conditions in which tissue modelling takes place 
such as infection, cancer (356), atherosclerosis (357) and autoimmune diseases (358-361). In 
addition, the cleavable MMP site can be tailored to be sensitive to the MMPs that are expressed 
predominantly in certain pathological conditions. Furthermore, certain cytokines with important 
biological functions but high toxicity in clinical trials could be made latent to ensure local action and 
increase their safety and therapeutic index. 
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Figure 1.7 Structure of a latent cytokine. A cytokine can be modified as latent cytokine by fusing it 
with the LAP of TGF-β via a MMP-sensitive linker. The LAP forms a protective shell around the 
cytokine, which prevents the interaction of the cytokine with its receptors and in turn converts it 
latent. The biological activity of a latent cytokine can be released by cleavage of the MMP-sensitive 
linker by MMP and due to the localised overexpression and abundance of MMPs, targeted to the site 
of active inflammatory pathology. LAP, latency-associated peptide; TGF-β, transforming growth 
factor-β; MMP, matrix metalloproteinase. Adams G et al. Nature Biotechnology 2003; 21:1314-1320. 
 
 
 
 
 
 
 
70 
 
1.6 Preclinical in vivo testing of new therapies for RA 
Preclinical in vivo testing of a newly devised therapy is an essential pre-requisite to its safe use in 
humans. This often involves production of a given therapeutic in large quantities, sufficient to allow 
multiple administrations to achieve an optimum therapeutic level. In vitro expression and 
purification of large quantities of recombinant therapeutic protein is costly, time consuming and 
technically difficult especially in the setting of non-industrial research laboratories. These limitations 
of protein-based therapy can be avoided by administering a given therapeutic in animals under 
study via in vivo gene therapy. Gene-based therapy precludes the need for in vitro purification of an 
investigational therapeutic by allowing its spontaneous in vivo expression. Gene therapy, because of 
its relative ease and low cost can be readily undertaken in research laboratories; thus providing a 
convenient alternative to protein based drug delivery to establish proof of principle for in vivo 
efficacy of new therapeutic strategies. 
1.6.1 Gene therapy as a modality for preclinical testing of new therapies 
Gene therapy is defined as transfer of new genetic material to the cells of a living organism for 
therapeutic purposes. Historically, human gene therapy was mainly focused on the treatment of 
monogenic diseases with the aim of replacing the defective gene and restoring its functions but in 
fact has much broader applications. For example, a novel therapeutic can be administered in animal 
models using gene therapy to assess its preclinical in vivo efficacy (Fig. 1.8). A solitary intravenous 
hydrodynamic delivery of plasmid DNA results in transgene expression that is sustained over weeks. 
The delivery and expression of a new gene into target cells can be facilitated by using either viral or 
non-viral vectors. Viral vectors due to their natural ability to enter and integrate their genetic 
material into target cells offer an excellent efficiency of gene delivery and expression but are difficult 
to produce and may impose the risk of immunogenicity and insertional mutagenesis. In contrast, 
non-viral vectors are generally safe and easy to produce but the efficiency of gene transfer is 
relatively weak.  
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1.6.1a Viral vectors 
Retrovirus, adenovirus and adeno-associated viruses (AAV) are the most widely used vectors for 
gene therapy applications. Other viruses including pox virus, herpes simplex virus and vaccinia virus 
have also been investigated. 
Retroviruses 
Retroviruses are small, enveloped, single stranded RNA viruses with genome capacity of 7-12kb. The 
retroviruses integrate their DNA into regions of host euchromatin, which provides stable long-term 
expression of the transgene in the host cell and descendent cells. The use of retroviruses is restricted 
to mitotic tissues as they cannot infect quiescent cells. The major limitation of retroviruses is the 
accompanied risk of insertional mutagenesis.  
Adenoviruses 
Adenoviruses are non-enveloped double stranded linear DNA viruses with a natural tropism for 
upper respiratory tract and ocular tissue. They can deliver up to an 8 kb cargo. The cargo delivered 
can be maintained as an episome which may remain transcriptionally active for the life of host cell. 
Adenoviruses are however highly immunogenic and many people have a pre-existing immune 
memory that affects its efficacy.  
Adeno-associated virus 
AAV is a non-pathogenic single stranded DNA virus with a genome of about 4.7kb. Like adenoviruses, 
they can infect dividing or quiescent cells. Many serotypes are available and they are used actively in 
clinical research including in RA. In a phase I/II clinical trial, patients treated with intra-articular 
injection of recombinant AAV containing TNFR-Fc gene reported greater improvement in target joint 
global visual analogue score at 12 weeks than placebo-treated group. The AAV delivered treatment 
resulted in site reaction in 12% patients and fatal disseminated histoplasmosis in one patient, that 
was thought to be unrelated to the study agent (362). 
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1.6.1b Non-viral methods  
Gene constructs if injected directly as naked DNA into skeletal muscles are expressed only at low 
levels.  Physical or chemical methods are usually required to enhance cellular uptake of naked DNA. 
Physical methods that facilitate the transfer of genes from extracellular to nucleus by creating 
transient membrane holes/defects using physical forces include local or rapid systemic injection, 
particle impact, electric pulse, ultrasound and laser irradiation. Chemical vectors such as cationic 
lipids or polymers form condensed complexes with negatively charged DNA (363), which in turn 
protect DNA and facilitate cell uptake and intracellular delivery.  
Hydrodynamic gene transfer 
The method of hydrodynamic gene transfer employs a high pressure as the driving force for the 
transfer of a gene. Intravenous  injection of a large volume, 8-12% of body weight in short time (3-5 
seconds) leads to a reversible permeability change in the endothelial lining and the generation of 
transient pores in hepatocyte membranes allowing the DNA molecules to diffuse internally (364). 
This is the most efficient non-viral gene transfer method in rodents. Hydrodynamic delivery has been 
used successfully in monkeys by delivery into skeletal muscle by temporarily blocking the limb 
circulation with a tourniquet (365). 
Electroporation 
Electroporation involves use of electric pulses which generate transient pores in cell membranes 
followed by intracellular electrophoretic DNA movement. Typically, in vivo electroporation is 
conducted by first injecting DNA to the target tissue followed by electric pulses, with varied voltage, 
pulse duration, and number of cycles, applied from two electrodes. In vivo electroporation 
technique is generally safe, efficient, and can produce good reproducibility and efficiency (366). 
Sonoporation 
Sonoporation uses ultrasound waves to create plasma membrane defects by acoustic cavitation. 
Most gene delivery techniques use ultrasound at frequency of 1-3MHz with intensity of 0.5-
2.5W/cm2 (367). Ultrasound may be combined with contrast agents or microbubbles (368) to 
73 
 
facilitate release of local shock waves that can disrupt the nearby cell membranes and promote 
transient pore formation to enhance local DNA transfer.  
Cationic lipids 
Cationic liposome-mediated gene transfer or lipofection is the most extensively investigated and 
commonly used non-viral gene delivery method. The various lipids used share the common structure 
of positively charged hydrophilic head and hydrophobic tail that are connected via a linker structure. 
The positively charged head binds with the negatively charged phosphate of DNA. The positively 
charged lipids surround the DNA and grant them protection against extra and intracellular nucleases. 
In addition, liposomes interact with negatively charged molecules of the cell membrane and 
facilitate their cellular uptake. The cationic lipids are inexpensive to produce and can be engineered 
to have targeted specificity but have drawbacks of short circulation half-life and acute toxicity.  
Cationic polymers 
Cationic polymers upon mixing with DNA form nanosized complexes called polyplexes. Amongst 
cationic polymers, polyethylenimine (PEI) is considered most effective. Upon systemic 
administration these polyplexes of small particle size aggregate to form larger complexes and 
accumulate in major tissues including lung and liver. Cationic polyplexes are more stable than 
lipoplexes but the level of cytokine induction is inferior to  the latter (369).  
Inorganic nanoparticles 
Inorganic nanoparticles are usually prepared from metals (e.g. iron, gold, silver), inorganic salts, or 
ceramics (370). The small particle size has advantage of bypassing most of the physiological and  
cellular barriers and produce higher gene expression (371). They can also be transported through the 
cellular membranes via specific membrane receptor nucleolin which delivers nanoparticles directly 
to the nucleus, skipping the endosomal-lysosomal degradation (372, 373). Nanoparticles have ability 
to efficiently transfect post-mitotic cells in vivo and in vitro, have low or no toxicity and are inert to 
immune responses.  
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Figure 1.8 Gene therapy as a modality for preclinical in vivo testing of new therapies. Gene-based 
therapy is an expedient alternative to protein-based therapy for preclinical in vivo testing of new 
therapies. The procedure of gene-based therapy is fast, easy and is feasible in the setting of research 
laboratories. As against, protein-based therapy involves in vitro expression and purification of large 
quantities of recombinant therapeutic protein, a procedure which is technically difficult, time 
consuming and exceedingly expensive. 
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1.6.2 Mouse models of experimental arthritis 
Animal models of experimental arthritis have been instrumental in studying the RA aetiology, 
pathophysiology and developing new therapeutic strategies. Induction of chronic inflammatory 
arthritis in susceptible inbred strains permits in vivo study under reproducible controlled conditions. 
Inflammatory arthritis in animals is stimulated by either overexpression or deletion of target gene, 
immunisation with putative autoantigens or synthetic chemical challenges. Although the animal 
models share features with human RA, none reflects all the characteristic articular, systemic, 
immunological and genetic features of the human disease. A preferential selection of an appropriate 
animal model that represents the expected outcome in the human clinical situation therefore is 
extremely important.  
Rodent models have been extensively used in RA research. Some of the commonly used mouse 
models of experimental arthritis and outcome of their responsiveness to IL-17 inhibition are 
described below.  
 
1.6.2a Collagen induced arthritis mice 
Collagen induced arthritis (CIA) is characterised by an autoimmune response-mediated synovitis and 
cartilage and bone erosion, which closely resemble RA making it the most widely used animal model 
for RA research. 
Mice with H-2q and H-2r major histocompatibility complex (MHC) class II haplotype, when 
immunized with homologous or heterologous native collagen II (CII) develop arthritis (374-377). 
Both cellular and humoral immunity to CII are necessary for the full development of arthritis in this 
model (377). An injection of anti-CII antibodies  also induces arthritis (378). The development of CIA 
critically depends on IL-1 (379) and IL-6 (380). While IL-17A (329), TNF (381, 382) and IL-23 are also 
involved, IFN-γ and IL-4 are involved only marginally. Il23-/-mice but not Il12a-/-mice are resistant to 
disease (383). 
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Il17a-/-mice exhibit a significant reduction in the sensitization of T cells following immunization with 
CII (329). Because both the incidence and the severity score was reduced in Il17a-/-mice with CIA, IL-
17 is thought to function at the sensitization as well as the elicitation phase of the arthritis. 
 
1.6.2b Anti-collagen II antibody-induced arthritis mice 
Anti-CII Ab-induced arthritis is produced by a mixture of monoclonal anti-CII abs, injected 
intravenously followed by intraperitoneal injection of LPS. Arthritis is induced within a few days and 
persists for 2 weeks in BALB/c mice (384, 385). The anti-CII Ab arthritis can also be induced in 
scid/scid mice (386) indicating that both T cells and B cells are not necessary for this disease model. 
Il17a-/- (379) and Il6-/-mice (386) develop full arthritis in this model but development of arthritis is 
completely suppressed in tnfr-/-mice (386) and significantly suppressed in Il1ra-/-mice (386).  
 
1.6.2c Human T cell-leukemia virus type I transgenic mice 
Transgenic mice carrying HTLV-1 tax gene with its own LTR promoter (HTLV-I Tg mice) develop 
chronic inflammatory polyarthropathy resembling RA (387-389).The expression of IL-1β, IL-2, IL-6, 
TNF-, IFN-γ, and IL-17A is upregulated in transgenic joints (390) and the development of arthritis is 
greatly suppressed in Il-17a-/-, Il-1/β-/- , Il-6-/-mice. 
 
1.6.2d IL-1 receptor antagonist deficient mice 
IL-1Ra-deficient, Il1ra-/- mice develop chronic inflammatory arthropathy (391). The expression of IL-
1, IL-17A, IL-6 and TNF- is augmented in these mice (391, 392). The development of arthritis in 
Il1ra-/-mice however was completely suppressed in Il17a-/-Il1ra-/-mice until 16 weeks of age  
while, more than 80% of Il17a+/+Il1ra-/- mice develop arthritis at 10 weeks of age (393). Deficiency 
of TNF- but not IL-6 led to the suppression of arthritis in these mice (379, 392). 
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1.6.2e SKG mice 
These mice, derived from BALB/c background have a mutation in -associated protein of 70 kDa 
(ZAP70) (394) and develop autoimmunity and arthritis spontaneously (395). The development of 
arthritis in SKG mice is completely suppressed by IL-17A or IL-6 deficiency and significantly by IL-1 or 
TNF- deficiency (306, 396, 397). 
 
1.6.2f TNF transgenic mice 
Transgenic mice carrying a modified human TNF gene under its own promoter and-globin 3’ end, 
produces a stable TNF mRNA, develop arthritis characterized by subchondral erosions within 4 
weeks of age (398). This arthritis develops in a rag1-/-background, which is suggestive of an innate 
and /or stromal rather than an autoimmune mechanism (399). In this model IL-6 deficiency does not 
affect the development of arthritis (380) but inhibition of IL-1RI (400) or TNFRI deficiency (399) 
completely suppresses arthritis development. Role of IL-17 in this animal model has not been 
determined. 
 
1.6.2g K/BxN mice 
K/BxN mice carry a TCR transgene, which is specific for the bovine RNase and also recognizes the 
MHC class II molecule A(g7) encoded on nucleotide oligomerization domain (NOD) (401). The 
development of spontaneous arthritis in this model depends on both T cells and B cells (402) and is 
mediated via antibodies to glucose-6-phosphate isomerase (anti-GPI) (403). Anti-GPI antibody 
containing immune complexes activate the C5a complement pathway in mast cells to induce 
secretion of inflammatory cytokines (404, 405). Mast-cell derived IL-1 (405), also TNF but not IL-6 is 
involved in the development of arthritis in this model (406). Neutralising IL-17A signaling did not 
affect this model of arthritis (407). 
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1.6.2h RA/severe combined immunodeficient mice 
Severe combined immunodeficient (SCID) mice are deficient in both T and B cell function and widely 
used as a host for the transplantation of various human tissues since their impaired T and B cell 
function prevents them from rejecting grafts. Transplantation of RA synovium into SCID mice 
enables targeting the human RA tissue directly, thereby providing an important step between 
standard animal models of experimental arthritis and clinical trials. 
This humanised arthritis model is used in two variants, each with its own advantages and limitations. 
In the RA synovial fibroblast (RASF) model, RASF are co-implanted with pieces of cartilage into SCID 
mice to study the capacity of the RASF to degrade matrix and invade the cartilage (408, 409). The RA 
synovium/SCID mouse model on the other hand involves transplantation of standardized pieces of 
RA synovial tissue subcutaneously on the back or under the renal capsule of SCID mice (410, 411). As 
this model uses the whole RA synovial tissue including various immune cells, it provides an excellent 
opportunity to investigate multiple cell types within the inflamed synovium and to test new 
therapies. For example, depletion of human T cells and B cells from the RA synovial grafts confirmed 
a crucial role for these cells in RA (412, 413) and MTX and anti-TNF treatment in the RA /SCID mouse 
model resulted in a decrease in the inflammatory cells in the graft (414, 415). 
Koenders et al. have recently confirmed the validity of the RA synovium /SCID mouse model by 
examining the effects of commonly prescribed therapies for RA including IL-1 and TNF antagonists, 
CTLA4-Ig, and anti-CD20 and anti-IL-17 antibodies (416).  
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1.7 Summary and objectives 
IL-17A plays a direct role in the pathogenesis of RA. Exogenous administration of IL-17A exacerbates 
whereas its neutralisation ameliorates experimental arthritis. Phase I/II clinical studies of inhibition 
of IL-17 have reported significant improvement in arthritis without notable side effects.  
(H161R) IL-17F mutant is a competitive inhibitor of wild-type IL-17F. In a Japanese population, 
homozygotes of (H161R) IL-17F mutant were protected from asthma. IL-17F shares structural, 
receptor binding and biological properties with IL-17A but is 30-100% less potent, which is 
suggestive of an additional inhibition of IL-17A by IL-17F mutant. 
Biological activities of cytokine-based therapies can be targeted to the site of active inflammation by 
modifying a given cytokine as LAP-MMP-cytokine fusion protein.  
 
Hypotheses 
1. Human (H161R) IL-17F mutant is an antagonist of IL-17A. 
2. (H161R) IL-17F mutant, due to its ability to suppress both IL-17A and IL-17F will be a 
powerful suppressor of IL-17-induced inflammation in RA. 
3. (H161R) IL-17F mutant if modified as LAP-IL-17F mutant would be a highly efficacious 
targeted therapy for RA. 
 
Aims 
1. To confirm that human (H161R) IL-17F mutant is an inhibitor of IL-17A. 
2. To construct mouse analogues of human (H161R) IL-17F mutant and characterise their in 
vitro biological properties. 
3. To test preclinical in vivo therapeutic efficacy of mouse LAP-IL-17F mutant in CIA mice or 
human LAP-IL-17F mutant in RA synovium/SCID mice model of RA. 
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MATERIAL AND METHODS 
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2.1 Cloning and expression of IL-17 
2.1.1 Harvesting cDNA from mouse splenocytes 
2.1.1a Harvesting T cells from mouse spleen 
Spleen dissected from NIH Swiss mouse (kindly provided by Dr D. Gould, BJRU) was transported in 20 
ml ice-cold complete RPMI medium supplemented with 10% FBS (Invitrogen, Paisley, UK), 2mM L-
glutamine and Penicillin (100 units/ml)/Streptomycin (100μg/ml) (Cambrex, Wockingham, UK); cut, 
mashed and filtered through 70m BD Falcon cell strainer, washed twice with 50 ml complete RPMI 
medium and centrifuged at 500rpm (Eppendorf centrifuge 5810R, Hamburg, Germany) for 5 minutes 
at 4C. The RBCs were lysed by adding 1ml RBC lysis buffer (0.15M ammonium chloride in 0.01M Tris 
HCl buffer, pH 7.50), re-filtered through 70 m BD Falcon cell strainer and washed twice with RPMI. 
The cell count was performed using haemocytometer. T lymphocytes were activated by incubating 
the cells with 3 g/ml Concanavalin A (Con A) in 10ml RPMI in 9cm culture plate at 37C in 10% CO2 
for 6 hours. The working-surface was cleaned with RNase free water and the plate was transferred 
on ice; medium aspirated in pre-cooled Eppendorf tubes. 500 l pre-cooled PBS was added to the 
adherent cells, the cells were scraped using a scraper and added to collected supernatant, 
centrifuged at 1200rpm for 5 minutes at 4C. The pellet was re-washed with 500l cold PBS and 
stored at -80C.  
2.1.1b RNA extraction  
RNA was extracted in a sterile environment using Ambion RNAqueous-4PCR kit. The harvested 
mouse spleen cells were treated with 200l lysis/binding solution per 106 cells and vortexed. The cell 
lysate was clarified by centrifugation, mixed with an equal volume of 64% ethanol and RNA was 
extracted as per the manufacturer’s instructions. In brief, the lysate/ethanol mixture was transferred 
to the filter cartridge, washed twice and RNA was eluted using elution buffer (pre-heated at 70-80C 
for 30 minutes). For the removal of DNA, 1l 10X DNase buffer and 0.1l DNase 1 was added to each 
9l RNA and incubated for 30 minutes at 37C. Finally 1l DNase inactivation solution added and the 
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extracted RNA stored at -80C. The extracted total RNA was analysed on 1% agarose gel to confirm 
the presence of expected ribosomal RNA bands of 28S and 18S. 
2.1.1c Reverse transcription with oligo dT primers  
The RNA extracted from mouse spleen was heated at 65C for 5 minutes and transferred on ice 
immediately. The reaction mixture containing 10X RT buffer (200mM Tris HCl, pH 8.4, 500mM KCL, 
Gibco BRL), 4l 25mM MgCl2, 1l 10mM dNTP, 1l oligo dT, 2l 0.1M DTT, RNase-free water, 0.5l 
Moloney murine leukemia virus (M-MLV) reverse transcriptase (200units/l, Promega, Madison, 
USA), 1l RNase inhibitor and RNA in a total volume of 20l was incubated  at 42C for 60 minutes, 
99C for 5 minutes and 4C for 5 minutes in a Peltier Technology Thermal cycler (PTC-200, MJ 
Research Inc., Waltham, MA). The reverse transcribed product containing single-stranded 
complementary DNA was stored at -20C. 
 
2.1.2 Cloning of human and mouse full-length IL-17 
All primers were ordered from Sigma-Aldrich Inc. (Haverhill, UK). All DNA restriction and modifying 
enzymes were purchased from New England Biolabs Inc. (Hitchin, UK). 
2.1.2a Cloning of human and mouse wild-type full-length IL-17 
Human full-length IL-17A (hFL-IL-17A) and IL-17F (hFL-IL-17F) were PCR-amplified using cDNA 
derived from RT-PCR of CD14- human peripheral blood lymphocytes (PBL) as template (kindly 
provided by Dr. N Yousaf, BJRU). Mouse full-length IL-17A (mFL-IL-17A) and IL-17F (mFL-IL-17F) were 
PCR-amplified using NIH Swiss mouse splenocyte cDNA (refer Section 2.1.1) as template employing 
the protocol described below (Section 2.2.1). The forward and reverse primers are listed in the Table 
2.1. Hot-start PCR (Section 2.2.2) was used to amplify mFL-IL-17A. Due to the presence of an 
additional band, the mFL-IL-17F was gel-purified using PureLink Quick Gel Extraction kit. As shown 
in the Fig. 2.1, the PCR products were digested with BamH1 and Xba1, and cloned in the 
corresponding sites of the plasmid expression vector pcDNA3 (Invitrogen).  
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Table 2.1 List of primers used for cloning of human and mouse full-length and LAP- IL-17 constructs 
Oligo primer name Sequence 5’-3’ 
hFL-IL-17A forward  5’CCGGATCCATGACTCCTGGGAAGACCTCA3’ 
hLAP-IL-17A forward 5’CGCGGCCGCAGGAATCACAATCCCACGAAT3’ 
hIL-17A reverse 5’GGTCTAGATTAGGCCACATGGTGGACAATCGG3’ 
hFL-IL-17F forward 5’CCGGATCCATGACAGTGAAGACCCTGCAT3’ 
hLAP-IL-17F forward 5’CGCGGCCGCAAAAATCCCCAAAGTAGGAACA3’ 
hIL-17F reverse 5’GGTCTAGATTACTGCACATGGTGGATGACAGG3’ 
hIL-17Fmutant oligo forward 5’CCCCTGTCATCCACCGTGTGCAGTAAT3’ 
hIL-17Fmutant oligo reverse 5’CTAGATTACTGCACACGGTGGATGACA3’ 
hLAP-IL-17Fmutant forward 5’CGC /G GCCGCA AAA ATC CCCAAAGTAGGAACA3’ 
mFL-IL-17A forward 5’CCGGATCCATGAGTCCAGGGAGAGCTTCA3’ 
mLAP-IL-17A forward 5’CGCGGCCGCAGCAGCGATCATCCCTCCAAGC3’ 
mIL-17A reverse 5’GGTCTAGAT TTAGGCTGCCTGGCGGACAATCGA 
mFL-IL-17F forward 5’CCGGATCCATGAAGTGCACCCGTGAACA3’ 
mLAP-IL-17F forward 5’CGCGGCCGCACGGAAGAACCCCAAAGCAGGG3’ 
mIL-17F reverse 5’GGTCTAGATTCAGGCCGCTTGGTGGACAATGGG3’ 
mFL-IL-17Fmutants forward 5’CCGGATCCATGAAGTGCACCCGTGAAACA3’ 
mLAP-IL-17Fmutants forward 5’GCCGCACGCCGGAAGAACCCCAAAGCAGGG3’ 
mIL-17F-mutant 1 reverse 5’GGTCTAGATTCAGGCCGCTCGGTGGACATGGG3’ 
mIL-17F-mutant 2 reverse 5’GGTCTAGATTCAGGCCGCTTGGCGGACAATGGG 
mIL-17F-mutant 3 reverse 5’GGTCTAGATTCAGGCCGCTTGGTGTCAAATGGGCTTGACACA 
 
The nucelotides marked in red represent the nucleotides that have been substituted in the wild-type 
IL-17F to create the desired mutations.  
 
 
 
 
84 
 
 
 
 
 
 
 
 
 
2.1.2b Cloning of human full-length (H161R) IL-17F mutant  
Annealing complementary oligonucleotides 
Previously PCR-amplified hFL-IL-17F fragment (Section 2.1.2a) was digested at BamH1 and BSPM1 
sites and gel-purified using PureLink Quick Gel Extraction kit. Complementary strands of 
oligonucleotides (Sigma-Aldrich, UK) were custom-ordered and annealed, which contained the 
desired mutation with codon sequence 5’CCCCTGTCATCCACCGTGTGCAGTAAT3’ and anti-codon 
sequence 5’CTAGATTACTGCACACGGTGGATGACA3’) along with BSPM1/Xba1 digestion sites. As 
shown in the Fig. 2.2, human FL-IL-17F mutant construct was developed by cloning together 
BamH1/BSPM1-digested FL-IL-17F fragment and annealed complementary oligonucleotides in 
pcDNA3 (Invitrogen) at the BamH1/Xba1 sites. 
 
Figure 2.1 Cloning of full-length IL-17 in pcDNA3. Human and mouse full-length IL-17A and IL-17F 
were constructed by cloning BamH1 and Xba1 digested  full-length IL-17 in the corresponding sites 
of plasmid expression vector pcDNA3.  
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Figure 2.2 Construction of human full-length (H161R) IL-17F mutant. (H161R) IL-17F mutation was 
created by substituting nucleotide A at position 485 (counted from signal peptide) in full-length IL-
17F by G. Previously amplified-type FL-IL-17F (section 2.1.2a) was digested at BSPM and Xba1 sites 
and the deleted C-terminal end was replaced by annealed complementary oligonucleotides 
containing the desired point mutation. FL-IL-17F mutant was then cloned in pcDNA3 at BamH1 and 
Xba1 sites. 
 
 
 
2.1.2c Cloning of mouse analogues of human (H161R) IL-17F mutant  
Human and mouse IL-17F sequences are 77% identical. The (H161R) mutation in human IL-17F is 
located at the extreme C- terminal end. The amino acid sequence at the C-terminal end in human IL-
17F includes HHVQ. In case of the (H161R) mutation, the third last Histidine in human IL-17F is 
replaced by Arginine. In comparison, the mouse IL-17F is 3 amino acids shorter and contains HQAA 
at the C-terminal end (Fig. 2.3). Based on these observations, three mouse analogues of human IL-
17F mutants were created as follows: 
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Mouse full-length (Q158R) IL-17F mutant (mFL-IL-17F mutant 1)  
The mouse IL-17F mutant 1 consisted of Arginine substitution of Glutamine at amino acid position 
158 in wild-type mouse IL-17F. Previously amplified mFL-IL-17F (Section 2.1.2a) was used as 
template and hot PCR-amplified using the forward and the reverse primers listed in Table 1. The PCR 
product was digested with BamH1/Xba1 and cloned in the corresponding sites of the expression 
vector pcDNA3 (Invitrogen).  
Mouse full-length (H157R) IL-17F mutant (mFL-IL-17F mutant 2) 
Mouse mutant 2 was developed by substituting Histidine at amino acid 157 by Arginine. Previously 
amplified mFL-IL-17F (Section 2.1.2a) was used as template and hot PCR-amplified using the forward 
and the reverse primers listed in table 1. The PCR product was digested at BamH1/Xba1 and cloned 
in the corresponding sites of pcDNA3 (Invitrogen).  
Mouse full-length truncated IL-17F mutant (mFL-IL-17F mutant 3) 
Mouse IL-17F mutant was developed by substituting Valine at amino acid 156 in wild-type IL-17F by 
stop codon in order to delete the last four amino acids. Previously amplified mFL-IL-17F (section 
2.1.2a) was used as template and hot PCR-amplified using the forward and the reverse primers listed 
in table 1. The PCR product was digested at BamH1/Xba1 sites and cloned in the corresponding sites 
of pcDNA3 (Invitrogen).  
 
 
Figure 2.3 C-terminal sequences of human and mouse IL-17F. Comparison of mouse IL-17F and 
human IL-17F sequences showed that mouse IL-17F was 3 amino acids shorter and the third last 
amino acid in mouse IL-17F was Glutamine instead of mutated Histidine in human IL-17F. Mouse IL-
17F however contained Histidine immediately preceding Glutamine. Based on these observations, 
three mouse analogues of human IL-17F mutant were created. Mouse mutant 1 involved 
substitution of Glutamine at amino acid position 158 by Arginine and mouse mutant 2 included 
substituting Histidine at 157 by Arginine. Mouse mutant 3 was developed as a truncated mutant by 
deletion of the last 4 amino acids. 
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2.1.3 Cloning of human and mouse wild-type and mutated LAP-IL-17  
The mature fragments of human and mouse IL-17A, IL-17F and IL-17F mutants were PCR amplified 
using corresponding full-length IL-17A, IL-17F and IL-17F mutants cDNA (section 2.1.2 ) as template 
and the forward and reverse primers as listed in the Table 1. mLAP-IL-17A was amplified using hot-
start PCR method (Section 2.1.4a). Due to the presence of an additional band, mLAP-IL-17F was 
isolated by gel-purification (Section 2.1.5a). The PCR products were digested at Not1 and Xba1 sites 
and cloned in the corresponding sites of the previously constructed expression vector pcDNA3-LAP-
MMP (353) (Fig. 2.4).  
 
 
 
Figure 2.4 Cloning of mature IL-17 in pcDNA3-LAP. Human and mouse LAP-IL-17A, LAP-IL-17F and 
LAP-IL-17F mutant were constructed by cloning Not1 and Xba1 digested mature IL-17 into the 
corresponding sites of previously constructed plasmid expression vector pcDNA3-LAP.  
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2.1.4 Polymerase chain reaction DNA amplification  
The PCR reactions containing 200ng DNA template, 0.1g each forward and reverse primer, 10X Pfu 
buffer, 2units high-fidelity DNA polymerase, PfuUltra (Stratagene Inc., CA), 2l 10mM mixed d-NTP 
and distilled water to a total volume of 50l was subjected to a protocol of an initial denaturation 
step at 95 C for 2 minutes, followed by 34 amplification cycles (denaturation at 95C for 30 sec, 
annealing of primers at 60C for 30 sec and strand amplification at 72C for 2 min) and a final 
extension step of annealing at 72C for 10 minutes using a Peltier Technology Thermal cycler (PTC-
200, MJ Research Inc., Waltham, MA). The correct size of the PCR-amplified cDNA fragment was 
confirmed by agarose gel electrophoresis: 2l PCR product in 8l distilled water was mixed with 2l 
6X Bromophenol blue loading dye (30% v/v glycerol in distilled water, 0.25% bromophenol blue, 
0.25% xylene blue) and separated on ethidium bromide (0.5g/ml) containing 1% agarose gel in 0.5X 
TAE buffer (0.02M Tris-acetate, 0.5mM EDTA, pH 8.0) in parallel with 10l (2g) 1Kb Plus DNA ladder 
(100-12000 bp) (Invitrogen Co., Paisley, UK) at 100V for approximately one hour. The ethidium 
bromide-bound DNA was visualised under ultraviolet light and the image was captured using a gel 
documentation system (Uvitec Ltd, Cambridge, UK). 
 
2.1.4a Hot-start PCR 
The PCR reaction mixture containing 10X Pfu buffer, 2l 10mM mixed d-NTP, 0.1g each forward 
and the reverse primer, 200ng DNA template was boiled for 5 minutes in screw-capped tubes; 
transferred on to ice immediately and centrifuged briefly. 2units of high-fidelity DNA polymerase 
PfuUltra (Stratagene Inc., La Jolla, CA) were added and PCR-amplification conducted as above 
(section 2.1.1) except that the annealing temperature was lowered to 52C.  
 
2.1.4b Phenol: chloroform extraction and sodium acetate precipitation of PCR products 
An equal volume of water saturated phenol:choloroform solution was added to PCR mix and 
vortexed for 30 seconds, centrifuged at 13,000rpm for 5 min using an Eppendorf Microcentrifuge 
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(541D, Eppendorf, Hamburg, Germany). The top aqueous phase was mixed with 10% sodium acetate 
3M, pH 5.2 and 2.5 volumes 100% cold ethanol, incubated at -20C for 30 min, centrifuged at 13,000 
rpm/min for 30 min at room temperature, pellet washed with 500l 70% ethanol, centrifuged at 
13,000rpm for 20 min, recovered DNA resuspended in distilled H2O, gel-analysed and stored at  
-20C.  
 
2.1.5 DNA restriction enzyme digestion 
The PCR products and plasmid vectors were digested with 5l and 10l respectively of appropriate 
enzymes, New England Biolabs, Hitchin, UK) using 10X corresponding buffer ± 100X BSA in a total 
reaction-volume of 100l by incubating at 37C overnight, gel-analysed and stored at -20C until 
utilized.  
DNA gel purification  
100l digested DNA product or 20μg plasmid vector was loaded in equal amount in 10 different 
wells of 1% agarose gel and separated at 100V. The DNA band of interest was visualized under 
ultraviolet transluminator (Uvitec Ltd), excised from the gel and purified, using PureLink Quick Gel 
extraction kit as per instructions from the manufacturer. In brief, the DNA-containing gel was 
dissolved in solubilisation buffer, incubated at 50C for 20 minutes, passed through column, washed; 
and the purified DNA recovered in distilled water and stored at -20C. 
Annealing complementary strands of oligonucelotides 
1g each of complementary strands of oligonucleotides (1g/l) mixed in 10X T4 DNA ligase buffer 
in a total 50l volume were annealed by boiling for 5 minutes, followed by slow cooling until the 
next day and stored at -20°C until cloned. 
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2.1.6 DNA Ligation  
Restriction enzyme digested PCR products were ligated in 10-fold molar excess to the 
correspondingly digested 1g plasmid vector in 10X T4 ligase buffer and 1.25l 400,000 units/ml T4 
DNA ligase (New England Biolabs, Ipswich, USA) in a total reaction volume of 25l by incubating at 
4C overnight.  
 
2.1.7 Transformation of E coli 
2.1.7a Preparation of competent E. coli  
Fresh E. Coli DH 5 were rendered competent for the uptake of plasmid DNA by using calcium 
chloride protocol (417). E. coli cells were grown overnight in 5ml LB at 37C with vigorous shaking. 
This starter culture was transferred to 500ml pre-warmed LB medium and grown at 37C with 
vigorous shaking until optical density (OD) read at 600nm reached values between 0.4 and 0.6. The 
bacterial culture was pelleted by centrifugation at 4000g for 10 minutes at 4C using Multispeed 
Centrifuge (PK 121, ALC International, Milan, Italy) and suspended in 50ml freshly made ice-cold 
0.1M MgCl2. Cells were pelleted again (1500g, 10 min, 4C), resuspended in 50ml ice-cold 0.1M CaCl2 
and incubated on ice for 20 minutes, re-centrifuged at 1500g for 10 minutes at 4C. Cells were 
resuspended in 12.5ml ice cold 0.1M Ca Cl2 with 14% glycerol, aliquoted, frozen on dry ice and 
stored at -80C. 
 
2.1.7b Transformation of competent E. coli DH 5 
25l DNA ligation product (obtained from step 2.2.7) was mixed with 100l competent E coli DH 5 
(prepared as described below) and incubated on ice for 30 minutes, heat-shocked at 42C for 2 
minutes, incubated on ice for further 2 minutes and grown in 5ml Luria Bertani (1% bactotyptone, 
0.5% bactoyeast extract, both from Invitrogen Corp., 0.17M NaCl, pH 7.4) without antibiotic with 
vigorous shaking at 37C for 90 minutes. 400l culture was then plated on a dry LB agar (1.5% w/v) 9 
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cm plates containing Ampicillin (100g/ml) (Sigma-Aldrich Inc., UK) and grown at 37C overnight, 
individual colonies picked and further analysed. 
 
2.1.8 Extraction of plasmid DNA from E. coli 
2.1.8a Small scale plasmid DNA extraction (Mini-preps) 
The bacterial colonies picked from the LB agar plates were cultured overnight in 5ml LB with 
100μg/ml Ampicillin at 37°C shaking. 1.5ml bacterial culture was centrifuged at 5000rpm for 5 
minutes at room temperature in an Eppendorf Microcentrifuge. DNA was extracted and purified 
from the pelleted cells using Purelink Quick Plasmid Miniprep Kit, Invitrogen as per the 
manufacturer’s instructions. In brief, the pelleted cells were resuspended in 250l resuspension 
buffer with RNase, lysed with 250l lysis buffer, precipitated with 350l precipitation buffer. 
Centrifugation was then carried out at 12,000rpm for 10 min at room temperature. The nucleic acids 
in the supernatant were transferred to exchange column and centrifuged at 12,000rpm for 1 minute. 
After washing the column twice, DNA was eluted in distilled water and stored at 4C. Miniprep-
derived DNA from each colony was digested with the restriction enzymes (same as those used for 
cloning) using 20l DNA, 10X buffer, 100X BSA and 1l each enzyme in total 30l volume and 
incubated at 37C for 2 hours, gel-analysed and sequenced at the Genome Centre, Queen Mary, 
London, UK. 
 
2.1.8b Large scale isolation of plasmid DNA (Maxi-prep)  
For large-scale cultures, 1ml of the 5ml starter culture was grown in 500ml LB containing Ampicillin 
(100g/ml) with vigorous shaking at 37C overnight and pelleted by centrifuging at 4000 x g at 4C 
for 20 min using Multispeed Centrifuge (PK 121, ALC International, Milan, Italy), then purified using 
Purelink HiPure Plasmid Maxiprep Kit (Invitrogen Corp.) as per the manufacturer’s instructions. In 
brief, the pellet was resuspended in resuspension buffer containing RNase, lysed with lysis buffer, 
precipitated with precipitation buffer and centrifuged at 4000g for 20 minutes. The supernatant was 
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transferred to the Maxiprep kit column, washed and DNA eluted in 15ml elution buffer. The eluted 
DNA was then precipitated with 10.5ml Isopropanol, pelleted by centrifuging at 4000rpm at 4C for 
90 minutes, washed with 70% alcohol, centrifuged at 4000rpm at 4C for 30 minutes. The pellet was 
suspended in distilled water and stored at 4C. Plasmid DNA concentration was determined at 
260nm using Pharmacia GeneQuant (Cambridge, UK) spectrophotometer. A sample of the purified 
plasmid DNA was digested (with enzymes used for cloning) and analysed on 1% agarose gel to 
confirm the presence of the insert of the correct size. 
 
2.1.9 Expression of IL-17 in mammalian cells 
All cell culture reagents were purchased from Cambrex Corp., Wokingham, UK. 
293T cell line 
The 293T cell line (418) was maintained in complete DMEM medium, supplemented with heat-
inactivated 10% fetal bovine serum (FBS), 100U/ml of Penicillin, 100g/ml of Streptomycin and 2mM 
L-Glutamine. The cells were detached using Trypsin-versene (Biowhittaker Lonza, Belgium) for 2 
minutes at 37C before plating. The cells were grown at 37C in humidified incubator, 10% CO2 and 
split 1:10 at 70% confluency. Stocks were prepared by resuspending 1 x 106 cells which had reached 
70% confluency in 1ml 10% DMSO in complete DMEM in cryostat tubes, slow frozen first on ice for 
an hour, then at -80C overnight and subsequently stored in liquid Nitrogen. 
CHO-suspension cell line 
CHO-S cells were maintained in L-glutamine containing Gibco® Freestyle ™ CHO medium (Invitrogen, 
UK) in polycarbonate Erlenmeyer flask (Corning Incorp,, USA) at 95-125rpm/min at 37°C in 8% CO2 
and split 1:10 at 70% confluency. 
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2.1.9a Transient transfection of mammalian cells  
Calcium phosphate co-precipitation method 
293T cells were transiently transfected as described previously (419). 1 x 106 293T cells were seeded 
in 9cm culture-plates in 10ml complete DMEM and incubated at 37C in 10% CO2 overnight. Next 
day, 20g plasmid DNA was added to 500l 2X HBS (280mM NaCl, 50mM HEPES, 1.5mM Na2HPO4, 
pH 7.1) and made upto 950l with distilled water. 50l 2.5M CaCl2 was added drop-wise with 
constant gentle shaking and incubated for 30 minutes at room temperature. The medium was 
removed from the 293T cells seeded previous day and the calcium phosphate DNA precipitate was 
added to the cells and incubated for 30 minutes at room temperature with gentle tilting every 5 
minutes. The cells were then topped with 9ml complete DMEM and grown at 37C in 10% CO2 
overnight. Next day, after removing the medium, 1ml 10% glycerol in serum-free DMEM was added 
to the cells for 4 minutes with tilting every 30 seconds. The cells were washed twice with 5ml serum-
free DMEM and grown in 6ml serum-free DMEM at 37C in 10% CO2 for 48 hours. The cell 
supernatant was collected, centrifuged at 3000rpm for 5 minutes and stored in aliquots at -80C.  
Polyethylene-imine (PEI) co-precipitation method 
Human and mouse IL-17A/F, IL-17F/F mutant, IL-17A/F mutant heterodimers were expressed by 
transient co-transfection of 293T cells using PEI co-precipitation method. 
Transient transfection with PEI, linear, MW 25,000 (Polysciences, Inc., Warrington, USA) was 
conducted in a similar manner to the calcium phosphate co-precipitation method except for the 
following differences. On day 2, 1ml DNA-PEI mixture was prepared by adding the following in the 
same order; 940l Opti-MEM (Invitrogen, UK), DNA 20g total (varying proportions of FL-IL-17A, IL-
17F, IL-17Fmutant and pcDNA3 as described below, 40l PEI (Polysciences, Inc., Warrington, PA), 
then vortexed and incubated for 10 minutes at room temperature before adding to the cells and the 
step of glycerol shock was omitted. 
For the expression of heterodimers, total 20g plasmid DNA was transfected using combinations of 
varying concentrations of IL-17A, IL-17F, IL-17F mutant and pcDNA3. For example, for the expression 
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of heterodimer IL-17A/F, IL-17A 15g, IL-17F 5g; IL-17A 10g, IL-17F 10g; IL-17A 15g, IL-17F 5g 
and IL-17A 5g, IL-17F 15g were co-transfected. When a single DNA was transfected, pcDNA3 was 
used to compensate to a final total of 20g DNA.  
 
2.1.9b Expression of non-secreted proteins 
Some of the proteins may not be secreted but retained within the cells after expression. As mFL-IL-
17F mutant 2 could not be detected in 293T cells supernatant, post-transfection the cells were lysed 
and lysate examined for the expressed protein. 2.5 x 105 /ml 293T cells were incubated in 2ml 
complete DMEM in a 6-well flat bottom Costar cell culture plate (Corning Incorporated, NY, USA) at 
37C in 10% CO2 overnight and transfected with 6μg plasmid DNA using calcium phosphate co-
precipitation method. Post-transfection, the cells were lysed by incubating with 250μl RIPA buffer, 
Sigma-Aldrich, UK (containing 150mM NaCl, 1% IGEPAL®, CA-630, 0.5% sodium deoxycholate, 0.1% 
SDS, 50mM Tris, pH 8.0) plus 2.5μl protease inhibitor cocktail 8340, Sigma-Aldrich, UK (containing 
AEBSF i.e. 2-aminoethyl benzenesulfonyl fluoride, 104mM, Aprotinin 80uM, Bestatin 4mM, E-64 
1.4mM, leupeptin 2mM, pepstatin A 1.5mM) at 4°C for 30 minutes. The cell lysate was centrifuged 
at 12,000rpm at 4°C for 20 minutes and collected in pre-cooled tubes and stored at -80°C. The 
concentration of total protein in the cell lysate was determined by using a Pierce® BCA protein assay 
kit (Thermo Scientific). In brief, 2-fold serial dilutions of cell lysate in serum-free DMEM and 25-
2000μg/ml BSA standard in serum free DMEM were incubated with 200μl fresh BCA working reagent 
(prepared by mixing 50 parts BCA reagent A with 1 part BCA reagent B) in a 96-well Maxisorp, Nunc 
ELISA plate at 37°C for 30 minutes. The plate was cooled to room temperature before reading with 
the spectrophotometer set to 562nm. The absorbance measurement of the blank standard was 
subtracted from the rest of the standards and samples values before deriving the total concentration 
of proteins in the cell lysates. 
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2.1.10 Expression and immunoaffinity purification of human IL-17F mutant 
2.1.10a Expression of human IL-17F mutant in CHO suspension cells  
Human FL- and LAP-IL-17F mutant were expressed by transient transfection of 2 litre culture of CHO-
suspension (CHO-S) cells grown at a density of 2 x 106 cells/ml with 800μg hFL-IL-17F mutant and 
LAP-IL-17F mutant plasmid DNA each using PEI co-precipitation method.  
The expression of hFL- and LAP-IL-17F mutant protein in the CHO-S cells supernatant was confirmed 
by Western blot. The expressed hFL- and LAP-IL-17 mutant proteins were purified by immunoaffinity 
purification. 
 
2.1.10b Binding of anti-human IL-17F antibody to Glycolink column 
Oxidation of IL-17F antibody 
1mg goat anti-human IL-17F polyclonal antibody (R&D Systems, UK) was diluted in Glycolink coupling 
buffer, pH 6 to a final volume of 1ml. In a microcentrifue tube, 2.1mg sodium meta-periodate was 
added to the 1ml antibody solution while gently pipetting until the powder dissolved (resulting in 
10mM periodate). The tube was wrapped in aluminium foil to protect from light and the mixture 
incubated at room temperature for 30 min.  
A 5ml Zeba desalting column was centrifuged at 1000g for 2 minutes at 4°C using a 15ml collection 
tube and equilibrated by adding 2ml Glycolink coupling buffer and centrifugation, the step repeated 
twice. The oxidised glycoprotein solution was then slowly applied to the centre of the compact resin 
bed. The column was centrifuged at 1000g for 2 minutes at 4°C using a 15ml collection tube and the 
sample collected in 15ml tube, the collected solution contained the oxidised IL-17F antibody. 
In the fume hood, 0.2M GlycoLink coupling catalyst was prepared by adding 18μl aniline to 1ml 
Glycolink coupling buffer. The catalyst was vortexed for 10 sec and the total volume added to the 
oxidised antibody sample (resulting in 0.1M aniline). 100μl sample was saved for subsequent 
determination of coupling efficiency. 
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Coupling oxidised antibody to Glycolink column  
Ensuring that the Glycolink column resin was not allowed to dry at any time, the resin in the column 
was suspended by end-over-end mixing. The column was centrifuged to remove the storage buffer 
taking care to avoid drawing of air into the column. 2ml Glycolink coupling buffer was added and the 
column centrifuged at 1000g for 2 minutes at 4°C using a 15ml collection tube. This step was 
repeated once. Oxidised antibody sample was added to the GlycoLink column and mixed withresin 
by end-over-end mixing at RT for 4 hours. The column was centrifuged at 1000g for 2 minutes at 4°C 
using a new 15ml collection tube to collect non-bound protein. The flow-through was saved and the 
coupling efficiency determined by comparing the protein concentrations of the non-bound fraction 
to the starting sample saved previously. The column was washed thrice with 2ml Glycolink coupling 
buffer and centrifuged. The column was then washed thrice with 2ml wash buffer and centrifuged. 
The column was equilibrated for storage by adding 2ml PBS with 0.05% sodium azide at pH7-8 and 
centrifuged at 1000g for 2 minutes at 4°C using a 15ml collection tube. This step was repeated three 
times. The column resin in 2ml PBS with 0.05% sodium azide, pH7-8 was stored upright at 4°C.  
 
2.1.10c Fast Protein Liquid Chromatography  
Immunoaffinity purification of human FL-IL-17F mutant 
The CHO-S cells supernatant containing the expressed hFL-IL-17F mutant protein was first dialysed 
using SnakeSkin Pleated Dialysis Tubing 10,000 MWCO (Thermoscientific, UK) at 4°C in a final total 
volume of 200 litre 1X PBS allowing buffer exchange for at least 4 hours in a cycle. The dialysed 
supernatant was filter sterilised using 0.22μm Polyether Sulfone filter system (Corning, USA) and 
purified by passing it through anti-IL-17F coupled Glycolink column at the rate of 0.5ml/hour at 4°C 
using FPLC (GE Healthcare, Uppsala, Sweden).Filter sterilised PBS, 0.2M glycine.HCl, pH 2.5-3.0 and 
1M sodium phosphate, pH 8-9 were used as binding/wash, elution and neutralisation buffers 
respectively. Eluted fractions of 1ml were collected after adding 100μl neutralisation buffer to the 
individual elution tubes. The expression of hFLIL-17F mutant in the eluted fractions was confirmed 
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by Western blotting and the fractions containing the IL-17F mutant protein were dialysed using 
Slide-A-LyzerDialysis cassette, 7,000 MWCO, 0.5-3ml capacity, Thermoscientific, Rockford, USA, 
aliquoted and stored at -80° C.  
 
Immunoaffinity purification of humanLAP-IL-17F mutant 
Human LAP-IL-17F mutant protein expressed and secreted in CHO-S cells supernatant was first 
dialysed using Spectra/Por® 6 dialysis membrane, MWCO, 50,000, Spectrum Laboratories Inc. 
(Dominguez, CA, USA) in the final total volume of 200 litre 1X PBS at 4°C allowing at least 4 hours of 
exchange during individual cycles. 
The supernatant was filter sterilised and purified by passing it through using HiTrap™ HeparinHP 1ml 
column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) at the rate of 0.5ml/hour at 4°C using 
FPLC. Filter sterilised 20mM Tris HCL, 20mM EDTA, pH 8 was used as binding buffer and 20mM Tris 
HCL, 20mM EDTA, pH 8 plus 1M NaCl was used as elution buffer. 
The heparin column purified hLAP-IL-17F containing CHO-S cell supernatant was subsequently 
immunoaffinity purified using anti-IL-17F antibody coupled with resin in a 10ml Sephadex column 
(Column PD-10, Sephadex G-25M, Pharmacia LKB, Sweden). The column was pre-washed with 5ml 
1X PBS at 4°C before running the supernatant at 0.5ml/hour, washed with 10ml PBS and purified 
LAP-IL-17F mutant eluted with 10ml glycine in fractions of 1ml each in tubes containing 100μl 
Sodium Phosphate buffer. OD of eluted fractions were estimated at 280nm, the fractions dialysed in 
1X PBS using Slide-A-Lyzer10K Dialysis Cassette, 10,000 MWCO, Pierce Biotechnology, Rockford, 
USA, aliquoted and stored at -80◦C.  
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2.2 Characterisation of immunological properties of expressed IL-17 proteins 
2.2.1 Western blotting 
In vitro cleavage of LAP-IL-17 by MMP-1  
200l 293T cell supernatants transfected with human and mouse LAP-IL-17 proteins were incubated 
in the presence of MMP buffer 10X (50mM Tris, 5mM CaCl2, 300mM NaCl, 20M ZnCl2 , 0.5% Brij-35 
and 30% glycerol, pH 7.5) with and without MMP-1 at 1:50 dilution at 37C overnight. On day 2, 
EDTA to the final concentration of 2.5mM was added to chelate the zinc and stop the MMP-1 
activity.  
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)  
Three volumes of transiently transfected 293T cells supernatant or immunoaffinity purified samples 
were mixed with 1 volume of Laemmli’s 4X reducing loading buffer (125mM Tris-HCL, pH 6.8, 0.4M 
DTT, 10% SDS, 40% glycerol, 0.002% bromophenol blue) (417) and boiled for 5 minutes before 
loaded onto the gel. 25l samples were loaded to 1.5mm thick, 4-12% gradient, 10-well NuPAGE 
Novex Bis-Tris gel in parallel with 10l standard (10-250kDa Precision Plus protein standard, Bio-Rad 
Laboratories Inc., Hemel Hampstead, UK). The gel was run in NuPAGE MOPS SDS running buffer 
(Invitrogen, UK) using X cell Sure Lock mini-cell (Invitrogen, UK) at 200V for 50 minutes.  
Transfer of electrophoresed proteins to PVDF membrane 
The gel was electro-blotted onto a polyvinylidene difluoride membrane (PVDF, Amersham 
International Plc, UK) by running in NuPAGE MOPS transfer buffer (Invitrogen, UK) in X cell II Blot 
Module (Invitrogen, UK) at 30V for the minimum of one hour. 
Blocking and immunoblotting of PVDF membrane 
PVDF membrane was incubated with 25ml 5% non-fat milk (Marvel Premier Foods Plc., St Albans, 
UK) in PBST (0.005% Tween20 in 1X PBS) with modest shaking for 2 hours at RT, probed with 25l 
primary antibody (goat anti-human or -mouse) in 1:1000 dilution in 25ml 5% non-fat milk in PBST by 
incubating overnight at 4C; membranes washed thrice, incubated with 1:1000 secondary antibody, 
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horseradish peroxidase (HRP)-conjugated mouse anti-goat IgG polyclonal antibody (Santa Cruz 
Biotechnology, Middlesex, UK) in 25ml fresh 5% non-fat dry milk in PBST with mild shaking for 1 hour 
at RT; washed 4 times, treated with activated enhanced chemiluminescence solution (ECL, 
Amersham international plc., UK.) for 1 minute and exposed to autoradiography films (Amersham 
Pharmacia Biotech Inc., Amersham, UK) for approximately 1-10 minutes and the films developed 
using Agfa Curix 60 processor (Agfa-Gevaert Ltd., Gevaert, Belgium). The expression of the plasmid 
DNA encoded protein was confirmed by the presence of band of the expected size. 
Silver staining of polyacrylamide gel 
A sample of the immunoaffnity purified human FL- and LAP-IL-17F mutant each was resolved by SDS-
PAGE and stained with Silver stain plus (Bio-Rad, UK) to verify the purity of the proteins. The 
polyacrylamide gel was first fixed by placing it in a total 400ml fixative enhancer solution (containing 
200ml reagent grade methanol, 40ml reagent grade acetic acid, 40ml fixative enhancer concentrate 
and 120ml deionized water ) and subjecting to gentle agitation for 30 min; gel rinsed with 400ml 
deionized water for 20 min with gentle agitation; stained in a mixture of freshly mixed 35ml 
deionized water, 5ml silver complex solution, 5ml reduction moderator solution and 5ml image 
development reagent, and 50ml accelerator solution with gentle agitation until desired staining 
intensity was reached; the reaction was stopped by placing the gel in 5% acetic acid for a minimum 
15 min. The gel was rinsed with deionised water for 5 min and photographed. 
 
2.2.2 Determining quantity of the expressed IL-17 proteins  
Antibodies and other reagents 
The polyclonal goat anti-human and anti-mouse IL-17A, IL-17F and LAP antibodies were purchased 
from R & D Systems, UK. The mouse anti-goat IgG-HRP was purchased from Santa Cruz 
Biotechnology. Recombinant human and mouse IL-17A and IL-17F were purchased from R & D 
Systems, UK and recombinant LAP was purchased from Sigma-Aldrich, UK. 
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Concentration of IL-17 containing 293T cell supernatants 
Full-length IL-17 proteins 
Mouse and human full-length IL-17F and IL-17F mutant expressed in supernatants of transiently 
transfected 293T cells were concentrated 20-fold using Centricon centrifugal filter device with YM-3 
membrane (Millipore Corporation, UK) by centrifuging at 4000g/min at 4°C. Further samples of 
human FL-IL-17A, FL-IL-17F and FL-IL-17F mutant 293T cells-derived supernatants were concentrated 
30-fold using Centricon centrifugal filter device with YM-10 membrane (Millipore Corporation, UK) 
so as to remove maximum possible impurities. 
LAP-IL-17 proteins 
Human LAP-IL-17A, LAP- IL-17F and LAP- IL-17F mutant expressed in the supernatant of transiently 
transfected 293 T cells were concentrated 30-fold using vivaspin 20 centrifugal concentrator MWCO 
50,000 (Sigma Aldrich, UK).  
 
2.2.2a Western blot quantitation of IL-17 in 293T cells supernatant 
25μl concentrated human and mouse full-length and LAP-IL-17 proteins in serial two-fold dilutions 
and 100, 50 and 25ng of recombinant human or mouse IL-17A, IL-17F or human LAP were resolved 
on SDS-PAGE as outlined in Section 2.2.1. The quantity of the 293T-cells expressed proteins were 
derived by comparing their intensities on film with that of known quantities of standards using 
image J software.  
 
2.2.2b ELISA quantitation of IL-17 in 293T cells supernatants 
96 MicroWell, MaxiSorp surface (Thermo Scientific Nunc, Denmark) plates were coated with 
50μl standard (100ng/ml) or 293T cells-derived supernatants in coating buffer (0.1M sodium 
carbonate buffer, pH 9.6) at 4C overnight, blocked with 200μl 5% non-fat dry milk in PBST for 2 
hours at room temperature, treated with 50μl primary antibody (goat anti-human or mouse IL-17A, 
IL-17F or LAP) in 1:250 dilution in 5% Marvel for 2 hours, then 100μl secondary antibody (mouse 
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anti-goat IgG-HRP) in 1:500 dilution in 5% Marvel for 1 hour at room temperature. After each step, 
the wells were washed thrice with 300μl washing buffer (1X PBS plus 0.005% Tween). Finally, 100μl 
freshly reconstituted substrate (Tetramethylbenzidin, KPL, Gaithersburg, MD 20878, USA) was added 
and reaction stopped with 50μl 2M sulphuric acid. The optical density was determined at 450nm 
using Tecan GENios microplate reader (MTX Lab Systems, Inc., Virginia, USA).  
 
2.2.2c Ultrasensitive ELISA quantitation of immunoaffinity purified IL-17F mutant  
An IL-17F ultrasensitive ELISA was developed and standardised by using human IL-17F Duoset ELISA 
(R&D Systems, UK) in conjunction with uncoated ELISA plate and 1% PBS or mouse diluents 4 and 5 
(MSD, USA) to allow testing of mouse serum samples for the expression of mouse IL-17F mutant and 
increasing the sensitivity of R&D Duoset ELISA. The lowest levels of IL-17F or IL-17F mutant that can 
be detected with Duoset ELISA are 312.5pg/ml.  
The assay was first standardized as follows: On day 1, two separate MSD ELISA plates were coated 
with 30μl per well 1, 2 and 4μg/ml capture antibody in PBS in duplicates and incubated at 4°C 
overnight. On day 2, the plates were washed thrice with PBST, blocked with 150μl 3% BSA for 1 hour 
at 175 rpm at RT. After washing thrice with PBST, one of the plates was incubated with 25μl diluent 
4 at 175rpm for 30 minutes. R&D IL-17F standard was 3-fold serially diluted in 1% BSA in PBS or 
diluent 4 at the starting concentration of 20,000pg/ml. The lowest concentration of IL-17F mutant 
that could be detected was 27.4pg/ml. The plates were incubated with 25μl/well standard for 2 
hours at 175rpm at RT and washed thrice with PBST. 25μl/well 0.1 and 0.5μg/ml detection antibody 
in 1% BSA in PBS or diluent 5 plus 1μg/ml Streptavidin sulfotag was added and plates incubated for 2 
hours at 175rpm at RT, washed thrice with PBST and 150μl 2X Read buffer in deionised water added. 
The plates were then analysed using Sector Imager 2400 (Meso Scale Discovery, Rockville, USA). 
The quantity of purified FL-and LAP-IL-17F mutant was analysed by human IL-17F ultrasensitive ELISA 
as described above using 2μg/ml capture and 0.5μg/ml detect antibody in 1% BSA in PBS. 
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2.3 Characterisation of in vitro biological properties of expressed  
IL-17 proteins 
HFFF2 cells 
Human Caucasian foetal foreskin fibroblast cell line, which is derived from foreskin of 14-18 weeks 
old human foetus were kindly provided by Dr Adrian Churchman, Bart’s Institute of Cancer, WHRI. 
The HFFF2 cells were maintained in complete DMEM at 37C in 10% CO2. The cells were passaged 
when 70% confluent by detaching with Trypsin-versene. 
HeLa cells 
HeLa cells were maintained in complete DMEM or complete RPMI at 37C in 10% CO2.  
57A HeLa cells 
57A Hela, a luciferase reporter cell line derived from stable transfection of HeLa cells with NF-B-
responsive luciferase (420) was kindly provided by Dr Apostolos Koutsokeras, BJRU. 57A HeLa cells 
were maintained in complete DMEM plus 500g/ml G418 (Geneticin 418) at 37C in 10% CO2. 
Hela cells stably transfected with IL-6 promoter-responsive luciferase 
HeLa cells were stably transfected with IL-6 promoter-responsive luciferase (kindly provided by Prof 
Chernajovsky, BJRU) and the cell line was maintained in complete DMEM plus 1μg/ml Blasticidin. 
NIH 3T3 cells 
The spontaneously immortalised Swiss mouse embryonic fibroblast cell line (421) was maintained in 
complete DMEM at 37C in 10% CO2. The cells were passaged when 70% confluent by detaching 
with Trypsin-versene.  
Raw 264.7 cells stably transfected with NF-B driven luciferase 
Mouse macrophage cells stably transfected with NF-B- responsive luciferase were kindly provided 
by Dr S. Vessillier, BJRU. These cells were maintained in complete DMEM plus 200g/ml G418 at 
37C in 10% CO2. The cells were passaged when 70% confluent by detaching the adherent cells using 
sterile cell scraper. 
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DTF cells stably transfected with IL-6 promoter-responsive luciferase 
DTF cells, which are conditionally SV40 large T immortalised DBA/1 fibroblasts (422) were stably 
transfected with IL-6 promoter-responsive luciferase and maintained in complete DMEM plus 2 
g/ml Blasticidin at 37C in 10% CO2. The cells were passaged when 70% confluent by detaching with 
Trypsin-versene. 
 
2.3.1 Characterisation of in vitro biological properties of expressed human IL-17 
2.3.1a Determining IL-17RC binding capability of human FL-IL-17F mutant  
Mouse polyhistidine monoclonal antibody, recombinant human IL-17A, IL-17F, hIL-17RC, biotinylated 
anti-human IL-17A and IL-17F antibodies and Streptavidin-HRP were purchased from R&D Systems, 
UK. 
The ability of human FL-IL-17F mutant to bind to humanIL-17RC was assessed by functional ELISA as 
per the manufacturer’s instructions. In brief, 96-well ELISA plate (Maxisorp, Nunc, Denmark) was 
coated with 10μg/ml mouse anti-polyhistidine in cold PBS (100μl/well) and incubated at room 
temperature overnight, blocked with 1%BSA in PBS (300μl/well) and incubated for 2 hours at 37°C. 
In a separate ELISA plate, 50μl hIL-17RC at the final concentration of 100ng/ml was mixed with 50μl 
3-fold serially diluted hFL-IL-17A or hFL-IL-17F mutant at the starting final concentration of 2μg/ml in 
0.5% BSA in PBS and incubated at 500rpm for 2 hours at room temperature. As a control, 50μl 
binding buffer instead of the hIL-17RC was added to the human IL-17 dilution wells to check the non-
specific binding hIL-17. 
After removing the blocking buffer, 100μl mixture of the hIL-17 and hIL-17RC or the binding buffer 
was added to each well and incubated at room temperature overnight. Next day after washing with 
1% PBST thrice, the plate was incubated with 3μg/ml goat biotinylated anti-human IL-17 (anti-IL-17A 
or anti-IL-17F) antibody in binding buffer (100μl/well) at RT for 2 hours, washed thrice and incubated 
with 1:200 diluted Streptavidin-HRP (100μl/well) at RT for 30 minutes. ELISA was developed by 
adding 100μl freshly prepared TMB (by mixing 50μl TMB substrate and reagent each) per well at RT 
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for 20-30 minutes. The reaction was finally stopped by adding 50μl 2mM Sulphuric acid per well and 
OD measured at 450nm. The net binding was obtained by subtracting the non-specific binding value 
from the total binding values.  
 
2.3.1b Fibroblast cells IL-6 induction IL-17 bioassay 
Analysis of IL-17 induced secretion of IL-6 in fibroblast cells is the standard bioassay for IL-17 activity 
(96, 107). Bioactivity of 293T cells expressed human IL-17 was analysed in human foetal foreskin 
fibroblast and mouse embryonic fibroblast cells. 
Evaluation of IL-17 induced secretion of IL-6 in HFFF2 cells 
1 x 104 HFFF2 cells in 100l complete DMEM in 96-well plate were incubated at 37C in 10% CO2 
until adherent and, stimulated with 100l/well 100ng/ml rhIL-17(IL-17A and IL-17F), FL-IL17(IL-17A, 
IL-17F, and IL-17F mutant), and MMP-1-treated and untreated LAP-IL-17 (IL-17A, IL-17F and IL-17F 
mutant), 10ng/ml rhIL-1, mock supernatant derived from transient transfection of 293T cells with 
pcDNA3 alone and complete DMEM in triplicates for 24 hours at 37C in 10% CO2 and supernatants 
analysed using human IL-6 Duoset ELISA (R & D Systems Europe Ltd., Abingdon, UK) as per the 
manufacturer’s instructions. 
For competitive inhibition assay, HFFF2 cells were co-stimulated with 293T cells supernatant 
containing 25ng/ml FL-IL-17A and two-fold serially diluted 25ng/ml FL-IL-17Fmutant for 24 hours and 
supernatant analysed for IL-6 as above.  
Evaluation of human IL-17-induced secretion of IL-6 in NIH 3T3 cell  
It has been shown that human IL-17A and human IL-17F are able to bind to both mouse IL-17RA and 
IL-17RC, and stimulate secretion of IL-6 in mouse fibroblast cells (95, 181). Biological effects of 
expressed human IL-17 proteins in 3T3 cells were analysed as below. 
5 x 103 NIH 3T3 cells in 100 l complete DMEM in 96-well plate were incubated in 10% CO2 at 37C 
until adherent, stimulated with 100 l 100ng/ml rhIL-17A and IL-17F , FL-IL17F mutant, and medium 
alone (complete) DMEM in triplicates in 10% CO2 at 37C for 24 hours. The supernatants were 
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analysed for IL-6 using mouse IL-6 Duoset ELISA (R & D Systems Europe Ltd., Abingdon, UK) as per 
the manufacturer’s instructions. For competitive inhibition assay, the cells were co-stimulated with 
two-fold serially diluted 1μg/ml rmIL-17A plus 50μl 293T cells supernatant containing human IL-17F 
mutant protein. 
 
2.3.1c Epithelial cells IL-6 induction IL-17 bioassay 
IL-6 is one of the earliest defined IL-17 gene targets. IL-17 has been shown to induce secretion of IL-6 
in endothelial, epithelial and fibroblast cells. Bioactivity of 293T cells-expressed IL-17 in HeLa cells 
was analysed as described below. 
Evaluation of IL-17-induced secretion of IL-6 in HeLa cells 
1 x 104 HeLa cells in 100 l complete DMEM in 96-well plate were incubated at 37C in 10% CO2 until 
adherent, and stimulated with 100l/well 100ng/ml or 10ng/ml rhIL-17A and IL-17F and 100ng/ml or 
10ng/ml immunoaffinity purified IL-17F mutant, 10ng/ml rhIL-1 as positive control and complete 
DMEM alone at 37C in 10% CO2 for 24 hours and the supernatant analysed for IL-6 by human IL-6 
Duoset ELISA (R & D Systems Europe Ltd., Abingdon, UK) as per the manufacturer’s instructions. 
For competitive inhibition assays, the cells were co-stimulated with 100ng/ml rhIL-17A or IL-17F plus 
100ng/ml immunoaffinity purified IL-17F mutant for 24 hours.  
IL-6 Duoset ELISA was carried out as follows: 96-well ELISA plate (Maxisorp, Nunc-Immunoplate, 
NuncTM, Roskilde, Denmark ) was coated with 50l/well capture antibody (2g/ml in PBS) overnight 
at RT, blocked with 200l 1% BSA (Fisher Scientific, Leicestershire, UK)in PBS for 2 hours at RT, 
washed with PBST (0.005% Tween 20 in PBS), incubated with 50l sample or standard in 1%BSA in 
PBS for 2 hours at RT, washed thrice with PBST, incubated with 50l/well detect antibody (0.2μg/ml 
in 1%BSA in PBS) for 2 hours at RT, washed thrice, incubated with 50l Streptavidin-HRP diluted 
1:200 in 1%BSA in PBS for 20 minutes at room temperature avoiding direct light, washed thrice, 
incubated with freshly prepared 50l 1:1 mixture of colour reagent A (H2O2) and colour reagent B 
Tetramethylbenzidine ( KPL, Gaithersburg, USA) for 20 minutes at room temperature avoiding direct 
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light, the reaction stopped with 25l 2M H2SO4 (WWR International Ltd., Poole, England) and OD 
determined at 450 nm.  
 
2.3.1d Evaluation of biological effects of IL-17F mutant on ERK1/2 signaling 
Extracellular signal-related kinase p42/44 (ERK) and p38 MAPK are phosphorylated following IL-17 
stimulation (423, 424). The biological effects of immunoaffinity purified IL-17F mutant on ERK1/2 
phosphorylation in HeLa cells were analysed as follows: 
1 x 106 HeLa cells in 1ml complete DMEM in 12-well culture plate were incubated at 37°C in 10% CO2 
until adherent, washed twice and serum starved in serum-free DMEM for 18 hours and stimulated 
with either 100ng/ml or 10ng/ml rhIL-17A and IL-17F plus 100ng/ml or 10ng/ml immunoaffinity 
purified FL-IL-17F mutant in serum free DMEM for 20 minutes and the cell lysates analysed for 
phosphorylation of ERK1/2 as described below. 
The cell lysates were prepared as follows: plates were kept on ice, cells washed twice with ice cold 
PBS and lysed with 250μl cold lysis buffer (containing 10mM Tris HCl, pH 7.4, 0.1% SDS, 100mM 
NaCl, sodium deoxycholate 0.5%, EDTA 1mM, EGTA 1mM, Triton X 100 1%, 10% glycerol, 1mM 
sodium fluoride, 20mM sodium phosphate with freshly added 2mM sodium vanadate, 1mM PMSF 
and Halt™ protease inhibitor single use cocktail, EDTA free,100X , Thermo Scientific, Rockford, USA) 
by incubating for 30 minutes at 4°C.The lysate was centrifuged at 12,000rpm for 20 minutes at 4°C, 
collected in pre-cooled tubes and stored at -80°C. The concentration of protein in cell lysate was 
determined by BCA assay as described in Section 2.1.9a.  
 
Analysing ERK1/2 phosphorylation by Western blot  
20μg cell lysate proteins were resolved by SDS-PAGE, transferred to PVDF membrane and probed 
with rabbit P44/P42 MAPK (ERK1/2) antibody (Cell signaling Technology, Inc., Danvers, MA, USA) or 
rabbit phospho-P44/P42 MAPK (ERK1/2) (Thr202/Tyr204) antibody (Cell signaling Technology, Inc., 
Danvers, MA, USA) and detected with sheep anti-rabbit IgG (AbD SeroTec, UK) detect antibody.  
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Analysing ERK1/2 phosphorylation by multiplex ELISA 
20μg cell lysate proteins were analysed for total and phosphorylated ERK1/2 using phospho 
(Thr202/Tyr204; Thr185/Tyr187)/total ERK1/2 whole cell lysate multiplex ELISA (MSD, USA) as per 
the manufacturer’s instructions. 
  
2.3.1e Developing a novel luciferase reporter assay to analyse bioactivity of human IL-17 
Cell culture luciferase reporter system 
Cell signaling processes leading to specific transcription factor activation can be analysed using 
reporter gene assays that measure transcription response element (RE) activity. Amongst the 
available reporters, firefly luciferase is ideal for the study of promoter activity in transfected cells 
due to its broad dynamic range, sensitivity, ease of quantification, and lack of endogenous activity. 
By coupling the operative regulatory elements to the expression of luciferase gene, typically by 
placing the transcription factor DNA binding site just upstream of luciferase gene, the cellular event 
can be readily detected by a luminescent signal. Luciferase reporter genes can be readily delivered 
to a variety of cells using approaches such as viral or chemical vectors and electroporation. 
Dual luciferase reporter system 
In the quantitation of gene expression using firefly luciferase in transiently transfected cultured cells, 
the experimental reporter gene is often co-transfected with a second reporter gene to correct for 
experimental variability. Such dual reporters allow comparative measurements within an 
experimental system. Typically the second reporter is used as an internal control that is coupled to a 
constitutive promoter that is unperturbed by various experimental conditions, against which the 
measurement of the experimental reporter is normalized. Sea pansy (Renilla reniformis) luciferase 
possesses distinct evolutionary origins from firefly luciferase and therefore has dissimilar enzyme 
structures and substrate requirements. Firefly luciferase uses luciferin in the presence of oxygen, 
ATP and magnesium to produce greenish yellow light at 550-570nm whereas Renilla luciferase uses 
coelentrazine and oxygen to produce a blue light at 480nm. Combining firefly luciferase reporter 
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systems with those of the Renilla reniformis luciferase therefore allows the sequential measurement 
of activities of both the luciferases from a single lysate. In this method the substrates for the firefly 
and Renilla luciferase are added to a sample sequentially and luminescence measured following the 
addition of each. 
57A HeLa cells NF-B-promoter-driven luciferase assay  
In an attempt to standardise a novel luciferase reporter assay in 57A HeLa cells, 1x104  cells in 100 l 
complete DMEM plus 500g/ml G418 were seeded in 96 well plate and incubated at 37C in 10% 
CO2 until adherent, after which the was medium changed to 0.1% FBS-containing DMEM without the 
antibiotic. The cells were incubated overnight at 37C in 10% CO2, washed twice with 0.1% FBS-
containing DMEM and stimulated in triplicates with 100l two-fold serially diluted rhIL-17A 
(500ng/ml),FL- IL-17A , FL- IL-17F, and rhIL-1 (50ng/ml) for 6 hours. The cell lysates were prepared 
by washing the cells with PBS twice and lysing with 50l passive lysis buffer (Promega Corp., UK). 
10l cell lysate in the presence of 50l substrate was analysed for luciferase activity using MLX 
microtitre plate luminometer, Dynex Technologies Inc.  
As 500ng/ml rhIL-17 failed to induce detectable luciferase activity in 57A HeLa cells, 2ng/ml rmTNF-α 
was added to enhance its activity. IL-17 activates IL-6 synergistically with many other cytokines 
including TNF-, IL-1β, IFN- and IL-22 (114, 115, 121, 425, 426) and IL-17A and IL-17F 
responsiveness is often evaluated in conjunction with suboptimal concentrations of TNF- (135).  
 
293T cells IL-6 promoter responsive dual luciferase assay 
1.25 x 105 293T cells in 1ml complete DMEM were seeded in 12-well plate and incubated overnight 
at 37°C in 10% CO2. The next day cells were transiently co-transfected with 2g pGL2 containing IL-6 
promoter responsive luciferase and 0.2g Renilla-CMV using calcium phosphate co-precipitation 
method, and incubated in 1ml complete DMEM overnight at 37°C in 10% CO2. On day 3, the cells 
were washed twice with serum free DMEM and in triplicates stimulated with 500ng/ml rhIL-17, 
50ng/ml rhIL-1, PMA, PMA+ Ionomycin, 0.5 % FBS containing DMEM for 24 hours at 37°C in 10% 
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CO2, washed twice with PBS, lysed with 250l reporter lysis buffer under moderate agitation for 30 
min at RT, lysate centrifuged at 1200rpm for 10 min. 10l lysate was transferred to luminometer 
reading plate and analysed by MLX microtitre plate luminometer, Dynex Technologies Inc. using Stop 
and Glow dual luciferase assay kit. The IL-6 responsive luciferase activity was analysed first in the 
presence of 50l luminometer substrate, followed by analysis of Renilla CMV activity in the presence 
of 50l Renilla substrate. 
 
Evaluation of IL-17 induced activation of IL-6 promoter-responsive luciferase in HeLa cells 
Stable transfection of HeLa cells with pGL2 containing IL-6 promoter responsive luciferase 
Hela cells were stably transfected with plasmid expression vector pGL2 with previously cloned IL-6-
promoter responsive luciferase (kindly provided by Prof Yuti Chernajovsky, BJRU) fused to Blasticidin 
resistant site containing plasmid vector pcDNA6.  
Fusion of plasmid vectors pGL2 and pcDNA6 
10μg pGL2 and 1μg pcDNA6 were linearized in buffer 4 by restriction digestion at FSP1 site, which 
cleaved pcDNA6 once and PGL2 twice, albeit within the Ampicillin resistant site; phenol: chloroform 
extracted; Sodium acetate and Ammonium acetate precipiated and ligated with 5μl T4 ligase in total 
150μl volume ligation reaction. The ligation mixture was Ammonium acetate precipitated, 
resuspended in 100μl H2O and frozen at -20°C. Efficiency of the ligation was visually confirmed on 
1% agar gel. 
Estimation of Blasticidin concentration for selection of HeLa cells 
2 x 105 HeLa cells in 5ml DMEM were incubated in eight separate 5ml tissue culture flasks in 10% 
CO2 at 37°C until adherent. The cells were then treated with DMEM plus Blasticidin in the 
concentrations of 0, 1, 2, 3, 5, 7, 8 and 10μg/ml and the antibiotic containing medium changed every 
3 days. The cells were visually assessed for cell apoptosis on daily basis for determination of the 
concentration of Blasticidin required for optimum cell selection. 
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Stable transfection of HeLa cells using calcium phosphate co-precipitation method 
0.5 x 106 cells were incubated in complete DMEM in 10% CO2 at 37°C until adherent, medium 
changed to fresh complete DMEM, after 6 hours cells were transfected with 50μl ligation mixture of 
plasmid DNAs pcDNA6 and pGL2 using calcium phosphate co-precipitation method as described in 
the Section 2.1.9a. Following glycerol shock, the cells were incubated in complete DMEM for 24 
hours in 10% CO2 at 37°C, split into 4 and incubated in complete DMEM plus 2μg/ml Blasticidin at 
37°C in 10% CO2. The antibiotic containing medium was changed every 3-4 days. Blasticidin selected 
cell clones were expanded to adequate size, ring cloned and individual clones incubated in complete 
DMEM plus 2μg/ml Blasticidin in 12-wells plates in 10% CO2  at 37°C until confluent. 
Stable transfection of HeLa cells using Fugene 6 transfection reagent  
1 x 106 cells in 10ml complete DMEM medium in 9cm culture plate were incubated in 10% CO2 at 
37°C until adherent and transfected with 50l ligation mixture of pcDNA6 and pGL2 using 18l 
Fugene6 (Roche Diagnostics Corporation, Indianapolis, IN) as per the manufacturer’s instruction. The 
cells were incubated for 48 hours in 10% CO2 at 37°C until ready for passage and antibiotic selection. 
Stable transfection of HeLa cells using electroporation  
1 x 106 HeLa cells were pelleted by centrifuging the cell suspension at 1000rpm for 10 minutes, 
mixed with 100l solution V and ligation mixture of pcDNA6 plus pGL2, transferred to Amaxa cuvette 
and electroporated using 2 different programmes, O-005 for better viability and I-013 for better 
efficiency of transfection. The electroporated cells were immediately transferred to 500l complete 
DMEM, the cell suspension divided into 3 equal parts and incubated in 6-well plate in 3ml complete 
DMEM overnight in 10%CO2 at 37C. Next day, after trypsinising, the cells were pooled together and 
incubated in 10ml complete DMEM plus 2μg/ml Blasticidin in 9cm plate in 10%CO2 at 37C until 
ready for ring cloning of Blasticidin selected clones. 
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Ring cloning  
No more than 2 clones per plate were ring cloned. The cells were washed with PBS twice and a 
sterile ring was placed around the selected clones using sterile paraffin, cells trypsinised with 50l 
Trysin-EDTA and individual cell clones transferred to 12-well plate in 2ml complete DMEM plus 
2μg/ml Blasticidin and incubated in 10% CO2 at 37°C until confluent. After adequate expansion, the 
cell clones were grown in 9cm plates in 10ml complete DMEM plus 2μg/ml Blasticidin in 10% CO2 at 
37°C until 70% confluent. The individual cell clones were then examined for their suitability for the 
future biological assays. 
Assessing biological activity of antibiotic selected clones  
1 x 104 HeLa cells stably transfected with IL-6 promoter-responsive luciferase were seeded in 100l 
DMEM plus 2μg/ml Blasticidin in 96-well plate and incubated at 37°C in 10% CO2 until adherent. The 
cells were serum starved by incubating in 0.5% FBS containing DMEM overnight at 37°C in 10% CO2 
and next day stimulated with 100ng/ml rhIL-17 in 0.5% serum containing DMEM for 24 hours in 10% 
CO2 at 37°C. The cell lysates were analysed for the background and IL-17- induced luciferase activity 
as described in Section 2.3.1d. 
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2.3.2 Characterisation of in vitro biological properties of expressed mouse IL-17 proteins 
2.3.2a Determining receptor binding affinity of mouse FL-IL-17F mutants 
A functional ELISA to assess the binding of mouse FL-IL-17F mutants to mIL-17RC was carried out 
similar to that for human IL-17F mutant (Section 2.3.1a) except for the following differences: The 
starting final concentration of mouse IL-17 was 0.3μg/ml and goat biotinylated anti-mouse IL-17F 
was used at the concentration of 1μg/ml. 
 
2.3.2b Fibroblast cells IL-6 induction mouse IL-17 bioassay 
Developing an in-house mouse IL-6 ELISA 
Anti-mouse IL-6 antibodies-producing hybridoma cells  
Anti-mouse IL-6 capture and detect antibodies producing hybridoma cells, HB10656 and HB10657 
were kindly gifted by Dr. Richard Williams, Kennedy Institute, Imperial College, London. The cells 
were maintained in complete RPMI supplemented with 10% FBS, 100U/ml Penicillin, 100g/ml 
Streptomycin and 2mM L-Glutamine. Approximately one litre cell culture supernatant from the cells 
grown at a final density of 0.5-1 x 106 cells/ml was collected and stored at -80°C until purified. 
Purification of antibodies containing supernatants  
The supernatants were filter sterilised prior to purification, using ProSep G columns (Millipore, 
Schenectady, USA). In brief, Prosep G resin was packed in binding buffer (0.5M glycine in PBS, pH 
7.4) in column and equilibrated with a minimum of 100 column volume/hour binding buffer ran 
through the column for 30-60 minutes. Then the following agents were run through the column at a 
speed of 1ml/min in the same order. The column was first cleaned with 5 column volumes of 6M 
Guanidine HCl, regenerated with 10 column volumes of HCl, pH 1.5 followed by 5 column volumes of 
1X PBS. Thereafter 5 column volume of binding buffer were passed through the column before 
running the antibody containing supernatants from the hybridomas. The column was washed with 5 
column volumes of binding buffer and protein eluted with 3M potassium thiocyanate in PBS in 
multiple 1ml fractions. The column was washed with 50-100ml of 1X PBS plus 0.2-1% sodium azide. 
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The OD of the eluted fractions was determined at 280nm. The eluate was dialysed in 1X PBS using 
Slide-A-Lyzer dialysis cassettes allowing at least 4 hours of exchange in total 100X volume of the 
eluate. A fraction of eluate was resolved by SDS-PAGE gel under non-reducing conditions and stained 
with Commassie Blue. Eluates were aliquoted and stored at -80C. 
Biotinylation of mouse anti- IL-6 detect antibody  
The mouse anti-IL-6 antibody was biotinylated using EZ-Link  sulfo-NHS-SS-Biotinylation kit (Pierce 
Biotechnology, Rockford, USA). 
10mM Biotin was freshly prepared by dissolving 2.2mg Biotin in 360l of deionised H2O. 19.8l 
Biotin was added to 1ml detect antibody in PBS (1.5mg/ml) and incubated for 30-60 minutes at RT. 
The excess Biotin was removed using equilibrated Zeba desalt column and centrifuging at 1000g 
for 2 minutes. The antibody containing flow through was collected and stored at -80°C. 
The level of Biotin incorporation was estimated using HABA assay as follows: 10 mg avidin and 600l 
10mM HABA (4-Hydroxyazobenzene-2-Carboxylic acid) was added to 19.4 ml of PBS and absorbance 
measured at 500nm to confirm that A500 of this solution was between 0.9-1.3 in a 1cm cuvette.  
First the absorbance of 180l HABA/avidin solution in the microplate was measured at 500nm on its 
own and repeated after adding 20μl biotinylated antibody solution. The degree of biotinylation was 
reflected by the difference between the two values and calculated as Moles of Biotin per Mole of 
protein. 
Testing immunoactivity of purified anti-IL-6 capture and detect antibodies  
On day 1, an ELISA plate was coated with 50μl/well capture antibody in varying concentrations as 
outlined in Fig. 2.5 and incubated at 4°C overnight. On day 2 after washing thrice with PBST (1%PBS 
plus 0.05% Tween20), the plate was blocked with 50μl 1% casein for 1 hour at RT; incubated with 
two-fold serially diluted 50μl/well recombinant mouse IL-6 in PBST at the starting concentration of 
20ng/ml for 1 hour at RT, then incubated with 50μl/well biotinylated antibody in PBST in varying 
dilutions (Fig. 2.5) for 1 hour at RT followed by incubation with 50μl/well Avidin/HRP (1:1000 diluted 
in PBST) for 1 hour at RT. The plate was washed with PBST thrice after each step. Finally, the plate 
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was incubated with 50μl substrate (freshly prepared by dissolving 1 tablet Sigma fast  o-
phenylenediamine dihydrochloride in 20 ml distilled water) in the dark for 15 minutes. The reaction 
was stopped with 10μl/well 20% sulphuric acid and absorbance read at 450nm. 
An ELISA to test immunoactivity was repeated by coating 2 separate ELISA plates with 50μl/well  
5g/ml capture antibody and blocking one plate with 1% casein and the 2nd plate without casein, 
using IL-6 standard at the starting concentration of 5ng/ml and detect antibody in 1:250 and 1:500 
dilutions substituting PBST by 1% casein as diluting reagent. 
 
 
Figure 2.5 Testing immunoactivity of purified mouse anti-IL-6 antibodies. Hybridoma cells derived 
mouse anti-IL-6 capture and detect antibodies were purified using Prosep G column, detect anti-IL-6 
antibody biotinylated and tested for immunoactivity by ELISA. Capture antibody in the 
concentrations of 2μg/ml, 5μg/ml and 10μg/ml were examined for IL-6 reactivity using two-fold 
serially diluted IL-6 standard in the starting concentration of 20ng/ml and biotinylated anti-IL-6 
detect antibody in 1:100, 1:200, 1:500 and 1:1000 dilution by sandwich ELISA and absorbance read 
at 450nm. 
 
 
 
 
115 
 
Mouse IL-17-Induced secretion of IL-6 in NIH 3T3 cells  
5 x 103 cells in 100l complete DMEM in 96-well plate were incubated in 10% CO2 at 37C until 
adherent and stimulated with 100l 100ng/ml rmIL-17A and -IL-17F; FL-IL-17A, -IL-17F and -IL-17F 
mutant 1; and MMP-1-treated and untreated LAP-IL-17A, -IL-17F and-IL-17F mutant 1 along with 
10ng/ml rmTNF- as positive control, complete DMEM alone in triplicates in 10% CO2 at 37C for 24 
hours. The supernatants were analysed using mouse IL-6 Duoset ELISA (R & D Systems Europe Ltd., 
Abingdon, UK) as per the manufacturer’s instructions. 
 
2.3.2c Developing a novel luciferase reporter assay to analyse bioactivity of mouse IL-17 
Raw 264.6 cells NF-B-promoter-driven luciferase assay  
1 x 106 raw264.7 NF-B luc cells (made by Dr. S. Vessillier of BJRU) were incubated in 2ml complete 
DMEM plus 200g/ml G418 in 12-well plate at 37C in 10% CO2 overnight, stimulated with 1ml/well 
500ng/ml rmIL-17A, FL- IL-17A and -IL-17F in serum-free DMEM in triplicates at 37C in 10% CO2. 
overnight. For the purpose of positive control, the cells were incubated with 1ml/well 10g/ml 
lipopolysaccharide for 4 hours at 37C in 10% CO2. The cells were washed with PBS twice, lysed with 
100l cold lysis buffer (200mM NaCl, 20mM Tris HCl, pH 8, 1% Triton X-100) and lysates examined 
for luciferase activity as described in Section 2.3.1d. 
 
DTF cells IL-6 promoter-responsive luciferase assay 
Stable transfection of DTF cells with IL-6 promoter responsive luciferase 
DTF cells were stably transfected with pGL2 containing IL-6 promoter responsive luciferase using the 
same protocol as that was used for transfection of HeLa cells (Section 2.3.1d). The concentration of 
Blasticidin for optimum selections of DTF cells was determined and the cells stably transfected using 
calcium phosphate co-precipitation, antibiotic selected clones expanded and screened for biological 
activity as described above for HeLa cells. One of the antibiotic selected clones which on screening 
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demonstrated a low background activity along with activation of luciferase in response to rmIL-17A 
and was further analysed as follows: 
2 x 104 DTF cells stably transfected with IL-6 promoter-responsive luciferase were stimulated with 
100l/well two-fold serially diluted rmIL-17 (500ng/ml), mouse FL-IL-17A and 17F in 0.1% FBS 
containing DMEM in triplicates for 6 hours at 37C in 10% CO2. The cells were lysed and lysates 
analysed for luciferase activity as described in the Section 2.3.1d. 
As 500ng/ml rmIL-17 failed to activate luciferase in these cells, 2ng/ml recombinant mouse TNF-α 
was added to enhance the activity of IL-17A. 
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2.4 Gene therapy in mouse models of inflammation 
Preparation of endotoxin-free plasmid DNA 
Plasmid DNA encoding human FL-IL-17A, LAP-IL-17A, FL-IL-17F mutant and LAP-IL-17F mutant was 
extracted and purified using Endofree® Plasmid Mega Kit (Qiagen Ltd, Crawley, UK) as per the 
manufacturer’s instructions. In brief, pellet of sterile 500ml high copy overnight LB bacterial culture 
obtained by centrifugation at 4000g at 4°C for 20 min using Multispeed Centrifuge (PK 121, ALC 
International, Milan, Italy) was homogeneously resuspended in 50ml Buffer P1 (50mM Tris HCl, pH 
8.0, 10mM EDTA and 100μg/ml RNase A), lysed in 50ml Buffer 2 (200mM NaOH, 1% SDS) by 
vigorously inverting 5 times and incubating at RT for 5 min, and neutralized with 50ml chilled Buffer 
P3 (3.0M potassium acetate, pH 5.5) by subjecting it to a thorough mixing by vigorously inverting 5 
times. The lysate was added to QIAfilter Mega Cartridge and incubated for 10 min; cleared under a 
vacuum source and washed with 50ml Buffer FWB2 (1M potassium acetate, pH 5.5) using vacuum. 
For removal of endotoxins, the cleared lysate was mixed with 12.5ml Buffer ER by inverting the tube 
10 times and incubated on ice for 30 min. The ER buffer-treated lysate was applied to a QIAGEN-tip 
2500 [pre-equilibrated with 35ml Buffer QBT (750mM NaCl, 50mM MOPS, pH 7.0, 15% isopropanol, 
0.15% Triton® X-100] and allowed to enter the resin by gravity flow, washed with 200ml Buffer QC 
(1.0M NaCl, 50mM MOPS, pH 7.0, 15% isopropanol). The bound plasmid DNA was eluted with 35ml 
Buffer QN (1.6M NaCl, 50mM MOPS, pH 7.0, 15% isopropanol), eluted DNA precipitated by adding 
24.5ml isopropanol and centrifuging at 4000rpm at 4°C for 90 min. The DNA pellet was washed with 
endotoxin-free 70% ethanol and centrifuged at 4000rpm at 4°C for 30 min, air-dried for 10-20 min, 
resuspended in endotoxin-free water (Qiagen Ltd, Crawley, UK) and stored at 4°C. Plasmid DNA 
concentration was determined at 260nm using Pharmacia GeneQuant spectrophotometer 
(Cambridge, UK). A sample of the purified plasmid DNA was digested with the enzymes used for 
cloning and analysed on 1% agarose gel to confirm the presence of insert of the correct size. 
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C57BL/6 mice 
Thirty 6 weeks-old male C57BL/6 mice (20-25g, Charles River UK Limited, UK) were kept under 
standard conditions and maintained in a 12 h/12 h light/dark cycle at 22 ± 1°C in accordance with 
United Kingdom Home Office regulations (Guidance on the Operation of Animals, Scientific 
Procedures Act 1986) and of the European Union directives. 
SCID mice 
Four female and 4 male, 6-weeks-old SCID beige mice (Charles River UK Limited) were kept under 
standard conditions as described above.  
 
Intravenous hydrodynamic delivery of plasmid DNA 
Mice were lightly anaesthetized with 4% Isoflurane (IsoFlo®, Abott Laboratories Ltd, Berkshire, UK) 
mixed in O2/NO at 1:1 atmosphere using Boyles’ apparatus (British Oxygen Company, London, UK). 
Mice were injected in the tail vein with 5μg/ml plasmid DNA in normal saline (NS), equating to 10% 
average mice body weight rapidly over 10-15 seconds. The untreated group of mice were injected 
with NS alone. 
 
Determining in vivo expression of human IL-17 transgene in mice  
Collection of serum 
Mice were tail bled or terminally bled via cardio-puncture after light anaesthesia. Blood was allowed 
to clot by storing overnight at 4°C, serum recovered by centrifuging at 14000 rpm at 4°C for 15 
minutes and frozen at -80°C.  
Harvesting mouse liver tissue 
After sacrificing the mice, liver was dissected out and 20mg harvested liver tissue was stabilised by 
immediately immersing in 200μl RNAlater® RNA stabilisation reagent (Qiagen, UK) and stored at -
80°C. A separate piece of liver tissue was snap frozen in liquid nitrogen and stored at -80°C until 
analysed. 
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Preparation of liver homogenates 
Approximately 5mm piece of liver tissue (previously snap frozen in liquid nitrogen and stored at  
-80°C) was homogenised in 500μl ice cold lysis buffer (20mM Tris HCl, pH 7.4, 150mM NaCl, 1% 
Triton X-100, 1% BSA, freshly added Halt™ Protease inhibitor, single use cocktail, EDTA free 100X, 
Thermo scientific, Rockford, USA) in pre-cooled homogenization tubes (Precellys CK14, Bertin 
Technologies) at 3000rpm, 2 x 20 sec pulses using Precellys™ control device (Stretton Scientific Ltd.). 
The homogenate was centrifuged at 1500rpm at 4°C for a maximum of 5 min. Protein concentration 
in the homogenised liver sample was estimated by BCA. The BCA standard and cell lysates were 
diluted in PBS at least 50-fold to eliminate protein reactivity intrinsic to the lysis buffer due to the 
presence of 1% BSA. 
Ultrasensitive ELISAs  
In vivo expression of human IL-17 transgene in mice following systemic gene therapy was analysed 
by human IL-17A and IL-17F ultrasensitive ELISAs. 
Human IL-17A ultrasensitive ELISA 
Levels of human IL-17A in mice serum were analysed using human IL-17A ultra-sensitive kit in 
association with diluents 4 and 5 (Meso Scale Discovery multi-array® System, Gaithersburg, USA) as 
per the manufacturer’s instructions. In brief, 25μl/well diluent 4 in the MSD ELISA plate was 
incubated at 175 rpm for 30 min at RT; 25μl mouse serum, airpouch lavage fluid or IL-17A standard 
(concentrations 2.4-10,000pg/ml) in diluent 4 in duplicate were incubated at 175rpm for 2 hours at 
room temperature; washed 3 times with PBST; 25μl detection antibody solution added and 
incubated at 175 rpm for 2 hours, washed 3 times with PBST; 150μl 2X read buffer added and the 
plate was analysed using MSD-sector imager 2400.  
Human IL-17F ultrasensitive ELISA 
Levels of human full-length and LAP-IL-17F mutant in mice serum, airpouch lavage fluid and liver 
homogenate samples were analysed using human IL-17F ultrasensitive ELISA using 2μg/ml capture 
and 0.5μg/ml detect antibody in diluents 4 and 5 as described in the Section 2.2.2c. 
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2.4.1 Human IL-17A systemic gene therapy in naïve SCID mice  
Six-weeks-old SCID beige mice (Charles River UK Ltd.) were divided into two groups of 4 mice each 
containing 2 female (average weight 17.5g) and 2 male mice (average weight 21.5g). Mice were 
treated with intravenous hydrodynamically delivered 5μg/ml human full-length IL-17A or LAP-IL-17A 
plasmid DNA. Blood was collected at 48 hours, 1 week and 2 weeks and serum recovered and stored. 
Levels of human IL-17 transgene in mice serum were analysed by human IL-17A ultra-sensitive ELISA.  
 
 
 
 
 
Figure 2.6 Evaluation of in vivo expression and pharmacokinetics of human IL-17 systemic gene 
therapy in naïve SCID mice. Four mice in groups of 2 were treated with intravenous 
hydrodynamically delivered hIL-17A or hLAP-IL-17A and blood collected at 48 hours, 1 week and 2 
weeks. Levels of hIL-17A in mice serum were analysed by IL-17A ultrasensitive ELISA.  
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2.4.2 Evaluation of human IL-17F mutant systemic gene therapy in mouse airpouch 
inflammation 
Preparation of airpouch and induction of acute inflammation 
After lightly anaesthetising C57BL/6 mice, dorsal airpouch were prepared by injecting 2.5ml air 
subcutaneously on days 1 and 4. On day 5, acute non-specific inflammation was induced by directly 
injecting 0.5ml 0.5% Carboxy methyl cellulose (CMC 0.5% w/v in sterile PBS) into pouch as previously 
described by Perretti et al. (427, 428).  
Hydrodynamic delivery of human IL-17 plasmid DNA 
On day 4, mice in groups of five were treated with intravenous hydrodynamically delivered 5μg/ml 
human FL-IL-17F mutant, LAP-IL-17F mutant DNA, FL-IL-17A, FL-IL-17A plus FL-IL-17F mutant, 1μg/ml 
LAP-IL-17F mutant and NS alone to investigate in vivo expression of human IL-17 transgene. Mouse 
serum, liver homogenates and airpouch lavage exudate were analysed for the expression of the 
transgene. The study was terminated at 52 hours post-DNA delivery to allow analysing transgene 
levels in acutely inflamed airpouch at 4 hours following its systemic expression at 48 hours. 
Collection of airpouch lavage fluid 
Mice were culled by cervical dislocation. Airpouch was washed thoroughly with 2ml PBS containing 
3mM EDTA through a small incision and the recovered lavage fluid was collected in 14ml 
polypropylene round-bottom FACS tubes (Becton Dickinson, USA), centrifuged at 1500rpm for 10 
min at 4°C to separate the exudate from the inflammatory cells. Inflammatory exudate was 
collected, total volume measured and frozen at -80°C. 
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Figure 2.7 Investigation of in vivo distribution of human IL-17F mutant gene delivery in mice 
airpouch. Six mice in each group were treated with intravenous hydrodynamic DNA delivery of hIL-
17F mutant plus hIL-IL-17A or hIL-17A, hFL-IL-17F mutant, hLAP-IL-17F mutant (1μg and 5μg/ml) and 
NS alone 52 hours before the termination of the study. This allowed a 48 hours period for the 
expression of transgene to take place and then study its distribution on tissues after CMC-induced 
inflammation for a total 4 hours. Expression of transgene was analysed in serum, airpouch lavage 
fluid and liver homogenate samples.  
 
 
 
 
 
Statistical analysis: One way ANOVA and students T test were used to compare the levels of induced 
cytokines between treatment groups and p values less than 0.05 were considered significant. Results 
are expressed as the mean ± SEM unless stated otherwise. 
 
 
 
 
 
 
123 
 
 
 
 
 
 
 
CHAPTER III 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLONING OF HUMAN, MOUSE AND LATENT  
IL-17 ISOFORMS 
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3.1 Introduction 
A new therapeutic agent can be developed and tested rapidly using recombinant DNA technology. 
Cloning of a therapeutic gene in a suitable expression vector enables its expression in protein form 
both in vitro and in vivo, thus allowing an expedient broad preclinical testing. Both viral and non-viral 
vectors can be used for expression of a gene of interest in mammalian cells. Non-viral or plasmid 
vectors are safer than viral vectors but require adjunct physical or chemical approaches for an 
adequate transfection efficiency. Plasmid expression vector pcDNA3 contains all the elements such 
as CMV promoter with enhancer, T7 site for forward DNA sequencing for expression in relevant E 
coli host, SV40 origin of replication, Neomycin and Ampicillin drug selection genes for use in 
eukaryotic and prokaryotic cells respectively, bovine growth hormone (BGH) polyadenylation site to 
stabilise the mRNA, multiple cloning sites required for efficient cloning in bacteria, and expression in 
eukaryotic cells (Fig. 3.1). The SP6 site allows for DNA sequencing using a well characterised reverse 
primer. pcDNA3-LAP encompasses pcDNA3 with a previously cloned LAP of TGF-β (353) . 
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Figure 3.1 Plasmid expression vector pcDNA3. pcDNA3 contains all the elements required for 
efficient cloning in bacteria, and cloning and translation in eukaryotic cells. CMV promoter/ 
enhancer permits efficient, high level expression of protein, T7 enhancer allows in vitro transcription 
in the sense orientation and sequencing through the insert, SV40 enhancer promoter and origin of 
replication facilitates high level protein expression and replication of plasmid in cell lines containing 
large T antigen, SV40 poly functions as transcription terminator, Bovine growth hormone polyA 
provides efficient transcription termination and mRNA polyadenylation, Neomycin resistant site is 
utilised for selection of stable transfectants in mammalian cells, Ampicillin resistant site allows 
selection of vector in E. coli, multiple cloning site allows insertion of gene of interest. 
 
 
 
IL-17 mRNA was derived from T cells, which produce IL-17 in both human and mouse. Prior to RT-
PCR, mRNA extracted from mouse splenic T cells was analysed for integrity. mRNA comprises only 1-
3% of total RNA and is not readily detectable even with the most sensitive of methods. Ribosomal 
RNA (rRNA) however comprises more than 80% of total RNA. mRNA quality has historically been 
assessed by visual assessment of quality and quantity of rRNA on 1% agarose gel electrophoresis. 
The majority of rRNA in mammalian system is comprised by the 28S and 18S rRNA and a 28S:18S 
ratio of 2:1 is taken as indicative of intact RNA.  
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Human CD14- PBMC and NIH Swiss mouse splenic T cells cDNA was used as template for PCR 
amplification of human and mouse IL-17. A hot-start PCR was employed if necessary. A manual 
heating of reaction components prior to adding polymerase to the denaturation temperature of 95° 
reduces non-specific amplification during the initial set up stages of the PCR. It also permits optimum 
denaturation of primers especially those with high CpG contents. Non-specific amplification can also 
be reduced by raising annealing temperature. In the event of presence of more than one band on 
agarose gel electrophoresis analysis of PCR reaction, band that represented the gene of interest was 
isolated and purified by gel extraction. 
 
Site-directed mutagenesis 
Mutation at a defined site in a DNA molecule can be created using one of the several approaches 
such as Kunkel’s method, cassette mutagenesis, PCR mutagenesis and whole plasmid mutagenesis. 
In Kunkel’s method, mutagenesis template is generated by insertion of wild-type DNA in phagemid 
such as M13mp18/19 and transforming in E. coli that are deficient in DNA repair enzymes (429). 
Cassette mutagenesis involves insertion of a complementary pair of oligonucleotide containing the 
mutated gene in plasmid whereas PCR mutagenesis involves amplification of DNA template using 
single primer that contains the desired mutation. PCR reaction mixture resulting from PCR 
mutagenesis however contains original unmutated DNA in addition to mutated DNA. PCR 
mutagenesis could also lead to counter selection of mutants due to presence of mismatch repair 
system which favors the methylated template DNA. The method of whole plasmid site-directed 
mutagenesis comprises amplification of entire plasmid using a pair of complementary mutagenic 
primers followed by elimination of template DNA. This method is highly efficient, relatively simple 
and commercially available as a kit.  
PCR amplified full-length and mature human and mouse wild-type and mutated IL-17 were cloned in 
pcDNA3 and pcDNA3-LAP at multiple cloning sites.The genes conferring resistance to Ampicillin were 
utilised for antibiotic selection of transformed E coli. The selected colonies were grown in Ampicillin 
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containing LB medium and plasmid extracted by alkaline lysis. The confirmation of correctly cloned 
constructs was attained by gene sequencing using ABI 3730xl capillary sequencer and restriction 
digestion with enzymes same as those used for cloning. 
 
3.1.1 Aims 
1. To harvest mRNA from mouse splenic T cells and RT-PCR it to generate cDNA. 
2. To create human (H161R) IL-17F mutant and 3 mouse analogues of human IL-17F mutant.  
3. To clone human and mouse full-length and mature IL-17 DNAs in plasmid expression vectors 
pcDNA3 and pcDNA3-LAP. 
 
 
 
 
 
 
 
 
 
 
 
 
 
128 
 
3.2 Results 
3.2.1 Confirming integrity of mouse splenic T cells mRNA 
Mouse IL-17 was amplified using template cDNA derived by reverse transcription of NIH Swiss 
mouse splenic T cells mRNA. Integrity of mouse spleen extracted RNA was analysed by visual 
assessment of 28S:18S rRNA ratio on 1% agarose gel. As shown in the figure 3.1, the 28S:18S ratio 
was approximately 2:1, which confirmed the integrity of mRNA. 
 
 
 
 
Figure 3.2 Confirming integrity of mouse splenic T cells mRNA. Swiss mouse splenic T cells cDNA 
was used as template to amplify mouse IL-17. RNA extracted from mouse spleen was analysed for 
integrity of mRNA by visual analysis of ribosomal RNA on 1% agarose gel electrophoresis. Lane 2 
shows presence of 5kb and 2kb sized 28S and 18S ribosomal RNA bands in an approximate ratio of 
2:1 indicating intact RNA. Lane 1 shows control RNA extracted from 293T cells. 
                
 
 
 
3.2.2 Cloning of human IL-17  
The PCR amplified human full-length IL-17A, IL-17F and IL-17F mutant genes were cloned in pcDNA3 
at BamH1 and Xba1 sites. The human (H161R) IL-17F mutant was created by restriction digestion of 
wild type IL-17F DNA at BSPM1 site and substitution of the deleted C-terminal end with custom 
ordered complementary oligonucleotides containing the desired mutation. Human LAP-IL-17 
constructs were generated by cloning mature IL-17A, IL-17F and IL-17F mutant in pcDNA3-LAP at 
Not1 and Xba1 sites. Generation of the correct constructs were confirmed by DNA sequencing and 
restriction enzyme digestion of plasmid DNA (Figs 3.3 and 3.4).  
                                    1         2                    
28S 
18S 
129 
 
 
Figure 3.3 Restriction enzyme analysis of human full-length IL-17 on 1% agarose gel confirming the 
correct cloning of IL-17 in pcDNA3. BamH1 and Xba1 restriction digestion of uncut plasmid DNAs 
(size 5.4kb, lanes 2, 5 and 8) released the insert and vector fragments of expected size. Lanes 3, 6 
and 9 show that the released full-length IL-17A, and IL-17F and IL-17F mutant fragments were of 
expected 465 and 489 bp size respectively (circled in red) confirming the correct cloning. The 1kb 
molecular weight DNA ladder was used to assess the size of DNA fragments (lanes 1, 4 and 7). 
 
 
 
 
 
 
Figure 3.4 Restriction enzyme analysis of human LAP-IL-17 on 1% agarose gel confirming the 
correct cloning of mature IL-17 in pcDNA3-LAP. Not1 and Xba1 restriction digestion of uncut 
plasmid DNAs (size 6.1kb, lanes 2, 5 and 8) released the insert and vector fragments of expected 
size. Lanes 3, 6 and 9 show that the released mature IL-17A, and IL-17F and IL-17F mutant fragments 
were of expected 393 and 399 bp size respectively (circled in red) confirming the correct cloning. The 
1kb molecular weight DNA ladder was used to assess the size of DNA fragments (lanes 1, 4 and 7). 
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3.2.3 Cloning of mouse IL-17  
The PCR amplified mouse full-length and mature wild-type and mutated IL-17 were cloned in 
pcDNA3 and pcDNA3-LAP similar to that for human IL-17 (Figs 3.5 and 3.6). Three mouse FL-IL-17F 
mutants namely (Q158R) IL-17F mutant 1, (H157R)IL-17F mutant 2 and a truncated  IL-17F mutant 3 
were derived by PCR mutagenesis of wild type IL-17F resulting in substitution of nucleotide T at 
position 464 by C, nucleotide A at 461 by G and codon GGA at 457-59 by stop codon respectively.  
 
 
 
                    
 
Figure 3.5 Restriction enzyme analysis of mouse full-length IL-17 on 1% agarose gel confirming the 
correct cloning of IL-17 in pcDNA3. BamH1 and Xba1 restriction digestion of uncut plasmid DNAs 
(size 5.4kb, lanes 2, 5, 8, 10 and 12) released the insert and vector fragments of expected size. The 
released full-length IL-17A (lane 3), IL-17F and IL-17F mutants 1 and 2 (lanes 6, 9 and 11) and IL-17F 
mutant 3(lane 13) fragments were of expected 474, 483 and 471 bp size respectively (circled in red) 
confirming the correct cloning. The 1kb molecular weight DNA ladder was used to assess the size of 
DNA fragments (lanes 1, 4 and 7). 
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Figure 3.6 Restriction enzyme analysis of mouse LAP-IL-17 on 1% agarose gel confirming the 
correct cloning of mature IL-17 in pcDNA3-LAP.Not1 and Xba1 restriction digestion of uncut plasmid 
DNAs (size 6.1kb, lanes 2, 5, 8, 10 and 12) released the insert and vector fragments of expected size. 
The released mature IL-17A, IL-17F, IL-17F mutants 1 and 2 (lanes 3, 6, 9 and 11) and IL-17F mutant 3 
(lane 13) fragments were of expected 399 and 387 bp size respectively (circled in red) confirming the 
correct cloning. The 1kb molecular weight DNA ladder was used to assess the size of DNA fragments. 
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3.3 Discussion 
 
Human and mouse full-length and mature wild-type and mutated IL-17 DNA were successfully 
cloned in plasmid expression vectors pcDNA3 and pcDNA3-LAP. BamH1 and Xba1 restriction sites at 
multiple cloning sites of pcDNA3 were utilised for cloning of human and mouse wild-type and 
mutated full-length IL-17 in pcDNA3, whereas Not1 and Xba1 sites were used for cloning of human 
and mouse wild-type and mutated mature IL-17 in pcDNA3-LAP. The MMP cleavable linker located 
between the LAP of TGF-β and mature IL-17 cytokine region allows the release of biologically active 
cytokine at the sites of high MMP activity. 
Mouse IL-17 was amplified using mouse splenic T cells cDNA as template. The integrity of mRNA 
extracted from mouse spleen was analysed by 1% agarose gel electrophoresis and confirmed by 
presence of 28S:18S rRNA bands in ratio 2:1. Mouse IL-17A and IL-17F mutants were amplified by 
hot-start PCR due to a relatively high CpG content of the primers. Non-specific PCR amplification of 
mouse IL-17F DNA could not be eliminated by raising annealing temperature; the correct DNA band 
was therefore isolated by gel-purification. Alternative splicing of mouse IL-17F has not been 
reported although human IL-17F has been shown to exist in two forms (131). 
Human (H161R) IL-17F mutant was created by substituting nucleotide A at position 485 by G using 
cassette mutagenesis. The presence of point mutation in IL-17F gene at the extreme C-terminal end 
and an adjacent BSPM restriction site allowed for an effective insertion of mutation containing 
complementary oligonucleotides. Mouse IL-17F is 3 amino acids shorter than human IL-17F and 
contains Glutamine at position equivalent to mutated Histidine in human IL-17F. The first mouse IL-
17F mutant analogue was therefore created by Arginine substitution of Glutamine at amino acid 
position 158 instead of Histidine at 161 in human IL-17F. Amino acid Histidine is however present in 
mouse IL-17F immediately preceding Glutamine at 158. The second mouse IL-17F mutant therefore 
comprised Arginine substitution of Histidine at 157. The third Mouse IL-17F mutant was created by 
deleting the last 4 amino acids in mouse IL-17 to create a truncated form. PCR mutagenesis was used 
to build the desired point mutations and the deletion mutation in wild-type IL-17F.  
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Following successful cloning IL-17 proteins were expressed in vitro and their immunological and 
biological properties analysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
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CHAPTER IV 
 
 
 
 
 
 
 
 
 
 
 
CHARACTERISATION OF IMMUNOLOGICAL 
PROPERTIES OF THE EXPRESSED  
IL-17 PROTEINS 
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4.1 Introduction 
Following successful cloning of human and mouse full-length and LAP-IL-17 in plasmid expression 
vector pcDNA3, IL-17 proteins were expressed in vitro under the control of CMV promoter by 
transient transfection of mammalian cells. Unlike prokaryotes or lower eukaryotes, mammalian cells 
have capability to conduct elaborate posttranslational modifications, especially N-glycosylation of 
the complex type, hence are often preferred host to produce human recombinant proteins. 293T 
cells derived from human embryonic kidney contain large T cell antigen, hence allowing replication 
of plasmid DNA that contains an SV40 origin of replication such as pcDNA3 and secretion of high 
quantity of expressed proteins. 293F or Chinese hamster ovary (CHO) suspension cell are currently 
used for medium scale production of recombinant proteins in our laboratory.  
Entry of naked DNA into mammalian cells requires facilitation by natural or synthetic vehicles that 
can compact DNA, promote binding to the cell membrane, and facilitate entry into the cell. Calcium 
phosphate and polycation polyethylenimine (PEI) are two very efficient transfection vehicles. 
Although both calcium phosphate and PEI bind and precipitate efficiently, PEI offers advantages over 
calcium phosphate for scaled up transfections in terms of simplicity of use and compatibility with 
serum-free medium. Also, CHO suspension cells are difficult to transfect with calcium phosphate 
(430). The use of serum-free medium is recommended for the expression of secreted recombinant 
proteins as it significantly facilitates their recovery and purification. PEI is available as branched and 
linear polymers with a wide range of molecular weights and polydispersities. Branched 25kDa PEI is 
more potent in transfection of adherent cells whereas linear 25kDa PEI is more potent for the 
transfection of suspension-growing 293F and CHO cells (430, 431).  
IL-17 proteins expressed and secreted in cell supernatant were separated by sodium dodecyl 
sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and analysed by Western blotting using 
specific antibodies. SDS is an anionic detergent that linearizes proteins and imparts a negative 
charge to linearized proteins in proportion to its mass, thus enabling fractionation of proteins by 
their approximate size during electrophoresis. SDS-PAGE is commonly done under reducing 
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condition by addition of another reducing agent such as dithiothreitol (DTT) or 2-mercaptoethanol. 
This allows further denaturing of proteins by reducing disulfide linkages, which are important to the 
folding and stability of proteins secreted in the extracellular medium. Under non-reducing SDS-PAGE 
disulfide bonds of proteins remain intact, hence allow study of its secondary structure.  
SDS-PAGE separated proteins are transferred to nitrocellulose or polyvinylidine fluoride (PVDF) 
membrane and stained with antibodies specific to target protein. Staining antibodies are linked to a 
reporter enzyme such as horseradish peroxidase (HRP) that on treatment with a chemiluminescent 
agent produces luminescence in proportion to the amount of protein, which can be recorded on a 
sensitive sheet of photographic film. Western blot also allows semi-quantitation of proteins by 
comparing the intensity of band generated with that of known quantity of control. 
 
4.1.1 Fast protein liquid chromatography 
FPLC is a form of liquid chromatography that is used to separate or purify proteins and other 
polymers from complex mixtures. Columns used with an FPLC can separate macromolecules based 
on size, charge distribution, hydrophobicity, reverse-phase or biorecognition. The chromatographic 
bed is composed by the gel beads inside the column. In FPLC the pumped solvent velocity is 
microprocessor-controlled through a software interface to ensure a constant flow rate of solvents. 
As a result of different components adhering to or diffusing through the gel, the sample mixture gets 
separated.  
 
4.1.2 Immunoaffinity chromatography 
Immunoaffinity chromatography (IAC) is a powerful technique for a selective purification of a target 
compound that combines the use of liquid chromatography with the specific binding of antibodies or 
related agents. IAC entails immobilising antibodies onto supports such as agarose, cellulose or 
synthetic organic compounds. A variety of techniques ranging from covalent attachment to 
adsorption-based methods can be used to immobilise antibodies. Using covalent attachment, 
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antibodies can be immobilised by random attachment via amino or carboxyl groups or selectively via 
modified carbohydrate residues or thiol groups. The easiest is the technique of random attachment 
but can lead to steric hindrance and a decrease in binding efficiency (432). The target protein is 
eluted by temporarily lowering the effective strength of antibody binding to the target. One of the 
common approaches to elution in IAC which has been shown to be effective in dissociating high 
affinity antibody-antigen complexes includes changing the mobile phase pH usually conducted by 
applying an acidic buffer (pH 1-3) typically at concentrations of 1.5-8 M to the column (433).  
 
 
4.1.3 Aims 
1. To confirm the correct expression of in vitro expressed human and mouse IL-17 proteins and 
quantitate their amount in transfected cell supernatants.  
2. To express human IL-17F mutant at a medium scale and purify by immunoaffinity 
purification. 
3. To confirm in vitro cleavage of LAP-IL-17 proteins into intact LAP and IL-17 domains by MMP. 
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4.2 Results 
4.2.1 Confirming the correct expression of IL-17 proteins derived from transient 
transfection of 293T cells 
The correct expression of IL-17 proteins was confirmed by resolving 293T cell supernatants 
containing IL-17 proteins in reducing SDS-PAGE and immunoblotting with specific antibodies. In vitro 
cleavage of LAP-IL-17 proteins by MMP-1 into intact LAP and IL-17 domains was confirmed by 
Western blot analysis of MMP-1 pre-treated LAP-IL-17 proteins. Human and mouse full-length IL-17 
proteins were immunoblotted with the corresponding anti-IL-17 antibodies whereas LAP-IL-17 
proteins were immunoblotted independently with both human anti-LAP antibody and corresponding 
anti-IL-17 antibodies to target both LAP and IL-17 domain (Figs. 4.2, 4.3 and 4.4).  
 
4.2.1a Determining optimum concentration of MMP-1 required for the complete cleaving of LAP-
IL-17 proteins  
MMP-1 used in all the experiments was produced in-house via expression in E coli. It was therefore 
important to determine the optimum dilution of in-house produced MMP-1 that was required for a 
complete cleaving of LAP-IL-17 proteins. For this, human LAP-IL-17F mutant was selected as 
representative LAP-IL-17 protein and 25μl 293T cell supernatant containing expressed LAP-IL-17F 
mutant was pre-incubated with MMP-1 in dilutions ranging from 1:10 to 1:640 at 37°C overnight, 
resolved with SDS-PAGE and immunoblotted independently with human anti-IL-17F and anti-LAP 
antibodies. As shown in the Fig.4.1, the bands generated were of the expected molecular weight 
(uncleaved LAP-IL-17F mutant 58kDa, cleaved IL-17F domain 21kDa and LAP domain 37kDa). 
Complete cleavage of LAP-IL-17F mutant was seen at MMP-1 dilutions 1:50 or less. For all future 
experiments including Western blots and biological assays, MMP-1 was used in dilution 1:50 for the 
pre-treatment of LAP-IL-17 proteins. It has been previously observed in our laboratory that MMP-1 
in the final concentration of 30μM results in an adequate cleaving of cell supernatants containing 
expressed LAP-IL-17 proteins.  
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4.2.1b Expression of IL-17 homodimers 
25μl 293T cell supernatants containing human and mouse full-length IL-17 proteins, and naïve plus 
MMP-1 pre-treated (incubated with 1:50 dilution MMP-1at 37°C overnight) LAP-IL-17 proteins were 
resolved by reducing SDS-PAGE and immunoblotted independently with corresponding anti-human 
or mouse IL-17 and anti-LAP antibodies. Fig. 4.2 shows Western blot analysis of human IL-17 proteins 
demonstrating bands of the expected molecular weights (human IL-17A 15 and 17kDa, FL-IL-17F and 
IL-17F mutant proteins 17kDa, naïve LAP-IL-17 proteins 54kDa and LAP domain 34kDa). These results 
Figure 4.1 Western blot analysis demonstrating optimum dilution of MMP-1 that is required for 
complete cleaving of LAP-IL-17. MMP-1 pre-incubated (dilutions 1:10 to 1:640) and naive human 
LAP-IL-17F mutant was resolved by reducing SDS-PAGE and immunoblotted independently with 
anti-human IL-17F and -LAP antibodies. Lane 1 shows naïve LAP-IL-17F mutant protein at the 
expected molecular weight of 58kDa. Bands generated by cleavage of LAP-IL-17F mutant with 
MMP-1 in dilutions 1:50, 1:10, 1:20 and 1:40 were again of expected molecular weights of21kDa 
and 38kDa, representing IL-17F mutant and LAP domains (lanes 2, 3, 4, 5 show the complete 
cleavage of LAP-IL-17F mutant). MMP-1 in dilutions 1:80 or above (lanes 6, 7, 8, 9) generated bands 
at molecular weights higher than expected, which is indicative of an incomplete cleavage ofLAP-IL-
17F mutant. Previous observations in our laboratory have demonstrated that MMP-1 in the final 
concentration of 30μM results in an adequate cleaving of cell supernatants containing expressed 
LAP-proteins. 
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indicate that human IL-17 proteins were expressed correctly and LAP-IL-17 proteins could be cleaved 
effectively by MMP-1.  
Similarly Western blot analysis of mouse IL-17 proteins (Fig. 4.3) showed the bands of expected 
molecular size (IL-17A 17 and 21kDA, IL-17F 17kDa and 25kDa and IL-17F mutants 1, 2 and 3 20kDa 
and 25kDa, and naïve LAP-IL-17 proteins 62kDa). Despite several attempts, in vitro expression of 
mouse FL-IL-17F mutant 2 could not be confirmed in either 293T cells supernatant or whole cell 
lysates. Interestingly, FL-IL-17F mutant 2 domain released from MMP-1 treated LAP-IL-17F mutant 2 
was detectable on Western blot under similar conditions. This suggests that either FL-IL-17F mutant 
2 was not translated or was not stable enough to allow detection by Western blot. 
 
 
 
Figure 4.2 Reducing SDS-PAGE resolution and immunoblot analysis of human IL-17 homodimers. 
293T cell supernatants containing human full-length and LAP-IL-17 proteins were resolved by 
reducing SDS-PAGE and immunoblotted with anti-human IL-17A, -IL-17F or -LAP antibodies. LAP-IL-
17 proteins were pre-incubated with MMP-1 at final dilution of 1:50 at 37°C overnight.  
Panel A, lane 1 shows bands at 15 and 17kDa demonstrating glycosylation of full-length IL-17A. Lane 
2 shows LAP-IL-17A protein at the expected molecular weight 58kDa and lane 3 shows bands at 15 
and 17kDa IL-17A released from LAP-IL-17A by the action of MMP-1.  
Panel B shows 17kDa bands in lanes 4 and 7, which represent full-length IL-17F and IL-17F mutant 
respectively. Lanes 5 and 8 show LAP-IL-17 and LAP-IL-17F mutant proteins at the expected 
molecular weight of 58 kDa and lanes 6 and 9 show bands at 17kDa representing IL-17F and IL-17F 
mutant released from their corresponding LAP-IL-17 proteins by the action of MMP-1.  
Panel C shows naïve LAP IL-17A, -IL-17F and -IL-17F mutant in lanes 10, 12 and 14 at the expected 
molecular weight of 58kDa and the released LAP domain at the expected molecular weight of 37kDa 
in lanes 11, 13 and 15.  
The data is representative of at least three experiments. These results confirmed the correct 
expression of proteins and cleavage of LAP-IL-17 proteins into intact LAP and IL-17 domains by MMP. 
Anti-hIL-17A, anti-human IL-17A antibody; anti-hIL-17F, anti-human IL-17F antibody; anti-hLAP, anti-
human LAP antibody. 
A B C 
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LAP-IL-17F LAP-mutant 
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Figure 4.3 Reducing SDS-PAGE resolution and immunoblot analysis of mouse IL-17 homodimers. 
293T cell supernatants containing mouse full-length and LAP-IL-17 proteins were resolved by 
reducing SDS-PAGE and immunoblotted with anti-mouse IL-17A or -IL-17F antibodies. LAP-IL-17 
proteins were pre-incubated with MMP-1 at final dilution of 1:50 at 37°C overnight.  
Panel A, lane 1 shows bands at 17 and 21kDa demonstrating glycosylation of full-length IL-17A. Lane 
2 shows naïve LAP-IL-17A protein at the expected molecular weight of 58kDa and lane 3 shows 
bands at 17 and 21kDa representing IL-17A released from LAP-IL-17 by the action of MMP-1. The 
concentrations of FL-IL-17A and LAP-IL-17A in 293T cell supernatants as determined by direct ELISA 
(Chapter 2, Section 2.2.2b) were 105ng/ml and 415ng/ml respectively. 
Panel B shows 17, 21 and 25kDa size bands in lanes 4 which represent full-length IL-17F. Lanes 5 
shows LAP-IL-17F at the expected molecular weight of 62kDa and lanes 6 shows bands at 17 and 
21kDa representing IL-17F released from LAP-IL-17F by the action of MMP-1. The concentrations of 
FL-IL-17F and LAP-IL-17F in 293T cell supernatants as determined by direct ELISA (Chapter 2, Section 
2.2.2b) were 55ng/ml and 140ng/ml respectively. 
Panel C shows 17kDa, 21kDa and 25kDa bands representing glycosylated full-length IL-17F mutant 1 
and 3 in lanes 7 and 13 respectively. Expression of full-length IL-17F mutant could not be detected, 
which is marked with a red cross in lane 10. LAPIL-17F mutants 1, 2 and 3 were expressed at the 
expected molecular weight of 62kDa as shown in the lanes 8, 11 and 14. Lanes 9, 12 and 15 show 
21kDa and 25kDa bands representing IL-17F mutant 1, 2 and 3 domains released from their 
corresponding LAP-IL-17F mutants by the action of MMP-1. The concentrations of FL-IL-17F mutant 
1, -IL-17F mutant 3, LAP-IL-17F mutant 1, -IL-17F mutant 2 and –IL-17F mutant 3 in 293T cell 
supernatants as determined by direct ELISA (Chapter 2, Section 2.2.2b) were 52ng/ml, 50ng/ml, 
300ng/ml, 270ng/ml and 300ng/ml respectively. 
The data is representative of at least three experiments. These results confirmed the correct 
expression of proteins and cleavage of LAP-IL-17 proteins into intact LAP and IL-17 domains by MMP. 
Anti-mIL-17A, anti-mouse IL-17A antibody; anti-mIL-17F, anti-mouse IL-17F antibody. 
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4.2.1c LAP-IL-17 proteins are secreted as homodimers 
Biological latency of a LAP-cytokine is related to LAP homodimer forming a protective shell around 
the cytokine, which prevents interaction between the cytokine and its receptor. To confirm that LAP-
IL-17 proteins were expressed and secreted as homodimers, 25μl 293T cells supernatants containing 
mouse LAP-IL-17 proteins were resolved by non-reducing SDS-PAGE and immunoblotted with anti-
human LAP antibody (Fig. 4.4). 
 
 
 
 
Figure 4.4 LAP-IL-17 proteins are secreted as homodimers. 25μl naïve and MMP-1 pre-treated 293T 
cells supernatants containing mouse LAP -IL-17A, -IL-17F and -IL-17F mutant 1 were resolved by non-
reducing SDS-PAGE and immunoblotted with anti-human LAP antibodies. The concentration of LAP-
IL-17A, -IL-17F and –IL-17F mutant 1 proteins in 293T cell supernatants as determined by direct ELISA 
(refer Chapter 2, Section 2.2.2b) was 415ng/ml, 140ng/ml and 300ng/ml respectively. Lanes 1, 3 and 
5 show 116kDa bands corresponding to homodimers of LAP-IL-17A, IL-17F and IL-17F mutant 1. 
MMP-1 pre-treatment of LAP-IL-17 proteins generated 74kDa bands corresponding to LAP 
homodimers (lanes 2, 4 and 6). The data is representative of at least three experiments. Anti-hLAP, 
anti-human LAP antibody. 
 
 
4.2.1d Expression of IL-17 heterodimers  
In addition to being secreted as homodimers, human and mouse IL-17A and IL-17F are also secreted 
as heterodimer ofIL-17A/IL-17F (142, 143). This raised the possibility of IL-17F mutant forming a 
heterodimer with IL-17A and IL-17F, which was investigated by transient co-transfection of 293T 
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cells with IL-17A or IL-17F plus IL-17F mutant. 293T cells were transiently transfected with total 20μg 
plasmid DNA in combinations of 15g/5g, 10g/10g, 5g/15g and 1g/19g IL-17A or IL-17F/ IL-
17F mutant. Additional co-transfections with IL-17A or IL-17F plus empty pcDNA3, and IL-17A plus IL-
17F were also examined. 25l cell supernatant were resolved by reducing SDS-PAGE and 
immunoblotted independently with anti-IL-17A and anti-IL-17F antibodies. As shown in Figs. 4.5 and 
4.6, the bands generated were of the expected molecular size of 17-21kDa. The intensity and 
thickness of the bands was proportionate to the proportion of DNA utilised for co-transfection. 
These results showed that human and mouse IL-17A and IL-17F were also expressed as heterodimers 
of IL-17A and IL-17F. Although heterodimers of mouse IL-17A/IL-17F mutant 1 and IL-17F/IL-17F 
mutant 1 could be expressed in vitro, heterodimers of human IL-17A or IL-17F with IL-17F mutant 
were not expressed by transient co-transfection of 293T cells. 
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Figure 4.5 Reducing SDS-PAGE resolution and immunoblot analysis of human IL-17 heterodimers. 
293T cells were co-transfected with human IL-17A or IL-17F plus IL-17F mutant or empty pcDNA3 or 
IL-17A plus IL-17F (see text for details). 25μl cell supernatants were resolved by reducing SDS-PAGE 
and immunoblotted independently with anti-human IL-17A and IL-17F antibodies. The bands 
generated were of expected molecular weight size of 17-21kDa.  
Panel A, immunoblotting with anti-human IL-17A shows a progressive decrease in thickness of bands 
generated by co-transfection with 20μg IL-17A plus 0μg pcDNA3 (lane 1), 15μg IL-17A plus 5μg 
pcDNA3, IL-17F mutant or IL-17F (lanes 2, 6, 10), 10μg IL-17A plus 10μg pcDNA3, IL-17F or IL-17F 
mutant (lanes 3, 7, 11), 5μg IL-17A plus 15μg pcDNA3, IL-17F or IL-17F mutant (lanes 4, 8, 12) and 
1μg IL-17A plus 19μg pcDNA3, IL-17F or IL-17F mutant (lanes 5, 9, 13).  
Panel B, immunoblotting with anti-human IL-17F shows a progressive decrease in thickness of bands  
generated by co-transfection with 20μg IL-17F plus 0μg pcDNA3 (lane 1), 15μg IL-17F plus 5μg 
pcDNA3, IL-17F mutant or IL-17A (lanes 2, 6, 13), 10μg IL-17F plus 10μg pcDNA3, IL-17F mutant or IL-
17A (lanes 3, 7, 12), 5μg IL-17F plus 15μg pcDNA3, IL-17F mutant or IL-17A (lanes 4, 8, 11) and 1μg 
IL-17F plus 19μg pcDNA3, IL-17F mutant or IL-17FA (lanes 5, 9, 10).  
Panel C, 293T cell supernatants derived from IL-17A plus IL-17F mutant co-transfection did not 
generate bands when immunoblotted with anti-human IL-17F (lanes 2 to 5). Supernatants derived 
from co-transfection with IL-17F plus IL-17F mutant generated bands which corresponded to the 
quantity of IL-17F utilised for the co-transfection (lanes 6-9). Lane 1 shows band representing IL-17F 
mutant 20μg plus empty pcDNA3. The data is representative of at least three experiments. Anti-hIL-
17A, anti-human IL-17A antibody; anti-hIL-17F, anti-human IL-17F antibody. 
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Figure 4.6 Reducing SDS-PAGE resolution and immunoblot analysis of mouse IL-17 heterodimers. 
293T cells were co-transfected with mouse IL-17A or IL-17F plus IL-17F mutant or empty pcDNA3, or 
IL-17A plus IL-17F as described in the text. 25μl cell supernatants were resolved by reducing SDS-
PAGE and immunoblotted independently with anti-mouse IL-17A and IL-17F antibodies. The bands 
generated were of expected molecular weight size of 17-21kDa. 
Panel A, Blotting with anti-IL-17A antibody shows a progressive decrease in the thickness of band 
generated from co-transfection with 20μg IL-17A plus 0μg pcDNA3 (lanes 1), 15μg IL-17A plus 5μg 
pcDNA3 or IL-17F mutant (lanes 2, 11), 10μg IL-17A plus 10μg pcDNA3 or IL-17F mutant (lanes 3, 12), 
5μg IL-17A plus 15μg pcDNA3 or IL-17F mutant (lanes 4, 13) and 1μg IL-17A plus 19μg pcDNA3,  or IL-
17F mutant (lanes 5, 14). Lanes 6-9 represent co-transfection with IL-17A plus IL-17F. No band is 
seen in lanes 7 and 8.   
Panel B, Blotting with anti-IL-17F antibody shows a progressive decrease in the thickness of band 
generated from co-transfection with 20μg IL-17F plus 0μg pcDNA3 (lane 1, 10), 15μg IL-17F plus 5μg 
pcDNA3 or IL-17A (lanes 2, 9), 10μg IL-17F plus 10μg pcDNA3 or IL-17A (lanes 3, 8), 5μg IL-17F plus 
15μg pcDNA3 or IL-17A (lanes 4, 7) and 1μg IL-17F plus 19μg pcDNA3 or IL-17FA (lanes 5, 6). Lanes 
10 to 13 shows bands of equal size generated by co-transfection of IL-17F and IL-17F mutant 
together in the quantities of 0/20μg, 15/5μg, 10/10μg and 5/15μg. Co-transfection with combined 
IL-17F mutant and IL-17A in the quantities 19/1μg, 15/5μg, 10/10μg and 5/15μg produced bands 
with a progressive decrease in the thickness and intensity (lanes 15, 16, 17 and 18). The data is 
representative of at least three experiments. Anti-mIL-17A, anti-mouse IL-17A antibody; anti-mIL-
17F, anti-mouse IL-17F antibody. 
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4.2.1e Efficiency of transfection with PEI is superior to calcium phosphate DNA co-precipitation  
As transfection with PEI is more simple and conevient than calcium phosphate co-precipitation, 
efficiency of the two methods was compared. 1 X 106 293T cells were co-transfected with human IL-
17A plus IL-17F plasmid DNAs in combinations of 15g/5g, 10g/10g, 5g/15g and 1g/19g 
using PEI or calcium phosphate co-precipitation under similar conditions. 25μl cell supernatants 
containing expressed proteins were resolved by reducing SDS-PAGE and immunoblotted 
independently with anti-human IL-17A and IL-17F antibodies. Efficiency of transfection was 
determined by comparing the intensity and thickness of the bands. As shown in Fig. 4.7, bands 
generated with PEI transfection were of greater intensity and thickness than by calcium phosphate 
suggestive of greater protein expression by PEI method.. This indicates that PEI transfection is 
superior to calcium phosphate co-precipitation.  
 
 
 
 
 
 
 
 
 
 
Figure 4.7 Transfection efficiency of PEI is superior to calcium phosphate co-precipitation. 
293T cells were transiently co-transfected with human IL-17A plus IL-17F in combinations of 
15g/5g, 10g/10g, 5g/15g and 1g/19g using PEI (lanes 1 to 4) or calcium phosphate 
(lanes 5 to 8). 25μl cell supernatants were resolved by reducing SDS-PAGE and immunoblotted 
independently with anti-human IL-17A (panel A) and IL-17F antibodies (panel B). The bands 
generated were of expected molecular weight size of 17-21kDa. The intensity and thickness of 
bands generated by PEI transfection was greater than calcium phosphate co-precipitation 
indicating PEI transfection is superior to calcium phosphate co-precipitation. Anti-hIL-17A, 
anti-human IL-17A antibody; anti-hIL-17F, anti-human IL-17F antibody. 
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4.2.1f Expression of human IL-17F mutant in CHO-S cells 
CHO-S cells were used for medium scale expression of human FL- and LAP-IL-17F mutant protein 
expression for the purpose of immunoaffinity purification. A total 2 litre cell culture of CHO-S cells 
was transiently transfected by human FL- and LAP-IL-17F mutnat in three separate batches each. The 
correct expression of proteins in cell supernatants was confirmed by Western blot analysis. 25μl 
supernatant from each of the three batches of FL-IL-17F mutant and MMP-1 untreated and pre-
treated LAP-IL-17F mutant were resolved by reducing SDS-PAGE and immunoblotted with anti-
human IL-17F antibody (Fig. 4.8). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8 Reducing SDS-PAGE resolution and immunoblot analysis of CHO-S expressed 
human IL-17F mutant. 25μl CHO-S cell supernatants containing FL-IL-17F and MMP-1 pre-
treated and untreated LAP-IL-17F mutant from 3 different batches each were resolved by 
reducing SDS-PAGE and immunoblotted with anti-human IL-17F antibodies. The bands 
generated were of expected size of 21kDa corresponding to FL-IL-17F mutant (lanes 1, 2, 3) 
and IL-17F mutant domain released from LAP-IL-17F mutant by the action of MMP-1 (lanes 
5, 7 and 9). LAP-IL-17F mutant was expressed at the expected molecular weight of 58kDa 
(lanes 4, 6, 8). The results confirmed that the proteins were expressed correctly. anti-hIL-
17F, anti-human IL-17F antibody. 
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4.2.2 Immunoaffinity purified human IL-17F mutant was more than 90% pure 
Human full-length IL-17F mutant expressed and secreted in CHO-S cells supernatant was purified via 
FPLC by immunoaffinity purification using 1mg anti-human IL-17F antibody bound to Glycolink 
column. Human LAP-IL-17F mutant was purified first via FPLC using Heparin column followed by 
immunoaffinity purification using anti-IL-17F antibody column. Purity of immunoaffinity purified IL-
17F mutant was analysed by silver plus staining of 25μl eluates resolved by reducing SDS PAGE (Fig. 
4.9). The eluates were also immunoblotted with anti-human IL-17F antibody to confirm that their 
integrity was retained following the purification procedure. 
 
 
Figure 4.9 Silver plus staining of immunoaffinity purified human IL-17F mutant resolved by 
reducing SDS PAGE. 25μl eluates of immunoaffinity purified human full-length and LAP-IL-17F 
mutants and recombinant human IL-17F were resolved by reducing SDS-PAGE and the separated 
proteins were analysed by Western blot (A and B) and silver plus staining of the polyacrylamide gel 
(C). 
Panel A shows FL-IL-17F eluates generated band of the expected size of 21kDa (lane 1 load, lane 2 
flow through, lanes 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 eluates fractions and lanes 13, 14 washes).  
Panel B shows LAP-IL-17F eluates at expected molecular weight of 58kDa (lanes 1, 2 eluates, lane 3 
flow through, lanes 4, 5 washes).  
Panel C shows bands at 15kDa representing 100ng, 50ng and 25ng rhIL-17F (lanes 1, 2, 3, circled in 
blue) and multiple additional bands. Lanes 4 shows band at 21kDa representing purified glycosylated 
human FL-IL-17F mutant and only occasional additional bands, which confirmed that purity of FL-IL-
17F mutant was more than 95%. Lane 6 shows band at 58kDa molecular weight representing LAP-IL-
17F mutant and additional bands that are similar to those present in lanes 1, 2 and 3 indicating that 
purity of LAP-IL-17F mutant was more than 90%. FL-IL-17F mutant, full-length IL-17F mutant; rhIL-
17F; recombinant human IL-17F. 
   
A B C 
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4.2.3 Quantitation of the expressed IL-17 proteins 
Quantitation of mouse IL-17 proteins expressed in 293T cells supernatant was carried out by direct 
ELISA (Table 4.1). 293T cell supernatants containing expressed IL-17 proteins were diluted in 
carbonated buffer and coated directly on ELISA plates. Bound IL-17 was detected by corresponding 
anti-mouse IL-17 or anti-human LAP antibodies.   
Quantities of expressed human full-length and LAP IL-17 proteins in 30-fold concentrated 293T cell 
supernatants was determined using Western blot.by comparing the intensity of band generated with 
that of known quantity of recombinant human IL-17 proteins (Fig. 4.10 and Table 4.2). The 
concentration of immunoaffinity purified human IL-17F mutant and LAP-IL-17F mutant determined 
by human IL-17F ultra-sensitive ELISA and was determined as 0.97μg/ml and 0.61μg/ml respectively. 
 
Table 4.1 ELISA quantitation of 293T cell expressed mouse IL-17 proteins 
Protein (ng/ml) 
FL-IL-17A 105 
FL-IL-17F 55 
FL-IL-17F mutant 1 52 
FL-IL-17F mutant 2 - 
FL-IL-17F mutant 3 50 
LAP-IL-17A 415 
LAP-IL-17F 140 
LAP-IL-17F mutant 1 300 
LAP-IL-17F mutant 2 270 
LAP-IL-17F mutant 3 300 
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Table 4.2 Western blot quantitation of human IL-17 proteins in 30-fold concentrated 293T cell 
supernatants 
Human IL-17 protein (μg/ml) 
FL-IL-17A 20 
FL-IL-17F 4 
FL-IL-17F mutant 53 
LAP-IL-17A 50 
LAP-IL-17F 21 
LAP-IL-17F mutant 95 
Figure 4.10 Semi-quantitation of expressed human full-length IL-17 proteins by Western blot. 
Commercial rhIL-17 A and IL-17F proteins and concentrated 25μl 293T cell supernatants 
containing IL-17 proteins were resolved by reducing SDS-PAGE and immunoblotted with anti-
human IL-17A (panel A) or IL-17F antibodies (panel B). Density of the bands was analysed by image 
J software.  
(A) Lanes 1, 2 and 3 show bands at 15 and 17kDa corresponding to rhIL-17A 100 ng (density 971, 
2936), 50ng (density 557, 1566) and 25ng (density 59, 944) and lanes 4, 5 and 6 show bands 
generated by 2-fold serially diluted 293T cell supernatants containing IL-17A in the final dilutions 
of 1:2 (density 6114, 5289), 1:4 (density 4070,4706) and 1:8 (density 2403, 3164).  
(B) Lanes 1, 2 and 3 show 17kDa bands generated by rhIL-17F 100ng (density 11606), 50ng 
(density 15472) and 25ng (6633)and lanes 4, 5, 6, 7, 8 and 9 show bands at 17kDa representing 2-
fold serially diluted 293T cell supernatants of IL-17F (density 8933, 6209, 3773) and IL-17F mutant 
(18137, 19071, 12997) in the final dilutions of 1:2, 1:4 and 1:8. Quantity of the expressed human 
IL-17 proteins was derived by comparing the densities of bands generated by rhIL-17A and 17F 
proteins. The data is representative of atleast three experiments. rhIL-17A, recombinant human 
IL-17A; FL-IL-17A, full-length IL-17A; rhIL-17F, recombinant human ILA-17F; FL-IL-17F, full-length 
IL-17F; FL-mutant, full-length IL-17F mutant. 
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4.3 Discussion 
Western blot analysis confirmed that following transient transfection of 293T cells, IL-17 proteins 
were correctly expressed in vitro and the expressed proteins retained their ability to bind to their 
corresponding antibodies. IL-17A is a disulfide-linked, homodimeric, variably glycosylated, secreted 
glycoprotein with a molecular mass of 35 kDa (107). An N-linked glycosylation site on human IL-17A 
was first identified after purification of the protein revealed two bands, one at 15 KDa and another 
at 20 KDa. In keeping with this, 293T cells expressed human full-length IL-17A proteins generated 
similar bands at 15kDa and 20kDa. Human full-length IL-17F and IL-17F mutant and mouse full-
length IL-17 proteins were also glycosylated and were confirmed to be expressed correctly. 
Biological latency of LAP cytokines is dependent on the release of cytokine domain by the action of 
MMP. It was therefore essential to first confirm not only the correct expression of LAP-IL-17 proteins 
but also their ability to undergo cleavage into intact LAP and IL-17 domains by the action of MMP. 
Western blot analysis confirmed that LAP-IL-17 proteins were expressed correctly and could be 
cleaved into intact LAP and IL-17 domains by MMP-1. The quantitation analysis of expressed 
proteins showed that LAP-IL-17 proteins were expressed and secreted in cell supernatants in two to 
six-fold higher concentrations than full-length IL-17 proteins. These results indicate that modifying a 
cytokine into LAP-cytokine enhances its in vitro expression significantly. Similarly, in vivo expression 
of IL-17 proteins in C57BL/6 and SCID mice (refer Sections 6.2.1 and 6.2.2 and Figs. 6.1 and 6.2) 
showed a 2.2-fold higher expression of LAP-IL-17F mutant and a 1400-fold higher expression of LAP-
IL-17A than their full-length counterparts. A higher in vitro and in vivo expression of LAP-IL-17 
proteins seems to be related to a greater stability of LAP-proteins. The reason for this is not exactly 
known but we think it is related to either enhanced secretion of LAP proteins and/or a reduction in 
their degradation due to interference with their ability to bind to their cognate receptors. Our group 
has previously reported that in vivo half-life of LAP-IFN-β in DBA/1 mice was 37-fold higher than 
naïve IFN-β. These observations imply that LAP-cytokines due to their higher level of expression and 
prolonged half-life are likely to be superior therapeutics than conventional cytokine-based therapies. 
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Existence of IL-17A/IL-17F heterodimers has been demonstrated in vitro and in vivo in both human 
and mouse. In this study possibility of IL-17F mutant forming a heterodimer with IL-17A and IL-17F 
was investigated by co-transfection of 293T cells with IL-17A or IL-17F plus IL-17F mutant. Although 
expression of mouse IL-17A/IL-17F mutant and IL-17F/IL-17F mutant heterodimers could be 
demonstrated, expression of human IL-17A/IL-17F mutant and IL-17F/IL-17F mutant could not be 
confirmed. It is possible that either the expressed heterodimers were not stable enough or 
homdimer formation was preferred over heterodimer formation with the mutant. However, a forced 
expression of IL-17A/IL-17F mutant heterodimer can be achieved by fusing the genes via a 
polyglycine linker (143). 
Comparison of transfection using PEI with calcium phosphate co-precipitation showed that under 
similar conditions transfection with PEI resulted in expression and secretion of higher quantities of 
IL-17 proteins. PEI also offers advantage over calcium phosphate precipitation method in terms of its 
simplicity. With PEI, the incubation time to form DNA complexes is much shorter, only 10 minutes as 
against 30 minutes with calcium phosphate, and there is no requirement for osmotic enhancement 
of DNA uptake with glycerol shock, which is often used as an adjucnt with calcium phosphate 
method.  
As the expressed proteins were not tagged, CHO-S cell supernatants containing human full-length IL-
17F mutant was purified by immunoaffinity using anti-human IL-17F antibody. The LAP domain of 
LAP-cytokines binds to heparin (434), hence LAP-IL-17F mutant was first purified using heparin 
column and then immunoaffinity purified using an anti-IL-17F antibody column. Immunoaffinity 
purification is a potent technique to separate target protein from a mixture. In this study, 
purification of human full-length and LAP-IL-17F mutant via FPLC using human anti-IL-17F antibody 
column yielded proteins which were more than 90% pure. 
To summarise, human and mouse IL-17 proteins except mouse IL-17F mutant 2 were successfully 
expressed in vitro. The correct expression of the proteins was confirmed by Western blotting. 
Immunoaffinity purified human full-length and LAP-IL-17F mutant were more than 90% pure. 
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CHAPTER V 
 
 
 
 
 
 
 
 
 
 
 
 
 
EVALUATION OF IN VITRO BIOLOGICAL 
ACTIVITY OF IL-17F MUTANT 
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5.1 Introduction 
The process of preclinical testing of an investigational drug requires that its biological activity is first 
tested in vitro on individual cells containing the drug target before in vivo examination in animal 
models. Developing and characterising an in vitro system that represents key features of some of the 
in vivo effects of a given therapeutic are paramount to an accurate initial prediction of its future 
clinical efficacy. 
Kawaguchi et al. (153) working in asthma reported that (H161R) IL-17F mutant, a natural variant of 
IL-17F is an antagonist of wild-type IL-17F. The IL-17F mutant blocked IL-17F induced IL-8 production 
in bronchial epithelial cells in a dose-dependent manner, inhibiting 50% of IL-17F induced IL-8 
production at equal concentrations. This inhibition reached 100% when the concentration of IL-17F 
mutant was increased to 5-fold that of IL-17F, which suggested that (H161R) IL-17F mutant is a 
competitive inhibitor of  IL-17F and the loss of its biological function was not a result of its inability 
to bind to the IL-17F receptor. However, at that time, the receptor for IL-17F had not been 
identified. It has now been shown that human IL-17A and IL-17F bind to IL-17RA/RC, a 
heteroreceptor complex of IL-17RA and IL-17RC to mediate their biological effects (173, 181). 
Although isoform and species specific differences exist in the binding affinities of the individual 
receptor components (189), both IL-17RA and IL-17RC are essential for the biological activity of IL-
17A and IL-17F (136, 435, 436).  
IL-17 induces secretion of pro-inflammatory cytokines, chemokines and growth factors in stromal 
cells such as endothelial, epithelial and fibroblast cells (96). IL-17 activates common signaling 
pathways such as NF-κB, MAPKs, C/EBPs and PI3K/JAK pathways (95, 114, 195, 437-439). Kawaguchi 
et al. (153) in their study showed that IL-17F mutant lacked the ability to activate ERK1/2 
phosphorylation in bronchial epithelial cells  
Human IL-17 has also been shown to induce biological response in murine cells. Human IL-17 induces 
secretion of IL-6 in mouse stromal cells (440, 441). It has also been demonstrated that human IL-17A 
and IL-17F are able to bind to mouse IL-17RA and IL-17RC (181). 
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5.1.1 Aims 
1. Examine in vitro biological activity of human and mouse IL-17F mutants.  
2. Develop a novel luciferase reporter system to assess biological activity of human and mouse 
IL-17. 
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5.2 Results 
5.2.1 Human IL-17F mutant lacks the ability to induce secretion of IL-6 in human and 
mouse fibroblast cells 
Biological activity of human IL-17 is most commonly evaluated by assessing production of IL-6 by IL-
17 stimulated human foreskin fibroblasts and mouse embryonic fibroblasts. These bioassays were 
therefore used to assess in vitro biological activity of human IL-17F mutant. First, the biological 
activity of full-length IL-17F mutant was assessed by analysing induction of IL-6 secretion in HFFF2 
and 3T3 cells in comparison with commercial recombinant or 293T cell expressed full-length IL-17A 
and IL-17F as positive controls (Figs. 5.1A and 5.1B). The results demonstrated that unlike IL-17A and 
IL-17F, IL-17F mutant was unable to induce the secretion of IL-6 in these cells, which confirmed that 
IL-17F mutant lacked the ability to stimulate secretion of IL-6 in both human and mouse fibroblast 
cells. 
 
5.2.2 Human IL-17F mutant inhibits IL-17A induced IL-6 secretion in human and mouse 
fibroblast cells 
After establishing that IL-17F mutant was unable to induce IL-6 secretion in fibroblast cells,, the 
hypothesis that IL-17F mutant is an inhibitor of IL-17A was tested by co-stimulating HFFF2 and 3T3 
cells together with IL-17A and IL-17F mutant. HFFF2 cells were co-stimulated with rhIL-17A at a 
constant concentration of 25ng/ml plus 2-fold serially diluted 293T cell supernatants containing IL-
17F mutant at the starting concentration of 25ng/ml (Fig. 5.2A). 3T3 cells were co-stimulated with a 
constant 50μl volume of 293T cells supernatant containing human full-length IL-17F mutant plus 2-
fold serially diluted 1μg/ml rhIL-17A (Fig. 5.2B). In equal concentrations of 25ng/ml, IL-17F mutant 
led to a 62% decrease in IL-17A induced secretion of IL-6 in HFFF2 cells. Keeping the concentration of 
IL-17A constant at 25ng/ml and serially decreasing the concentration of added IL-17F mutant led to a 
progressive increase in IL-17A induced secretion of IL-6 confirming that IL-17F mutant competitively 
inhibited IL-17A. In keeping with results in human fibroblast cells, human IL-17F mutant was also 
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able to inhibit human IL-17A induced IL-6 secretion in 3T3 cells. Taken together these results confirm 
the hypothesis that the human IL-17F mutant is an inhibitor of IL-17A. 
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Figure 5.1 Human IL-17F mutant is unable to induce secretion of IL-6 in HFFF2 and 3T3 cells. (A) 1 x 
104 HFFF2 cells and (B) 5 x103 3T3 cells were stimulated with 2-fold serial dilution of 293T cells 
supernatants containing the expressed human full-length IL-17F mutant in parallel with (A) 293T 
cells expressed FL-IL-17A and -IL-17F proteins or (B) commercial rhIL-17A and IL-17F at the starting 
concentration of 1μg/ml. HFFF2 cells were also stimulated with rhIL-1β 10ng/ml as a positive 
control. Twenty four hours post-stimulation the induced secretion of human IL-6 in HFFF2 cells and 
mouse IL-6 in 3T3 cells was analysed by ELISA. Unlike IL-17A and IL-17F, IL-17F mutant was unable to 
induce the secretion of IL-6. IL-17A induced a significantly higher secretion of IL-6 in HFFF2 but not in 
3T3 cells. * (p<0.05), ** (p<0.005); HFFF2, human foetal foreskin fibroblasts; 3T3 cells, mouse foetal 
fibroblasts; rhIL-1, recombinant human IL-1; rhIL-17A, recombinant human IL-17A; rhIL-17F, 
recombinant human IL-17F; FL-IL-17A, full-length IL-17A; FL-IL-17F, full-length IL-17F; FL-IL-17F 
mutant, full-length IL-17F mutant. 
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Figure 5.2 Human IL-17F mutant inhibits IL-17A induced IL-6 secretion in HFFF2 and 3T3 cells. (A) 1 
x104 HFFF2 cells were co-stimulated with 25ng/ml rhIL-17A and two-fold serially diluted 293T cell 
supernatant containing 25ng/ml FL-IL-17F mutant and (B) 5 x103 3T3 cells were co-stimulated with 
two-fold serially diluted 1μg/ml rhIL-17A with or without 50μl 293T cells supernatants containing 
human IL-17F mutant and analysed for induced secretion of IL-6 by ELISA. (A) In equal 
concentrations of 25ng/ml FL-IL-17F mutant led to a 62% decrease in IL-17A induced IL-6 secretion. A 
serial reduction in the concentration of added IL-17F mutant led to the corresponding increase in the 
induced secretion of IL-6 by IL-17A. (B) Similar to HFFF2 cells, human IL-17F mutant inhibited IL-17 
induced IL-6 secretion in 3T3 cells. Taken together, these findings imply that IL-17F mutant is an 
inhibitor of IL-17A. *p < 0.05; HFFF2 cells, human foetal foreskin fibroblast cells; 3T3 cells, mouse 
embryonic fibroblasts; rhIL-17A, recombinant human IL-17A; FL-IL-17F mutant, full-length IL-17F 
mutant; medium, complete DMEM. 
B 
rhIL-17A (ng/ml)        1000                500                  250                  125 
 
159 
 
5.2.3 In vitro biological effects of IL-17F mutant are specific to its biological activity 
Transiently transfected 293T cell supernatants, in addition to the expressed proteins also contain 
multiple other substances including impurities and non-specific inhibitors. It was therefore possible 
that one of the non-specific inhibitors rather than IL-17F mutant was responsible for the apparent IL-
17A inhibition by the mutant. The specificity of biological activity of IL-17F mutant was therefore 
assessed in several ways. For example, by examining capability of IL-17F mutant to bind to IL-17 
receptor, by repeating the assays of biological activity using immunoaffinity purified IL-17F mutant 
and additionally assessing whether biological effects of IL-17F mutant could be reversed in the 
presence of a neutralising anti-IL-17F antibody. In addition, modulation of ERK1/2 signaling by IL-17F 
mutant was also analysed.  
 
5.2.3a IL-17F mutant binds to IL-17RC 
Human IL-17A and IL-17F bind to IL-17RA/IL-17RC, a heteroreceptor complex and require both the 
receptor components to mediate their biological activity. Human IL-17F however binds to IL-17RC 
with a much stronger affinity than IL-17RA where as human IL-17A binds to both IL-17RA and IL-17RC 
with an equal affinity (181). Based on these observations, ability of IL-17F mutant to bind to IL-17RC 
was assessed using a commercially available functional ELISA (described in detail in Chapter 2, 
Section 2.3.1a). As high concentrations of IL-17F mutant were required for the assays, 293T cells 
supernatants containing IL-17F mutant and full-length IL-17A (used as control) were first 30-fold 
concentrated using a Centricon centrifugal filter device (refer Chapter 2, Section 2.2.2). The results 
confirmed that human IL-17F mutant was able to bind to IL-17RC although the strength of its binding 
to IL-17RC was 1.4-fold less than full-length IL-17A (Fig.5.3). This finding provided an initial 
circumstantial evidence for the specificity of biological activity of IL-17F mutant. 
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Figure 5.3 Human IL-17F mutant binds to IL-17RC. A competitive binding inhibition assay of 30-fold 
concentrated 293T cell supernatants containing human FL- IL-17F mutant and - IL-17A to human IL-
17RC was performed using functional ELISA (Chapter 2, Section 2.3.1a). In brief, a mixture of hIL-
17RC at the final concentration of 100ng/ml or binding buffer (control) and 3-fold serially diluted 
human FL-IL-17A or FL-IL-17F mutant at the starting final concentration of 2μg/ml were incubated at 
500rpm for 2 hours at room temperature and captured with 10μg/ml anti-polyhistidine and 
detected with 3μg/ml anti-human IL-17A or IL-17F antibody.The results confirmed that IL-17F 
mutant was able to bind to IL-17RC but its strength of binding to the receptor was 1.4-fold less than 
IL-17A. FL-IL-17A, full-length IL-17A; FL- IL-17F mutant, full-length IL-17F mutant; OD, optical density.  
 
 
5.2.3b Immunoaffinity purified IL-17F mutant is unable to stimulate IL-6 secretion and ERK1/2 
activation in HeLa cells 
In order to confirm the specificity of biological activity of IL-17F mutant, unwanted impurities 
including non-specific inhibitors were eliminated from the transiently transfected CHO-S cell 
supernatant containing IL-17F mutant by immunoaffinity purification (Chapter 4, Section 4.2.2).  
Besides fibroblasts, IL-17 also induces the secretion of IL-6 in epithelial cells (442). IL-17 has been 
shown to induce IL-6 and also upregulate ERK1/2 phosphorylation in HeLa, a human cervical 
epithelial cell carcinoma cell line (443). HeLa instead of HFFF2 cells were used for this part of the 
study mainly because growth and expansion of HFFF2 cells was very slow. HeLa cells were stimulated 
with immunoaffinity purified IL-17F mutant and induced secretion of IL-6 and ERK1/2 activation in 
cell lysates were analysed (Chapter 2, Sections 2.3.1b and 2.3.1c). Based on a time course analysis 
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study by Kawaguchi et al. which showed that IL-17 induced phosphorylation of ERK1/2 in primary 
bronchial epithelial cells reached a maximum at approximately 20 minutes and returned to baseline 
levels by 60 minutes (444), ERK1/2 phosphorylation was analysed after stimulation of HeLa cells for 
20 minutes. 
As shown in the Fig. 5.4A, immunoaffinity purified IL-17F mutant failed to induce the secretion of IL-
6 in HeLa cells. Furthermore, unlike recombinant IL-17A and IL-17F, after 20 minutes of stimulation, 
immunoaffinity purified IL-17F mutant was unable to activate ERK1/2 phosphorylation (Fig. 5.4B). 
These findings taken together with the results of experiments described in the Sections 5.2.1 and 
5.2.3a confirmed that inability of IL-17F mutant to stimulate IL-6 secretion in epithelial or fibroblasts 
was specific to its biological activity and not merely due to the lack of binding to IL-17R or presence 
of non-specific inhibitor(s) in 293T cell supernatants. 
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Figure 5.4 Immunoaffinity purified IL-17F mutant is unable to induce IL-6 secretion and ERK1/2 
activation in HeLa cells. (A) and (B) 1 x 104 HeLa cells were stimulated with 100ng/ml and 10ng/ml 
immunoaffinity purified IL-17F mutant in parallel with rhIL-17A and IL-17F and analysed for secretion 
of IL-6 and activation of ERK1/2. 10ng/ml rhIL-1 was used as a positive control. Unlike IL-17A and IL-
17F, immunoaffinity purified IL-17F mutant was unable to induce secretion of IL-6 and 
phosphorylate ERK1/2 in HeLa cells. PhosphoERK1/2 data represents percentage of total ERK1/2 that 
was phosphorylated (refer Chapeter 2, Section 2.3.1d). Both these assays have been done only once 
and the graphs therefore do not contain error bars. rhIL-17A, recombinant human IL-17A; rhIL-17F, 
recombinant human IL-17F; rhIL-1, recombinant human IL-1; IL-17F mutant, immunoaffinity purified 
human full-length IL-17F mutant; medium, complete RPMI. 
A 
B 
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5.2.3c Inhibition of IL-17A by immunoaffinity purified IL-17F mutant is reversed by a neutralising 
anti-IL-17F antibody 
The biological specificity of IL-17F mutant was further confirmed by assessing whether its biological 
effects could be reversed in the presence of a neutralising anti-IL-17F antibody. HeLa cells were co-
stimulated with rhIL-17A plus immunoaffinity purified IL-17F mutant with or without 10μg/ml 
neutralising anti-IL-17F antibody. In equal concentration of 100ng/ml, IL-17F mutant led to a 72% 
decrease in IL-17A induced IL-6 secretion and this could be reversed by a neutralising anti-IL-17F 
antibody (Fig. 5.5). These findings confirmed that inhibition of IL-17A induced IL-6 secretion by IL-17F 
mutant is specific to its biological activity.. 
IL
-6
 p
g
/m
l
0
5000
10000
15000
rhIL-17A   -   + + +   - - - 
rhIL-17F   -   - - -   + + + 
FL-IL-17F mutant   +   - + +   - + + 
Anti-IL-17F antibody   -   - - +   - - + 
 
Medium
rhIL-1
 
Figure 5.5 Inhibition of IL-17A by immunoaffinity purified IL-17F mutant is reversed by a 
neutralising anti-IL-17F antibody. HeLa cells were co-stimulated with 100ng/ml rhIL-17A or IL-17F 
plus immunoaffinity purified IL-17F mutant with or without 10μg/ml neutralising anti-IL-17F 
antibody. 10ng/ml rhIL-1 was used as a positive control. IL-17F mutant led to a 72% decrease in IL-
17A induced IL-6 secretion and this decrease in IL-6 was reversed by a neutralising anti-IL-17F 
antibody, thus confirming that the inhibition of IL-17A by IL-17F mutant is specific to its the 
biological activity. rhIL-17A, recombinant human IL-17A; rhIL-17F, recombinant human IL-17F; rhIL-1, 
recombinant human IL-1; IL-17F mutant, immunoaffinity purified human full-length IL-17F mutant; 
medium, complete RPMI. 
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5.2.4 Treatment with MMP-1 releases IL-17 activity from latent LAP-IL-17 molecules   
In order to investigate the release of biological activity of LAP-IL-17 proteins, HFFF2 cells were 
stimulated with untreated or MMP-1 treated 293T cell supernatants containing the expressed 
human LAP-IL-17 proteins for 24 hours and analysed for the induced secretion of IL-6. As shown in 
the Fig. 5.6, IL-6 secretion was significantly higher when cells were stimulated with MMP-1 pre-
treated than untreated LAP-IL-17 proteins. These results indicate that the biological activity of LAP-
IL-17 is released in the presence of MMP. The unexpected finding of stimulation of IL-6 secretion by 
MMP-1 pre-treated LAP-IL-17F mutant seems to be related to LPS contamination of in-house MMP-1 
that was expressed in E. coli. 
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Figure 5.6 Biological latency of human LAP-IL-17 proteins is released by MMP. 1 x 104 HFFF2 cells 
were stimulated with MMP-1 treated and untreated 293T cells supernatants containing human LAP-
IL-17 proteins and analysed for IL-6 secretion by ELISA. MMP-1 treatment of LAP-IL-17 proteins 
resulted in a significant increase in the secretion of IL-6 than untreated LAP-IL-17 proteins implying 
that biological activity of LAP-IL-17 proteins is released by the action of MMP. *p<0.05, **p<0.005, 
***p<0.0005; HFFF2, human foetal foreskin fibroblasts; FL-IL-17A, full-length IL-17A; FL-IL-17F, full-
length IL-17F; MMP-1, matrix metalloprotease 1; medium, complete Dulbecco’s modified eagle 
medium. 
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5.2.5 IL-17 is unable to activate luciferase in 57A HeLa cells 
IL-17 activates transcription factor NF-B in HeLa cells (443). As 57A HeLa cells contain NF-B 
dependent luciferase (420), it was attempted to standardise a luciferase reporter assay in response 
to IL-17 in these cells. 
Activation of luciferase in 57A HeLa cells could not be induced even with 500ng/ml rhIL-17A (data 
not shown). Based on a study by Ruddy M et al., which reported a synergistic enhancement of IL-17 
induced IL-6 secretion in osteoclast cells with 0.2 to 2ng/ml TNF- (114), an amplification of IL-17 
induced luciferase activation was attempted by co-stimulating 57A HeLa cells with IL-17A plus 
2ng/ml mouse TNF-. However, even with TNF- amplification, activation of luciferase could not be 
induced (Fig 5.7) and therefore a luciferase reporter assay as a readout for the biological activity of 
IL-17 could not be standardised in HeLa cells.  
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Figure 5.7 IL-17 is unable to activate luciferase in 57A cells. 57A HeLa cells were co-stimulated with 
293T cell supernatants containing expressed FL-IL-17A and -IL-17F plus 2ng/ml mTNF- in an 
attempt to amplify IL-17 induced activation of luciferase. Combination of IL-17A and suboptimal 
concentration of TNF- did not induce activation of luciferase in 57A HeLa cells.FL-IL-17A, full-length 
IL-17A; FL-IL-17F, full-length IL-17F; mTNF, mouse TNF-; RLU, relative luminescent units. 
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5.2.6 IL-17 was unable to activate IL-6 promoter responsive luciferase in epithelial cells 
As IL-17 stimulated production of IL-6 in HeLa cells (Section 5.2.3b) it was decided to attempt and 
develop an IL-6 promoter responsive luciferase reporter system in response to IL-17 in HeLa cells. In 
addition, ability of IL-17 to activate IL-6 promoter responsive luciferase in 293T cells was also 
examined (Chapter 2, Section 2.3.1g). This system however produced a very high background 
activity. 
For developing an IL-6 promoter responsive luciferase assay in HeLa cells, the cells were stably 
transfected with a plasmid expression vector containing IL-6 promoter responsive luciferase 
(Chapter 2, Section 2.3.1g). However, none of the eleven clones selected with Blasticidin were 
responsive to IL-17.  
 
 
5.2.7 Mouse IL-17F mutant 1 but not IL-17F mutant 3 binds to IL-17RC 
Of the three mouse analogues of human IL-17F mutant that were constructed, only mouse IL-17F 
mutant 1 and mutant 3 were further analysed. Mouse IL-17F mutant 2 could not be expressed in 
vitro and therefore could not be further examined. 
Ability of mouse IL-17F mutants to bind to mouse IL-17 receptor was first assessed. Mouse IL-17F 
binds to both mouse IL-17RC and IL-17RA. IL-17RC binding affinities of mouse IL-17F mutants 1 and 3 
were analysed using a commercially available functional ELISA (Chapter 2, Section 2.3.2a). The 
results showed that mouse IL-17F mutant 1 but not mutant 3 could bind to IL-17RC (Fig. 5.8). The 
binding strength of IL-17F mutant 1 to IL-17RC was 1.75-fold higher than commercial rmIL-17F, 
which in turn was 1.73-fold higher than 293T cells expressed full-length IL-17F. These results showed 
that mouse IL-17F mutant 1 but not mutant 3 was able to bind to mouse IL-17RC. 
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Figure 5.8 Mouse IL-17F mutant 1 but not IL-17F mutant 3 binds to IL-17RC. Ability of mouse FL-
IL-17F mutants 1 and 3 to mouse IL-17RC was analysed by functional ELISA determining 
competitive binding inhbition as described in Chapter 2, Section 2.3.2a. IL-17F mutant 1 but not 
IL-17F mutant 3 could to bind to IL-17RC. The strength of binding of IL-17F mutant 1 to IL-17RC 
was 1.75-fold higher than rmIL-17F, which in turn was 1.73-fold higher than 293T cells expressed 
FL-IL-17F. FL-IL-17F; full-length IL-17F; rmIL-17F, recombinant mouse IL-17F; FL-IL-17F mutant 1, 
full-length IL-17F mutant 1; FL-IL-17F mutant 3, full-length IL-17F mutant 3; OD, optical density. 
168 
 
5.2.8 Mouse IL-17F mutant 1 is an agonist of IL-17 
Mouse IL-17F mutants 2 and 3 were not further examined because the mutant 2 could not be 
expressed in vitro and the mutant 3 was unable to bind to IL-17RC.   
Similar to human IL-17, mouse IL-17 stimulates secretion of IL-6 in stromal cells (445). Biological 
activity of IL-17F mutant 1 was assessed by stimulating mouse embryonic fibroblasts, 3T3 cells and 
analysing the induced secretion of IL-6. Mouse IL-17F mutant 1 unexpectedly resulted in stimulation 
of IL-6 secretion in 3T3 cells, which was significantly higher than that induced by IL-17A and IL-17F, 
p<0.005 (Fig. 5.9). These results imply that mouse IL-17F mutant 1 is an agonist rather than 
antagonist of IL-17.  
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Figure 5.9 Mouse IL-17F mutant 1 is an agonist of IL-17. 5x103 3T3 cells were stimulated with 293T 
cell supernatant containing the expressed mouse full-length I IL-17F mutant in parallel with IL-17A 
and IL-17F and the induced secretion of IL-6 was by analysed by ELISA. 25ng/ml rmTNF- was used 
as a positive control. IL-17F mutant 1 unexpectedly stimulated the secretion of IL-6, which was 
significantly higher than that induced by IL-17A and IL-17F (p<0.005). ** p<0.005; 3T3, mouse 
embryonic fibroblasts; FL-IL-17A, full-length IL-17A; FL-IL-17F, full-length IL-17F, FL-IL-17F mutant 1, 
full-length IL-17F mutant 1; mTNF, mouse TNF-; medium, complete DMEM.  
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5.2.9 Biological latency of mouse LAP-IL-17 proteins is released by MMP 
Release of biological activity of mouse LAP-IL-17 proteins was assessed using the protocol same as 
that was used for human LAP-IL-17 proteins. 3T3 cells were stimulated with 293T cell supernatants 
containing mouse full-length IL-17 proteins, untreated or MMP-1 treated LAP-IL-17 proteins and 
analysed for the induced secretion of IL-6 (Fig. 5.10). Untreated LAP-IL-17A and -IL-17F proteins 
although induced a secretion of IL-6 that was higher than that induced by medium alone, it was 
significantly less than that induced by their corresponding full-length IL-17 proteins. MMP-1 
treatment of LAP-IL-17A and IL-17F proteins resulted in a significant increase in the secretion of IL-6. 
These results confirmed that biological activity of LAP-IL-17 proteins can be released by MMP. 
Interestingly, IL-6 secretion induced by untreated LAP-IL-17F mutant 1 was significantly higher than 
that induced by full-length IL-17F mutant 1, which further increased with MMP-1 treatment 
(p<0.0005)..  
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Figure 5.10 Biological activity of mouse LAP-IL-17 proteins is released by MMP. 5x103 3T3 cells 
were stimulated with 293T cell supernatants containing the expressed mouse full-length IL-17 
proteins, and untreated or MMP-1 treated LAP-IL-17 proteins and induced secretion of IL-6 was 
analysed by ELISA. 10ng/ml rmTNF- was used as a positive control. MMP-1 treatment of LAP-IL-17 
proteins resulted in a significant increase in the induced IL-6 secretion implying that biological 
activity of LAP-IL-17 proteins is released by MMP. Stimulation of IL-6 secretion by MMP-1 untreated 
LAP-IL-17 proteins seems to be related to the presence of endogenous MMP-1 in 293T cells 
supernatants. * p<0.05; **p<0.005; ***p<0.0005; 3T3, mouse embryonic fibroblasts; FL-IL-17A, full-
length IL-17A; FL-IL-17F, full-length IL-17F; FL-IL-17F mutant 1; full-length IL-17F mutant 1; rmTNF, 
recombinant mouse TNF-; medium, complete Dulbecco’s modified eagle medium.  
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5.2.10 A novel IL-6 promoter responsive luciferase reporter system to assess biological 
activity of mouse IL-17 is developed and standardised 
Murine IL-17 induces production of a number of cytokines and chemokines in macrophage cells 
(446). Jovanovic et al. have shown that IL-17 induces NF-B in human macrophage cells (106). Raw 
264.7 cells, a mouse macrophage cell line which was previously selected in G418 to express an NF-B 
driven luciferase construct (kindly provided by Dr. Vessillier, BJRU) were stimulated with mouse IL-17 
proteins for 24 hours and the cell lysates were analysed for luciferase activity. The results showed 
that IL-17 did not activate luciferase in these cells although lipopolysaccharide (LPS) used as a 
positive control was able to activate luciferase in these cells (data not shown). A NF-B driven 
luciferase reporter assay as a readout for biological activity of mouse IL-17 therefore could not be 
developed in Raw 264.7 cells. 
Development and standardisation of a IL-6 promoter responsive luciferase assay was therefore 
attempted. First, DBA/1 mouse fibroblast cells were stably transfected with a plasmid expression 
vector containing IL-6 promoter responsive luciferase (Chapter 2, Section 2.3.2c). However, 
stimulation of these cells even with 500ng/ml rmIL-17A did not result in the activation of IL-6 
promoter responsive luciferase (data not shown). The cells were then stimulated with IL-17 in 
combination with a small amount of TNF- to see whether synergistic activity of these two cytokines 
could lead to stimulation of IL-6 promoter responsive luciferase. 
As shown in the Fig. 5.11, addition of 2ng/ml rmTNF- to mouse IL-17A and IL-17F led to a 
synergistic activation of IL-6 promoter responsive luciferase in DTF cells. Although, not used here, a 
chequerboard experiment using different concentrations of TNF- and IL-17 would have ideal to 
demonstrate the synergistic activation of IL-6 by TNF- and IL-17 together. As luciferase reporter 
assays are sensitive yet simple and efficient assay systems, use of herewith developed and 
standardised novel IL-6 promoter responsive cell culture luciferase reporter system would allow an 
easy testing of biological activity of mouse IL-17. 
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Figure 5.11 DTF cells stably transfected with IL-6 promoter driven luciferase are responsive to 
mouse IL-17A plus 2ng/ml TNF-. DTF cells were stably transfected with pGL2 containing IL-6 
promoter responsive luciferase under Blasticidin selection (Chapter 2, Section 2.3.2c). The stably 
transfected DTF cells were stimulated with 293T cells supernatants containing expressed mouse FL-
IL-17A or –IL-17F alone or in combination with 2ng/ml rmTNF- for 6 hours and cell lysates analysed 
for luciferase activity. Addition of suboptimal concentrations of rmTNF- resulted in a synergistic 
amplification of induction of luciferase activation by IL-17A and IL-17F. ***p<0.0005; FL-IL-17A, full-
length IL-17A; FL-IL-17F, full-length IL-17F, medium, 0.5% FBS containing DMEM; RLU, relative 
luminescent unit. 
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5.3. Discussion 
 
In vitro functional assays showed that in equal concentrations, human (H161R) IL-17F mutant 
reduced IL-17A induced secretion of IL-6 by more than 50% in HFFF2, 3T3 and HeLa cells. The 
inhibition of IL-17A by IL-17F mutant was reversed in the presence of a neutralising anti-IL-17F 
antibody. Although not used in this experiment, use of a control IgG to demonstrate that reversal of 
IL-17A induced reduction in secreted IL-6 was achieved by anti-IL-17F neutralising antibody but not 
the control IgG would have been highly desirable to further confirm the specificity of biological 
activity of IL-17F mutant. The mutant on its own was unable to induce secretion of IL-6 in all the 
three cell lines and lacked the ability to activate ERK1/2 in HeLa cells. Taken together these results 
confirm the hypothesis that human (H161R) IL-17F mutant is an inhibitor of IL-17A. Inhibition of IL-
17F but not IL-17A by IL-17F mutant has been previously reported (153). This study for the first time 
demonstrates an additional inhibition of IL-17A by the mutant. IL-17A is the major proinflammatory 
IL-17 cytokine and 30-100 times more potent than IL-17F (143). An inhibition of IL-17A by IL-17F 
mutant is likely to result in a therapeutically effective suppression of IL-17 mediated inflammation in 
RA and similar autoimmune conditions. All the three mouse analogues of human IL-17F mutant that 
were developed for in vivo investigation proved unsuitable for testing in CIA mice. The RA 
synovium/SCID model would have allowed direct targeting of human RA tissue by human IL-17F 
mutant but suitable RA synovial samples could not be obtained. 
This part of the study also demonstrated that IL-17F mutant is able to bind to IL-17RC. IL-17A and IL-
17F bind to a heteroreceptor complex IL-17RA/RC and require both the receptor to mediate 
their signaling effects (136, 435, 436). In contrast to IL-17RC, which binds both IL-17A and IL-17F 
with a high affinity, IL-17RA binds IL-17A effectively but binds IL-17F with 1000-fold lower affinity 
(447). Binding of IL-17F mutant to IL-17RA was not examined. However, irrespective of whether or 
not IL-17F mutant binds to IL-17RA, demonstration of its binding to IL-17RC suggests that the mutant 
would be able to inhibit both IL-17A and IL-17F mediated signaling effects. While, either anti-IL-17RA 
or anti-IL-17RC antibody resulted in a significant reduction in in vitro biological activity of IL-17A and 
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IL-17F (447), a soluble form of IL-17RC but not IL-17RA blocked binding of both IL-17A and IL-17F, 
and inhibited the signaling effects in response to both the cytokines (181). It has been shown that in 
the absence of IL-17RC, IL-17A and IL-17F are unable to activate downstream pathways (173, 181). 
IL-17F mutant would compete with both IL-17A and IL-17F for binding to IL-17RC and therefore 
would inhibit both IL-17A and IL-17F mediated signaling effects.  
The receptor binding assays of mouse IL-17F mutants showed rather unexpected results (IL-17F 
mutant 2 due to undetectable expression in vitro was not examined). Interestingly, the strength of 
affinity of the mouse IL-17F mutant 1 s analysed by a competitive binding inhibition ELISA was 1.75-
fold higher than wild-type IL-17F whereas mouse IL-17F mutant 3 did not bind to IL-17RC at all. 
These changes in receptor binding affinity of mouse IL-17F mutants seem to be related to the fact 
that the mutations involved an important receptor binding site of IL-17F (179). Substitution of 
Glutamine by Arginine in mouse IL-17F mutant 1 caused a gain of function mutation resulting in 
enhancement of its receptor binding affinity, whereas deletion of the last 4 amino acids in the 
truncated IL-17F mutant 3 resulted in the loss of receptor binding affinity. In line with the results of 
receptor binding, mouse IL-17F mutant 1 stimulated rather than inhibited IL-6 secretion from 3T3 
cells. All the three mouse analogues of human IL-17F mutant thus displayed either immunological or 
biological properties that were contrary to those expected. 
The functional assays demonstrated that MMP-1 pre-treated LAP-IL-17 proteins induced significantly 
higher secretion of IL-6 than naïve LAP-IL-17 proteins, thus confirming in vitro release of biological 
latency of human and mouse LAP-IL-17 by MMP. Stimulation of fibroblast cells with MMP-1 pre-
treated LAP-IL-17F mutant unexpectedly resulted in induction than inhibition of IL-6 secretion, which 
seems to be related to LPS contamination of in-house MMP-1 that was expressed in E. coli. Also, the 
biological activity of naïve LAP proteins was higher than that induced by medium alone. 293T cells 
contain endogenous MMPs, which seem to be responsible for partial release of biological activity of 
naïve LAP-IL-17 proteins. The LAP cytokine approach was pioneered in our laboratory first using IFN-
 and since has been validated for a number of other cytokines and small molecules including MSH-α 
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and VIP (355). Use of LAP-cytokine allows targeting of biological effects of cytokine-based therapies 
to the sites, where MMPs are overexpressed. In addition, LAP-cytokine approach offers other 
advantages such as significant enhancement in in vitro and in vivo expression of a given cytokine as 
shown in this study and a significant prolongation of in vivo half-life as shown previously. Half-life of 
LAP-IFN- was thirty-seven fold higher than naive IFN- and its therapeutic efficacy was superior to 
IFN-β in CIA mice (353). Similarly, in vivo therapeutic effects of LAP-MSH were superior to free MSH 
in a peritonitis mouse model (355).  
A novel IL-6 promoter responsive luciferase reporter system to analyse biological activity of mouse 
IL-17 was developed and standardised. DTF cells (DBA/1 mouse fibroblasts) were stably transfected 
withIL-6 promoter responsive luciferase. Although not used in this study, a chequerboard 
experiment using different concentrations of rmTNF-α and IL-17A or IL-17F would have been ideal to 
demonstrate the observed synergy between IL-17A and TNF-α. The cells demonstrated a synergistic 
activation of luciferase in response to mouse IL-17A and IL-17F in combination with 2ng/ml TNF- 
but not when stimulated by IL-17A or IL-17F alone. It has been shown that IL-17 induces secretion of 
IL-6 primarily by activating the transcription factor C/EBP- and , having a minimal activity on NF-
B, but in combination with TNF-, even in suboptimal concentrations can induce a much greater 
secretion of IL-6 by synergistically activating C/EBD-δ and β (114). In addition, stabilisation of mRNA 
of IL-6 and other TNF- target genes by IL-17 further enhances the synergism between the two 
cytokines (185). 
Development and standardisation of anIL-6 promoter driven luciferase reporter system in 293T and 
HeLa cells to assess biological activity of human IL-17 was not successful. Similarly, standardisation 
of a NF-B responsive luciferase reporter system in 57A HeLa cells (420) and Raw 264.7 cells (mouse 
macrophage cells stably transfected with NF-B driven luciferase) to assess biological activity of 
human and mouse IL-17 could not be achieved. All these cell lines failed to activate luciferase in 
response to IL-17. Shen et al. have previously reported a lack of NF-B-linked luciferase activity in 
response to IL-17 in a number of mammalian cell lines (135). 
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To conclude, in vitro biological assays confirmed the hypothesis that human IL-17F mutant is an 
inhibitor of IL-17A. The study also demonstrated that in vitro biological activity of LAP-IL-17 proteins 
can be released by MMP. A novel IL-6 promoter responsive luciferase reporter system to assess 
biological activity of mouse IL-17 was successfully developed and standardised. 
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EVALUATION OF IN VIVO EXPRESSION OF 
HUMAN IL-17 TRANSGENE IN MOUSE MODELS  
OF INFLAMMATION 
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6.1 Introduction 
In vitro studies in primary cells or cell lines, although extremely important, they do not fully 
reproduce the situation in vivo, which is much more complex and less well defined. It is therefore 
important to test preclinical efficacy of an investigational therapy in vivo in animal models of disease 
before clinical testing in humans. CIA in mice bears close resemblance to RA (448, 449) and is well 
recognised for its robustness in predicting efficacy of anti-TNF therapy (450). This model of RA was 
initially selected for in vivo testing of IL-17F mutant but could not be pursued due to unexpected in 
vitro properties of the mouse analogues of human IL-17F mutant that were constructed for this 
purpose. Mouse IL-17F mutant 1 displayed IL-17 agonist rather than antagonist activity whereas in 
vitro expression of IL-17F mutant 2 could not be detected at all. The third mouse IL-17F mutant 
failed to bind to mouse IL-17RC.  
The RA synovium/SCID mouse model of RA provides a unique opportunity to directly examine 
efficacy of therapeutics of human origin in mice implanted with human RA synovium. Koenders et al. 
(416) have confirmed the validity of this model in predicting therapeutic efficacy of currently used 
biological therapies for RA. Investigation of IL-17 inhibition in this model showed that a significant 
response to anti-IL-17 treatment was seen only in the mice which were transplanted with RA 
synovium enriched in CD3+T cells, implying that the responsiveness to anti-IL-17 is dependent on the 
presence of CD3+ T cells in a RA joint.  
Mouse stromal cells secrete IL-6 in response to human IL-17 (440, 445). In keeping with these 
observations, as described in Chapter 5, Section 5.2.1, 3T3 cells were responsive to human IL-17 and 
produced IL-6 when stimulated with human IL-17A and IL-17F. As in human fibroblast and epithelial 
cells, human IL-17F mutant was unable to induce secretion of IL-6 in 3T3 cells and inhibited human 
IL-17A induced secretion of IL-6 in these cells (Chapter 5, sections 5.2.1 and 5.2.2).  
Murine airpouch model is considered a model of synovial-like tissue inflammation (451). Airpouch 
pouch cavity formed by subcutaneous injection of sterile air into the back of a mouse is lined with 
cells that resembles the synovial membrane after 6 days (452). Injection of non-specific irritants such 
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as Carboxymethyl cellulose (CMC) into an air pouch induces an acute inflammatory response that 
can be readily evaluated by analysing the volume of exudate produced, the infiltration of cells, and 
the release of inflammatory mediators.  
Amongst non-viral approaches to gene transfer, intravenous hydrodynamic delivery (364) results in 
highest gene transfer and expression and seems to be well tolerated in rodents despite rapid 
injection of a relatively large volume of normal saline. In comparison with other physical and 
chemical methods, the procedure of intravenous hydrodynamic delivery is relatively simple and does 
not require special equipment or chemical adjuncts. Intravenous administration of plasmid DNA in 
normal saline in volume equivalent to 10% body weight rapidly over 3-5 seconds alters 
transmembrane permeability of hepatocytes by creating transient pores and allows uptake of 
injected DNA by liver cells. DNA transferred to hepatocytes then becomes available for translation 
and expression into its protein and is eventually secreted into the circulation. Due to its high 
efficiency and a non-viral nature of delivery, hydrodynamic gene delivery is under active 
investigation for human use. Hydrodynamic limb vein delivery in large research animals has 
demonstrated an efficiency that is comparable to small research animals (365) and holds a good 
promise for human use. A therapeutic gene can be delivered to an isolated limb by infusing plasmid 
DNA into a limb vein and facilitating gene transfer by the placement of a proximal tourniquet, which 
in turn will result in a transient increase in vascular pressure and aid extravasation of plasmid DNA 
(453). 
After demonstrating that human IL-17F mutant but none of the three cloned mouse IL-17F mutants 
were able to inhibit IL-17A in vitro, it was decided to examine in vivo therapeutic therapeutic efficacy 
of human IL-17F mutant in RA synovium/SCID mice model of RA. As a preliminary to this, in vivo 
expression of intravenous hydrodynamically delivered human full-length and LAP-IL-17A plasmid 
DNA and its pharmacokinetics over the two weeks period was first examined in naïve SCID mice. IL-
17A instead of IL-17F mutant was used for this part of the study as a commercial ELISA to analyse 
expression of human IL-17F in mouse serum was not available. It was also believed that due to the 
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striking similarities between IL-17A and IL-17F, the necessary information about in vivo expression of 
human IL-17F mutant transgene in mouse serum required for the future definitive experiement 
could be well obtained by using IL-17A in the preliminary experiment.  
As in vitro assays also demonstrated that human IL-17F mutant inhibited IL-17A induced secretion of 
IL-6 not only in human but also mouse fibroblast cells, it was also decided to examine in vivo 
therapeutic efficacy of human IL-17F mutant in CIA mice. Although an immune response to human 
IL-17F mutant would be inevitable in mice, the short duration, approximately 10 days of post-
treatment assessment would have still allowed the completion of CIA experiment. As a preliminary 
to this, in vivo expression of human full-length and LAP-IL-17F mutant was first examined in C57BL/6 
mice. In addition, airpouch were created over the dorsum of these mice and actute non-specific 
inflammation induced in the pouch to enable investigation of therapeutic transgene expression at 
the site of actual inflammation. After successful development and standardisation of an 
ultrasensitive ELISA (Chapeter 2, Section 2.2.2c) to analyse expression of human IL-17F in mouse 
serum, systemic gene therapy with human IL-17F mutant was used for this part of the experiment. 
As mouse airpouch model offers an opportunity to examine actue inflammatory response, number 
of neutrophils in airpouch lavage fluid, and levels of KC and IL-6 in mouse airpouch lavage exudate 
and serum were also analysed as a preliminary to investigation of therapeutic efficacy of human IL-
17F mutant in CIA mice. The results however showed that the numbers of neutrophils and levels of 
KC and IL-6 in IL-17F mutant treated group were not different than the control group of normal 
saline treated mice (data not shown). CIA experiment therefore was not pursued. 
 
6.1.1 Aims 
1. To evaluate systemic expression and pharmacokinetics of intravenous hydrodynamically 
delivered human IL-17A gene therapy in naïve SCID mice.  
2. To examine expression of intravenous hydrodynamically delivered human IL-17F mutant 
gene therapy in serum and airpouch exudate in C57BL/6 mice.  
180 
 
6.2 Results 
6.2.1 Expression of human FL- and LAP-IL-17A transgenes in naïve SCID mice 
Pharmacokinetics and in vivo expression of intravenous hydrodynamically delivered human full-
length- and LAP-IL-17 plasmid DNA were studied in naïve SCID mice as a preliminary to assessing in 
vivo therapeutic efficacy of human IL-17F gene therapy in RA synovium/SCID model of RA. Due to 
the need to use human RA tissue in RA/SCID model, it was essential to confirm that intravenous 
hydrodynamic plasmid-based gene therapy with human IL-17 led to an adequate in vivo transgene 
expression in SCID mice and that the expression of transgene was sustained for at least one week, 
before conducting the final study. Human IL-17A instead of IL-17F mutant was used for this part of 
the study as a commercial ELISA sensitive enough to detect human IL-17A but not human IL-17F in 
mouse serum was available. It was believed that due to the striking structural and functional 
similarities between IL-17A and IL-17F, the expression and pharmacokinetic characteristics of IL-17F 
mutant would be well represented by IL-17A.  
Previous observations in our laboratory have shown that 5μg/ml plasmid DNA delivered via 
intravenous hydrodynamic tail injection in mice resulted in a transgene expression that was first 
detected at 48 hours and lasted over several weeks. On the basis of these findings, naïve SCID mice 
were treated with intravenous hydrodynamically delivered 5μg/ml human full-length and LAP-IL-17A 
plasmid DNA and levels of transgene expression in mouse serum analysed at 48 hours, 1 week and 2 
weeks. The treatment had to be discontinued prematurely in 2 female mice due to technical 
difficulties. One of these female mice received 8.5μg FL-IL-17A in 1.5ml NS and another received 
only 3.5μg LAP-IL-17A in 0.7ml NS. Two mice (one male and one female) from the LAP-IL-17A treated 
group died unexpectedly; the male mouse died at the time of intravenous injection of the plasmid 
DNA and the female mouse died 30 hours post-LAP-IL-17A injection from unknown causes. The 
results (Fig. 6.1) showed that the levels of human LAP- IL-17A transgene in mice serum were 1400-
fold higher than full-length IL-17A. The serum levels of both full-length and LAP-IL-17A declined to 
20% and 2% of the baseline at the end of the first and second week respectively. 
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Figure 6.1 Expression of human IL-17 transgene in naïve SCID mice. Naïve SCID mice (n=4) were 
treated with intravenous hydrodynamic human full-length or LAP-IL-17A gene therapy and levels of 
expressed transgenes in individual mouse serum were analysed at 48 hours, 1 week and 2 weeks by 
ELISA. The expression of LAP-IL-17A was 1400- fold higher than full-length IL-17A and the levels of 
expressed transgenes declined to 20% and 2% of the baseline levels at 1 and 2 weeks period 
respectively. IL-17A, full-length IL-17A. 
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6.2.2 Expression of human FL- and LAP-IL-17 transgenes in C57BL/6 mice 
Thirty C57BL/6 mice were injected dorsally to develop an airpouch and treated with intravenous 
hydrodynamically delivery 5μg/ml human IL-17F mutant or control plasmid DNAs. Expression of 
transgene was analysed at 52 hours post-plasmid DNA administration. 
Expression of human full-length IL-17A and IL-17F mutant, administered either alone or in 
combination, and LAP-IL-17F mutant, administered in two different doses of 1μg/ml and 5μg/ml in 
mouse serum, airpouch lavage exudate and liver homogenates was analysed by human IL-17A and a 
modified human IL-17F ultrasensitive ELISA. An ultrasensitive ELISA was developed and standardised 
for detection of human IL-17F in mouse serum by using human IL-17F Duoset ELISA (R&D Systems, 
UK) in conjunction with uncoated ELISA plate and mouse diluents 4 and 5 (MSD, USA) (Chapter 2, 
section 2.2.2c). As seen in the Fig. 6.2, levels of human full-length IL-17F mutant in mouse serum and 
airpouch lavage exudate were 1000-fold higher than full-length IL-17A. The concentrations of 
expressed transgene in mouse serum following co-administration of full-length IL-17A plus IL-17F 
mutant in an equal concentration of 2.5μg/ml were 7700-fold higher and in airpouch lavage exudate 
134-fold higher on detection with anti-human IL-17F than anti-human IL-17A antibody. The levels of 
expressed LAP-IL-17F mutant in mice serum were 2.2-fold higher than full-length IL-17F mutant 
Administration of LAP-IL-17F mutant in two different doses of 1μg/ml and 5μg/ml led to a dose-
dependent expression of LAP-IL-17F mutant transgene in mice serum, airpouch lavage exudate and 
liver homogenate samples. The levels of LAP-IL-17F mutant in mouse serum, airpouch lavage 
exudate and liver homogenates following treatment with 5ug/ml LAP-IL-17F mutant were 5.2, 3 and 
2.4-fold higher than the treatment with 1ug/ml LAP-IL-17F mutant. Interestingly, only 0.35% serum 
LAP-IL-17F mutant was expressed in airpouch lavage exudate as against a 4.5% expression of serum 
full-length IL-17F mutant in airpouch lavage exudate. 
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Figure 6.2 Expression of human IL-17 transgene in C57BL/6 mice. 52 hours post- hydrodynamic 
gene delivery, levels of human IL-17 transgenes expressed in vivo were analysed in mouse serum, 
airpouch lavage fluid and liver homogenates by ELISA. Expression of IL-17A in liver homogenates was 
not examined. Levels of IL-17F mutant in serum and airpouch lavage exudat were significantly higher 
than IL-17A (p<0.05). Administration of 5μg/ml LAP-IL-17F mutant in comparison with 1μg/ml 
resulted in a significant higher expression of transgene in serum, airouch exudate and liver 
homogenates (p<0.005). Levels of transgene detected in serum following co-administration of IL-17A 
plus IL-17F mutant were significantly higher when detected with anti-human IL-17F than anti-human 
IL-17A antibody. Levels of LAP-IL-17F mutant and FL-IL-17F mutant in airpouch lavage exudate were 
only 0.35% and 4.5% of their serum levels. FL-IL-17A, full-length IL-17A; FL-IL-17F mutant, full-length 
IL-17F mutant, IL-17A/IL-17F mutant, IL-17A/IL-17F heterodimer. 
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6.3 Discussion 
Intravenous hydrodynamic injection of human full-length and LAP- IL-17 plasmid DNA constructs via 
tail vein in SCID and C57BL/6 mice resulted in a detectable expression of human IL-17 transgenes at 
protein level in mice serum and airpouch lavage exudate. These findings support the previous 
reports of a high efficiency of gene transfer achieved with this relatively simple non-viral method of 
gene delivery (454, 455).  
The levels of expressed IL-17 transgene however declined rapidly and progressively over the two 
week study period. The expression of transgene was 20% of the baseline at the end of first week and 
only 2% of the baseline after 2 weeks. Longevity of transgene expression is inﬂuenced by the 
methylation status of the plasmid vectors (456). Expression vectors produced in bacteria such as 
pcDNA3 contain numerous methylated CpG dinucleotides, which may generate a proinﬂammatory 
cytokine response by activating TLR 9 (457) and cause a rapid decline in the level of expressed 
transgene as seen in this study.  
It was thus demonstrated that systemic gene therapy with human full-length and LAP-IL-17 led to a 
successful expression of human IL-17 transgene in naïve SCID and C57BL/6 mice although the 
transgene levels declined rapidly over the two weeks period. The results also showed that human IL-
17F mutant was unable to suppress mouse airpouch inflammation as assessed by analysing the 
number of neutrophils and levels of KC and IL-6 in airpouch lavage fluid (data not shown). It was 
therefore decided to further investigate in vivo therapeutic efficacy of human IL-17F mutant in RA 
synovium/SCID mice model of RA. Although the levels of transgene declined rapidly, the very fact 
that these could still be detected in mouse serum at the end of two weeks would have still allowed 
the completion of the study, which required post-treatment assessment over one week period. Due 
to difficulty in obtaining suitable RA synovium samples and SCID mice, this experiment however 
could not be conducted. 
In vivo expression of IL-17F mutant transgene in serum and airpouch lavage exudate in C57BL/6 mice 
was 1000-fold higher than IL-17A. Similarly, serum and airpouch exudate levels of expressed 
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transgene following co-administration of IL-17A plus IL-17F mutant were 7700-and 135-fold higher 
when detected with anti-human IL-17F antibody than anti-human IL-17A antibody. These results 
imply that IL-17F mutant had a longer half-life in vivo and was more stable than IL-17A. It is also 
possible that the majority of the transgene expression following co-administration of IL-17A plus IL-
17F mutant was either in the form of IL-17F mutant homodimers or expressed as IL-17A/IL-17F 
mutant heterodimer which was better detected with anti-IL-17F than anti-IL-17A antibody. A 
preferred expression of IL-17F over IL-17A has been previously reported. Wright et al. (143) have 
shown that activated human CD4+ T cells secreted minimal IL-17A but 10-fold or greater IL-17F and 
Liang et al. (144) have reported a higher expression of IL-17F than IL-17A from naïve mouse CD4+ T 
cells.  
In vivo expression of LAP-IL-17A in SCID mice was 1400-fold higher than full-length IL-17A whereas 
expression of LAP-IL-17F mutant was 2.2-fold higher than full-length IL-17F mutant in C57BL/6 mice. 
Similarly, in vitro expression of LAP-IL-17A, IL-17F and IL-17F mutant proteins was two to six-folds 
higher than corresponding full-length IL-17. These results imply that modification of a cytokine as 
LAP-cytokine significantly enhances both its in vitro and in vivo expression. A significant prolongation 
of in vivo half-life of LAP-IFN-β in the order of 37-fold higher than naïve IFN-β in CIA mice has been 
previously reported (353). A LAP-cytokine approach therefore offers advantage of a superior 
expression and a prolonged half-life over naïve cytokine and a potential for reduction in the dose 
and frequency of administration of a cytokine based therapy.  
The local expression of transgenes in airpouch lavage exudate was only slight in comparison to the 
systemic expression. The levels of LAP-IL-17F mutant in airpouch lavage exudate were only 0.35% of 
its serum level as against airpouch lavage exudate levels of full-length IL-17F mutant, which were 
4.5% of its systemic levels. The less efficient migration of LAP-IL-17F locally into acutely inflamed 
airpouch does not seem to be related to its size. The molecular weight ofLAP-IL-17F mutant 
homodimer is approximately 108kDa, much lower than that of immunoglobulins, which are able to 
easily migrate through vascular endothelium. It will be of interest to investigate whether 
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thrombospondin in the basal surface of endothelial cells (458, 459) interacted with LAP domain (460) 
of LAP-IL-17F mutant and prevented its migration through the local vasculature. 
Although this study has helped in arriving at some important conclusions such as confirmation of 
efficiency of intravenous hydrodynamic plasmid injection via tail vein in achieveing an effective in 
vivo transgene expression in mice and significantly enhanced in vivo expression of LAP-IL-17 in 
comparsion to full-length IL-17, some of the key experiments to essentially investigate in vivo 
therapeutic efficacy of IL-17F mutant could not be conducted. After a successful in vivo expression of 
human full-length and LAP-IL-17 transgenes in naïve SCID mice, a further confirmation of therapeutic 
effectiveness of IL-17F mutant could not be carried out due to difficulties in obtaining suitable RA 
synovial samples. Although both human IL-17F mutant and LAP-IL-17F mutant could aslo be 
successfully expressed in C57BL/6 mice, a preliminary analysis of therapeutic efficacy of human IL-
17F mutant did not show expected results. Rather, no difference between the treatment and 
untreated group was observed. The levels of KC, IL-6 and degree of neutrophilia were almost similar 
in treatment group, positive control treated with human IL-17A and a control group of mice treated 
with normal saline alone. One would have liked to examine therapeutic efficacy of human IL-17F 
mutant in CIA mice, if the preliminary experiments in mouse airpouch model of inflammation were 
successful. It would therefore be highly desirable to examine in vivo therapeutic efficacy of human 
IL-17F mutant in RA synovium/SCID mice model. 
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RA was defined as a Th1 mediated disease until the discovery of Th17 cells. Both Th1 and Th17 cells 
have been recognised in RA and the research in this important field continues. A recent study by van 
Hamburg et al. showed that Th17 but not Th1 cells cooperated with RASF in a proinflammatory 
feedback loop underscoring the importance of Th17 cells (461). In treatment-naïve, early RA 
patients, serum and SF IL-17A levels were shown to correlate strongly with DAS28, ACPA, RF and 
histopathology score (462). Increased levels of IL-17 mRNA in synovium are predictive of more 
severe joint damage progression (303). Phase I/II clinical trials of humanised anti-IL-17 monoclonal 
antibodies in RA have demonstrated therapeutic efficacy without notable side effects (339, 341). 
Likewise, in phase II clinical trials of psoriasis, neutralisation of IL-17 by a humanised anti-IL-17 
monoclonal antibody or human anti-IL-17 receptor antibody resulted in significant clinical 
improvement (463, 464). IL-17 in these studies was inhibited using either an anti-IL-17 or anti-IL-17R 
monoclonal antibody similar to using anti-TNF and other cytokine inhibiting therapies in RA (41, 465-
468). These therapies, however, cause a non-targeted inhibition of cytokines that are also needed 
for other important immune functions. This approach results in a state of generalised immune 
suppression and consequently increases the risk of systemic infections. Such unwanted side-effects 
of a cytokine-based therapy can be avoided by modifying a cytokine as a latent cytokine (353). A 
non-covalent fusion of a cytokine with LAP of TGF-β via a MMP-sensitive linker allows targeting 
biological actions of a pleiotropic cytokine to the site of active inflammation, prolongs its half-life 
and enhances its overall therapeutic efficacy (353). The aim of this study was to develop a novel 
latent IL-17 antagonist for targeted therapy of RA and examine its preclinical therapeutic efficacy in 
CIA mice via plasmid- based systemic gene therapy. 
Kawaguchi et al. (153) in their study of IL-17F polymorphism reported that (H161R) IL-17F mutant 
was an antagonist of IL-17F and protective against asthma in a Japanese population. The fact that IL-
17F is structurally and functionally similar to IL-17A but biologically 30-100 times less potent, (143, 
144, 469) suggested to us that the protective effect of IL-17F mutant in asthma was due to additional 
inhibition of IL-17A. We therefore hypothesised that (H161R) IL-17F mutant is also an inhibitor of IL-
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17A. We further hypothesised that IL-17F mutant, if modified as LAP- IL-17F mutant would be 
superior to conventional IL-17 or IL-17R inhibiting therapies in RA. 
Plasmid expression vectors encoding human full-length and LAP-IL-17F mutant were constructed and 
the proteins expressed in vitro. The results of in vitro biological assays showed that IL-17A induced 
secretion of IL-6 was inhibited by IL-17F mutant. The mutant lacked the ability to induce secretion of 
IL-6 in HFFF2, 3T3 and HeLa cells, and activate phosphorylation of ERK1/2 in HeLa cells. These 
biological effects were specific to the biological activity of IL-17F mutant as confirmed by 
demonstrating that IL-17F mutant was able to bind to IL-17 receptor and its ability to inhibit IL-17A 
was reversed in the presence of a neutralising anti-IL-17F antibody. Taken together, these findings 
confirmed the hypothesis that IL-17F mutant is an inhibitor of IL-17A (manuscript in preparation). 
The findings that IL-17F mutant was able to bind to IL-17RC but inhibited IL-17A induced secretion of 
IL-6 in fibroblast and epithelial cells suggest that IL-17F mutant is a receptor antagonist of IL-17A. 
Furthermore, as this novel inhibitor of IL-17A is a cytokine variant and not a monoclonal antibody or 
receptor fusion protein, it offers an opportunity for modifying it as LAP-IL-17F mutant for targeted 
therapy of RA. 
The targeted activity of LAP-cytokines is dependent on MMPs, which releases its biological activity 
by cleaving the linker that binds the cytokine to LAP. The release of biological activity of expressed 
LAP-IL-17 proteins by MMP was confirmed in vitro by demonstrating that naïve LAP-cytokines 
induced significantly less secretion of IL-6 than their corresponding full-length proteins but when 
pre-incubated with MMP-1, resulted in a significant increase in the induced secretion of IL-6. Use of 
LAP-IL-17F mutant in the treatment of RA is expected to provide superior therapeutic efficacy than 
inhibition of IL-17 via monoclonal antibodies or receptor fusion proteins. Our group has previously 
demonstrated that biological activity of LAP-IFN-β could be released by pre-incubation with synovial 
fluid from RA or osteoarthritis patients. The half-life of LAP-IFN-β was 37 fold higher than naive IFN-β 
and it was effective in ameliorating established CIA in mice (353). The LAP cytokine approach since 
first used for IFN- in our laboratory has been validated for a number of other cytokines and small 
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molecules including MSH-α and VIP (355). In vivo therapeutic effects of LAP-MSH were superior to 
free MSH in a peritonitis mouse model (355). Therapeutic efficacy of LAP-cytokines in the treatment 
of RA and similar autoimmune conditions, due to their targeted biological activity, prolonged half-
life and significantly enhanced in vitro and in vivo expression (as shown in this study) is expected to 
be superior to conventional cytokine inhibiting therapies. 
All the three mouse analogues of human IL-17F mutant, which were developed for the purpose of in 
vivo testing in CIA mice, exhibited unexpected immunological or biological activities. Mouse IL-17F 
mutant 1 did not inhibit but stimulated IL-6 secretion in fibroblast cells, in vitro expression of mouse 
IL-17F mutant 2 could not be detected in either transfected cells supernatant or lysate, and mouse 
IL-17F mutant 3 failed to bind to mouse IL-17RC. The crystal structure of human IL-17F bound to IL-
17RA revealed that one of the major receptor bindings sites of IL-17F is located at its C-terminal end 
(179). It seems that the site-specific point and deletion mutations, which are located within this 
important receptor binding region of IL-17F were significant enough to alter the receptor binding 
affinities. A total lack of expression of mouse IL-17F mutant 2 in vitro points towards the possibility 
of severe compromise of its stability. 
Thus, only the human IL-17F mutant construct could be assessed in vivo. RA synovium/SCID mice 
model allows a direct testing of therapeutics of human origin in SCID mice implanted with human RA 
synovium (410, 411). As a preliminary to investigating in vivo therapeutic efficacy of human IL-17F 
mutant in this model of RA, expression and pharmacokinetics of intravenous hydrodynamically 
delivered human full-length and LAP-IL-17A in naïve SCID were studied. In vivo expression of LAP-IL-
17A in mice serum was 1400-fold higher than full-length IL-17A. Similarly, in vivo expression of LAP-
IL-17F mutant in C57BL/6 mice serum was 2.2-fold higher than FL-IL-17F mutant and in vitro 
expression of LAP-IL-17 proteins was two-six-fold higher than their corresponding full-length IL-17 
proteins. An enhanced expression of LAP-cytokines, as shown in this study, in conjunction with a 
significantly prolonged half-life (353) would help decresing the dose and frequency of therapy.   
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The levels of transgene expression in SCID mice declined rapidly. The serum levels of both FL-and 
LAP-IL-17A were only 20% and 2% of the baseline at the end of first and second week respectively. 
The levels of the expressed transgene however still would have been adequate to evaluate 
therapeutic response after a week’s treatment in RA/SCID mice. The rapid decline in transgene 
expression in mice seems to be related to generation of a proinflammatory TLR induced response to 
CpG dinucleotides in pcDNA3 plasmid DNA (456, 457). Transgene expression could also be reduced 
by the CpG methylation of the promoter region in the plasmid expression vector (470). 
In vivo expression of intravenous hydrodynamically delivered human IL-17F mutant transgene at the 
site of inflammation was examined in C57BL/6 mouse airpouch inflammation. The local expression 
of human full-length and LAP-IL-17F mutant transgenes was negligible in comparison to their 
systemic levels. Interestingly, expression of IL-17F mutant in C57BL/6 mouse serum and airpouch 
lavage exudate was 1000-fold higher than IL-17A. Also, concentrations of expressed transgene 
following co-administration of IL-17A plus IL-17F mutant were 7700-fold higher in mouse serum and 
at least 134-fold higher in airpouch lavage exudate on detection with anti-IL-17F antibody than anti-
IL-17A antibody. Although this difference may be related to a superior detection of IL-17A/IL-17F 
mutant heterodimer by anti-IL-17F than anti-IL-17A detection antibody, it is more likely to be related 
to a better stability of IL-17F mutant than IL-17A. It is also possible that co-administration of IL-17A 
plus IL-17F mutant resulted in a preferred expression of IL-17F mutant homodimers. Wright et al. 
(143) have previously shown that activated human CD4+ T cells secreted minimal IL-17A but 10-fold 
or greater IL-17F. Similarly, Liang et al. (144) have demonstrated a higher expression of IL-17F than 
IL-17A in naïve mouse CD4+T cells. 
After demonstrating successful in vivo transgene expression of human IL-17 in mice following 
systemic gene therapy, an experiment to investigate in vivo therapeutic efficacy of human IL-17F 
mutant in RA synovium/SCID mice was planned but could not be conducted due to difficltly in 
obtaining suitable RA synovium samples. The readouts for in vivo therapeutic efficacy of IL-17F 
mutant included histopathology of implanted synovium for the severity of inflamamtion, mRNA 
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levels of KC, IL-6, IL-8, IL-1β and TNF- in the synovial tissue and proteins levels of KC, IL-6, IL-8, IL-1β 
and TNF- in mouse serum, which would have been comapred between FL-IL-17F mutant, LAP-IL-
17F mutant, FL-IL-17A treated group (as a positive control) and untreated group. 
A novel IL-6 promoter responsive reporter system was developed and standardised to assess 
biological activity of mouse IL-17. DTF (DBA/1 mouse fibroblasts) cells were stably transfected with 
IL-6 promoter responsive luciferase. A combination of mouse IL-17A or IL-17F and 2ng/ml TNF- but 
not IL-17A or IL-17F alone induced an activation of luciferase in these cells. It has been previously 
reported that IL-17 induces IL-6 secretion primarily by activating the transcription factor C/EBP- and 
, having a minimal activity on NF-B but IL-17 in combination with even suboptimal concentrations 
of TNF-, can induce a much greater secretion of IL-6 by synergistically activating C/EBD-δ and β 
(114). Unlike DTF cells, an IL-6 promoter responsive luciferase reporter system in HeLa and 293T cells 
did not demonstrate luciferase activation in response to human IL-17. Similarly, human and mouse 
IL-17 were unable to activate NF-B driven luciferase in 57A HeLa (420) and Raw 264.7 cells, 
previously transfected with NF-B driven luciferase. A lack of NF-B-linked luciferase activity in 
response to IL-17 in a number of mammalian cell lines has been previously reported (135).  
In conclusion, this study for the first time demonstrates that human (H161R) IL-17F mutant is an 
inhibitor of IL-17A. It was also demonstrated that modification of a cytokine as LAP-cytokine 
enhances its in vitro and in vivo expression. A novel IL-6 promoter responsive luciferase reporter 
system to assess biological activity of mouse IL-17 was developed and standardised. Lastly, 
intravenous hydrodynamic gene therapy delivered via tail vein in mice resulted in detectable levels 
of transgene in mouse serum, thus confirming that this method of in vivo gene transfer is highly 
efficient. 
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The aim of this study was to develop a novel latent IL-17 antagonist for targeted therapy of RA. The 
study has for the first time demonstrated that (H161R) IL-17F mutant, a natural inhibitor of human 
IL-17F is an additional inhibitor of IL-17A. The study has also confirmed that LAP-IL-17F mutant was 
biologically latent and that its biological activity can be released by the action of MMP. Taken 
together, the results of the study support the proposition that LAP-IL-17F mutant is likely to be an 
effective targeted therapy for RA. It will therefore be important to substantiate the findings of this 
study by examining biological effects of IL-17F mutant ex vivo in RA synovial explants and in vivo in a 
suitable preclinical model of RA. A direct in vivo testing of therapeutics of human origin is possible in 
SCID mice implanted with RA synovium (410, 411). The RA synovium/SCID therefore would be an 
ideal rodent model to study preclinical in vivo therapeutic efficacy of IL-17F mutant. As 
responsiveness to IL-17 targeted therapies in RA is dependent on rich infiltration of CD3+T cells in RA 
synovium (416), it will be important to pre-screen RA synovial samples before engrafting in mice. For 
a rapid preclinical testing, human IL-17F mutant can be delivered via intravenous hydrodynamic 
gene therapy. Therapeutic efficacy of the therapy can be assessed by analysing synovial 
inflammation, levels of IL-6 and IL-8 mRNA in engrafted synovium and IL-6 and IL-8 proteins in mice 
serum.  
Although gene therapy is an easy and quick method to test preclinical in vivo therapeutic efficacy of 
investigational and new therapies, it has its own limitations. For example, some of the problems 
encountered in the study were varied levels of transgene expression despite administration of equal 
quantity of plasmid DNA, and a rapid decline in the levels of expressed transgenes. Moreover, gene 
therapy in humans is still in experimental stages. Therefore its will be desirable to also assess 
preclinical in vivo therapeutic efficacy of IL-17F mutant delivered via protein-based therapy.  
IL-17F binds only weakly to IL-17RA. The binding affinity of human IL-17A to IL-17RA is 1000 stronger 
than that of IL-17F (181). This suggests that a heterodimer of IL-17A/IL-17F mutant would bind to IL-
17RA more strongly than IL-17F mutant homodimer and therefore mediate a more potent inhibition 
ofIL-17A than IL-17F mutant homodimer. A forced expression of IL-17A/IL-17F mutant heterodimer 
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can be achieved by fusing IL-17A to IL-17F mutant via a polyglycine linker (143). In vitro biological 
actions and in vivo therapeutic efficacy of expressed IL-17A/IL-17 F mutant then be analysed using 
the assays same as those used for IL-17F mutant homodimer. 
Finally, if human IL-17F mutant homodimer and/or IL-17A/IL-17F heterodimer are proven to be 
effective in preclinical models of RA, the findings can be translated and integrated with clinical 
research. 
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DNA sequence of human and mouse IL-17 constructs  
Shown below are the open reading frames (ORF) of DNA sequences of human and mouse full-length 
and LAP-IL-17 constructs. One letter code translation is shown for each ORF where * indicates 
termination of the translation. 
 
A1. Human FL-IL-17A 
 
 
     <SdeAI   >Bbr7I  
    <MlyI       >BbsI  
    >BspD6I     >AjuI     <SdeOSI  
    <PleI      >CchII     <NgoAVIII                     BlpI  
    |  |       ||         |                             | 
  ATG ACT CCT GGG AAG ACC TCA TTG GTG TCA CTG CTA CTG CTG CTG AGC CTG GAG GCC ATA  < 60 
  M   T   P   G   K   T   S   L   V   S   L   L   L   L   L   S   L   E   A   I    
              10           20           30            40           50  
 
                                                          Tsp509I  
                                        PfoI            ApoI            >DraRI  <AquIV  
                                        |               | |             |       | 
  GTG AAG GCA GGA ATC ACA ATC CCA CGA AAT CCA GGA TGC CCA AAT TCT GAG GAC AAG AAC  < 120 
  V   K   A   G   I   T   I   P   R   N   P   G   C   P   N   S   E   D   K   N    
              70           80           90            100          110  
 
                       >RdeGBIII  
       NciI       <NlaCI  
       EcoHI  HpyCH4III   HincII                   BsaWI  
       |      |   |    |  |                        | 
  TTC CCC CGG ACT GTG ATG GTC AAC CTG AAC ATC CAT AAC CGG AAT ACC AAT ACC AAT CCC  < 180 
  F   P   R   T   V   M   V   N   L   N   I   H   N   R   N   T   N   T   N   P    
              130          140          150           160          170  
 
                                                                       >BsrDI  
      Sse8647I                                    StyI            MslI  
      |                                           |               |    | 
  AAA AGG TCC TCA GAT TAC TAC AAC CGA TCC ACC TCA CCT TGG AAT CTC CAC CGC AAT GAG  < 240 
  K   R   S   S   D   Y   Y   N   R   S   T   S   P   W   N   L   H   R   N   E    
              190          200          210           220          230  
 
                                        <TstI              BglI  
  <SimI        EcoRV                    <BsaXI         TauI     <CchIII  
  |            |                        |              |   |    | 
  GAC CCT GAG AGA TAT CCC TCT GTG ATC TGG GAG GCA AAG TGC CGC CAC TTG GGC TGC ATC  < 300 
  D   P   E   R   Y   P   S   V   I   W   E   A   K   C   R   H   L   G   C   I    
              250          260          270           280          290  
 
                   HpyCH4IV  
                   TaiI  
       <PlaDI   >PsrI                 >TspDTI     <BsmFI               BstYI  
       |        |  |                  |           |                    | 
  AAC GCT GAT GGG AAC GTG GAC TAC CAC ATG AAC TCT GTC CCC ATC CAG CAA GAG ATC CTG  < 360 
  N   A   D   G   N   V   D   Y   H   M   N   S   V   P   I   Q   Q   E   I   L    
              310          320          330           340          350  
 
        HhaI  
        HinP1I  
        GlaI                                                            >BsrI  
       FspI                                 <CstMI                  <BaeI  
       ||                                   |                       |   | 
  GTC CTG CGC AGG GAG CCT CCA CAC TGC CCC AAC TCC TTC CGG CTG GAG AAG ATA CTG GTG  < 420 
  V   L   R   R   E   P   P   H   C   P   N   S   F   R   L   E   K   I   L   V    
              370          380          390           400          410  
 
   BtgI                                       DraIII  
  <TspGWI   <BsgI                           PflMI  
  ||        |                               | | 
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  TCC GTG GGC TGC ACC TGT GTC ACC CCG ATT GTC CAC CAT GTG GCC TAA  < 468 
  S   V   G   C   T   C   V   T   P   I   V   H   H   V   A   *    
              430          440          450           460        
 
Signal peptide starts from nucleotide 1, mature peptide starts from nucleotide 
136. 
   
 
A2. Human LAP-IL-17A 
 
 
HindIII  
  | 
  AAG CTT ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA  < 60 
  K   L   M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L    
              10           20           30            40           50  
 
                            KroI  
                            NaeI                      >BspMI  
            BsaHI           NgoMIV                  >AarI  <BcgI      >ApyPI  
            |               |                       | |    |          | 
  CTG GTG CTG ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC tgc AAG ACT ATC GAC ATG  < 120 
  L   V   L   T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M    
              70           80           90            100          110  
 
                            >CdiI                   <Bsp24I  
                            |                       | 
  GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG  < 180 
  E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R    
              130          140          150           160          170  
 
 
   
  CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC  < 240 
  L   A   S   P   P   S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L    
              190          200          210           220          230  
 
       BsrGI  
       | 
  GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG  < 300 
  A   L   Y   N   S   T   R   D   R   V   A   G   E   S   A   E   P   E   P   E    
              250          260          270           280          290  
 
  Bsu36I                                AleI                           >RleAI  
  |                                     |                              | 
  CCT GAG GCC GAC TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC  < 360 
  P   E   A   D   Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N    
              310          320          330           340          350  
 
                        >Tth111II  
                        | 
  GAA ATC TAT GAC AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA  < 420 
  E   I   Y   D   K   F   K   Q   S   T   H   S   I   Y   M   F   F   N   T   S    
              370          380          390           400          410  
 
  >UcoMSI  
  SacI              KpnI                           SmaI  
  Eco53kI           Acc65I                         XmaI  
  |                 |                              | 
  GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG  < 480 
  E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R   L   L    
              430          440          450           460          470  
 
      <BpuEI                      PmlI  
      SmlI    MseI                BsaAI  
      |       |                   | 
  AGG CTC AAG TTA AAA GTG GAG CAG CAC GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC  < 540 
  R   L   K   L   K   V   E   Q   H   V   E   L   Y   Q   K   Y   S   N   N   S    
              490          500          510           520          530  
 
                   >AlfI                >RdeGBII  
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                   |                    | 
  TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT  < 600 
  W   R   Y   L   S   N   R   L   L   A   P   S   D   S   P   E   W   L   S   F    
              550          560          570           580          590  
 
                      <AquII  
                      | 
  GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC  < 660 
  D   V   T   G   V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R    
              610          620          630           640          650  
 
      HaeII  
      LpnI  
      | 
  CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG GAC ATC AAC GGG  < 720 
  L   S   A   H   C   S   C   D   S   R   D   N   T   L   Q   V   D   I   N   G    
              670          680          690           700          710  
 
                   >NmeAIII  
                   | 
  TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG  < 780 
  F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R   P   F   L    
              730          740          750           760          770  
 
                                   ApaI  
                                   PspOMI  
               BstXI               BaeGI                      EcoRI           >EciI  
               |                   |                          |               | 
  CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC  < 840 
  L   L   M   A   T   P   L   E   R   A   Q   H   L   Q   S   E   F   G   G   G    
              790          800          810           820          830  
 
                                                                            >AjuI  
                                                                            >Bbr7I  
                                                                            >BbsI  
  BamHI   >BsrBI        <PspOMII                  NotI                     >CchII  
  |       |             |                         |                        || 
  GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCA ATG ACT CCT GGG AAG  < 900 
  G   S   P   L   G   L   W   A   G   G   G   S   A   A   A   M   T   P   G   K    
              850          860          870           880          890  
 
      <SdeOSI  
      <NgoAVIII  
      | 
  ACC TCA TTG GTG TCA CTG CTA CTG CTG CTG AGC CTG GAG GCC ATA GTG AAG GCA GGA ATC  < 960 
  T   S   L   V   S   L   L   L   L   L   S   L   E   A   I   V   K   A   G   I    
              910          920          930           940          950  
 
                                                                              <NlaCI  
                    PfoI                            >DraRI  <AquIV        HpyCH4III  
                    |                               |       |             |   | 
  ACA ATC CCA CGA AAT CCA GGA TGC CCA AAT TCT GAG GAC AAG AAC TTC CCC CGG ACT GTG  < 
1020 
  T   I   P   R   N   P   G   C   P   N   S   E   D   K   N   F   P   R   T   V    
              970          980          990           1000         1010  
 
      HincII                                                      Sse8647I  
      |                                                           | 
  ATG GTC AAC CTG AAC ATC CAT AAC CGG AAT ACC AAT ACC AAT CCC AAA AGG TCC TCA GAT  < 
1080 
  M   V   N   L   N   I   H   N   R   N   T   N   T   N   P   K   R   S   S   D    
              1030         1040         1050          1060         1070  
 
                                                              <SimI        EcoRV  
                                                              |            | 
  TAC TAC AAC CGA TCC ACC TCA CCT TGG AAT CTC CAC CGC AAT GAG GAC CCT GAG AGA TAT  < 
1140 
  Y   Y   N   R   S   T   S   P   W   N   L   H   R   N   E   D   P   E   R   Y    
              1090         1100         1110          1120         1130  
 
                    <BsaXI  
                    <TstI                   <CchIII                         >PsrI  
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                    |                       |                               | 
  CCC TCT GTG ATC TGG GAG GCA AAG TGC CGC CAC TTG GGC TGC ATC AAC GCT GAT GGG AAC  < 
1200 
  P   S   V   I   W   E   A   K   C   R   H   L   G   C   I   N   A   D   G   N    
              1150         1160         1170          1180         1190  
 
                                                                   FspI  
                                                                   | 
  GTG GAC TAC CAC ATG AAC TCT GTC CCC ATC CAG CAA GAG ATC CTG GTC CTG CGC AGG GAG  < 
1260 
  V   D   Y   H   M   N   S   V   P   I   Q   Q   E   I   L   V   L   R   R   E    
              1210         1220         1230          1240         1250  
 
                                                <BaeI         <TspGWI  
                                                |             | 
  CCT CCA CAC TGC CCC AAC TCC TTC CGG CTG GAG AAG ATA CTG GTG TCC GTG GGC TGC ACC  < 
1320 
  P   P   H   C   P   N   S   F   R   L   E   K   I   L   V   S   V   G   C   T    
              1270         1280         1290          1300         1310  
 
                          DraIII  
                        PflMI  
                        | | 
  TGT GTC ACC CCG ATT GTC CAC CAT GTG GCC TAA  < 1353 
  C   V   T   P   I   V   H   H   V   A   *    
              1330         1340         1350  
 
 
Signal peptide of LAP from nucleotide 7, mature peptide of IL-17A from 
nucleotide 886. 
 
 
 
A3. Human FL-IL-17F 
 
 
                                       NcoI  
                                >GsaI  BtgI        ScaI  
                                >BseYI     >RdeGBIII                <ApyPI  
                                |      |   |       |                | 
  ATG ACA GTG AAG ACC CTG CAT GGC CCA GCC ATG GTC AAG TAC TTG CTG CTG TCG ATA TTG  < 60 
  M   T   V   K   T   L   H   G   P   A   M   V   K   Y   L   L   L   S   I   L    
              10           20           30            40           50  
 
                                   >AceIII  
                                   | 
  GGG CTT GCC TTT CTG AGT GAG GCG GCA GCT CGG AAA ATC CCC AAA GTA GGA CAT ACT TTT  < 120 
  G   L   A   F   L   S   E   A   A   A   R   K   I   P   K   V   G   H   T   F    
              70           80           90            100          110  
 
                                  EcoNI  
                            >Sth132I  
                            >FauI          >SdeAI             HindIII  
                            |     |        |                  | 
  TTC CAA AAG CCT GAG AGT TGC CCG CCT GTG CCA GGA GGT AGT ATG AAG CTT GAC ATT GGC  < 180 
  F   Q   K   P   E   S   C   P   P   V   P   G   G   S   M   K   L   D   I   G    
              130          140          150           160          170  
 
                          SelI  
                          BstUI  
                        HhaI                HpyCH4IV  
                        HinP1I              TaiI          >BplI  
                        GlaI               BsaAI    >CdiI       >BsrBI  
                        | |                ||       |     |     | 
  ATC ATC AAT GAA AAC CAG CGC GTT TCC ATG TCA CGT AAC ATC GAG AGC CGC TCC ACC TCC  < 240 
  I   I   N   E   N   Q   R   V   S   M   S   R   N   I   E   S   R   S   T   S    
              190          200          210           220          230  
 
                                VpaK11AI  
                                AvaII  
                                Psp03I         Acc65I  
201 
 
                               PpuMI           BanI  
                               >BsmFI          KpnI  
                               EcoO109I    BsrFI  
                               KflI        >NmeDI  
                               PssI        AgeI                     BsrGI      <BmrI  
                               ||          |   |                    |          | 
  CCC TGG AAT TAC ACT GTC ACT TGG GAC CCC AAC CGG TAC CCC TCG GAA GTT GTA CAG GCC  < 300 
  P   W   N   Y   T   V   T   W   D   P   N   R   Y   P   S   E   V   V   Q   A    
              250          260          270           280          290  
 
                                       <BpuEI                           EcoRI  
                                       SmlI                 MslI        ApoI  <TspGWI  
                                       |                    |           |     | 
  CAG TGT AGG AAC TTG GGC TGC ATC AAT GCT CAA GGA AAG GAA GAC ATC TCC ATG AAT TCC  < 360 
  Q   C   R   N   L   G   C   I   N   A   Q   G   K   E   D   I   S   M   N   S    
              310          320          330           340          350  
 
                        PshAI  
                      <BsmAI                >AquIV  
       >BccI          <BsaI            BspEI  
       |              | |              |    | 
  GTT CCC ATC CAG CAA GAG ACC CTG GTC GTC CGG AGG AAG CAC CAA GGC TGC TCT GTT TCT  < 420 
  V   P   I   Q   Q   E   T   L   V   V   R   R   K   H   Q   G   C   S   V   S    
              370          380          390           400          410  
 
                                                           <NgoAVIII  
        >RpaI                                   >AarI  <HgaI  
        <MmeI   <HpyAV                     MwoI   >BspMI   <SdeOSI            DraIII  
        |       |                          |    | |    |   |                  | 
  TTC CAG TTG GAG AAG GTG CTG GTG ACT GTT GGC TGC ACC TGC GTC ACC CCT GTC ATC CAC  < 480 
  F   Q   L   E   K   V   L   V   T   V   G   C   T   C   V   T   P   V   I   H    
              430          440          450           460          470  
 
 
   
  CAT GTG CAG TAA  < 492 
  H   V   Q   *    
              490  
 
Signal peptide from nucleotide 1, mature peptide from nucleotide 91. 
 
 
 
A4. Human LAP-IL-17F 
 
 
             BglI  
                | 
  AAG CTT ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA  < 60 
  K   L   M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L    
              10           20           30            40           50  
 
                            NaeI  
                            NgoMIV  
            BsaHI           KroI                           <BcgI      >ApyPI  
            |               |                              |          | 
  CTG GTG CTG ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC tgc AAG ACT ATC GAC ATG  < 120 
  L   V   L   T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M    
              70           80           90            100          110  
 
                                                    <Bsp24I  
                                                    | 
  GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG  < 180 
  E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R    
              130          140          150           160          170  
 
 
   
  CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC  < 240 
  L   A   S   P   P   S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L    
              190          200          210           220          230  
202 
 
 
   
  GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG  < 300 
  A   L   Y   N   S   T   R   D   R   V   A   G   E   S   A   E   P   E   P   E    
              250          260          270           280          290  
 
  Bsu36I                      >CstMI    AleI                           >RleAI  
  |                           |         |                              | 
  CCT GAG GCC GAC TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC  < 360 
  P   E   A   D   Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N    
              310          320          330           340          350  
 
                        >Tth111II                                          >PlaDI  
                        |                                                  | 
  GAA ATC TAT GAC AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA  < 420 
  E   I   Y   D   K   F   K   Q   S   T   H   S   I   Y   M   F   F   N   T   S    
              370          380          390           400          410  
 
  >UcoMSI  
  Eco53kI                                          XmaI  
  SacI                                             SmaI  
  |                                                | 
  GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG  < 480 
  E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R   L   L    
              430          440          450           460          470  
 
              MseI                PmlI  
              |                   | 
  AGG CTC AAG TTA AAA GTG GAG CAG CAC GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC  < 540 
  R   L   K   L   K   V   E   Q   H   V   E   L   Y   Q   K   Y   S   N   N   S    
              490          500          510           520          530  
 
                                                  >BspD6I  
                                                  <MlyI  
                                                  HinfI  
                   >AlfI                >RdeGBII  <PleI  
                   |                    |         | 
  TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT  < 600 
  W   R   Y   L   S   N   R   L   L   A   P   S   D   S   P   E   W   L   S   F    
              550          560          570           580          590  
 
 
   
  GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC  < 660 
  D   V   T   G   V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R    
              610          620          630           640          650  
 
      LpnI  
      HaeII  
      | 
  CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG GAC ATC AAC GGG  < 720 
  L   S   A   H   C   S   C   D   S   R   D   N   T   L   Q   V   D   I   N   G    
              670          680          690           700          710  
 
                   >NmeAIII  
                   | 
  TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG  < 780 
  F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R   P   F   L    
              730          740          750           760          770  
 
                                   PspOMI  
                                   ApaI  
                          >BpmI    BaeGI  
               BstXI      >Eco57MI                                            >EciI  
               |          |        |                                          | 
  CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC  < 840 
  L   L   M   A   T   P   L   E   R   A   Q   H   L   Q   S   E   F   G   G   G    
              790          800          810           820          830  
 
  BamHI                 <PspOMII           BlpI   NotI     >TstI  
  |                     |                  |      |        | 
  GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCA CGG AAA ATC CCC AAA  < 900 
203 
 
  G   S   P   L   G   L   W   A   G   G   G   S   A   A   A   R   K   I   P   K    
              850          860          870           880          890  
 
                                                      EcoNI  
                                                      | 
  GTA GGA CAT ACT TTT TTC CAA AAG CCT GAG AGT TGC CCG CCT GTG CCA GGA GGT AGT ATG  < 960 
  V   G   H   T   F   F   Q   K   P   E   S   C   P   P   V   P   G   G   S   M    
              910          920          930           940          950  
 
                                                                              >BplI  
                                                                              | 
  AAG CTT GAC ATT GGC ATC ATC AAT GAA AAC CAG CGC GTT TCC ATG TCA CGT AAC ATC GAG  < 
1020 
  K   L   D   I   G   I   I   N   E   N   Q   R   V   S   M   S   R   N   I   E    
              970          980          990           1000         1010  
 
                                                    AvaII  
                                                    Psp03I  
                                                    VpaK11AI  
                                                   KflI  
                                                   PpuMI       AgeI  
                                                   ||          | 
  AGC CGC TCC ACC TCC CCC TGG AAT TAC ACT GTC ACT TGG GAC CCC AAC CGG TAC CCC TCG  < 
1080 
  S   R   S   T   S   P   W   N   Y   T   V   T   W   D   P   N   R   Y   P   S    
              1030         1040         1050          1060         1070  
 
                                                                          >BbsI  
                   <BmrI                                                  >Bbr7I  
                   |                                                      | 
  GAA GTT GTA CAG GCC CAG TGT AGG AAC TTG GGC TGC ATC AAT GCT CAA GGA AAG GAA GAC  < 
1140 
  E   V   V   Q   A   Q   C   R   N   L   G   C   I   N   A   Q   G   K   E   D    
              1090         1100         1110          1120         1130  
 
                                            PshAI  
                                          <BsmAI                >AquIV  
                                          <BsaI            BspEI  
                                          | |              |    | 
  ATC TCC ATG AAT TCC GTT CCC ATC CAG CAA GAG ACC CTG GTC GTC CGG AGG AAG CAC CAA  < 
1200 
  I   S   M   N   S   V   P   I   Q   Q   E   T   L   V   V   R   R   K   H   Q    
              1150         1160         1170          1180         1190  
 
                            <MmeI                                              <NgoAVIII  
                            >RpaI   <HpyAV                                     <SdeOSI  
                            |       |                                          | 
  GGC TGC TCT GTT TCT TTC CAG TTG GAG AAG GTG CTG GTG ACT GTT GGC TGC ACC TGC GTC  < 
1260 
  G   C   S   V   S   F   Q   L   E   K   V   L   V   T   V   G   C   T   C   V    
              1210         1220         1230          1240         1250  
 
                  DraIII  
                  | 
  ACC CCT GTC ATC CAC CAT GTG CAG TAA  < 1287 
  T   P   V   I   H   H   V   Q   *    
              1270         1280      
 
 
Signal peptide of LAP from nucleotide 7, mature peptide of IL-17F from 
nucleotide 886. 
 
 
 
 
 
 
 
 
204 
 
A5. Human FL-IL-17F mutant 
 
 
                                       NcoI  
                                >GsaI  BtgI        ScaI  
                                >BseYI     >RdeGBIII                <ApyPI  
                                |      |   |       |                | 
  ATG ACA GTG AAG ACC CTG CAT GGC CCA GCC ATG GTC AAG TAC TTG CTG CTG TCG ATA TTG  < 60 
  M   T   V   K   T   L   H   G   P   A   M   V   K   Y   L   L   L   S   I   L    
              10           20           30            40           50  
 
                                   >AceIII  
                                   | 
  GGG CTT GCC TTT CTG AGT GAG GCG GCA GCT CGG AAA ATC CCC AAA GTA GGA CAT ACT TTT  < 120 
  G   L   A   F   L   S   E   A   A   A   R   K   I   P   K   V   G   H   T   F    
              70           80           90            100          110  
 
                                  EcoNI  
                            >FauI  
                            >Sth132I       >SdeAI             HindIII  
                            |     |        |                  | 
  TTC CAA AAG CCT GAG AGT TGC CCG CCT GTG CCA GGA GGT AGT ATG AAG CTT GAC ATT GGC  < 180 
  F   Q   K   P   E   S   C   P   P   V   P   G   G   S   M   K   L   D   I   G    
              130          140          150           160          170  
 
                          SelI  
                          BstUI  
                        GlaI                TaiI  
                        HhaI                HpyCH4IV      >BplI  
                        HinP1I             BsaAI    >CdiI       >BsrBI  
                        | |                ||       |     |     | 
  ATC ATC AAT GAA AAC CAG CGC GTT TCC ATG TCA CGT AAC ATC GAG AGC CGC TCC ACC TCC  < 240 
  I   I   N   E   N   Q   R   V   S   M   S   R   N   I   E   S   R   S   T   S    
              190          200          210           220          230  
 
                                AvaII  
                                Psp03I  
                                VpaK11AI       BanI  
                               >BsmFI          KpnI  
                               PssI            Acc65I  
                               KflI        AgeI  
                               EcoO109I    >NmeDI  
                               PpuMI       BsrFI                    BsrGI      <BmrI  
                               ||          |   |                    |          | 
  CCC TGG AAT TAC ACT GTC ACT TGG GAC CCC AAC CGG TAC CCC TCG GAA GTT GTA CAG GCC  < 300 
  P   W   N   Y   T   V   T   W   D   P   N   R   Y   P   S   E   V   V   Q   A    
              250          260          270           280          290  
 
                                       <BpuEI                           EcoRI  
                                       SmlI                 MslI        ApoI  <TspGWI  
                                       |                    |           |     | 
  CAG TGT AGG AAC TTG GGC TGC ATC AAT GCT CAA GGA AAG GAA GAC ATC TCC ATG AAT TCC  < 360 
  Q   C   R   N   L   G   C   I   N   A   Q   G   K   E   D   I   S   M   N   S    
              310          320          330           340          350  
 
                        PshAI  
                      <BsaI                 >AquIV  
       >BccI          <BsmAI           BspEI  
       |              | |              |    | 
  GTT CCC ATC CAG CAA GAG ACC CTG GTC GTC CGG AGG AAG CAC CAA GGC TGC TCT GTT TCT  < 420 
  V   P   I   Q   Q   E   T   L   V   V   R   R   K   H   Q   G   C   S   V   S    
              370          380          390           400          410  
 
                                                           <NgoAVIII  
        <MmeI                                   >AarI  <HgaI  
        >RpaI   <HpyAV                     MwoI   >BspMI   <SdeOSI            DraIII  
        |       |                          |    | |    |   |                  | 
  TTC CAG TTG GAG AAG GTG CTG GTG ACT GTT GGC TGC ACC TGC GTC ACC CCT GTC ATC CAC  < 480 
  F   Q   L   E   K   V   L   V   T   V   G   C   T   C   V   T   P   V   I   H    
              430          440          450           460          470  
 
205 
 
 
   
  CGT GTG CAG TAA  < 492 
  R   V   Q   *    
              490  
 
 
Signal peptide from nucleotide 1, mature peptide from nucleotide 91. 
 
 
 
A6. Human LAP-IL-17F mutant 
 
  BglI  
                | 
  AAG CTT ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA  < 60 
  K   L   M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L    
              10           20           30            40           50  
 
                            NaeI  
                            NgoMIV  
            BsaHI           KroI                           <BcgI      >ApyPI  
            |               |                              |          | 
  CTG GTG CTG ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC tgc AAG ACT ATC GAC ATG  < 120 
  L   V   L   T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M    
              70           80           90            100          110  
 
                                                    <Bsp24I  
                                                    | 
  GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG  < 180 
  E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R    
              130          140          150           160          170  
 
 
   
  CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC  < 240 
  L   A   S   P   P   S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L    
              190          200          210           220          230  
 
 
   
  GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG  < 300 
  A   L   Y   N   S   T   R   D   R   V   A   G   E   S   A   E   P   E   P   E    
              250          260          270           280          290  
 
  Bsu36I                      >CstMI    AleI                           >RleAI  
  |                           |         |                              | 
  CCT GAG GCC GAC TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC  < 360 
  P   E   A   D   Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N    
              310          320          330           340          350  
 
                        >Tth111II                                          >PlaDI  
                        |                                                  | 
  GAA ATC TAT GAC AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA  < 420 
  E   I   Y   D   K   F   K   Q   S   T   H   S   I   Y   M   F   F   N   T   S    
              370          380          390           400          410  
 
  SacI  
  Eco53kI                                          SmaI  
  >UcoMSI                                          XmaI  
  |                                                | 
  GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG  < 480 
  E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R   L   L    
              430          440          450           460          470  
 
              MseI                PmlI  
              |                   | 
  AGG CTC AAG TTA AAA GTG GAG CAG CAC GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC  < 540 
  R   L   K   L   K   V   E   Q   H   V   E   L   Y   Q   K   Y   S   N   N   S    
              490          500          510           520          530  
 
206 
 
                                                  <MlyI  
                                                  >BspD6I  
                                                  <PleI  
                   >AlfI                >RdeGBII  HinfI  
                   |                    |         | 
  TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT  < 600 
  W   R   Y   L   S   N   R   L   L   A   P   S   D   S   P   E   W   L   S   F    
              550          560          570           580          590  
 
 
   
  GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC  < 660 
  D   V   T   G   V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R    
              610          620          630           640          650  
 
      HaeII  
      LpnI  
      | 
  CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG GAC ATC AAC GGG  < 720 
  L   S   A   H   C   S   C   D   S   R   D   N   T   L   Q   V   D   I   N   G    
              670          680          690           700          710  
 
                   >NmeAIII  
                   | 
  TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG  < 780 
  F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R   P   F   L    
              730          740          750           760          770  
 
                                   BaeGI  
                                   PspOMI  
                          >BpmI    ApaI  
               BstXI      >Eco57MI                                            >EciI  
               |          |        |                                          | 
  CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC  < 840 
  L   L   M   A   T   P   L   E   R   A   Q   H   L   Q   S   E   F   G   G   G    
              790          800          810           820          830  
 
  BamHI                 <PspOMII           BlpI   NotI     >TstI  
  |                     |                  |      |        | 
  GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCA CGG AAA ATC CCC AAA  < 900 
  G   S   P   L   G   L   W   A   G   G   G   S   A   A   A   R   K   I   P   K    
              850          860          870           880          890  
 
                                                      EcoNI  
                                                      | 
  GTA GGA CAT ACT TTT TTC CAA AAG CCT GAG AGT TGC CCG CCT GTG CCA GGA GGT AGT ATG  < 960 
  V   G   H   T   F   F   Q   K   P   E   S   C   P   P   V   P   G   G   S   M    
              910          920          930           940          950  
 
                                                                              >BplI  
                                                                              | 
  AAG CTT GAC ATT GGC ATC ATC AAT GAA AAC CAG CGC GTT TCC ATG TCA CGT AAC ATC GAG  < 
1020 
  K   L   D   I   G   I   I   N   E   N   Q   R   V   S   M   S   R   N   I   E    
              970          980          990           1000         1010  
 
                                                    VpaK11AI  
                                                    AvaII  
                                                    Psp03I  
                                                   PpuMI  
                                                   KflI        AgeI  
                                                   ||          | 
  AGC CGC TCC ACC TCC CCC TGG AAT TAC ACT GTC ACT TGG GAC CCC AAC CGG TAC CCC TCG  < 
1080 
  S   R   S   T   S   P   W   N   Y   T   V   T   W   D   P   N   R   Y   P   S    
              1030         1040         1050          1060         1070  
 
                                                                          >Bbr7I  
                   <BmrI                                                  >BbsI  
                   |                                                      | 
  GAA GTT GTA CAG GCC CAG TGT AGG AAC TTG GGC TGC ATC AAT GCT CAA GGA AAG GAA GAC  < 
1140 
207 
 
  E   V   V   Q   A   Q   C   R   N   L   G   C   I   N   A   Q   G   K   E   D    
              1090         1100         1110          1120         1130  
 
                                            PshAI  
                                          <BsmAI                >AquIV  
                                          <BsaI            BspEI  
                                          | |              |    | 
  ATC TCC ATG AAT TCC GTT CCC ATC CAG CAA GAG ACC CTG GTC GTC CGG AGG AAG CAC CAA  < 
1200 
  I   S   M   N   S   V   P   I   Q   Q   E   T   L   V   V   R   R   K   H   Q    
              1150         1160         1170          1180         1190  
 
                            >RpaI                                              <NgoAVIII  
                            <MmeI   <HpyAV                                     <SdeOSI  
                            |       |                                          | 
  GGC TGC TCT GTT TCT TTC CAG TTG GAG AAG GTG CTG GTG ACT GTT GGC TGC ACC TGC GTC  < 
1260 
  G   C   S   V   S   F   Q   L   E   K   V   L   V   T   V   G   C   T   C   V    
              1210         1220         1230          1240         1250  
 
                  DraIII  
                  | 
  ACC CCT GTC ATC CAC CGT GTG CAG TAA  < 1287 
  T   P   V   I   H   R   V   Q   *    
              1270         1280      
 
Signal peptide of LAP from nucleotide 7, mature peptide of IL-17F mutant from 
nucleotide 886. 
 
 
 
A7. Mouse FL-IL-17A 
 
 
          <SdeOSI   >BsmAI  
                          <NgoAVIII       <PlaDI  
                          |         |     | 
  ATG AGT CCA GGG AGA GCT TCA TCT GTG TCT CTG ATG CTG TTG CTG CTG CTG AGC CTG GCG  < 60 
  M   S   P   G   R   A   S   S   V   S   L   M   L   L   L   L   L   S   L   A    
              10           20           30            40           50  
 
   SfcI                     >Hin4I                             >Tth111II        >DraRI  
   |                        |                                  |                | 
  GCT ACA GTG AAG GCA GCA GCG ATC ATC CCT CAA AGC TCA GCG TGT CCA AAC ACT GAG GCC  < 120 
  A   T   V   K   A   A   A   I   I   P   Q   S   S   A   C   P   N   T   E   A    
              70           80           90            100          110  
 
           <CchII                 HincII  
        <AquIV                    Hpy166II             MseI  
        |  |                      |                    | 
  AAG GAC TTC CTC CAG AAT GTG AAG GTC AAC CTC AAA GTC TTT AAC TCC CTT GGC GCA AAA  < 180 
  K   D   F   L   Q   N   V   K   V   N   L   K   V   F   N   S   L   G   A   K    
              130          140          150           160          170  
 
                                                          <HphI  
    SacI                                                  <SspD5I  
    Eco53kI                                             MaeIII  
    BanII   >SdeAI                                      Tsp45I  
    >UcoMSI                                           HpyCH4IV  
    Bsp1286I      PssI                                TaiI  
    BsiHKAI       EcoO109I                          >BmgBI  
    |       |     |                                 | | | | 
  GTG AGC TCC AGA AGG CCC TCA GAC TAC CTC AAC CGT TCC ACG TCA CCC TGG ACT CTC CAC  < 240 
  V   S   S   R   R   P   S   D   Y   L   N   R   S   T   S   P   W   T   L   H    
              190          200          210           220          230  
 
          >BbsI                                                                AfeI  
          >Bbr7I           EcoRV                                               LpnI  
   >BsrDI             BsaBI                         <TstI                      HaeII  
   |      |           |    |                        |                          | 
208 
 
  CGC AAT GAA GAC CCT GAT AGA TAT CCC TCT GTG ATC TGG GAA GCT CAG TGC CGC CAC CAG  < 300 
  R   N   E   D   P   D   R   Y   P   S   V   I   W   E   A   Q   C   R   H   Q    
              250          260          270           280          290  
 
                                                    ApoI  
                                                NlaIII  
                                                FaiI  
                                                FatI  Tsp509I  
                                                CviAII  
          <MaqI   >CdpI                     >CjePI  EcoRI  
          |       |                         |   |   | | 
  CGC TGT GTC AAT GCG GAG GGA AAG CTG GAC CAC CAC ATG AAT TCT GTT CTC ATC CAG CAA  < 360 
  R   C   V   N   A   E   G   K   L   D   H   H   M   N   S   V   L   I   Q   Q    
              310          320          330           340          350  
 
                    <EarI  
    <AlwI         >AcuI  
   BstYI        BslI        NlaIV       <AceIII  
   ||           | | |       |           | 
  GAG ATC CTG GTC CTG AAG AGG GAG CCT GAG AGC TGC CCC TTC ACT TTC AGG GTC GAG AAG  < 420 
  E   I   L   V   L   K   R   E   P   E   S   C   P   F   T   F   R   V   E   K    
              370          380          390           400          410  
 
                              >BspMI  
                            >AarI  
                            AleI  
                          HpyCH4V  
                <RleAI  <BsgI                          <EciI  
                |       | | | |                        | 
  ATG CTG GTG GGT GTG GGC TGC ACC TGC GTG GCC TCG ATT GTC CGC CAG GCA GCC TAA  < 477 
  M   L   V   G   V   G   C   T   C   V   A   S   I   V   R   Q   A   A   *    
              430          440          450           460          470  
 
 
 
Signal peptide from nucleotide 1, mature peptide from nucleotide 76. 
 
 
 
A8. Mouse LAP-IL-17A 
 
 
HindIII       BglI                                                            >BsrI  
  |             |                                                               | 
  AAG CTT ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA  < 60 
  K   L   M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L    
              10           20           30            40           50  
 
                            KroI  
                            NgoMIV  
            BsaHI           NaeI        >BsmFI             <BcgI      >ApyPI  
            |               |           |                  |          | 
  CTG GTG CTG ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC tgc AAG ACT ATC GAC ATG  < 120 
  L   V   L   T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M    
              70           80           90            100          110  
 
                            >CdiI      >BccI        <Bsp24I  
                            |          |            | 
  GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG  < 180 
  E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R    
              130          140          150           160          170  
 
 
   
  CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC  < 240 
  L   A   S   P   P   S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L    
              190          200          210           220          230  
 
       BsrGI  
       | 
209 
 
  GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG  < 300 
  A   L   Y   N   S   T   R   D   R   V   A   G   E   S   A   E   P   E   P   E    
              250          260          270           280          290  
 
  Bsu36I                      >CstMI  
  |                           | 
  CCT GAG GCC GAC TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC  < 360 
  P   E   A   D   Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N    
              310          320          330           340          350  
 
                                                                           >PlaDI  
                                                                           | 
  GAA ATC TAT GAC AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA  < 420 
  E   I   Y   D   K   F   K   Q   S   T   H   S   I   Y   M   F   F   N   T   S    
              370          380          390           400          410  
 
                    KpnI                           SmaI  
                    Acc65I                         XmaI  
                    |                              | 
  GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG  < 480 
  E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R   L   L    
              430          440          450           460          470  
 
      SmlI                        PmlI  
      <BpuEI                      BsaAI  
      |                           | 
  AGG CTC AAG TTA AAA GTG GAG CAG CAC GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC  < 540 
  R   L   K   L   K   V   E   Q   H   V   E   L   Y   Q   K   Y   S   N   N   S    
              490          500          510           520          530  
 
                   >AlfI                >RdeGBII  
                   |                    | 
  TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT  < 600 
  W   R   Y   L   S   N   R   L   L   A   P   S   D   S   P   E   W   L   S   F    
              550          560          570           580          590  
 
                      <AquII  
                      | 
  GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC  < 660 
  D   V   T   G   V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R    
              610          620          630           640          650  
 
 
   
  CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG GAC ATC AAC GGG  < 720 
  L   S   A   H   C   S   C   D   S   R   D   N   T   L   Q   V   D   I   N   G    
              670          680          690           700          710  
 
                   >NmeAIII  
                   | 
  TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG  < 780 
  F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R   P   F   L    
              730          740          750           760          770  
 
                                   BaeGI  
                                   ApaI  
               BstXI               PspOMI  
               |                   | 
  CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC  < 840 
  L   L   M   A   T   P   L   E   R   A   Q   H   L   Q   S   E   F   G   G   G    
              790          800          810           820          830  
 
  BamHI   >BsrBI        <PspOMII                  NotI  
  |       |             |                         | 
  GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCA GCA GCG ATC ATC CCT  < 900 
  G   S   P   L   G   L   W   A   G   G   G   S   A   A   A   A   A   I   I   P    
              850          860          870           880          890  
 
                                                   <CchII  
                                        >DraRI  <AquIV                    HincII  
                                        |       |  |                      | 
  CAA AGC TCA GCG TGT CCA AAC ACT GAG GCC AAG GAC TTC CTC CAG AAT GTG AAG GTC AAC  < 960 
210 
 
  Q   S   S   A   C   P   N   T   E   A   K   D   F   L   Q   N   V   K   V   N    
              910          920          930           940          950  
 
 
   
  CTC AAA GTC TTT AAC TCC CTT GGC GCA AAA GTG AGC TCC AGA AGG CCC TCA GAC TAC CTC  < 
1020 
  L   K   V   F   N   S   L   G   A   K   V   S   S   R   R   P   S   D   Y   L    
              970          980          990           1000         1010  
 
                                                  >Bbr7I  
            >BmgBI                                >BbsI            EcoRV  
   HpyCH4III                               >BsrDI             BsaBI  
   |        |                              |      |           |    | 
  AAC CGT TCC ACG TCA CCC TGG ACT CTC CAC CGC AAT GAA GAC CCT GAT AGA TAT CCC TCT  < 
1080 
  N   R   S   T   S   P   W   T   L   H   R   N   E   D   P   D   R   Y   P   S    
              1030         1040         1050          1060         1070  
 
            <TstI                      AfeI       <MaqI   >CdpI  
            |                          |          |       | 
  GTG ATC TGG GAA GCT CAG TGC CGC CAC CAG CGC TGT GTC AAT GCG GAG GGA AAG CTG GAC  < 
1140 
  V   I   W   E   A   Q   C   R   H   Q   R   C   V   N   A   E   G   K   L   D    
              1090         1100         1110          1120         1130  
 
                                                            <EarI  
                                                          >AcuI  
                                                          | | 
  CAC CAC ATG AAT TCT GTT CTC ATC CAG CAA GAG ATC CTG GTC CTG AAG AGG GAG CCT GAG  < 
1200 
  H   H   M   N   S   V   L   I   Q   Q   E   I   L   V   L   K   R   E   P   E    
              1150         1160         1170          1180         1190  
 
 
   
  AGC TGC CCC TTC ACT TTC AGG GTC GAG AAG ATG CTG GTG GGT GTG GGC TGC ACC TGC GTG  < 
1260 
  S   C   P   F   T   F   R   V   E   K   M   L   V   G   V   G   C   T   C   V    
              1210         1220         1230          1240         1250  
 
 
   
  GCC TCG ATT GTC CGC CAG GCA GCC TAA  < 1287 
  A   S   I   V   R   Q   A   A   *    
              1270         1280      
 
 
Signal peptide of LAP from nucleotide 7, mature peptide of IL-17A from 
nucleotide 886. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
211 
 
A9. Mouse FL-IL-17F 
 
 
 
   ApaLI  
        BaeGI  >Sth132I  
        BsiHKAI                    >RdeGBIII  
        |      |                   | 
  ATG AAG TGC ACC CGT GAA ACA GCC ATG GTC AAG TCT TTG CTA CTG TTG ATG TTG GGA CTT  < 60 
  M   K   C   T   R   E   T   A   M   V   K   S   L   L   L   L   M   L   G   L    
              10           20           30            40           50  
 
                            AluI  
                           >AceIII                                            >SdeAI  
                           ||                                                 | 
  GCC ATT CTG AGG GAG GTA GCA GCT CGG AAG AAC CCC AAA GCA GGG GTT CCT GCC TTG CAG  < 120 
  A   I   L   R   E   V   A   A   R   K   N   P   K   A   G   V   P   A   L   Q    
              70           80           90            100          110  
 
                                                                       HinfI  
      <GsaI                                                            TfiI  
      <BseYI                                              HincII   BstBI      AgsI  
      |                                                   |        |   |      | 
  AAG GCT GGG AAC TGT CCT CCC CTG GAG GAT AAC ACT GTG AGA GTT GAC ATT CGA ATC TTC  < 180 
  K   A   G   N   C   P   P   L   E   D   N   T   V   R   V   D   I   R   I   F    
              130          140          150           160          170  
 
                                    HpyCH4IV  
                                    TaiI  
                                   BsaAI  
                                   >TstI  ApoI  
                                   PmlI   EcoRI         >BsrBI  
                                   ||     |             | 
  AAC CAA AAC CAG GGC ATT TCT GTC CCA CGT GAA TTC CAG AAC CGC TCC AGT TCC CCA TGG  < 240 
  N   Q   N   Q   G   I   S   V   P   R   E   F   Q   N   R   S   S   S   P   W    
              190          200          210           220          230  
 
                       <BsmAI  
                   Nli3877I         Sth302II  
                   AvaI             HpaII               ChaI  
                   SmlI            >NmeDI               MboI  <Bpu10I  
                   XhoI            AgeI                 Asi256I  
                   SciI            BsrFI                DpnI  <BbvCI  
            >NlaCI     <BsaI       BsaWI                BstKTI         <BmrI  
            |      |   |           ||                   |     |        | 
  GAT TAC AAC ATC ACT CGA GAC CCC CAC CGG TTC CCC TCA GAG ATC GCT GAG GCC CAG TGC  < 300 
  D   Y   N   I   T   R   D   P   H   R   F   P   S   E   I   A   E   A   Q   C    
              250          260          270           280          290  
 
                                              >BbsI                     Hpy99I  
                                              >Bbr7I                  <TspGWI  
                                              |                       | | 
  AGA CAC TCA GGC TGC ATC AAT GCC CAG GGT CAG GAA GAC AGC ACC ATG AAC TCC GTC GCC  < 360 
  R   H   S   G   C   I   N   A   Q   G   Q   E   D   S   T   M   N   S   V   A    
              310          320          330           340          350  
 
                        Psp03I  
                        VpaK11AI                                                >RpaI  
                        AvaII             BanII                         <AcuI   <MmeI  
                        |                 |                             |       | 
  ATT CAG CAA GAA ATC CTG GTC CTT CGG AGG GAG CCC CAG GGC TGT TCT AAT TCC TTC AGG  < 420 
  I   Q   Q   E   I   L   V   L   R   R   E   P   Q   G   C   S   N   S   F   R    
              370          380          390           400          410  
 
                                                                              TauI  
                                                                              | 
  TTG GAG AAG ATG CTC CTA AAA GTT GGC TGC ACC TGT GTC AAG CCC ATT GTC CAC CAA GCG  < 480 
  L   E   K   M   L   L   K   V   G   C   T   C   V   K   P   I   V   H   Q   A    
              430          440          450           460          470  
 
 
212 
 
   
  GCC TGA  < 486 
  A   *    
         
 
Signal peptide from nucleotide 1, mature peptide from nucleotide 76. 
 
 
 
A10. Mouse LAP-IL-17F  
 
HindIII       BglI  
  |             | 
  AAG CTT ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA  < 60 
  K   L   M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L    
              10           20           30            40           50  
 
                            KroI  
                            NgoMIV                    >BspMI  
            BsaHI           NaeI                    >AarI  <BcgI      >ApyPI  
            |               |                       | |    |          | 
  CTG GTG CTG ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC tgc AAG ACT ATC GAC ATG  < 120 
  L   V   L   T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M    
              70           80           90            100          110  
 
                                        <StsI  
                                        <FokI  
                                        <BtsCI  
                            >CdiI      >BccI        <Bsp24I  
                            |          ||           | 
  GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG  < 180 
  E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R    
              130          140          150           160          170  
 
 
   
  CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC  < 240 
  L   A   S   P   P   S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L    
              190          200          210           220          230  
 
       BsrGI  
       | 
  GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG  < 300 
  A   L   Y   N   S   T   R   D   R   V   A   G   E   S   A   E   P   E   P   E    
              250          260          270           280          290  
 
  Bsu36I                      >CstMI    AleI                           >RleAI  
  |                           |         |                              | 
  CCT GAG GCC GAC TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC  < 360 
  P   E   A   D   Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N    
              310          320          330           340          350  
 
                        >Tth111II                                          >PlaDI  
                        |                                                  | 
  GAA ATC TAT GAC AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA  < 420 
  E   I   Y   D   K   F   K   Q   S   T   H   S   I   Y   M   F   F   N   T   S    
              370          380          390           400          410  
 
  SacI  
  Eco53kI           Acc65I                         SmaI  
  >UcoMSI           KpnI                           XmaI  
  |                 |                              | 
  GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG  < 480 
  E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R   L   L    
              430          440          450           460          470  
 
      <BpuEI  MseI  
      |       | 
  AGG CTC AAG TTA AAA GTG GAG CAG CAC GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC  < 540 
  R   L   K   L   K   V   E   Q   H   V   E   L   Y   Q   K   Y   S   N   N   S    
              490          500          510           520          530  
213 
 
 
                                                  <MlyI  
                                                  >BspD6I  
                   >AlfI                >RdeGBII  <PleI  
                   |                    |         | 
  TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT  < 600 
  W   R   Y   L   S   N   R   L   L   A   P   S   D   S   P   E   W   L   S   F    
              550          560          570           580          590  
 
 
   
  GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC  < 660 
  D   V   T   G   V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R    
              610          620          630           640          650  
 
      HaeII  
      LpnI  
      | 
  CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG GAC ATC AAC GGG  < 720 
  L   S   A   H   C   S   C   D   S   R   D   N   T   L   Q   V   D   I   N   G    
              670          680          690           700          710  
 
                   >NmeAIII  
                   | 
  TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG  < 780 
  F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R   P   F   L    
              730          740          750           760          770  
 
                                   PspOMI  
                                   ApaI  
                                   BaeGI  
                                  PssI  
               BstXI              EcoO109I                                    >EciI  
               |                  ||                                          | 
  CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC  < 840 
  L   L   M   A   T   P   L   E   R   A   Q   H   L   Q   S   E   F   G   G   G    
              790          800          810           820          830  
 
  BamHI                 <PspOMII           BlpI   NotI  
  |                     |                  |      | 
  GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCA CGG AAG AAC CCC AAA  < 900 
  G   S   P   L   G   L   W   A   G   G   G   S   A   A   A   R   K   N   P   K    
              850          860          870           880          890  
 
 
   
  GCA GGG GTT CCT GCC TTG CAG AAG GCT GGG AAC TGT CCT CCC CTG GAG GAT AAC ACT GTG  < 960 
  A   G   V   P   A   L   Q   K   A   G   N   C   P   P   L   E   D   N   T   V    
              910          920          930           940          950  
 
                   TfiI  
      HincII   BstBI                                           >TstI  
      |        |   |                                           | 
  AGA GTT GAC ATT CGA ATC TTC AAC CAA AAC CAG GGC ATT TCT GTC CCA CGT GAA TTC CAG  < 
1020 
  R   V   D   I   R   I   F   N   Q   N   Q   G   I   S   V   P   R   E   F   Q    
              970          980          990           1000         1010  
 
                                                   <BsaI  
                                               SciI  
                                               XhoI  
                      NcoI              >NlaCI     <BsmAI      AgeI  
                      |                 |      |   |           | 
  AAC CGC TCC AGT TCC CCA TGG GAT TAC AAC ATC ACT CGA GAC CCC CAC CGG TTC CCC TCA  < 
1080 
  N   R   S   S   S   P   W   D   Y   N   I   T   R   D   P   H   R   F   P   S    
              1030         1040         1050          1060         1070  
 
                                                                          >BbsI  
                   <BmrI                                                  >Bbr7I  
                   |                                                      | 
214 
 
  GAG ATC GCT GAG GCC CAG TGC AGA CAC TCA GGC TGC ATC AAT GCC CAG GGT CAG GAA GAC  < 
1140 
  E   I   A   E   A   Q   C   R   H   S   G   C   I   N   A   Q   G   Q   E   D    
              1090         1100         1110          1120         1130  
 
                                                    Psp03I  
                                                    VpaK11AI  
                    Hpy99I                          AvaII  
                    |                               | 
  AGC ACC ATG AAC TCC GTC GCC ATT CAG CAA GAA ATC CTG GTC CTT CGG AGG GAG CCC CAG  < 
1200 
  S   T   M   N   S   V   A   I   Q   Q   E   I   L   V   L   R   R   E   P   Q    
              1150         1160         1170          1180         1190  
 
                            >RpaI  
                    <AcuI   <MmeI  
                    |       | 
  GGC TGT TCT AAT TCC TTC AGG TTG GAG AAG ATG CTC CTA AAA GTT GGC TGC ACC TGT GTC  < 
1260 
  G   C   S   N   S   F   R   L   E   K   M   L   L   K   V   G   C   T   C   V    
              1210         1220         1230          1240         1250  
 
 
   
  AAG CCC ATT GTC CAC CAA GCG GCC TGA  < 1287 
  K   P   I   V   H   Q   A   A   *    
              1270         1280      
 
 
Signal peptide of LAP from nucleotide 7, mature peptide of IL-17F from 
nucleotide 886. 
 
 
 
A11. Mouse FL-IL-17F mutant 1(Q158R mutation) 
 
   ApaLI  
        BaeGI  >Sth132I  
        BsiHKAI                    >RdeGBIII  
        |      |                   | 
  ATG AAG TGC ACC CGT GAA ACA GCC ATG GTC AAG TCT TTG CTA CTG TTG ATG TTG GGA CTT  < 60 
  M   K   C   T   R   E   T   A   M   V   K   S   L   L   L   L   M   L   G   L    
              10           20           30            40           50  
 
                            AluI  
                           >AceIII                                            >SdeAI  
                           ||                                                 | 
  GCC ATT CTG AGG GAG GTA GCA GCT CGG AAG AAC CCC AAA GCA GGG GTT CCT GCC TTG CAG  < 120 
  A   I   L   R   E   V   A   A   R   K   N   P   K   A   G   V   P   A   L   Q    
              70           80           90            100          110  
 
                                                                       HinfI  
      <GsaI                                                            TfiI  
      <BseYI                                              HincII   BstBI      AgsI  
      |                                                   |        |   |      | 
  AAG GCT GGG AAC TGT CCT CCC CTG GAG GAT AAC ACT GTG AGA GTT GAC ATT CGA ATC TTC  < 180 
  K   A   G   N   C   P   P   L   E   D   N   T   V   R   V   D   I   R   I   F    
              130          140          150           160          170  
 
                                    HpyCH4IV  
                                    TaiI  
                                   BsaAI  
                                   >TstI  ApoI  
                                   PmlI   EcoRI         >BsrBI  
                                   ||     |             | 
  AAC CAA AAC CAG GGC ATT TCT GTC CCA CGT GAA TTC CAG AAC CGC TCC AGT TCC CCA TGG  < 240 
  N   Q   N   Q   G   I   S   V   P   R   E   F   Q   N   R   S   S   S   P   W    
              190          200          210           220          230  
 
                       <BsmAI  
                   Nli3877I         Sth302II  
215 
 
                   AvaI             HpaII               ChaI  
                   SmlI            >NmeDI               MboI  <Bpu10I  
                   XhoI            AgeI                 Asi256I  
                   SciI            BsrFI                DpnI  <BbvCI  
            >NlaCI     <BsaI       BsaWI                BstKTI         <BmrI  
            |      |   |           ||                   |     |        | 
  GAT TAC AAC ATC ACT CGA GAC CCC CAC CGG TTC CCC TCA GAG ATC GCT GAG GCC CAG TGC  < 300 
  D   Y   N   I   T   R   D   P   H   R   F   P   S   E   I   A   E   A   Q   C    
              250          260          270           280          290  
 
                                              >BbsI                     Hpy99I  
                                              >Bbr7I                  <TspGWI  
                                              |                       | | 
  AGA CAC TCA GGC TGC ATC AAT GCC CAG GGT CAG GAA GAC AGC ACC ATG AAC TCC GTC GCC  < 360 
  R   H   S   G   C   I   N   A   Q   G   Q   E   D   S   T   M   N   S   V   A    
              310          320          330           340          350  
 
                        Psp03I  
                        VpaK11AI                                                >RpaI  
                        AvaII             BanII                         <AcuI   <MmeI  
                        |                 |                             |       | 
  ATT CAG CAA GAA ATC CTG GTC CTT CGG AGG GAG CCC CAG GGC TGT TCT AAT TCC TTC AGG  < 420 
  I   Q   Q   E   I   L   V   L   R   R   E   P   Q   G   C   S   N   S   F   R    
              370          380          390           400          410  
 
                                                                              TauI  
                                                                              | 
  TTG GAG AAG ATG CTC CTA AAA GTT GGC TGC ACC TGT GTC AAG CCC ATT GTC CAC CAA GCG  < 480 
  L   E   K   M   L   L   K   V   G   C   T   C   V   K   P   I   V   H   Q   A    
              430          440          450           460          470  
 
 
   
  GCC TGA  < 486 
  A   *    
 
 
Signal peptide from nucleotide 1, mature peptide from nucleotide 85. 
 
 
 
A12. Mouse LAP-IL-17F mutant 1(Q158R mutation) 
 
HindIII       BglI  
  |             | 
  AAG CTT ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA  < 60 
  K   L   M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L    
              10           20           30            40           50  
 
                            KroI  
                            NgoMIV                    >BspMI  
            BsaHI           NaeI                    >AarI  <BcgI      >ApyPI  
            |               |                       | |    |          | 
  CTG GTG CTG ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC tgc AAG ACT ATC GAC ATG  < 120 
  L   V   L   T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M    
              70           80           90            100          110  
 
                                        <StsI  
                                        <FokI  
                                        <BtsCI  
                            >CdiI      >BccI        <Bsp24I  
                            |          ||           | 
  GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG  < 180 
  E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R    
              130          140          150           160          170  
 
 
   
  CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC  < 240 
  L   A   S   P   P   S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L    
              190          200          210           220          230  
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       BsrGI  
       | 
  GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG  < 300 
  A   L   Y   N   S   T   R   D   R   V   A   G   E   S   A   E   P   E   P   E    
              250          260          270           280          290  
 
  Bsu36I                      >CstMI    AleI                           >RleAI  
  |                           |         |                              | 
  CCT GAG GCC GAC TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC  < 360 
  P   E   A   D   Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N    
              310          320          330           340          350  
 
                        >Tth111II                                          >PlaDI  
                        |                                                  | 
  GAA ATC TAT GAC AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA  < 420 
  E   I   Y   D   K   F   K   Q   S   T   H   S   I   Y   M   F   F   N   T   S    
              370          380          390           400          410  
 
  SacI  
  Eco53kI           Acc65I                         SmaI  
  >UcoMSI           KpnI                           XmaI  
  |                 |                              | 
  GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG  < 480 
  E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R   L   L    
              430          440          450           460          470  
 
      <BpuEI  MseI  
      |       | 
  AGG CTC AAG TTA AAA GTG GAG CAG CAC GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC  < 540 
  R   L   K   L   K   V   E   Q   H   V   E   L   Y   Q   K   Y   S   N   N   S    
              490          500          510           520          530  
 
                                                  <MlyI  
                                                  >BspD6I  
                   >AlfI                >RdeGBII  <PleI  
                   |                    |         | 
  TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT  < 600 
  W   R   Y   L   S   N   R   L   L   A   P   S   D   S   P   E   W   L   S   F    
              550          560          570           580          590  
 
 
   
  GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC  < 660 
  D   V   T   G   V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R    
              610          620          630           640          650  
 
      HaeII  
      LpnI  
      | 
  CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG GAC ATC AAC GGG  < 720 
  L   S   A   H   C   S   C   D   S   R   D   N   T   L   Q   V   D   I   N   G    
              670          680          690           700          710  
 
                   >NmeAIII  
                   | 
  TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG  < 780 
  F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R   P   F   L    
              730          740          750           760          770  
 
                                   PspOMI  
                                   ApaI  
                                   BaeGI  
                                  PssI  
               BstXI              EcoO109I                                    >EciI  
               |                  ||                                          | 
  CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC  < 840 
  L   L   M   A   T   P   L   E   R   A   Q   H   L   Q   S   E   F   G   G   G    
              790          800          810           820          830  
 
  BamHI                 <PspOMII           BlpI   NotI  
  |                     |                  |      | 
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  GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCA CGG AAG AAC CCC AAA  < 900 
  G   S   P   L   G   L   W   A   G   G   G   S   A   A   A   R   K   N   P   K    
              850          860          870           880          890  
 
 
   
  GCA GGG GTT CCT GCC TTG CAG AAG GCT GGG AAC TGT CCT CCC CTG GAG GAT AAC ACT GTG  < 960 
  A   G   V   P   A   L   Q   K   A   G   N   C   P   P   L   E   D   N   T   V    
              910          920          930           940          950  
 
                   TfiI  
      HincII   BstBI                                           >TstI  
      |        |   |                                           | 
  AGA GTT GAC ATT CGA ATC TTC AAC CAA AAC CAG GGC ATT TCT GTC CCA CGT GAA TTC CAG  < 
1020 
  R   V   D   I   R   I   F   N   Q   N   Q   G   I   S   V   P   R   E   F   Q    
              970          980          990           1000         1010  
 
                                                   <BsaI  
                                               SciI  
                                               XhoI  
                      NcoI              >NlaCI     <BsmAI      AgeI  
                      |                 |      |   |           | 
  AAC CGC TCC AGT TCC CCA TGG GAT TAC AAC ATC ACT CGA GAC CCC CAC CGG TTC CCC TCA  < 
1080 
  N   R   S   S   S   P   W   D   Y   N   I   T   R   D   P   H   R   F   P   S    
              1030         1040         1050          1060         1070  
 
                                                                          >BbsI  
                   <BmrI                                                  >Bbr7I  
                   |                                                      | 
  GAG ATC GCT GAG GCC CAG TGC AGA CAC TCA GGC TGC ATC AAT GCC CAG GGT CAG GAA GAC  < 
1140 
  E   I   A   E   A   Q   C   R   H   S   G   C   I   N   A   Q   G   Q   E   D    
              1090         1100         1110          1120         1130  
 
                                                    Psp03I  
                                                    VpaK11AI  
                    Hpy99I                          AvaII  
                    |                               | 
  AGC ACC ATG AAC TCC GTC GCC ATT CAG CAA GAA ATC CTG GTC CTT CGG AGG GAG CCC CAG  < 
1200 
  S   T   M   N   S   V   A   I   Q   Q   E   I   L   V   L   R   R   E   P   Q    
              1150         1160         1170          1180         1190  
 
                            >RpaI  
                    <AcuI   <MmeI  
                    |       | 
  GGC TGT TCT AAT TCC TTC AGG TTG GAG AAG ATG CTC CTA AAA GTT GGC TGC ACC TGT GTC  < 
1260 
  G   C   S   N   S   F   R   L   E   K   M   L   L   K   V   G   C   T   C   V    
              1210         1220         1230          1240         1250  
 
 
   
  AAG CCC ATT GTC CAC CAA GCG GCC TGA  < 1287 
  K   P   I   V   H   Q   A   A   *    
              1270         1280     
 
 
Signal peptide of LAP from nucleotide 7, mature peptide of IL-17F mutant 1 from 
nucleotide 886. 
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A13. Mouse FL-IL-17F mutant 2 (H157R mutation) 
  ApaLI  
        BaeGI  >Sth132I  
        BsiHKAI                    >RdeGBIII  
        |      |                   | 
  ATG AAG TGC ACC CGT GAA ACA GCC ATG GTC AAG TCT TTG CTA CTG TTG ATG TTG GGA CTT  < 60 
  M   K   C   T   R   E   T   A   M   V   K   S   L   L   L   L   M   L   G   L    
              10           20           30            40           50  
 
                            AluI  
                           >AceIII                                            >SdeAI  
                           ||                                                 | 
  GCC ATT CTG AGG GAG GTA GCA GCT CGG AAG AAC CCC AAA GCA GGG GTT CCT GCC TTG CAG  < 120 
  A   I   L   R   E   V   A   A   R   K   N   P   K   A   G   V   P   A   L   Q    
              70           80           90            100          110  
 
                                                                       TfiI  
      <BseYI                                                           HinfI  
      <GsaI                                               HincII   BstBI      AgsI  
      |                                                   |        |   |      | 
  AAG GCT GGG AAC TGT CCT CCC CTG GAG GAT AAC ACT GTG AGA GTT GAC ATT CGA ATC TTC  < 180 
  K   A   G   N   C   P   P   L   E   D   N   T   V   R   V   D   I   R   I   F    
              130          140          150           160          170  
 
                                    HpyCH4IV  
                                    TaiI  
                                   BsaAI  
                                   >TstI  ApoI  
                                   PmlI   EcoRI         >BsrBI  
                                   ||     |             | 
  AAC CAA AAC CAG GGC ATT TCT GTC CCA CGT GAA TTC CAG AAC CGC TCC AGT TCC CCA TGG  < 240 
  N   Q   N   Q   G   I   S   V   P   R   E   F   Q   N   R   S   S   S   P   W    
              190          200          210           220          230  
 
                       <BsmAI  
                   XhoI             Sth302II  
                   SmlI             HpaII               Asi256I  
                   AvaI            BsrFI                DpnI  
                   SciI            AgeI                 ChaI  <BbvCI  
                   Nli3877I        BsaWI                MboI  <Bpu10I  
            >NlaCI     <BsaI       >NmeDI               BstKTI         <BmrI  
            |      |   |           ||                   |     |        | 
  GAT TAC AAC ATC ACT CGA GAC CCC CAC CGG TTC CCC TCA GAG ATC GCT GAG GCC CAG TGC  < 300 
  D   Y   N   I   T   R   D   P   H   R   F   P   S   E   I   A   E   A   Q   C    
              250          260          270           280          290  
 
                                              >BbsI                     Hpy99I  
                                              >Bbr7I                  <TspGWI  
                                              |                       | | 
  AGA CAC TCA GGC TGC ATC AAT GCC CAG GGT CAG GAA GAC AGC ACC ATG AAC TCC GTC GCC  < 360 
  R   H   S   G   C   I   N   A   Q   G   Q   E   D   S   T   M   N   S   V   A    
              310          320          330           340          350  
 
                        Psp03I  
                        VpaK11AI                                                <MmeI  
                        AvaII             BanII                         <AcuI   >RpaI  
                        |                 |                             |       | 
  ATT CAG CAA GAA ATC CTG GTC CTT CGG AGG GAG CCC CAG GGC TGT TCT AAT TCC TTC AGG  < 420 
  I   Q   Q   E   I   L   V   L   R   R   E   P   Q   G   C   S   N   S   F   R    
              370          380          390           400          410  
 
                                                                   <EciI      TauI  
                                                                   |          | 
  TTG GAG AAG ATG CTC CTA AAA GTT GGC TGC ACC TGT GTC AAG CCC ATT GTC CGC CAA GCG  < 480 
  L   E   K   M   L   L   K   V   G   C   T   C   V   K   P   I   V   R   Q   A    
              430          440          450           460          470  
 
 
   
  GCC TGA  < 486 
  A   *    
         
 
Signal peptide from nucleotide 1, mature peptide from nucleotide 85. 
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A14. Mouse LAP-IL-17F mutant 2 (H157R mutation) 
HindIII       BglI  
  |             | 
  AAG CTT ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA  < 60 
  K   L   M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L    
              10           20           30            40           50  
 
                            KroI  
                            NaeI                      >BspMI  
            BsaHI           NgoMIV                  >AarI  <BcgI      >ApyPI  
            |               |                       | |    |          | 
  CTG GTG CTG ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC tgc AAG ACT ATC GAC ATG  < 120 
  L   V   L   T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M    
              70           80           90            100          110  
 
                                        <BtsCI  
                                        <StsI  
                                        <FokI  
                            >CdiI      >BccI        <Bsp24I  
                            |          ||           | 
  GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG  < 180 
  E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R    
              130          140          150           160          170  
 
 
   
  CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC  < 240 
  L   A   S   P   P   S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L    
              190          200          210           220          230  
 
       BsrGI  
       | 
  GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG  < 300 
  A   L   Y   N   S   T   R   D   R   V   A   G   E   S   A   E   P   E   P   E    
              250          260          270           280          290  
 
  Bsu36I                      >CstMI    AleI                           >RleAI  
  |                           |         |                              | 
  CCT GAG GCC GAC TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC  < 360 
  P   E   A   D   Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N    
              310          320          330           340          350  
 
                        >Tth111II                                          >PlaDI  
                        |                                                  | 
  GAA ATC TAT GAC AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA  < 420 
  E   I   Y   D   K   F   K   Q   S   T   H   S   I   Y   M   F   F   N   T   S    
              370          380          390           400          410  
 
  Eco53kI  
  >UcoMSI           Acc65I                         SmaI  
  SacI              KpnI                           XmaI  
  |                 |                              | 
  GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG  < 480 
  E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R   L   L    
              430          440          450           460          470  
 
      <BpuEI  MseI  
      |       | 
  AGG CTC AAG TTA AAA GTG GAG CAG CAC GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC  < 540 
  R   L   K   L   K   V   E   Q   H   V   E   L   Y   Q   K   Y   S   N   N   S    
              490          500          510           520          530  
 
                                                  <MlyI  
                                                  >BspD6I  
                   >AlfI                >RdeGBII  <PleI  
                   |                    |         | 
  TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT  < 600 
  W   R   Y   L   S   N   R   L   L   A   P   S   D   S   P   E   W   L   S   F    
              550          560          570           580          590  
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  GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC  < 660 
  D   V   T   G   V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R    
              610          620          630           640          650  
 
      HaeII  
      LpnI  
      | 
  CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG GAC ATC AAC GGG  < 720 
  L   S   A   H   C   S   C   D   S   R   D   N   T   L   Q   V   D   I   N   G    
              670          680          690           700          710  
 
                   >NmeAIII  
                   | 
  TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG  < 780 
  F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R   P   F   L    
              730          740          750           760          770  
 
                                   ApaI  
                                   PspOMI  
                                   BaeGI  
                                  PssI  
               BstXI              EcoO109I  
               |                  || 
  CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC  < 840 
  L   L   M   A   T   P   L   E   R   A   Q   H   L   Q   S   E   F   G   G   G    
              790          800          810           820          830  
 
  BamHI                 <PspOMII           BlpI   NotI  
  |                     |                  |      | 
  GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCA CGG AAG AAC CCC AAA  < 900 
  G   S   P   L   G   L   W   A   G   G   G   S   A   A   A   R   K   N   P   K    
              850          860          870           880          890  
 
 
   
  GCA GGG GTT CCT GCC TTG CAG AAG GCT GGG AAC TGT CCT CCC CTG GAG GAT AAC ACT GTG  < 960 
  A   G   V   P   A   L   Q   K   A   G   N   C   P   P   L   E   D   N   T   V    
              910          920          930           940          950  
 
                   TfiI  
      HincII   BstBI                                           >TstI  
      |        |   |                                           | 
  AGA GTT GAC ATT CGA ATC TTC AAC CAA AAC CAG GGC ATT TCT GTC CCA CGT GAA TTC CAG  < 
1020 
  R   V   D   I   R   I   F   N   Q   N   Q   G   I   S   V   P   R   E   F   Q    
              970          980          990           1000         1010  
 
                                                   <BsaI  
                                               XhoI  
                                               SciI  
                      NcoI              >NlaCI     <BsmAI      AgeI  
                      |                 |      |   |           | 
  AAC CGC TCC AGT TCC CCA TGG GAT TAC AAC ATC ACT CGA GAC CCC CAC CGG TTC CCC TCA  < 
1080 
  N   R   S   S   S   P   W   D   Y   N   I   T   R   D   P   H   R   F   P   S    
              1030         1040         1050          1060         1070  
 
                                                                          >Bbr7I  
                   <BmrI                                                  >BbsI  
                   |                                                      | 
  GAG ATC GCT GAG GCC CAG TGC AGA CAC TCA GGC TGC ATC AAT GCC CAG GGT CAG GAA GAC  < 
1140 
  E   I   A   E   A   Q   C   R   H   S   G   C   I   N   A   Q   G   Q   E   D    
              1090         1100         1110          1120         1130  
 
                                                    AvaII  
                                                    Psp03I  
                    Hpy99I                          VpaK11AI  
                    |                               | 
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  AGC ACC ATG AAC TCC GTC GCC ATT CAG CAA GAA ATC CTG GTC CTT CGG AGG GAG CCC CAG  < 
1200 
  S   T   M   N   S   V   A   I   Q   Q   E   I   L   V   L   R   R   E   P   Q    
              1150         1160         1170          1180         1190  
 
                            >RpaI  
                    <AcuI   <MmeI  
                    |       | 
  GGC TGT TCT AAT TCC TTC AGG TTG GAG AAG ATG CTC CTA AAA GTT GGC TGC ACC TGT GTC  < 
1260 
  G   C   S   N   S   F   R   L   E   K   M   L   L   K   V   G   C   T   C   V    
              1210         1220         1230          1240         1250  
 
 
   
  AAG CCC ATT GTC CGC CAA GCG GCC TGA  < 1287 
  K   P   I   V   R   Q   A   A   *    
              1270         1280      
 
 
Signal peptide of LAP from nucleotide 7, mature peptide of IL-17F mutant 2 from 
nucleotide 886. 
 
 
A15. Mouse FL-IL-17F mutant 3 (deletion of the last 4 amino acids) 
 
 
        ApaLI  
        BaeGI  >Sth132I  
        BsiHKAI                    >RdeGBIII  
        |      |                   | 
  ATG AAG TGC ACC CGT GAA ACA GCC ATG GTC AAG TCT TTG CTA CTG TTG ATG TTG GGA CTT  < 60 
  M   K   C   T   R   E   T   A   M   V   K   S   L   L   L   L   M   L   G   L    
              10           20           30            40           50  
 
                            AluI  
                           >AceIII                                            >SdeAI  
                           ||                                                 | 
  GCC ATT CTG AGG GAG GTA GCA GCT CGG AAG AAC CCC AAA GCA GGG GTT CCT GCC TTG CAG  < 120 
  A   I   L   R   E   V   A   A   R   K   N   P   K   A   G   V   P   A   L   Q    
              70           80           90            100          110  
 
                                                                       HinfI  
      <GsaI                                                            TfiI  
      <BseYI                                              HincII   BstBI      AgsI  
      |                                                   |        |   |      | 
  AAG GCT GGG AAC TGT CCT CCC CTG GAG GAT AAC ACT GTG AGA GTT GAC ATT CGA ATC TTC  < 180 
  K   A   G   N   C   P   P   L   E   D   N   T   V   R   V   D   I   R   I   F    
              130          140          150           160          170  
 
                                    HpyCH4IV  
                                    TaiI  
                                   BsaAI  
                                   PmlI   ApoI          >BsrBI  
                                   >TstI  EcoRI         >AciI  
                                   ||     |             | 
  AAC CAA AAC CAG GGC ATT TCT GTC CCA CGT GAA TTC CAG AAC CGC TCC AGT TCC CCA TGG  < 240 
  N   Q   N   Q   G   I   S   V   P   R   E   F   Q   N   R   S   S   S   P   W    
              190          200          210           220          230  
 
                       <BsaI  
                   AvaI             HpaII  
                   XhoI             Sth302II            MboI  
                   SciI            BsrFI                DpnI  <BbvCI  
                   Nli3877I        AgeI                 Asi256I     AoxI  
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                   SmlI            >NmeDI               BstKTI      HaeIII  
            >NlaCI     <BsmAI      BsaWI                ChaI  <Bpu10I  <BmrI  
            |      |   |           ||                   |     |     |  | 
  GAT TAC AAC ATC ACT CGA GAC CCC CAC CGG TTC CCC TCA GAG ATC GCT GAG GCC CAG TGC  < 300 
  D   Y   N   I   T   R   D   P   H   R   F   P   S   E   I   A   E   A   Q   C    
              250          260          270           280          290  
 
                                              >Bbr7I                    Hpy99I  
                                              >BbsI                   <TspGWI  
                                              |                       | | 
  AGA CAC TCA GGC TGC ATC AAT GCC CAG GGT CAG GAA GAC AGC ACC ATG AAC TCC GTC GCC  < 360 
  R   H   S   G   C   I   N   A   Q   G   Q   E   D   S   T   M   N   S   V   A    
              310          320          330           340          350  
 
                        VpaK11AI  
                        Psp03I                                                  <MmeI  
                        AvaII             BanII                         <AcuI   >RpaI  
                        |                 |                             |       | 
  ATT CAG CAA GAA ATC CTG GTC CTT CGG AGG GAG CCC CAG GGC TGT TCT AAT TCC TTC AGG  < 420 
  I   Q   Q   E   I   L   V   L   R   R   E   P   Q   G   C   S   N   S   F   R    
              370          380          390           400          410  
 
 
   
  TTG GAG AAG ATG CTC CTA AAA GTT GGC TGC ACC TGT GTC AAG CCC ATT TGA  < 471 
  L   E   K   M   L   L   K   V   G   C   T   C   V   K   P   I   *    
              430          440          450           460          470  
 
Signal peptide from nucleotide 1, mature peptide from nucleotide 85. 
 
 
A16. Mouse LAP-IL-17F mutant 3 (deletion of the last 4 amino acids) 
HindIII       BglI  
  |             | 
  AAG CTT ATG CCG CCC TCC GGG CTG CGG CTG CTG CCG CTG CTG CTA CCG CTG CTG TGG CTA  < 60 
  K   L   M   P   P   S   G   L   R   L   L   P   L   L   L   P   L   L   W   L    
              10           20           30            40           50  
 
                            NaeI  
                            NgoMIV                    >BspMI  
            BsaHI           KroI                    >AarI  <BcgI      >ApyPI  
            |               |                       | |    |          | 
  CTG GTG CTG ACG CCT GGC CCG CCG GCC GCG GGA CTA TCC ACC tgc AAG ACT ATC GAC ATG  < 120 
  L   V   L   T   P   G   P   P   A   A   G   L   S   T   C   K   T   I   D   M    
              70           80           90            100          110  
 
                                        <FokI  
                                        <BtsCI  
                                        <StsI  
                            >CdiI      >BccI        <Bsp24I  
                            |          ||           | 
  GAG CTG GTG AAG CGG AAG CGC ATC GAG GCC ATC CGC GGC CAG ATC CTG TCC AAG CTG CGG  < 180 
  E   L   V   K   R   K   R   I   E   A   I   R   G   Q   I   L   S   K   L   R    
              130          140          150           160          170  
 
 
   
  CTC GCC AGC CCC CCG AGC CAG GGG GAG GTG CCG CCC GGC CCG CTG CCC GAG GCC GTG CTC  < 240 
  L   A   S   P   P   S   Q   G   E   V   P   P   G   P   L   P   E   A   V   L    
              190          200          210           220          230  
 
       BsrGI  
       | 
  GCC CTG TAC AAC AGC ACC CGC GAC CGG GTG GCC GGG GAG AGT GCA GAA CCG GAG CCC GAG  < 300 
  A   L   Y   N   S   T   R   D   R   V   A   G   E   S   A   E   P   E   P   E    
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              250          260          270           280          290  
 
  Bsu36I                      >CstMI    AleI                           >RleAI  
  |                           |         |                              | 
  CCT GAG GCC GAC TAC TAC GCC AAG GAG GTC ACC CGC GTG CTA ATG GTG GAA ACC CAC AAC  < 360 
  P   E   A   D   Y   Y   A   K   E   V   T   R   V   L   M   V   E   T   H   N    
              310          320          330           340          350  
 
                        >Tth111II                                          >PlaDI  
                        |                                                  | 
  GAA ATC TAT GAC AAG TTC AAG CAG AGT ACA CAC AGC ATA TAT ATG TTC TTC AAC ACA TCA  < 420 
  E   I   Y   D   K   F   K   Q   S   T   H   S   I   Y   M   F   F   N   T   S    
              370          380          390           400          410  
 
  >UcoMSI  
  Eco53kI           Acc65I                         SmaI  
  SacI              KpnI                           XmaI  
  |                 |                              | 
  GAG CTC CGA GAA GCG GTA CCT GAA CCC GTG TTG CTC TCC CGG GCA GAG CTG CGT CTG CTG  < 480 
  E   L   R   E   A   V   P   E   P   V   L   L   S   R   A   E   L   R   L   L    
              430          440          450           460          470  
 
      <BpuEI  MseI  
      |       | 
  AGG CTC AAG TTA AAA GTG GAG CAG CAC GTG GAG CTG TAC CAG AAA TAC AGC AAC AAT TCC  < 540 
  R   L   K   L   K   V   E   Q   H   V   E   L   Y   Q   K   Y   S   N   N   S    
              490          500          510           520          530  
 
                                                  >BspD6I  
                                                  <MlyI  
                   >AlfI                >RdeGBII  <PleI  
                   |                    |         | 
  TGG CGA TAC CTC AGC AAC CGG CTG CTG GCA CCC AGC GAC TCG CCA GAG TGG TTA TCT TTT  < 600 
  W   R   Y   L   S   N   R   L   L   A   P   S   D   S   P   E   W   L   S   F    
              550          560          570           580          590  
 
 
   
  GAT GTC ACC GGA GTT GTG CGG CAG TGG TTG AGC CGT GGA GGG GAA ATT GAG GGC TTT CGC  < 660 
  D   V   T   G   V   V   R   Q   W   L   S   R   G   G   E   I   E   G   F   R    
              610          620          630           640          650  
 
      LpnI  
      HaeII  
      | 
  CTT AGC GCC CAC TGC TCC TGT GAC AGC AGG GAT AAC ACA CTG CAA GTG GAC ATC AAC GGG  < 720 
  L   S   A   H   C   S   C   D   S   R   D   N   T   L   Q   V   D   I   N   G    
              670          680          690           700          710  
 
                   >NmeAIII  
                   | 
  TTC ACT ACC GGC CGC CGA GGT GAC CTG GCC ACC ATT CAT GGC ATG AAC CGG CCT TTC CTG  < 780 
  F   T   T   G   R   R   G   D   L   A   T   I   H   G   M   N   R   P   F   L    
              730          740          750           760          770  
 
                                   PspOMI  
                                   ApaI  
                                   BaeGI  
                                  PssI  
               BstXI              EcoO109I                                    >EciI  
               |                  ||                                          | 
  CTT CTC ATG GCC ACC CCG CTG GAG AGG GCC CAG CAT CTG CAA AGC GAA TTC GGG GGA GGC  < 840 
  L   L   M   A   T   P   L   E   R   A   Q   H   L   Q   S   E   F   G   G   G    
              790          800          810           820          830  
 
  BamHI                 <PspOMII           BlpI   NotI  
  |                     |                  |      | 
  GGA TCC CCG CTC GGG CTT TGG GCG GGA GGG GGC TCA GCG GCC GCA CGG AAG AAC CCC AAA  < 900 
  G   S   P   L   G   L   W   A   G   G   G   S   A   A   A   R   K   N   P   K    
              850          860          870           880          890  
 
 
224 
 
   
  GCA GGG GTT CCT GCC TTG CAG AAG GCT GGG AAC TGT CCT CCC CTG GAG GAT AAC ACT GTG  < 960 
  A   G   V   P   A   L   Q   K   A   G   N   C   P   P   L   E   D   N   T   V    
              910          920          930           940          950  
 
                   TfiI  
      HincII   BstBI                                           >TstI  
      |        |   |                                           | 
  AGA GTT GAC ATT CGA ATC TTC AAC CAA AAC CAG GGC ATT TCT GTC CCA CGT GAA TTC CAG  < 
1020 
  R   V   D   I   R   I   F   N   Q   N   Q   G   I   S   V   P   R   E   F   Q    
              970          980          990           1000         1010  
 
                                                   <BsaI  
                                               XhoI  
                                               SciI  
                      NcoI              >NlaCI     <BsmAI      AgeI  
                      |                 |      |   |           | 
  AAC CGC TCC AGT TCC CCA TGG GAT TAC AAC ATC ACT CGA GAC CCC CAC CGG TTC CCC TCA  < 
1080 
  N   R   S   S   S   P   W   D   Y   N   I   T   R   D   P   H   R   F   P   S    
              1030         1040         1050          1060         1070  
 
                                                                          >BbsI  
                   <BmrI                                                  >Bbr7I  
                   |                                                      | 
  GAG ATC GCT GAG GCC CAG TGC AGA CAC TCA GGC TGC ATC AAT GCC CAG GGT CAG GAA GAC  < 
1140 
  E   I   A   E   A   Q   C   R   H   S   G   C   I   N   A   Q   G   Q   E   D    
              1090         1100         1110          1120         1130  
 
                                                    AvaII  
                                                    VpaK11AI  
                    Hpy99I                          Psp03I  
                    |                               | 
  AGC ACC ATG AAC TCC GTC GCC ATT CAG CAA GAA ATC CTG GTC CTT CGG AGG GAG CCC CAG  < 
1200 
  S   T   M   N   S   V   A   I   Q   Q   E   I   L   V   L   R   R   E   P   Q    
              1150         1160         1170          1180         1190  
 
                            >RpaI  
                    <AcuI   <MmeI  
                    |       | 
  GGC TGT TCT AAT TCC TTC AGG TTG GAG AAG ATG CTC CTA AAA GTT GGC TGC ACC TGT GTC  < 
1260 
  G   C   S   N   S   F   R   L   E   K   M   L   L   K   V   G   C   T   C   V    
              1210         1220         1230          1240         1250  
 
 
   
  AAG CCC ATT TGA  < 1272 
  K   P   I   *    
              1270  
 
Signal peptide of LAP from nucleotide 7, mature peptide of IL-17F mutant 3 from 
nucleotide 886. 
 
 
 
 
 
225 
 
Scientific communications 
Oral Presentations 
Human (H161R) IL-17F mutant is a dual antagonist of IL-17A and IL-17F. Sixth Gene Therapy Meeting, 
May 2011, London, UK 
Development of a latent IL-17 antagonist for targeted therapy of rheumatoid arthritis. North West 
London Rheumatology Club, June 2010, London, UK 
Poster Presentations 
G Mittal, R Mageed, Y Chernajovsky. Human (H161R) IL-17F mutant is a dual antagonist of IL-17A 
and IL-17F. British Society of Rheumatology AGM, April 2011, Brighton, UK. 
G Mittal, R Mageed, Y Chernajovsky. Human (H161R) IL-17F mutant is a dual antagonist of IL-17A 
and IL-17F. William Harvey Research Day, St Bartholomew’s Hospital, October 2010, London, UK. 
Publications 
L. Mullen, G. Adams, R. Fatah, D. Gould, A. Rigby, M. Sclanders, A. Koutsokeras, G. Mittal, S. 
Vessillier & Y. Chernajovsky. Development of latent cytokine fusion proteins in Fusion protein 
technologies for biopharmaceuticals: Applications and Challenges, S.R. Schmidt (Ed.) Wiley-Blackwell 
(in Press), 2012    
Lisa Mullen, Anne Rigby, Michelle Sclanders, Gill Adams, Gayatri Mittal, Julia Colston, Rewas Fatah, 
Maria  Subang, Julie Foster, Philippa Francis-West, Mario Köster, Hansjörg Hauser, Lorna Layward, 
Sandrine Vessillier, Alex Annenkov, Sarah Al-Izki, Gareth Pryce, Chris Bolton, David Baker, David J. 
Gould and Yuti Chernajovsky. Aggrecanase-released cytokine confers arthritis-specific drug delivery 
(submitted). 
Mittal, G., Vessillier, S., Mullen, L., Mageed, R.A. and Chernajovsky, Y. Development of a latent IL-17 
antagonistfor targeted therapy of RA (in preparation). 
 
 
226 
 
References 
1. Berkanovic E, Hurwicz ML. Rheumatoid arthritis and comorbidity. J Rheumatol. 
1990;17(7):888-92. 
2. Myasoedova E, Davis JM, 3rd, Crowson CS, Gabriel SE. Epidemiology of rheumatoid arthritis: 
rheumatoid arthritis and mortality. Curr Rheumatol Rep. 2010;12(5):379-85. 
3. Lanchbury JS. The HLA association with rheumatoid arthritis. Clin Exp Rheumatol. 
1992;10(3):301-4. 
4. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to 
understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis 
Rheum. 1987;30(11):1205-13. 
5. Plenge RM, Cotsapas C, Davies L, Price AL, de Bakker PI, Maller J, et al. Two independent 
alleles at 6q23 associated with risk of rheumatoid arthritis. Nat Genet. 2007;39(12):1477-82. 
6. Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al. STAT4 and the risk 
of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007;357(10):977-
86. 
7. Plenge RM, Seielstad M, Padyukov L, Lee AT, Remmers EF, Ding B, et al. TRAF1-C5 as a risk 
locus for rheumatoid arthritis--a genomewide study. N Engl J Med. 2007;357(12):1199-209. 
8. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, et al. A 
missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase 
(PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet. 2004;75(2):330-7. 
9. Gregersen PK, Amos CI, Lee AT, Lu Y, Remmers EF, Kastner DL, et al. REL, encoding a member 
of the NF-kappaB family of transcription factors, is a newly defined risk locus for rheumatoid 
arthritis. Nat Genet. 2009;41(7):820-3. 
10. Irigoyen P, Lee AT, Wener MH, Li W, Kern M, Batliwalla F, et al. Regulation of anti-cyclic 
citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and 
the shared epitope alleles. Arthritis Rheum. 2005;52(12):3813-8. 
11. Sigurdsson S, Padyukov L, Kurreeman FA, Liljedahl U, Wiman AC, Alfredsson L, et al. 
Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene 
with rheumatoid arthritis. Arthritis Rheum. 2007;56(7):2202-10. 
12. Lorentzen JC, Flornes L, Eklow C, Backdahl L, Ribbhammar U, Guo JP, et al. Association of 
arthritis with a gene complex encoding C-type lectin-like receptors. Arthritis Rheum. 
2007;56(8):2620-32. 
13. Symmons DP, Bankhead CR, Harrison BJ, Brennan P, Barrett EM, Scott DG, et al. Blood 
transfusion, smoking, and obesity as risk factors for the development of rheumatoid 
arthritis: results from a primary care-based incident case-control study in Norfolk, England. 
Arthritis Rheum. 1997;40(11):1955-61. 
14. Klareskog L, Stolt P, Lundberg K, Kallberg H, Bengtsson C, Grunewald J, et al. A new model 
for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-
restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 
2006;54(1):38-46. 
15. Hyrich KL, Inman RD. Infectious agents in chronic rheumatic diseases. Curr Opin Rheumatol. 
2001;13(4):300-4. 
16. Wegner N, Wait R, Sroka A, Eick S, Nguyen KA, Lundberg K, et al. Peptidylarginine deiminase 
from Porphyromonas gingivalis citrullinates human fibrinogen and alpha-enolase: 
implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 2010;62(9):2662-72. 
17. Blass S, Engel JM, Burmester GR. The immunologic homunculus in rheumatoid arthritis. 
Arthritis Rheum. 1999;42(12):2499-506. 
18. Gravallese EM. Bone destruction in arthritis. Ann Rheum Dis. 2002;61 Suppl 2:ii84-6. 
227 
 
19. Haringman JJ, Gerlag DM, Zwinderman AH, Smeets TJ, Kraan MC, Baeten D, et al. Synovial 
tissue macrophages: a sensitive biomarker for response to treatment in patients with 
rheumatoid arthritis. Ann Rheum Dis. 2005;64(6):834-8. 
20. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev 
Immunol. 1996;14:397-440. 
21. Feldmann M, Maini RN. The role of cytokines in the pathogenesis of rheumatoid arthritis. 
Rheumatology (Oxford). 1999;38 Suppl 2:3-7. 
22. Aupperle KR, Boyle DL, Hendrix M, Seftor EA, Zvaifler NJ, Barbosa M, et al. Regulation of 
synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene. Am J 
Pathol. 1998;152(4):1091-8. 
23. Inazuka M, Tahira T, Horiuchi T, Harashima S, Sawabe T, Kondo M, et al. Analysis of p53 
tumour suppressor gene somatic mutations in rheumatoid arthritis synovium. Rheumatology 
(Oxford). 2000;39(3):262-6. 
24. Kullmann F, Judex M, Neudecker I, Lechner S, Justen HP, Green DR, et al. Analysis of the p53 
tumor suppressor gene in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 
1999;42(8):1594-600. 
25. Yamanishi Y, Hiyama K, Maeda H, Ishioka S, Murakami T, Hiyama E, et al. Telomerase activity 
in rheumatoid synovium correlates with the mononuclear cell infiltration level and disease 
aggressiveness of rheumatoid arthritis. J Rheumatol. 1998;25(2):214-20. 
26. Kinne RW, Boehm S, Iftner T, Aigner T, Vornehm S, Weseloh G, et al. Synovial fibroblast-like 
cells strongly express jun-B and C-fos proto-oncogenes in rheumatoid- and osteoarthritis. 
Scand J Rheumatol Suppl. 1995;101:121-5. 
27. Ritchlin C. Fibroblast biology. Effector signals released by the synovial fibroblast in arthritis. 
Arthritis Res. 2000;2(5):356-60. 
28. Brennan FM, Hayes AL, Ciesielski CJ, Green P, Foxwell BM, Feldmann M. Evidence that 
rheumatoid arthritis synovial T cells are similar to cytokine-activated T cells: involvement of 
phosphatidylinositol 3-kinase and nuclear factor kappaB pathways in tumor necrosis factor 
alpha production in rheumatoid arthritis. Arthritis Rheum. 2002;46(1):31-41. 
29. Panayi GS, Corrigall VM, Pitzalis C. Pathogenesis of rheumatoid arthritis. The role of T cells 
and other beasts. Rheum Dis Clin North Am. 2001;27(2):317-34. 
30. Tak PP, van der Lubbe PA, Cauli A, Daha MR, Smeets TJ, Kluin PM, et al. Reduction of synovial 
inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis. 
Arthritis Rheum. 1995;38(10):1457-65. 
31. Muirden KD, Mills KW. Do lymphocytes protect the rheumatoid joint? Br Med J. 
1971;4(5781):219-21. 
32. Nakken B, Munthe LA, Konttinen YT, Sandberg AK, Szekanecz Z, Alex P, et al. B-cells and their 
targeting in rheumatoid arthritis--current concepts and future perspectives. Autoimmun 
Rev. 2011;11(1):28-34. 
33. Macaulay AE, DeKruyff RH, Umetsu DT. Antigen-primed T cells from B cell-deficient JHD mice 
fail to provide B cell help. J Immunol. 1998;160(4):1694-700. 
34. Cascao R, Rosario HS, Souto-Carneiro MM, Fonseca JE. Neutrophils in rheumatoid arthritis: 
More than simple final effectors. Autoimmun Rev. 2010;9(8):531-5. 
35. Nigrovic PA, Lee DM. Synovial mast cells: role in acute and chronic arthritis. Immunol Rev. 
2007;217:19-37. 
36. Hueber AJ, Asquith DL, Miller AM, Reilly J, Kerr S, Leipe J, et al. Mast cells express IL-17A in 
rheumatoid arthritis synovium. J Immunol. 2010;184(7):3336-40. 
37. McMurray RW. Adhesion molecules in autoimmune disease. Semin Arthritis Rheum. 
1996;25(4):215-33. 
38. Houssiau FA. Cytokines in rheumatoid arthritis. Clin Rheumatol. 1995;14 Suppl 2:10-3. 
228 
 
39. Kudo O, Sabokbar A, Pocock A, Itonaga I, Fujikawa Y, Athanasou NA. Interleukin-6 and 
interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. 
Bone. 2003;32(1):1-7. 
40. Kurihara N, Bertolini D, Suda T, Akiyama Y, Roodman GD. IL-6 stimulates osteoclast-like 
multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. 
J Immunol. 1990;144(11):4226-30. 
41. Singh JA, Beg S, Lopez-Olivo MA. Tocilizumab for rheumatoid arthritis: a Cochrane systematic 
review. J Rheumatol. 2011;38(1):10-20. 
42. Feldmann M, Brennan FM, Maini RN. Rheumatoid arthritis. Cell. 1996;85(3):307-10. 
43. Hess A, Axmann R, Rech J, Finzel S, Heindl C, Kreitz S, et al. Blockade of TNF-alpha rapidly 
inhibits pain responses in the central nervous system. Proc Natl Acad Sci U S A. 
2011;108(9):3731-6. 
44. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev 
Immunol. 2007;7(6):429-42. 
45. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin 
Invest. 2008;118(11):3537-45. 
46. Clark W, Jobanputra P, Barton P, Burls A. The clinical and cost-effectiveness of anakinra for 
the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. 
Health Technol Assess. 2004;8(18):iii-iv, ix-x, 1-105. 
47. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? Arthritis 
Rheum. 1990;33(6):768-73. 
48. Volin MV, Koch AE. Interleukin-18: a mediator of inflammation and angiogenesis in 
rheumatoid arthritis. J Interferon Cytokine Res. 2011;31(10):745-51. 
49. Kunisch E, Chakilam S, Gandesiri M, Kinne RW. IL-33 regulates TNF-alpha dependent effects 
in synovial fibroblasts. Int J Mol Med. 2012;29(4):530-40. 
50. Xiangyang Z, Lutian Y, Lin Z, Liping X, Hui S, Jing L. Increased levels of interleukin-33 
associated with bone erosion and interstitial lung diseases in patients with rheumatoid 
arthritis. Cytokine. 2012;58(1):6-9. 
51. Niu X, He D, Zhang X, Yue T, Li N, Zhang JZ, et al. IL-21 regulates Th17 cells in rheumatoid 
arthritis. Hum Immunol. 2010;71(4):334-41. 
52. Yuan FL, Li X, Sun JM, Xu RS. Emerging role of IL-23 in rheumatoid arthritis. Clin Rheumatol. 
2011;30(8):1135-6. 
53. Pickens SR, Chamberlain ND, Volin MV, Pope RM, Talarico NE, Mandelin AM, 2nd, et al. 
Characterization of interleukin-7 and interleukin-7 receptor in the pathogenesis of 
rheumatoid arthritis. Arthritis Rheum. 2011;63(10):2884-93. 
54. Miranda-Carus ME, Balsa A, Benito-Miguel M, Perez de Ayala C, Martin-Mola E. IL-15 and the 
initiation of cell contact-dependent synovial fibroblast-T lymphocyte cross-talk in 
rheumatoid arthritis: effect of methotrexate. J Immunol. 2004;173(2):1463-76. 
55. Gracie JA, Forsey RJ, Chan WL, Gilmour A, Leung BP, Greer MR, et al. A proinflammatory role 
for IL-18 in rheumatoid arthritis. J Clin Invest. 1999;104(10):1393-401. 
56. Hsu YH, Li HH, Hsieh MY, Liu MF, Huang KY, Chin LS, et al. Function of interleukin-20 as a 
proinflammatory molecule in rheumatoid and experimental arthritis. Arthritis Rheum. 
2006;54(9):2722-33. 
57. Ikeuchi H, Kuroiwa T, Hiramatsu N, Kaneko Y, Hiromura K, Ueki K, et al. Expression of 
interleukin-22 in rheumatoid arthritis: potential role as a proinflammatory cytokine. Arthritis 
Rheum. 2005;52(4):1037-46. 
58. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, et al. IL-32, a 
proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci U S A. 
2006;103(9):3298-303. 
59. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, et al. TWEAK is a novel arthritogenic 
mediator. J Immunol. 2006;177(4):2610-20. 
229 
 
60. Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, et al. Enhanced production 
of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest. 
1992;90(3):772-9. 
61. Haringman JJ, Gerlag DM, Smeets TJ, Baeten D, van den Bosch F, Bresnihan B, et al. A 
randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) 
monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 
2006;54(8):2387-92. 
62. Amin AR, Attur M, Abramson SB. Nitric oxide synthase and cyclooxygenases: distribution, 
regulation, and intervention in arthritis. Curr Opin Rheumatol. 1999;11(3):202-9. 
63. Brooks PM. Clinical management of rheumatoid arthritis. Lancet. 1993;341(8840):286-90. 
64. Cattell V, Jansen A. Inducible nitric oxide synthase in inflammation. Histochem J. 
1995;27(10):777-84. 
65. Clancy RM, Amin AR, Abramson SB. The role of nitric oxide in inflammation and immunity. 
Arthritis Rheum. 1998;41(7):1141-51. 
66. Weinberg JB. Nitric oxide synthase 2 and cyclooxygenase 2 interactions in inflammation. 
Immunol Res. 2000;22(2-3):319-41. 
67. Brennan FM, Maini RN, Feldmann M. Role of pro-inflammatory cytokines in rheumatoid 
arthritis. Springer Semin Immunopathol. 1998;20(1-2):133-47. 
68. Trabandt A, Gay RE, Fassbender HG, Gay S. Cathepsin B in synovial cells at the site of joint 
destruction in rheumatoid arthritis. Arthritis Rheum. 1991;34(11):1444-51. 
69. Nguyen Q, Mort JS, Roughley PJ. Cartilage proteoglycan aggregate is degraded more 
extensively by cathepsin L than by cathepsin B. Biochem J. 1990;266(2):569-73. 
70. Hughes CE, Caterson B, Fosang AJ, Roughley PJ, Mort JS. Monoclonal antibodies that 
specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix 
metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro. 
Biochem J. 1995;305 ( Pt 3):799-804. 
71. Gravallese EM, Harada Y, Wang JT, Gorn AH, Thornhill TS, Goldring SR. Identification of cell 
types responsible for bone resorption in rheumatoid arthritis and juvenile rheumatoid 
arthritis. Am J Pathol. 1998;152(4):943-51. 
72. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, et al. Dickkopf-1 is a master 
regulator of joint remodeling. Nat Med. 2007;13(2):156-63. 
73. Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M. Immunoregulatory role of 
interleukin 10 in rheumatoid arthritis. J Exp Med. 1994;179(5):1517-27. 
74. Fava R, Olsen N, Keski-Oja J, Moses H, Pincus T. Active and latent forms of transforming 
growth factor beta activity in synovial effusions. J Exp Med. 1989;169(1):291-6. 
75. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-
binding protein purified to homogeneity from human urine protects cells from tumor 
necrosis factor toxicity. J Biol Chem. 1989;264(20):11974-80. 
76. Seckinger P, Isaaz S, Dayer JM. A human inhibitor of tumor necrosis factor alpha. J Exp Med. 
1988;167(4):1511-6. 
77. Cope AP, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones AC, et al. Increased levels of 
soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with 
rheumatic diseases. Arthritis Rheum. 1992;35(10):1160-9. 
78. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR 
recommendations for the management of early arthritis: report of a task force of the 
European Standing Committee for International Clinical Studies Including Therapeutics 
(ESCISIT). Ann Rheum Dis. 2007;66(1):34-45. 
79. Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS. Methotrexate as the "anchor drug" for the 
treatment of early rheumatoid arthritis. Clin Exp Rheumatol. 2003;21(5 Suppl 31):S179-85. 
80. Kremer JM. Toward a better understanding of methotrexate. Arthritis Rheum. 
2004;50(5):1370-82. 
230 
 
81. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of 
rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a 
combination of all three medications. N Engl J Med. 1996;334(20):1287-91. 
82. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant 
leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of 
methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 
2002;137(9):726-33. 
83. Lee YH, Woo JH, Rho YH, Choi SJ, Ji JD, Song GG. Meta-analysis of the combination of TNF 
inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison 
of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int. 
2008;28(6):553-9. 
84. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of 
Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-
modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-84. 
85. Jain R, Lipsky PE. Treatment of rheumatoid arthritis. Med Clin North Am. 1997;81(1):57-84. 
86. Guidelines for the management of rheumatoid arthritis. American College of Rheumatology 
Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum. 1996;39(5):713-22. 
87. Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression 
to perform indirect comparisons to estimate the efficacy of biologic treatments in 
rheumatoid arthritis. Stat Med. 2007;26(6):1237-54. 
88. Kaine J, Gladstein G, Strusberg I, Robles M, Louw I, Gujrathi S, et al. Evaluation of abatacept 
administered subcutaneously in adults with active rheumatoid arthritis: impact of 
withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW 
study). Ann Rheum Dis. 2012;71(1):38-44. 
89. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a 
target for mAb therapy. Curr Dir Autoimmun. 2005;8:140-74. 
90. Smolen JS, Keystone EC, Emery P, Breedveld FC, Betteridge N, Burmester GR, et al. 
Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann 
Rheum Dis. 2007;66(2):143-50. 
91. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O'Shea JJ. Therapeutic targeting of Janus 
kinases. Immunol Rev. 2008;223:132-42. 
92. Kremer JM, Bloom BJ, Breedveld FC, Coombs JH, Fletcher MP, Gruben D, et al. The safety 
and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a 
double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus 
placebo. Arthritis Rheum. 2009;60(7):1895-905. 
93. Bajpai M, Chopra P, Dastidar SG, Ray A. Spleen tyrosine kinase: a novel target for therapeutic 
intervention of rheumatoid arthritis. Expert Opin Investig Drugs. 2008;17(5):641-59. 
94. Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral 
spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 
2010;363(14):1303-12. 
95. Yao Z, Fanslow WC, Seldin MF, Rousseau AM, Painter SL, Comeau MR, et al. Herpesvirus 
Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity. 
1995;3(6):811-21. 
96. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-
17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp 
Med. 1996;183(6):2593-603. 
97. Shin HC, Benbernou N, Esnault S, Guenounou M. Expression of IL-17 in human memory 
CD45RO+ T lymphocytes and its regulation by protein kinase A pathway. Cytokine. 
1999;11(4):257-66. 
98. Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic 
neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity. 2005;22(3):285-94. 
231 
 
99. Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, Luger D, et al. Cutting edge: NKT cells 
constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon 
receptor ligation in an IL-6-independent fashion. J Immunol. 2008;180(8):5167-71. 
100. Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C, et al. Langerhans cell 
histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med. 
2008;14(1):81-7. 
101. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nature 
reviews. Immunology. 2010;10(7):479-89. 
102. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, et al. IL-17 is increased in asthmatic 
airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin 
Immunol. 2001;108(3):430-8. 
103. Ferretti S, Bonneau O, Dubois GR, Jones CE, Trifilieff A. IL-17, produced by lymphocytes and 
neutrophils, is necessary for lipopolysaccharide-induced airway neutrophilia: IL-15 as a 
possible trigger. J Immunol. 2003;170(4):2106-12. 
104. Spriggs MK. Interleukin-17 and its receptor. J Clin Immunol. 1997;17(5):366-9. 
105. Broxmeyer HE. Is interleukin 17, an inducible cytokine that stimulates production of other 
cytokines, merely a redundant player in a sea of other biomolecules? J Exp Med. 
1996;183(6):2411-5. 
106. Jovanovic DV, Di Battista JA, Martel-Pelletier J, Jolicoeur FC, He Y, Zhang M, et al. IL-17 
stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-
alpha, by human macrophages. J Immunol. 1998;160(7):3513-21. 
107. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, et al. Human IL-17: a novel 
cytokine derived from T cells. J Immunol. 1995;155(12):5483-6. 
108. Schwarzenberger P, Huang W, Ye P, Oliver P, Manuel M, Zhang Z, et al. Requirement of 
endogenous stem cell factor and granulocyte-colony-stimulating factor for IL-17-mediated 
granulopoiesis. J Immunol. 2000;164(9):4783-9. 
109. Schwarzenberger P, La Russa V, Miller A, Ye P, Huang W, Zieske A, et al. IL-17 stimulates 
granulopoiesis in mice: use of an alternate, novel gene therapy-derived method for in vivo 
evaluation of cytokines. J Immunol. 1998;161(11):6383-9. 
110. Ye P, Rodriguez FH, Kanaly S, Stocking KL, Schurr J, Schwarzenberger P, et al. Requirement of 
interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating 
factor expression, neutrophil recruitment, and host defense. J Exp Med. 2001;194(4):519-27. 
111. Yu JJ, Ruddy MJ, Wong GC, Sfintescu C, Baker PJ, Smith JB, et al. An essential role for IL-17 in 
preventing pathogen-initiated bone destruction: recruitment of neutrophils to inflamed 
bone requires IL-17 receptor-dependent signals. Blood. 2007;109(9):3794-802. 
112. Witowski J, Pawlaczyk K, Breborowicz A, Scheuren A, Kuzlan-Pawlaczyk M, Wisniewska J, et 
al. IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha 
chemokine from mesothelial cells. J Immunol. 2000;165(10):5814-21. 
113. Ruddy MJ, Shen F, Smith JB, Sharma A, Gaffen SL. Interleukin-17 regulates expression of the 
CXC chemokine LIX/CXCL5 in osteoblasts: implications for inflammation and neutrophil 
recruitment. J Leukoc Biol. 2004;76(1):135-44. 
114. Ruddy MJ, Wong GC, Liu XK, Yamamoto H, Kasayama S, Kirkwood KL, et al. Functional 
cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by 
CCAAT/enhancer-binding protein family members. J Biol Chem. 2004;279(4):2559-67. 
115. Chabaud M, Fossiez F, Taupin JL, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 
and leukemia inhibitory factor production by rheumatoid arthritis synoviocytes and its 
regulation by Th2 cytokines. J Immunol. 1998;161(1):409-14. 
116. Chabaud M, Miossec P. The combination of tumor necrosis factor alpha blockade with 
interleukin-1 and interleukin-17 blockade is more effective for controlling synovial 
inflammation and bone resorption in an ex vivo model. Arthritis Rheum. 2001;44(6):1293-
303. 
232 
 
117. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic 
anti-Candida albicans host defense in mice. J Infect Dis. 2004;190(3):624-31. 
118. van Beelen AJ, Zelinkova Z, Taanman-Kueter EW, Muller FJ, Hommes DW, Zaat SA, et al. 
Stimulation of the intracellular bacterial sensor NOD2 programs dendritic cells to promote 
interleukin-17 production in human memory T cells. Immunity. 2007;27(4):660-9. 
119. Shen F, Hu Z, Goswami J, Gaffen SL. Identification of common transcriptional regulatory 
elements in interleukin-17 target genes. J Biol Chem. 2006;281(34):24138-48. 
120. Kao CY, Chen Y, Thai P, Wachi S, Huang F, Kim C, et al. IL-17 markedly up-regulates beta-
defensin-2 expression in human airway epithelium via JAK and NF-kappaB signaling 
pathways. J Immunol. 2004;173(5):3482-91. 
121. Liang SC, Tan XY, Luxenberg DP, Karim R, Dunussi-Joannopoulos K, Collins M, et al. 
Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance 
expression of antimicrobial peptides. J Exp Med. 2006;203(10):2271-9. 
122. Chen Y, Thai P, Zhao YH, Ho YS, DeSouza MM, Wu R. Stimulation of airway mucin gene 
expression by interleukin (IL)-17 through IL-6 paracrine/autocrine loop. J Biol Chem. 
2003;278(19):17036-43. 
123. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, et al. Interleukin-17 
mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. 
Mult Scler. 1999;5(2):101-4. 
124. Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin-17 is 
produced by both Th1 and Th2 lymphocytes, and modulates interferon-gamma- and 
interleukin-4-induced activation of human keratinocytes. J Invest Dermatol. 2000;115(1):81-
7. 
125. Kebir H, Kreymborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M, et al. Human TH17 
lymphocytes promote blood-brain barrier disruption and central nervous system 
inflammation. Nat Med. 2007;13(10):1173-5. 
126. Yagi Y, Andoh A, Inatomi O, Tsujikawa T, Fujiyama Y. Inflammatory responses induced by 
interleukin-17 family members in human colonic subepithelial myofibroblasts. J 
Gastroenterol. 2007;42(9):746-53. 
127. Schnyder-Candrian S, Togbe D, Couillin I, Mercier I, Brombacher F, Quesniaux V, et al. 
Interleukin-17 is a negative regulator of established allergic asthma. J Exp Med. 
2006;203(12):2715-25. 
128. Yi T, Zhao D, Lin CL, Zhang C, Chen Y, Todorov I, et al. Absence of donor Th17 leads to 
augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood. 
2008;112(5):2101-10. 
129. Ogawa A, Andoh A, Araki Y, Bamba T, Fujiyama Y. Neutralization of interleukin-17 aggravates 
dextran sulfate sodium-induced colitis in mice. Clin Immunol. 2004;110(1):55-62. 
130. Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, et al. Regulation of inflammatory 
responses by IL-17F. J Exp Med. 2008;205(5):1063-75. 
131. Kawaguchi M, Onuchic LF, Li XD, Essayan DM, Schroeder J, Xiao HQ, et al. Identification of a 
novel cytokine, ML-1, and its expression in subjects with asthma. J Immunol. 
2001;167(8):4430-5. 
132. Hymowitz SG, Filvaroff EH, Yin JP, Lee J, Cai L, Risser P, et al. IL-17s adopt a cystine knot fold: 
structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. 
EMBO J. 2001;20(19):5332-41. 
133. Starnes T, Robertson MJ, Sledge G, Kelich S, Nakshatri H, Broxmeyer HE, et al. Cutting edge: 
IL-17F, a novel cytokine selectively expressed in activated T cells and monocytes, regulates 
angiogenesis and endothelial cell cytokine production. J Immunol. 2001;167(8):4137-40. 
134. Kawaguchi M, Kokubu F, Odaka M, Watanabe S, Suzuki S, Ieki K, et al. Induction of 
granulocyte-macrophage colony-stimulating factor by a new cytokine, ML-1 (IL-17F), via Raf 
I-MEK-ERK pathway. J Allergy Clin Immunol. 2004;114(2):444-50. 
233 
 
135. Shen F, Gaffen SL. Structure-function relationships in the IL-17 receptor: implications for 
signal transduction and therapy. Cytokine. 2008;41(2):92-104. 
136. McAllister F, Henry A, Kreindler JL, Dubin PJ, Ulrich L, Steele C, et al. Role of IL-17A, IL-17F, 
and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-
stimulating factor in bronchial epithelium: implications for airway inflammation in cystic 
fibrosis. J Immunol. 2005;175(1):404-12. 
137. Aujla SJ, Chan YR, Zheng M, Fei M, Askew DJ, Pociask DA, et al. IL-22 mediates mucosal host 
defense against Gram-negative bacterial pneumonia. Nat Med. 2008;14(3):275-81. 
138. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, et al. Differential roles of 
interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and 
allergic responses. Immunity. 2009;30(1):108-19. 
139. Saijo S, Ikeda S, Yamabe K, Kakuta S, Ishigame H, Akitsu A, et al. Dectin-2 recognition of 
alpha-mannans and induction of Th17 cell differentiation is essential for host defense 
against Candida albicans. Immunity. 2010;32(5):681-91. 
140. Nakae S, Komiyama Y, Nambu A, Sudo K, Iwase M, Homma I, et al. Antigen-specific T cell 
sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and 
humoral responses. Immunity. 2002;17(3):375-87. 
141. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct 
CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 
2003;278(3):1910-4. 
142. Chang SH, Dong C. A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates 
inflammatory responses. Cell Res. 2007;17(5):435-40. 
143. Wright JF, Guo Y, Quazi A, Luxenberg DP, Bennett F, Ross JF, et al. Identification of an 
interleukin 17F/17A heterodimer in activated human CD4+ T cells. J Biol Chem. 
2007;282(18):13447-55. 
144. Liang SC, Long AJ, Bennett F, Whitters MJ, Karim R, Collins M, et al. An IL-17F/A heterodimer 
protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. J 
Immunol. 2007;179(11):7791-9. 
145. Shaw G, Kamen R. A conserved AU sequence from the 3' untranslated region of GM-CSF 
mRNA mediates selective mRNA degradation. Cell. 1986;46(5):659-67. 
146. Hurst SD, Muchamuel T, Gorman DM, Gilbert JM, Clifford T, Kwan S, et al. New IL-17 family 
members promote Th1 or Th2 responses in the lung: in vivo function of the novel cytokine 
IL-25. J Immunol. 2002;169(1):443-53. 
147. Hoshino H, Lotvall J, Skoogh BE, Linden A. Neutrophil recruitment by interleukin-17 into rat 
airways in vivo. Role of tachykinins. Am J Respir Crit Care Med. 1999;159(5 Pt 1):1423-8. 
148. Yamaguchi Y, Fujio K, Shoda H, Okamoto A, Tsuno NH, Takahashi K, et al. IL-17B and IL-17C 
are associated with TNF-alpha production and contribute to the exacerbation of 
inflammatory arthritis. J Immunol. 2007;179(10):7128-36. 
149. Starnes T, Broxmeyer HE, Robertson MJ, Hromas R. Cutting edge: IL-17D, a novel member of 
the IL-17 family, stimulates cytokine production and inhibits hemopoiesis. J Immunol. 
2002;169(2):642-6. 
150. Lee J, Ho WH, Maruoka M, Corpuz RT, Baldwin DT, Foster JS, et al. IL-17E, a novel 
proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol Chem. 
2001;276(2):1660-4. 
151. Pan G, French D, Mao W, Maruoka M, Risser P, Lee J, et al. Forced expression of murine IL-
17E induces growth retardation, jaundice, a Th2-biased response, and multiorgan 
inflammation in mice. J Immunol. 2001;167(11):6559-67. 
152. Angkasekwinai P, Park H, Wang YH, Chang SH, Corry DB, Liu YJ, et al. Interleukin 25 promotes 
the initiation of proallergic type 2 responses. J Exp Med. 2007;204(7):1509-17. 
234 
 
153. Kawaguchi M, Takahashi D, Hizawa N, Suzuki S, Matsukura S, Kokubu F, et al. IL-17F 
sequence variant (His161Arg) is associated with protection against asthma and antagonizes 
wild-type IL-17F activity. J Allergy Clin Immunol. 2006;117(4):795-801. 
154. Qian F, Zhang Q, Zhou L, Ma G, Jin G, Huang Q, et al. Association between polymorphisms in 
IL17F and male asthma in a Chinese population. J Investig Allergol Clin Immunol. 
2012;22(4):257-63. 
155. Ramsey CD, Lazarus R, Camargo CA, Jr., Weiss ST, Celedon JC. Polymorphisms in the 
interleukin 17F gene (IL17F) and asthma. Genes Immun. 2005;6(3):236-41. 
156. Chen B, Zeng Z, Hou J, Chen M, Gao X, Hu P. Association of interleukin-17F 7488 single 
nucleotide polymorphism and inflammatory bowel disease in the Chinese population. Scand 
J Gastroenterol. 2009;44(6):720-6. 
157. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, et al. The influence of 
polymorphisms of interleukin-17A and interleukin-17F genes on the susceptibility to 
ulcerative colitis. J Clin Immunol. 2008;28(1):44-9. 
158. Seiderer J, Elben I, Diegelmann J, Glas J, Stallhofer J, Tillack C, et al. Role of the novel Th17 
cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression 
in active Crohn's disease and analysis of the IL17F p.His161Arg polymorphism in IBD. 
Inflamm Bowel Dis. 2008;14(4):437-45. 
159. Saitoh T, Tsukamoto N, Koiso H, Mitsui T, Yokohama A, Handa H, et al. Interleukin-17F gene 
polymorphism in patients with chronic immune thrombocytopenia. Eur J Haematol. 
2011;87(3):253-8. 
160. Arisawa T, Tahara T, Shibata T, Nagasaka M, Nakamura M, Kamiya Y, et al. Genetic 
polymorphisms of molecules associated with inflammation and immune response in 
Japanese subjects with functional dyspepsia. Int J Mol Med. 2007;20(5):717-23. 
161. Shibata T, Tahara T, Hirata I, Arisawa T. Genetic polymorphism of interleukin-17A and -17F 
genes in gastric carcinogenesis. Hum Immunol. 2009;70(7):547-51. 
162. Shibata S, Saeki H, Tsunemi Y, Kato T, Nakamura K, Kakinuma T, et al. IL-17F single 
nucleotide polymorphism is not associated with psoriasis vulgaris or atopic dermatitis in the 
Japanese population. J Dermatol Sci. 2009;53(2):163-5. 
163. Metzger K, Fremont M, Roelant C, De Meirleir K. Lower frequency of IL-17F sequence variant 
(His161Arg) in chronic fatigue syndrome patients. Biochem Biophys Res Commun. 
2008;376(1):231-3. 
164. Jang WC, Nam YH, Ahn YC, Lee SH, Park SH, Choe JY, et al. Interleukin-17F gene 
polymorphisms in Korean patients with Behcet's disease. Rheumatol Int. 2008;29(2):173-8. 
165. Pei F, Han Y, Zhang X, Yan C, Huang M, Deng J, et al. Association analysis of the IL-17F 
His161Arg polymorphism in myocardial infarction. Coron Artery Dis. 2009;20(8):513-7. 
166. Wang L, Jiang Y, Zhang Y, Wang Y, Huang S, Wang Z, et al. Association analysis of IL-17A and 
IL-17F polymorphisms in Chinese Han women with breast cancer. PLoS One. 
2012;7(3):e34400. 
167. Paradowska-Gorycka A, Wojtecka-Lukasik E, Trefler J, Wojciechowska B, Lacki JK, Maslinski S. 
Association between IL-17F gene polymorphisms and susceptibility to and severity of 
rheumatoid arthritis (RA). Scand J Immunol. 2010;72(2):134-41. 
168. Novatchkova M, Leibbrandt A, Werzowa J, Neubuser A, Eisenhaber F. The STIR-domain 
superfamily in signal transduction, development and immunity. Trends Biochem Sci. 
2003;28(5):226-9. 
169. Yao Z, Spriggs MK, Derry JM, Strockbine L, Park LS, VandenBos T, et al. Molecular 
characterization of the human interleukin (IL)-17 receptor. Cytokine. 1997;9(11):794-800. 
170. Maitra A, Shen F, Hanel W, Mossman K, Tocker J, Swart D, et al. Distinct functional motifs 
within the IL-17 receptor regulate signal transduction and target gene expression. Proc Natl 
Acad Sci U S A. 2007;104(18):7506-11. 
235 
 
171. Lindemann MJ, Hu Z, Benczik M, Liu KD, Gaffen SL. Differential regulation of the IL-17 
receptor by gammac cytokines: inhibitory signaling by the phosphatidylinositol 3-kinase 
pathway. J Biol Chem. 2008;283(20):14100-8. 
172. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, et al. Synergy of IL-21 and IL-
15 in regulating CD8+ T cell expansion and function. J Exp Med. 2005;201(1):139-48. 
173. Toy D, Kugler D, Wolfson M, Vanden Bos T, Gurgel J, Derry J, et al. Cutting edge: interleukin 
17 signals through a heteromeric receptor complex. J Immunol. 2006;177(1):36-9. 
174. Rickel EA, Siegel LA, Yoon BR, Rottman JB, Kugler DG, Swart DA, et al. Identification of 
functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. J 
Immunol. 2008;181(6):4299-310. 
175. Rong Z, Wang A, Li Z, Ren Y, Cheng L, Li Y, et al. IL-17RD (Sef or IL-17RLM) interacts with IL-17 
receptor and mediates IL-17 signaling. Cell Res. 2009;19(2):208-15. 
176. Kramer JM, Hanel W, Shen F, Isik N, Malone JP, Maitra A, et al. Cutting edge: identification of 
a pre-ligand assembly domain (PLAD) and ligand binding site in the IL-17 receptor. J 
Immunol. 2007;179(10):6379-83. 
177. Kramer JM, Gaffen SL. Interleukin-17: a new paradigm in inflammation, autoimmunity, and 
therapy. J Periodontol. 2007;78(6):1083-93. 
178. Kramer JM, Yi L, Shen F, Maitra A, Jiao X, Jin T, et al. Evidence for ligand-independent 
multimerization of the IL-17 receptor. J Immunol. 2006;176(2):711-5. 
179. Ely LK, Fischer S, Garcia KC. Structural basis of receptor sharing by interleukin 17 cytokines. 
Nat Immunol. 2009;10(12):1245-51. 
180. Haudenschild DR, Curtiss SB, Moseley TA, Reddi AH. Generation of interleukin-17 receptor-
like protein (IL-17RL) in prostate by alternative splicing of RNA. Prostate. 2006;66(12):1268-
74. 
181. Kuestner RE, Taft DW, Haran A, Brandt CS, Brender T, Lum K, et al. Identification of the IL-17 
receptor related molecule IL-17RC as the receptor for IL-17F. J Immunol. 2007;179(8):5462-
73. 
182. Haudenschild D, Moseley T, Rose L, Reddi AH. Soluble and transmembrane isoforms of novel 
interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J Biol 
Chem. 2002;277(6):4309-16. 
183. Pancer Z, Mayer WE, Klein J, Cooper MD. Prototypic T cell receptor and CD4-like coreceptor 
are expressed by lymphocytes in the agnathan sea lamprey. Proc Natl Acad Sci U S A. 
2004;101(36):13273-8. 
184. Song X, Zhu S, Shi P, Liu Y, Shi Y, Levin SD, et al. IL-17RE is the functional receptor for IL-17C 
and mediates mucosal immunity to infection with intestinal pathogens. Nat Immunol. 
2011;12(12):1151-8. 
185. Hartupee J, Liu C, Novotny M, Li X, Hamilton T. IL-17 enhances chemokine gene expression 
through mRNA stabilization. J Immunol. 2007;179(6):4135-41. 
186. Sun D, Novotny M, Bulek K, Liu C, Li X, Hamilton T. Treatment with IL-17 prolongs the half-
life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 
(ASF). Nat Immunol. 2011;12(9):853-60. 
187. Bulek K, Liu C, Swaidani S, Wang L, Page RC, Gulen MF, et al. The inducible kinase IKKi is 
required for IL-17-dependent signaling associated with neutrophilia and pulmonary 
inflammation. Nat Immunol. 2011;12(9):844-52. 
188. Sonder SU, Saret S, Tang W, Sturdevant DE, Porcella SF, Siebenlist U. IL-17-induced NF-
kappaB activation via CIKS/Act1: physiologic significance and signaling mechanisms. J Biol 
Chem. 2011;286(15):12881-90. 
189. Ho AW, Gaffen SL. IL-17RC: a partner in IL-17 signaling and beyond. Semin Immunopathol. 
2010;32(1):33-42. 
190. Hu Y, Shen F, Crellin NK, Ouyang W. The IL-17 pathway as a major therapeutic target in 
autoimmune diseases. Ann N Y Acad Sci. 2011;1217:60-76. 
236 
 
191. Schwandner R, Yamaguchi K, Cao Z. Requirement of tumor necrosis factor receptor-
associated factor (TRAF)6 in interleukin 17 signal transduction. J Exp Med. 2000;191(7):1233-
40. 
192. Li X, Commane M, Nie H, Hua X, Chatterjee-Kishore M, Wald D, et al. Act1, an NF-kappa B-
activating protein. Proc Natl Acad Sci U S A. 2000;97(19):10489-93. 
193. Leonardi A, Chariot A, Claudio E, Cunningham K, Siebenlist U. CIKS, a connection to Ikappa B 
kinase and stress-activated protein kinase. Proc Natl Acad Sci U S A. 2000;97(19):10494-9. 
194. Kanamori M, Kai C, Hayashizaki Y, Suzuki H. NF-kappaB activator Act1 associates with IL-
1/Toll pathway adaptor molecule TRAF6. FEBS Lett. 2002;532(1-2):241-6. 
195. Huang F, Kao CY, Wachi S, Thai P, Ryu J, Wu R. Requirement for both JAK-mediated PI3K 
signaling and ACT1/TRAF6/TAK1-dependent NF-kappaB activation by IL-17A in enhancing 
cytokine expression in human airway epithelial cells. J Immunol. 2007;179(10):6504-13. 
196. Chang SH, Park H, Dong C. Act1 adaptor protein is an immediate and essential signaling 
component of interleukin-17 receptor. J Biol Chem. 2006;281(47):35603-7. 
197. Qian Y, Liu C, Hartupee J, Altuntas CZ, Gulen MF, Jane-Wit D, et al. The adaptor Act1 is 
required for interleukin 17-dependent signaling associated with autoimmune and 
inflammatory disease. Nat Immunol. 2007;8(3):247-56. 
198. Shi P, Zhu S, Lin Y, Liu Y, Liu Y, Chen Z, et al. Persistent stimulation with interleukin-17 
desensitizes cells through SCFbeta-TrCP-mediated degradation of Act1. Sci Signal. 
2011;4(197):ra73. 
199. Yang XO, Nurieva R, Martinez GJ, Kang HS, Chung Y, Pappu BP, et al. Molecular antagonism 
and plasticity of regulatory and inflammatory T cell programs. Immunity. 2008;29(1):44-56. 
200. Dong C, Flavell RA. Cell fate decision: T-helper 1 and 2 subsets in immune responses. 
Arthritis Res. 2000;2(3):179-88. 
201. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, et al. A distinct lineage of CD4 T cells 
regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6(11):1133-
41. 
202. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 
17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 
and 2 lineages. Nat Immunol. 2005;6(11):1123-32. 
203. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, Sedgwick JD, et al. IL-23 drives 
a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 
2005;201(2):233-40. 
204. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming 
growth factor-beta induces development of the T(H)17 lineage. Nature. 
2006;441(7090):231-4. 
205. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin-22 mediates early 
host defense against attaching and effacing bacterial pathogens. Nat Med. 2008;14(3):282-9. 
206. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental 
pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 
2006;441(7090):235-8. 
207. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an 
inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. 
Immunity. 2006;24(2):179-89. 
208. Zhou L, Ivanov, II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs T(H)-17 cell 
differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat 
Immunol. 2007;8(9):967-74. 
209. Korn T, Bettelli E, Gao W, Awasthi A, Jager A, Strom TB, et al. IL-21 initiates an alternative 
pathway to induce proinflammatory T(H)17 cells. Nature. 2007;448(7152):484-7. 
210. Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, et al. Essential autocrine 
regulation by IL-21 in the generation of inflammatory T cells. Nature. 2007;448(7152):480-3. 
237 
 
211. Korn T, Mitsdoerffer M, Croxford AL, Awasthi A, Dardalhon VA, Galileos G, et al. IL-6 controls 
Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ 
regulatory T cells. Proc Natl Acad Sci U S A. 2008;105(47):18460-5. 
212. Ghoreschi K, Laurence A, Yang XP, Tato CM, McGeachy MJ, Konkel JE, et al. Generation of 
pathogenic T(H)17 cells in the absence of TGF-beta signalling. Nature. 2010;467(7318):967-
71. 
213. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and 
functional features of human Th17 cells. J Exp Med. 2007;204(8):1849-61. 
214. Cosmi L, De Palma R, Santarlasci V, Maggi L, Capone M, Frosali F, et al. Human interleukin 
17-producing cells originate from a CD161+CD4+ T cell precursor. J Exp Med. 
2008;205(8):1903-16. 
215. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. Human Th17 cells: are they different 
from murine Th17 cells? Eur J Immunol. 2009;39(3):637-40. 
216. Kryczek I, Wei S, Vatan L, Escara-Wilke J, Szeliga W, Keller ET, et al. Cutting edge: opposite 
effects of IL-1 and IL-2 on the regulation of IL-17+ T cell pool IL-1 subverts IL-2-mediated 
suppression. J Immunol. 2007;179(3):1423-6. 
217. Stockinger B, Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol. 
2007;19(3):281-6. 
218. Watanabe H, Gehrke S, Contassot E, Roques S, Tschopp J, Friedmann PS, et al. Danger 
signaling through the inflammasome acts as a master switch between tolerance and 
sensitization. J Immunol. 2008;180(9):5826-32. 
219. Coquet JM, Chakravarti S, Smyth MJ, Godfrey DI. Cutting edge: IL-21 is not essential for Th17 
differentiation or experimental autoimmune encephalomyelitis. J Immunol. 
2008;180(11):7097-101. 
220. Ivanov, II, Frutos Rde L, Manel N, Yoshinaga K, Rifkin DB, Sartor RB, et al. Specific microbiota 
direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small 
intestine. Cell Host Microbe. 2008;4(4):337-49. 
221. Sonderegger I, Kisielow J, Meier R, King C, Kopf M. IL-21 and IL-21R are not required for 
development of Th17 cells and autoimmunity in vivo. Eur J Immunol. 2008;38(7):1833-8. 
222. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1beta and 6 but 
not transforming growth factor-beta are essential for the differentiation of interleukin 17-
producing human T helper cells. Nat Immunol. 2007;8(9):942-9. 
223. Evans HG, Suddason T, Jackson I, Taams LS, Lord GM. Optimal induction of T helper 17 cells 
in humans requires T cell receptor ligation in the context of Toll-like receptor-activated 
monocytes. Proc Natl Acad Sci U S A. 2007;104(43):17034-9. 
224. van Beelen AJ, Teunissen MB, Kapsenberg ML, de Jong EC. Interleukin-17 in inflammatory 
skin disorders. Curr Opin Allergy Clin Immunol. 2007;7(5):374-81. 
225. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blumenschein WM, Mattson JD, et al. 
Development, cytokine profile and function of human interleukin 17-producing helper T 
cells. Nat Immunol. 2007;8(9):950-7. 
226. Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupe P, Barillot E, et al. A critical function for 
transforming growth factor-beta, interleukin 23 and proinflammatory cytokines in driving 
and modulating human T(H)-17 responses. Nat Immunol. 2008;9(6):650-7. 
227. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bettelli E, Oukka M, et al. IL-21 and TGF-
beta are required for differentiation of human T(H)17 cells. Nature. 2008;454(7202):350-2. 
228. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires 
transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat 
Immunol. 2008;9(6):641-9. 
229. Chen Z, Tato CM, Muul L, Laurence A, O'Shea JJ. Distinct regulation of interleukin-17 in 
human T helper lymphocytes. Arthritis Rheum. 2007;56(9):2936-46. 
238 
 
230. Lyakh L, Trinchieri G, Provezza L, Carra G, Gerosa F. Regulation of interleukin-12/interleukin-
23 production and the T-helper 17 response in humans. Immunol Rev. 2008;226:112-31. 
231. Das J, Ren G, Zhang L, Roberts AI, Zhao X, Bothwell AL, et al. Transforming growth factor 
beta is dispensable for the molecular orchestration of Th17 cell differentiation. J Exp Med. 
2009;206(11):2407-16. 
232. Santarlasci V, Maggi L, Capone M, Frosali F, Querci V, De Palma R, et al. TGF-beta indirectly 
favors the development of human Th17 cells by inhibiting Th1 cells. Eur J Immunol. 
2009;39(1):207-15. 
233. Ichiyama K, Sekiya T, Inoue N, Tamiya T, Kashiwagi I, Kimura A, et al. Transcription factor 
Smad-independent T helper 17 cell induction by transforming-growth factor-beta is 
mediated by suppression of eomesodermin. Immunity. 2011;34(5):741-54. 
234. Yang Y, Weiner J, Liu Y, Smith AJ, Huss DJ, Winger R, et al. T-bet is essential for 
encephalitogenicity of both Th1 and Th17 cells. J Exp Med. 2009;206(7):1549-64. 
235. Jager A, Dardalhon V, Sobel RA, Bettelli E, Kuchroo VK. Th1, Th17, and Th9 effector cells 
induce experimental autoimmune encephalomyelitis with different pathological phenotypes. 
J Immunol. 2009;183(11):7169-77. 
236. Gutcher I, Donkor MK, Ma Q, Rudensky AY, Flavell RA, Li MO. Autocrine transforming growth 
factor-beta1 promotes in vivo Th17 cell differentiation. Immunity. 2011;34(3):396-408. 
237. Li MO, Wan YY, Flavell RA. T cell-produced transforming growth factor-beta1 controls T cell 
tolerance and regulates Th1- and Th17-cell differentiation. Immunity. 2007;26(5):579-91. 
238. Veldhoen M, Hocking RJ, Flavell RA, Stockinger B. Signals mediated by transforming growth 
factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to 
sustain disease. Nat Immunol. 2006;7(11):1151-6. 
239. Zhou L, Lopes JE, Chong MM, Ivanov, II, Min R, Victora GD, et al. TGF-beta-induced Foxp3 
inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature. 
2008;453(7192):236-40. 
240. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, et al. Interleukin-22, 
a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature. 
2007;445(7128):648-51. 
241. Yang XO, Pappu BP, Nurieva R, Akimzhanov A, Kang HS, Chung Y, et al. T helper 17 lineage 
differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. 
Immunity. 2008;28(1):29-39. 
242. Zhang F, Meng G, Strober W. Interactions among the transcription factors Runx1, 
RORgammat and Foxp3 regulate the differentiation of interleukin 17-producing T cells. Nat 
Immunol. 2008;9(11):1297-306. 
243. Eberl G, Marmon S, Sunshine MJ, Rennert PD, Choi Y, Littman DR. An essential function for 
the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells. 
Nat Immunol. 2004;5(1):64-73. 
244. Egawa T, Eberl G, Taniuchi I, Benlagha K, Geissmann F, Hennighausen L, et al. Genetic 
evidence supporting selection of the Valpha14i NKT cell lineage from double-positive 
thymocyte precursors. Immunity. 2005;22(6):705-16. 
245. Sun Z, Unutmaz D, Zou YR, Sunshine MJ, Pierani A, Brenner-Morton S, et al. Requirement for 
RORgamma in thymocyte survival and lymphoid organ development. Science. 
2000;288(5475):2369-73. 
246. Ivanov, II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear 
receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper 
cells. Cell. 2006;126(6):1121-33. 
247. Leppkes M, Becker C, Ivanov, II, Hirth S, Wirtz S, Neufert C, et al. RORgamma-expressing 
Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and 
IL-17F. Gastroenterology. 2009;136(1):257-67. 
239 
 
248. Lochner M, Peduto L, Cherrier M, Sawa S, Langa F, Varona R, et al. In vivo equilibrium of 
proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells. J Exp Med. 
2008;205(6):1381-93. 
249. Ichiyama K, Yoshida H, Wakabayashi Y, Chinen T, Saeki K, Nakaya M, et al. Foxp3 inhibits 
RORgammat-mediated IL-17A mRNA transcription through direct interaction with 
RORgammat. J Biol Chem. 2008;283(25):17003-8. 
250. Wei L, Laurence A, Elias KM, O'Shea JJ. IL-21 is produced by Th17 cells and drives IL-17 
production in a STAT3-dependent manner. J Biol Chem. 2007;282(48):34605-10. 
251. Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, et al. Selective regulatory 
function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci U S A. 
2006;103(21):8137-42. 
252. Mathur AN, Chang HC, Zisoulis DG, Stritesky GL, Yu Q, O'Malley JT, et al. Stat3 and Stat4 
direct development of IL-17-secreting Th cells. J Immunol. 2007;178(8):4901-7. 
253. Milner JD, Brenchley JM, Laurence A, Freeman AF, Hill BJ, Elias KM, et al. Impaired T(H)17 
cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 
2008;452(7188):773-6. 
254. Durant L, Watford WT, Ramos HL, Laurence A, Vahedi G, Wei L, et al. Diverse targets of the 
transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity. 
2010;32(5):605-15. 
255. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR, et al. 
Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 
and STAT5. Nat Immunol. 2011;12(3):247-54. 
256. Ono M, Yaguchi H, Ohkura N, Kitabayashi I, Nagamura Y, Nomura T, et al. Foxp3 controls 
regulatory T-cell function by interacting with AML1/Runx1. Nature. 2007;446(7136):685-9. 
257. Huber M, Brustle A, Reinhard K, Guralnik A, Walter G, Mahiny A, et al. IRF4 is essential for IL-
21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc Natl 
Acad Sci U S A. 2008;105(52):20846-51. 
258. Brustle A, Heink S, Huber M, Rosenplanter C, Stadelmann C, Yu P, et al. The development of 
inflammatory T(H)-17 cells requires interferon-regulatory factor 4. Nat Immunol. 
2007;8(9):958-66. 
259. Liu XK, Lin X, Gaffen SL. Crucial role for nuclear factor of activated T cells in T cell receptor-
mediated regulation of human interleukin-17. J Biol Chem. 2004;279(50):52762-71. 
260. Chen Z, Laurence A, O'Shea JJ. Signal transduction pathways and transcriptional regulation in 
the control of Th17 differentiation. Semin Immunol. 2007;19(6):400-8. 
261. Bauquet AT, Jin H, Paterson AM, Mitsdoerffer M, Ho IC, Sharpe AH, et al. The costimulatory 
molecule ICOS regulates the expression of c-Maf and IL-21 in the development of follicular T 
helper cells and TH-17 cells. Nat Immunol. 2009;10(2):167-75. 
262. Okamoto K, Iwai Y, Oh-Hora M, Yamamoto M, Morio T, Aoki K, et al. IkappaBzeta regulates 
T(H)17 development by cooperating with ROR nuclear receptors. Nature. 
2010;464(7293):1381-5. 
263. Nguyen LP, Bradfield CA. The search for endogenous activators of the aryl hydrocarbon 
receptor. Chem Res Toxicol. 2008;21(1):102-16. 
264. Veldhoen M, Hirota K, Westendorf AM, Buer J, Dumoutier L, Renauld JC, et al. The aryl 
hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. 
Nature. 2008;453(7191):106-9. 
265. Laurence A, Tato CM, Davidson TS, Kanno Y, Chen Z, Yao Z, et al. Interleukin-2 signaling via 
STAT5 constrains T helper 17 cell generation. Immunity. 2007;26(3):371-81. 
266. Chen Q, Yang W, Gupta S, Biswas P, Smith P, Bhagat G, et al. IRF-4-binding protein inhibits 
interleukin-17 and interleukin-21 production by controlling the activity of IRF-4 transcription 
factor. Immunity. 2008;29(6):899-911. 
240 
 
267. Hermann-Kleiter N, Gruber T, Lutz-Nicoladoni C, Thuille N, Fresser F, Labi V, et al. The 
nuclear orphan receptor NR2F6 suppresses lymphocyte activation and T helper 17-
dependent autoimmunity. Immunity. 2008;29(2):205-16. 
268. Ichiyama K, Hashimoto M, Sekiya T, Nakagawa R, Wakabayashi Y, Sugiyama Y, et al. Gfi1 
negatively regulates T(h)17 differentiation by inhibiting RORgammat activity. Int Immunol. 
2009;21(7):881-9. 
269. Joshi S, Pantalena LC, Liu XK, Gaffen SL, Liu H, Rohowsky-Kochan C, et al. 1,25-
dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of 
interleukin-17A. Mol Cell Biol. 2011;31(17):3653-69. 
270. Elias KM, Laurence A, Davidson TS, Stephens G, Kanno Y, Shevach EM, et al. Retinoic acid 
inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 
independent signaling pathway. Blood. 2008;111(3):1013-20. 
271. Moisan J, Grenningloh R, Bettelli E, Oukka M, Ho IC. Ets-1 is a negative regulator of Th17 
differentiation. J Exp Med. 2007;204(12):2825-35. 
272. Akimzhanov AM, Yang XO, Dong C. Chromatin remodeling of interleukin-17 (IL-17)-IL-17F 
cytokine gene locus during inflammatory helper T cell differentiation. J Biol Chem. 
2007;282(9):5969-72. 
273. Cosmi L, Cimaz R, Maggi L, Santarlasci V, Capone M, Borriello F, et al. Evidence of the 
transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of 
patients with juvenile idiopathic arthritis. Arthritis Rheum. 2011;63(8):2504-15. 
274. Annunziato F, Romagnani S. The transient nature of the Th17 phenotype. Eur J Immunol. 
2010;40(12):3312-6. 
275. Beriou G, Costantino CM, Ashley CW, Yang L, Kuchroo VK, Baecher-Allan C, et al. IL-17-
producing human peripheral regulatory T cells retain suppressive function. Blood. 
2009;113(18):4240-9. 
276. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, et al. Phenotype, distribution, 
generation, and functional and clinical relevance of Th17 cells in the human tumor 
environments. Blood. 2009;114(6):1141-9. 
277. Ratajczak P, Janin A, Peffault de Latour R, Leboeuf C, Desveaux A, Keyvanfar K, et al. 
Th17/Treg ratio in human graft-versus-host disease. Blood;116(7):1165-71. 
278. Voo KS, Wang YH, Santori FR, Boggiano C, Arima K, Bover L, et al. Identification of IL-17-
producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A. 2009;106(12):4793-
8. 
279. Koenen HJ, Smeets RL, Vink PM, van Rijssen E, Boots AM, Joosten I. Human 
CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 
2008;112(6):2340-52. 
280. Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, Bioley G, et al. Human memory 
FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific 
transcription factor RORgamma t. Proc Natl Acad Sci U S A. 2009;106(21):8635-40. 
281. Oukka M. Interplay between pathogenic Th17 and regulatory T cells. Ann Rheum Dis. 
2007;66 Suppl 3:iii87-90. 
282. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, Ashby M, et al. 
Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T 
cells in vivo. Nat Immunol. 2009;10(9):1000-7. 
283. Weaver CT, Hatton RD. Interplay between the TH17 and TReg cell lineages: a (co-
)evolutionary perspective. Nat Rev Immunol. 2009;9(12):883-9. 
284. Nistala K, Wedderburn LR. Th17 and regulatory T cells: rebalancing pro- and anti-
inflammatory forces in autoimmune arthritis. Rheumatology (Oxford). 2009;48(6):602-6. 
285. Deknuydt F, Bioley G, Valmori D, Ayyoub M. IL-1beta and IL-2 convert human Treg into 
T(H)17 cells. Clin Immunol. 2009;131(2):298-307. 
241 
 
286. Awasthi A, Riol-Blanco L, Jager A, Korn T, Pot C, Galileos G, et al. Cutting edge: IL-23 receptor 
gfp reporter mice reveal distinct populations of IL-17-producing cells. J Immunol. 
2009;182(10):5904-8. 
287. Bai H, Cheng J, Gao X, Joyee AG, Fan Y, Wang S, et al. IL-17/Th17 promotes type 1 T cell 
immunity against pulmonary intracellular bacterial infection through modulating dendritic 
cell function. J Immunol. 2009;183(9):5886-95. 
288. Lin Y, Ritchea S, Logar A, Slight S, Messmer M, Rangel-Moreno J, et al. Interleukin-17 is 
required for T helper 1 cell immunity and host resistance to the intracellular pathogen 
Francisella tularensis. Immunity. 2009;31(5):799-810. 
289. Damsker JM, Hansen AM, Caspi RR. Th1 and Th17 cells: adversaries and collaborators. Ann N 
Y Acad Sci. 2010;1183:211-21. 
290. Kebir H, Ifergan I, Alvarez JI, Bernard M, Poirier J, Arbour N, et al. Preferential recruitment of 
interferon-gamma-expressing TH17 cells in multiple sclerosis. Ann Neurol. 2009;66(3):390-
402. 
291. Brucklacher-Waldert V, Stuerner K, Kolster M, Wolthausen J, Tolosa E. Phenotypical and 
functional characterization of T helper 17 cells in multiple sclerosis. Brain. 2009;132(Pt 
12):3329-41. 
292. Boniface K, Blumenschein WM, Brovont-Porth K, McGeachy MJ, Basham B, Desai B, et al. 
Human Th17 cells comprise heterogeneous subsets including IFN-gamma-producing cells 
with distinct properties from the Th1 lineage. J Immunol. 2010;185(1):679-87. 
293. Bending D, De la Pena H, Veldhoen M, Phillips JM, Uyttenhove C, Stockinger B, et al. Highly 
purified Th17 cells from BDC2.5NOD mice convert into Th1-like cells in NOD/SCID recipient 
mice. J Clin Invest. 2009;119(3):565-72. 
294. Shi G, Cox CA, Vistica BP, Tan C, Wawrousek EF, Gery I. Phenotype switching by 
inflammation-inducing polarized Th17 cells, but not by Th1 cells. J Immunol. 
2008;181(10):7205-13. 
295. Hirota K, Duarte JH, Veldhoen M, Hornsby E, Li Y, Cua DJ, et al. Fate mapping of IL-17-
producing T cells in inflammatory responses. Nat Immunol. 2011;12(3):255-63. 
296. Cosmi L, Maggi L, Santarlasci V, Capone M, Cardilicchia E, Frosali F, et al. Identification of a 
novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4. J 
Allergy Clin Immunol. 2010;125(1):222-30 e1-4. 
297. Wang YH, Voo KS, Liu B, Chen CY, Uygungil B, Spoede W, et al. A novel subset of CD4(+) 
T(H)2 memory/effector cells that produce inflammatory IL-17 cytokine and promote the 
exacerbation of chronic allergic asthma. J Exp Med. 2010;207(11):2479-91. 
298. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, et al. Role of Th17 
cells in human autoimmune arthritis. Arthritis Rheum. 2010;62(10):2876-85. 
299. Chabaud M, Durand JM, Buchs N, Fossiez F, Page G, Frappart L, et al. Human interleukin-17: 
A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis 
Rheum. 1999;42(5):963-70. 
300. Kehlen A, Thiele K, Riemann D, Langner J. Expression, modulation and signalling of IL-17 
receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin Exp 
Immunol. 2002;127(3):539-46. 
301. Kokkonen H, Soderstrom I, Rocklov J, Hallmans G, Lejon K, Rantapaa Dahlqvist S. Up-
regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis 
Rheum. 2010;62(2):383-91. 
302. Raza K, Falciani F, Curnow SJ, Ross EJ, Lee CY, Akbar AN, et al. Early rheumatoid arthritis is 
characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal 
cell origin. Arthritis Res Ther. 2005;7(4):R784-95. 
303. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KM, Bird PA, Lee CS, et al. Synovial membrane 
cytokine expression is predictive of joint damage progression in rheumatoid arthritis: a two-
year prospective study (the DAMAGE study cohort). Arthritis Rheum. 2006;54(4):1122-31. 
242 
 
304. Honorati MC, Meliconi R, Pulsatelli L, Cane S, Frizziero L, Facchini A. High in vivo expression 
of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis 
patients. Rheumatology (Oxford). 2001;40(5):522-7. 
305. Chabaud M, Lubberts E, Joosten L, van Den Berg W, Miossec P. IL-17 derived from juxta-
articular bone and synovium contributes to joint degradation in rheumatoid arthritis. 
Arthritis Res. 2001;3(3):168-77. 
306. Hirota K, Yoshitomi H, Hashimoto M, Maeda S, Teradaira S, Sugimoto N, et al. Preferential 
recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid 
arthritis and its animal model. J Exp Med. 2007;204(12):2803-12. 
307. Evans HG, Gullick NJ, Kelly S, Pitzalis C, Lord GM, Kirkham BW, et al. In vivo activated 
monocytes from the site of inflammation in humans specifically promote Th17 responses. 
Proc Natl Acad Sci U S A. 2009;106(15):6232-7. 
308. Ferraccioli GF, Tomietto P, De Santis M. Rationale for T cell inhibition by cyclosporin A in 
major autoimmune diseases. Ann N Y Acad Sci. 2005;1051:658-65. 
309. Canete JD, Llena J, Collado A, Sanmarti R, Gaya A, Gratacos J, et al. Comparative cytokine 
gene expression in synovial tissue of early rheumatoid arthritis and seronegative 
spondyloarthropathies. Br J Rheumatol. 1997;36(1):38-42. 
310. Olszewski WL, Pazdur J, Kubasiewicz E, Zaleska M, Cooke CJ, Miller NE. Lymph draining from 
foot joints in rheumatoid arthritis provides insight into local cytokine and chemokine 
production and transport to lymph nodes. Arthritis Rheum. 2001;44(3):541-9. 
311. Rasmussen TK, Andersen T, Hvid M, Hetland ML, Horslev-Petersen K, Stengaard-Pedersen K, 
et al. Increased interleukin 21 (IL-21) and IL-23 are associated with increased disease activity 
and with radiographic status in patients with early rheumatoid arthritis. J Rheumatol. 
2010;37(10):2014-20. 
312. Thakker P, Leach MW, Kuang W, Benoit SE, Leonard JP, Marusic S. IL-23 is critical in the 
induction but not in the effector phase of experimental autoimmune encephalomyelitis. J 
Immunol. 2007;178(4):2589-98. 
313. Ferraccioli G, Zizzo G. The potential role of Th17 in mediating the transition from acute to 
chronic autoimmune inflammation: rheumatoid arthritis as a model. Discov Med. 
2011;11(60):413-24. 
314. Sen M, Chamorro M, Reifert J, Corr M, Carson DA. Blockade of Wnt-5A/frizzled 5 signaling 
inhibits rheumatoid synoviocyte activation. Arthritis Rheum. 2001;44(4):772-81. 
315. Maurice MM, Lankester AC, Bezemer AC, Geertsma MF, Tak PP, Breedveld FC, et al. 
Defective TCR-mediated signaling in synovial T cells in rheumatoid arthritis. J Immunol. 
1997;159(6):2973-8. 
316. Isomaki P, Panesar M, Annenkov A, Clark JM, Foxwell BM, Chernajovsky Y, et al. Prolonged 
exposure of T cells to TNF down-regulates TCR zeta and expression of the TCR/CD3 complex 
at the cell surface. J Immunol. 2001;166(9):5495-507. 
317. Zhang Z, Gorman CL, Vermi AC, Monaco C, Foey A, Owen S, et al. TCRzetadim lymphocytes 
define populations of circulating effector cells that migrate to inflamed tissues. Blood. 
2007;109(10):4328-35. 
318. Zizzo G, De Santis M, Bosello SL, Fedele AL, Peluso G, Gremese E, et al. Synovial fluid-derived 
T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis. 
Clin Immunol. 2011;138(1):107-16. 
319. Fossiez F, Banchereau J, Murray R, Van Kooten C, Garrone P, Lebecque S. Interleukin-17. Int 
Rev Immunol. 1998;16(5-6):541-51. 
320. Hwang SY, Kim JY, Kim KW, Park MK, Moon Y, Kim WU, et al. IL-17 induces production of IL-6 
and IL-8 in rheumatoid arthritis synovial fibroblasts via NF-kappaB- and PI3-kinase/Akt-
dependent pathways. Arthritis Res Ther. 2004;6(2):R120-8. 
243 
 
321. Jones CE, Chan K. Interleukin-17 stimulates the expression of interleukin-8, growth-related 
oncogene-alpha, and granulocyte-colony-stimulating factor by human airway epithelial cells. 
Am J Respir Cell Mol Biol. 2002;26(6):748-53. 
322. Zrioual S, Toh ML, Tournadre A, Zhou Y, Cazalis MA, Pachot A, et al. IL-17RA and IL-17RC 
receptors are essential for IL-17A-induced ELR+ CXC chemokine expression in synoviocytes 
and are overexpressed in rheumatoid blood. J Immunol. 2008;180(1):655-63. 
323. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y, et al. Th17 functions 
as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J 
Exp Med. 2006;203(12):2673-82. 
324. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, et al. IL-17 in synovial 
fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J 
Clin Invest. 1999;103(9):1345-52. 
325. Pollinger B, Junt T, Metzler B, Walker UA, Tyndall A, Allard C, et al. Th17 cells, not IL-17+ 
gammadelta T cells, drive arthritic bone destruction in mice and humans. J Immunol. 
2011;186(4):2602-12. 
326. Stamp LK, Cleland LG, James MJ. Upregulation of synoviocyte COX-2 through interactions 
with T lymphocytes: role of interleukin 17 and tumor necrosis factor-alpha. J Rheumatol. 
2004;31(7):1246-54. 
327. Stamp LK, James MJ, Cleland LG. Interleukin-17: the missing link between T-cell 
accumulation and effector cell actions in rheumatoid arthritis? Immunol Cell Biol. 
2004;82(1):1-9. 
328. Tat SK, Pelletier JP, Lajeunesse D, Fahmi H, Duval N, Martel-Pelletier J. Differential 
modulation of RANKL isoforms by human osteoarthritic subchondral bone osteoblasts: 
influence of osteotropic factors. Bone. 2008;43(2):284-91. 
329. Nakae S, Nambu A, Sudo K, Iwakura Y. Suppression of immune induction of collagen-induced 
arthritis in IL-17-deficient mice. J Immunol. 2003;171(11):6173-7. 
330. Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone 
erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion 
protein. Arthritis Rheum. 2002;46(3):802-5. 
331. Lubberts E, Koenders MI, Oppers-Walgreen B, van den Bersselaar L, Coenen-de Roo CJ, 
Joosten LA, et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the 
onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and 
bone erosion. Arthritis Rheum. 2004;50(2):650-9. 
332. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK, et al. IL-
1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-
induced arthritis. J Immunol. 2001;167(2):1004-13. 
333. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova 
FE, et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents 
joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am J Pathol. 
2005;167(1):141-9. 
334. Dong C, Nurieva RI. Regulation of immune and autoimmune responses by ICOS. J 
Autoimmun. 2003;21(3):255-60. 
335. Rohn TA, Jennings GT, Hernandez M, Grest P, Beck M, Zou Y, et al. Vaccination against IL-17 
suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol. 2006;36(11):2857-
67. 
336. Koenders MI, Lubberts E, van de Loo FA, Oppers-Walgreen B, van den Bersselaar L, Helsen 
MM, et al. Interleukin-17 acts independently of TNF-alpha under arthritic conditions. J 
Immunol. 2006;176(10):6262-9. 
337. Notley CA, Inglis JJ, Alzabin S, McCann FE, McNamee KE, Williams RO. Blockade of tumor 
necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for 
Th1 and Th17 cells. J Exp Med. 2008;205(11):2491-7. 
244 
 
338. Bose F, Raeli L, Garutti C, Frigerio E, Cozzi A, Crimi M, et al. Dual role of anti-TNF therapy: 
enhancement of TCR-mediated T cell activation in peripheral blood and inhibition of 
inflammation in target tissues. Clin Immunol. 2011;139(2):164-76. 
339. Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, et al. LY2439821, a 
humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with 
rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-
concept study. Arthritis Rheum. 2010;62(4):929-39. 
340. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, et al. Efficacy 
and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, 
double-blind, randomised, placebo controlled study. Ann Rheum Dis. 2012. 
341. Hueber W, Patel DD, Dryja T, Wright AM, Koroleva I, Bruin G, et al. Effects of AIN457, a fully 
human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl 
Med. 2010;2(52):52ra72. 
342. Gillies SD, Young D, Lo KM, Foley SF, Reisfeld RA. Expression of genetically engineered 
immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody. 
Hybridoma. 1991;10(3):347-56. 
343. Tao MH, Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein 
as a vaccine for B-cell lymphoma. Nature. 1993;362(6422):755-8. 
344. Zhao L, Rai SK, Grosmaire LS, Ledbetter JA, Fell HP. Construction, expression, and 
characterization of anticarcinoma sFv fused to IL-2 or GM-CSF. J Hematother Stem Cell Res. 
1999;8(4):393-9. 
345. Gillies SD, Lan Y, Wesolowski JS, Qian X, Reisfeld RA, Holden S, et al. Antibody-IL-12 fusion 
proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J 
Immunol. 1998;160(12):6195-203. 
346. Gillies SD, Reilly EB, Lo KM, Reisfeld RA. Antibody-targeted interleukin 2 stimulates T-cell 
killing of autologous tumor cells. Proc Natl Acad Sci U S A. 1992;89(4):1428-32. 
347. Becker JC, Pancook JD, Gillies SD, Furukawa K, Reisfeld RA. T cell-mediated eradication of 
murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med. 
1996;183(5):2361-6. 
348. Trachsel E, Bootz F, Silacci M, Kaspar M, Kosmehl H, Neri D. Antibody-mediated delivery of 
IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther. 
2007;9(1):R9. 
349. Schwager K, Kaspar M, Bootz F, Marcolongo R, Paresce E, Neri D, et al. Preclinical 
characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits 
the progression of collagen-induced arthritis. Arthritis Res Ther. 2009;11(5):R142. 
350. Hughes C, Faurholm B, Dell'Accio F, Manzo A, Seed M, Eltawil N, et al. Human single-chain 
variable fragment that specifically targets arthritic cartilage. Arthritis Rheum. 
2010;62(4):1007-16. 
351. Taipale J, Saharinen J, Keski-Oja J. Extracellular matrix-associated transforming growth 
factor-beta: role in cancer cell growth and invasion. Adv Cancer Res. 1998;75:87-134. 
352. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB. 
Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats 
than active transforming growth factor beta 1, and a different tissue distribution. J Clin 
Invest. 1990;86(6):1976-84. 
353. Adams G, Vessillier S, Dreja H, Chernajovsky Y. Targeting cytokines to inflammation sites. Nat 
Biotechnol. 2003;21(11):1314-20. 
354. Pepinsky RB, LePage DJ, Gill A, Chakraborty A, Vaidyanathan S, Green M, et al. Improved 
pharmacokinetic properties of a polyethylene glycol-modified form of interferon-beta-1a 
with preserved in vitro bioactivity. J Pharmacol Exp Ther. 2001;297(3):1059-66. 
355. Vessillier S, Adams G, Montero-Melendez T, Jones R, Seed M, Perretti M, et al. Molecular 
engineering of short half-life small peptides (VIP, alphaMSH and gamma(3)MSH) fused to 
245 
 
latency-associated peptide results in improved anti-inflammatory therapeutics. Ann Rheum 
Dis. 2012;71(1):143-9. 
356. DeClerck YA, Perez N, Shimada H, Boone TC, Langley KE, Taylor SM. Inhibition of invasion 
and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res. 
1992;52(3):701-8. 
357. Libby P. The interface of atherosclerosis and thrombosis: basic mechanisms. Vasc Med. 
1998;3(3):225-9. 
358. Anthony DC, Ferguson B, Matyzak MK, Miller KM, Esiri MM, Perry VH. Differential matrix 
metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl 
Neurobiol. 1997;23(5):406-15. 
359. Leppert D, Ford J, Stabler G, Grygar C, Lienert C, Huber S, et al. Matrix metalloproteinase-9 
(gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple 
sclerosis. Brain. 1998;121 ( Pt 12):2327-34. 
360. Singer, II, Scott S, Kawka DW, Bayne EK, Weidner JR, Williams HR, et al. Aggrecanase and 
metalloproteinase-specific aggrecan neo-epitopes are induced in the articular cartilage of 
mice with collagen II-induced arthritis. Osteoarthritis Cartilage. 1997;5(6):407-18. 
361. Baugh MD, Perry MJ, Hollander AP, Davies DR, Cross SS, Lobo AJ, et al. Matrix 
metalloproteinase levels are elevated in inflammatory bowel disease. Gastroenterology. 
1999;117(4):814-22. 
362. Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, et al. Safety, tolerability, and 
clinical outcomes after intraarticular injection of a recombinant adeno-associated vector 
containing a tumor necrosis factor antagonist gene: results of a phase 1/2 Study. J 
Rheumatol. 2010;37(4):692-703. 
363. Morille M, Passirani C, Vonarbourg A, Clavreul A, Benoit JP. Progress in developing cationic 
vectors for non-viral systemic gene therapy against cancer. Biomaterials. 2008;29(24-
25):3477-96. 
364. Zhang G, Gao X, Song YK, Vollmer R, Stolz DB, Gasiorowski JZ, et al. Hydroporation as the 
mechanism of hydrodynamic delivery. Gene Ther. 2004;11(8):675-82. 
365. Hagstrom JE, Hegge J, Zhang G, Noble M, Budker V, Lewis DL, et al. A facile nonviral method 
for delivering genes and siRNAs to skeletal muscle of mammalian limbs. Mol Ther. 
2004;10(2):386-98. 
366. Andre F, Mir LM. DNA electrotransfer: its principles and an updated review of its therapeutic 
applications. Gene Ther. 2004;11 Suppl 1:S33-42. 
367. Kim HJ, Greenleaf JF, Kinnick RR, Bronk JT, Bolander ME. Ultrasound-mediated transfection 
of mammalian cells. Hum Gene Ther. 1996;7(11):1339-46. 
368. Endoh M, Koibuchi N, Sato M, Morishita R, Kanzaki T, Murata Y, et al. Fetal gene transfer by 
intrauterine injection with microbubble-enhanced ultrasound. Mol Ther. 2002;5(5 Pt 1):501-
8. 
369. Hwang SJ, Davis ME. Cationic polymers for gene delivery: designs for overcoming barriers to 
systemic administration. Curr Opin Mol Ther. 2001;3(2):183-91. 
370. Sokolova V, Epple M. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew 
Chem Int Ed Engl. 2008;47(8):1382-95. 
371. Cai X, Conley S, Naash M. Nanoparticle applications in ocular gene therapy. Vision Res. 
2008;48(3):319-24. 
372. Davis PB, Cooper MJ. Vectors for airway gene delivery. AAPS J. 2007;9(1):E11-7. 
373. Peng XH, Qian X, Mao H, Wang AY, Chen ZG, Nie S, et al. Targeted magnetic iron oxide 
nanoparticles for tumor imaging and therapy. Int J Nanomedicine. 2008;3(3):311-21. 
374. Courtenay JS, Dallman MJ, Dayan AD, Martin A, Mosedale B. Immunisation against 
heterologous type II collagen induces arthritis in mice. Nature. 1980;283(5748):666-8. 
246 
 
375. Holmdahl R, Andersson M, Goldschmidt TJ, Gustafsson K, Jansson L, Mo JA. Type II collagen 
autoimmunity in animals and provocations leading to arthritis. Immunol Rev. 1990;118:193-
232. 
376. Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model 
of arthritis. J Exp Med. 1977;146(3):857-68. 
377. Wooley PH, Luthra HS, Stuart JM, David CS. Type II collagen-induced arthritis in mice. I. 
Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med. 
1981;154(3):688-700. 
378. Stuart JM, Cremer MA, Townes AS, Kang AH. Type II collagen-induced arthritis in rats. 
Passive transfer with serum and evidence that IgG anticollagen antibodies can cause 
arthritis. J Exp Med. 1982;155(1):1-16. 
379. Saijo S, Asano M, Horai R, Yamamoto H, Iwakura Y. Suppression of autoimmune arthritis in 
interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 
ligand and OX40 expression on T cells. Arthritis Rheum. 2002;46(2):533-44. 
380. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, et al. Interleukin 6 is required for 
the development of collagen-induced arthritis. J Exp Med. 1998;187(4):461-8. 
381. Mori L, Iselin S, De Libero G, Lesslauer W. Attenuation of collagen-induced arthritis in 55-kDa 
TNF receptor type 1 (TNFR1)-IgG1-treated and TNFR1-deficient mice. J Immunol. 
1996;157(7):3178-82. 
382. Tada Y, Ho A, Koarada S, Morito F, Ushiyama O, Suzuki N, et al. Collagen-induced arthritis in 
TNF receptor-1-deficient mice: TNF receptor-2 can modulate arthritis in the absence of TNF 
receptor-1. Clin Immunol. 2001;99(3):325-33. 
383. Murphy CA, Langrish CL, Chen Y, Blumenschein W, McClanahan T, Kastelein RA, et al. 
Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune 
inflammation. J Exp Med. 2003;198(12):1951-7. 
384. Terato K, Harper DS, Griffiths MM, Hasty DL, Ye XJ, Cremer MA, et al. Collagen-induced 
arthritis in mice: synergistic effect of E. coli lipopolysaccharide bypasses epitope specificity in 
the induction of arthritis with monoclonal antibodies to type II collagen. Autoimmunity. 
1995;22(3):137-47. 
385. Terato K, Hasty KA, Reife RA, Cremer MA, Kang AH, Stuart JM. Induction of arthritis with 
monoclonal antibodies to collagen. J Immunol. 1992;148(7):2103-8. 
386. Kagari T, Doi H, Shimozato T. The importance of IL-1 beta and TNF-alpha, and the 
noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis. J 
Immunol. 2002;169(3):1459-66. 
387. Habu K, Nakayama-Yamada J, Asano M, Saijo S, Itagaki K, Horai R, et al. The human T cell 
leukemia virus type I-tax gene is responsible for the development of both inflammatory 
polyarthropathy resembling rheumatoid arthritis and noninflammatory ankylotic 
arthropathy in transgenic mice. J Immunol. 1999;162(5):2956-63. 
388. Iwakura Y, Tosu M, Yoshida E, Takiguchi M, Sato K, Kitajima I, et al. Induction of 
inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. 
Science. 1991;253(5023):1026-8. 
389. Yamamoto H, Sekiguchi T, Itagaki K, Saijo S, Iwakura Y. Inflammatory polyarthritis in mice 
transgenic for human T cell leukemia virus type I. Arthritis Rheum. 1993;36(11):1612-20. 
390. Iwakura Y, Saijo S, Kioka Y, Nakayama-Yamada J, Itagaki K, Tosu M, et al. Autoimmunity 
induction by human T cell leukemia virus type 1 in transgenic mice that develop chronic 
inflammatory arthropathy resembling rheumatoid arthritis in humans. J Immunol. 
1995;155(3):1588-98. 
391. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic 
inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor 
antagonist-deficient mice. J Exp Med. 2000;191(2):313-20. 
247 
 
392. Horai R, Nakajima A, Habiro K, Kotani M, Nakae S, Matsuki T, et al. TNF-alpha is crucial for 
the development of autoimmune arthritis in IL-1 receptor antagonist-deficient mice. J Clin 
Invest. 2004;114(11):1603-11. 
393. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is 
required for the spontaneous development of destructive arthritis in mice deficient in IL-1 
receptor antagonist. Proc Natl Acad Sci U S A. 2003;100(10):5986-90. 
394. Sakaguchi N, Takahashi T, Hata H, Nomura T, Tagami T, Yamazaki S, et al. Altered thymic T-
cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. 
Nature. 2003;426(6965):454-60. 
395. Yoshitomi H, Sakaguchi N, Kobayashi K, Brown GD, Tagami T, Sakihama T, et al. A role for 
fungal {beta}-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in 
genetically susceptible mice. J Exp Med. 2005;201(6):949-60. 
396. Hirota K, Hashimoto M, Yoshitomi H, Tanaka S, Nomura T, Yamaguchi T, et al. T cell self-
reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause 
autoimmune arthritis. J Exp Med. 2007;204(1):41-7. 
397. Hata H, Sakaguchi N, Yoshitomi H, Iwakura Y, Sekikawa K, Azuma Y, et al. Distinct 
contribution of IL-6, TNF-alpha, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune 
arthritis in mice. J Clin Invest. 2004;114(4):582-8. 
398. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice 
expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J. 
1991;10(13):4025-31. 
399. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation 
of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-
associated immunopathologies. Immunity. 1999;10(3):387-98. 
400. Probert L, Plows D, Kontogeorgos G, Kollias G. The type I interleukin-1 receptor acts in series 
with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice. Eur J Immunol. 
1995;25(6):1794-7. 
401. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D. Organ-specific 
disease provoked by systemic autoimmunity. Cell. 1996;87(5):811-22. 
402. Korganow AS, Ji H, Mangialaio S, Duchatelle V, Pelanda R, Martin T, et al. From systemic T 
cell self-reactivity to organ-specific autoimmune disease via immunoglobulins. Immunity. 
1999;10(4):451-61. 
403. Matsumoto I, Staub A, Benoist C, Mathis D. Arthritis provoked by linked T and B cell 
recognition of a glycolytic enzyme. Science. 1999;286(5445):1732-5. 
404. Ji H, Ohmura K, Mahmood U, Lee DM, Hofhuis FM, Boackle SA, et al. Arthritis critically 
dependent on innate immune system players. Immunity. 2002;16(2):157-68. 
405. Nigrovic PA, Binstadt BA, Monach PA, Johnsen A, Gurish M, Iwakura Y, et al. Mast cells 
contribute to initiation of autoantibody-mediated arthritis via IL-1. Proc Natl Acad Sci U S A. 
2007;104(7):2325-30. 
406. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for 
interleukin 1 and tumor necrosis factor alpha in antibody-induced arthritis. J Exp Med. 
2002;196(1):77-85. 
407. Jacobs JP, Wu HJ, Benoist C, Mathis D. IL-17-producing T cells can augment autoantibody-
induced arthritis. Proceedings of the National Academy of Sciences of the United States of 
America. 2009;106(51):21789-94. 
408. Geiler T, Kriegsmann J, Keyszer GM, Gay RE, Gay S. A new model for rheumatoid arthritis 
generated by engraftment of rheumatoid synovial tissue and normal human cartilage into 
SCID mice. Arthritis Rheum. 1994;37(11):1664-71. 
409. Pap T, Meinecke I, Muller-Ladner U, Gay S. Are fibroblasts involved in joint destruction? Ann 
Rheum Dis. 2005;64 Suppl 4:iv52-4. 
248 
 
410. Wahid S, Blades MC, De Lord D, Brown I, Blake G, Yanni G, et al. Tumour necrosis factor-
alpha (TNF-alpha) enhances lymphocyte migration into rheumatoid synovial tissue 
transplanted into severe combined immunodeficient (SCID) mice. Clin Exp Immunol. 
2000;122(1):133-42. 
411. Rendt KE, Barry TS, Jones DM, Richter CB, McCachren SS, Haynes BF. Engraftment of human 
synovium into severe combined immune deficient mice. Migration of human peripheral 
blood T cells to engrafted human synovium and to mouse lymph nodes. J Immunol. 
1993;151(12):7324-36. 
412. Klimiuk PA, Yang H, Goronzy JJ, Weyand CM. Production of cytokines and metalloproteinases 
in rheumatoid synovitis is T cell dependent. Clin Immunol. 1999;90(1):65-78. 
413. Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid 
synovium is B cell dependent. J Immunol. 2001;167(8):4710-8. 
414. Nakazawa F, Matsuno H, Yudoh K, Katayama R, Sawai T, Uzuki M, et al. Methotrexate 
inhibits rheumatoid synovitis by inducing apoptosis. J Rheumatol. 2001;28(8):1800-8. 
415. Matsuno H, Yudoh K, Katayama R, Nakazawa F, Uzuki M, Sawai T, et al. The role of TNF-alpha 
in the pathogenesis of inflammation and joint destruction in rheumatoid arthritis (RA): a 
study using a human RA/SCID mouse chimera. Rheumatology (Oxford). 2002;41(3):329-37. 
416. Koenders MI, Marijnissen RJ, Joosten LA, Abdollahi-Roodsaz S, Di Padova FE, van de Loo FA, 
et al. T cell lessons from the rheumatoid arthritis synovium SCID mouse model: CD3-rich 
synovium lacks response to CTLA-4Ig but is successfully treated by interleukin-17 
neutralization. Arthritis Rheum. 2012;64(6):1762-70. 
417. Sambrook J, Fritsch E, Maniatis T., ed. Molecular cloning: a laboratory manual: Cold Sprinh 
Harbor Laboratory Press; 1989. 
418. Naldini L, Blomer U, Gallay P, Ory D, Mulligan R, Gage FH, et al. In vivo gene delivery and 
stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272(5259):263-7. 
419. Wigler M, Pellicer A, Silverstein S, Axel R, Urlaub G, Chasin L. DNA-mediated transfer of the 
adenine phosphoribosyltransferase locus into mammalian cells. Proc Natl Acad Sci U S A. 
1979;76(3):1373-6. 
420. Rodriguez MS, Thompson J, Hay RT, Dargemont C. Nuclear retention of IkappaBalpha 
protects it from signal-induced degradation and inhibits nuclear factor kappaB 
transcriptional activation. J Biol Chem. 1999;274(13):9108-15. 
421. Todaro GJ, Green H. Quantitative studies of the growth of mouse embryo cells in culture and 
their development into established lines. J Cell Biol. 1963;17:299-313. 
422. Triantaphyllopoulos KA, Williams RO, Tailor H, Chernajovsky Y. Amelioration of collagen-
induced arthritis and suppression of interferon-gamma, interleukin-12, and tumor necrosis 
factor alpha production by interferon-beta gene therapy. Arthritis Rheum. 1999;42(1):90-9. 
423. Hata K, Andoh A, Shimada M, Fujino S, Bamba S, Araki Y, et al. IL-17 stimulates inflammatory 
responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts. Am J 
Physiol Gastrointest Liver Physiol. 2002;282(6):G1035-44. 
424. Faour WH, Mancini A, He QW, Di Battista JA. T-cell-derived interleukin-17 regulates the level 
and stability of cyclooxygenase-2 (COX-2) mRNA through restricted activation of the p38 
mitogen-activated protein kinase cascade: role of distal sequences in the 3'-untranslated 
region of COX-2 mRNA. J Biol Chem. 2003;278(29):26897-907. 
425. Shimada M, Andoh A, Hata K, Tasaki K, Araki Y, Fujiyama Y, et al. IL-6 secretion by human 
pancreatic periacinar myofibroblasts in response to inflammatory mediators. J Immunol. 
2002;168(2):861-8. 
426. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and 
interferon-gamma synergize in the enhancement of proinflammatory cytokine production by 
human keratinocytes. J Invest Dermatol. 1998;111(4):645-9. 
427. Perretti M, Flower RJ. Modulation of IL-1-induced neutrophil migration by dexamethasone 
and lipocortin 1. J Immunol. 1993;150(3):992-9. 
249 
 
428. Maione F, Paschalidis N, Mascolo N, Dufton N, Perretti M, D'Acquisto F. Interleukin 17 
sustains rather than induces inflammation. Biochem Pharmacol. 2009;77(5):878-87. 
429. Kunkel TA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc 
Natl Acad Sci U S A. 1985;82(2):488-92. 
430. Derouazi M, Girard P, Van Tilborgh F, Iglesias K, Muller N, Bertschinger M, et al. Serum-free 
large-scale transient transfection of CHO cells. Biotechnol Bioeng. 2004;87(4):537-45. 
431. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein 
production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic 
Acids Res. 2002;30(2):E9. 
432. Wilchek M, Miron T. Limitations of N-hydroxysuccinimide esters in affinity chromatography 
and protein immobilization. Biochemistry. 1987;26(8):2155-61. 
433. Sica V, Puca GA, Molinari AM, Buonaguro FM, Bresciani F. Effect of chemical perturbation 
with NaSCN on receptor-estradiol interaction. A new exchange assay at low temperature. 
Biochemistry. 1980;19(1):83-8. 
434. Yang Y, Dignam JD, Gentry LE. Role of carbohydrate structures in the binding of beta1-
latency-associated peptide to ligands. Biochemistry. 1997;36(39):11923-32. 
435. Ye P, Garvey PB, Zhang P, Nelson S, Bagby G, Summer WR, et al. Interleukin-17 and lung host 
defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol. 2001;25(3):335-
40. 
436. Hu Y, Ota N, Peng I, Refino CJ, Danilenko DM, Caplazi P, et al. IL-17RC is required for IL-17A- 
and IL-17F-dependent signaling and the pathogenesis of experimental autoimmune 
encephalomyelitis. J Immunol. 2010;184(8):4307-16. 
437. Laan M, Lotvall J, Chung KF, Linden A. IL-17-induced cytokine release in human bronchial 
epithelial cells in vitro: role of mitogen-activated protein (MAP) kinases. Br J Pharmacol. 
2001;133(1):200-6. 
438. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nature reviews. Immunology. 
2009;9(8):556-67. 
439. Kim KW, Cho ML, Park MK, Yoon CH, Park SH, Lee SH, et al. Increased interleukin-17 
production via a phosphoinositide 3-kinase/Akt and nuclear factor kappaB-dependent 
pathway in patients with rheumatoid arthritis. Arthritis Res Ther. 2005;7(1):R139-48. 
440. Zhou L, Wang J, Peng S, Duan J, Cai X, Zou M, et al. High-level expression of human 
interleukin-17 in the yeast Pichia pastoris. Biochem Mol Biol Int. 1998;46(6):1109-16. 
441. Kennedy J, Rossi DL, Zurawski SM, Vega F, Jr., Kastelein RA, Wagner JL, et al. Mouse IL-17: a 
cytokine preferentially expressed by alpha beta TCR + CD4-CD8-T cells. J Interferon Cytokine 
Res. 1996;16(8):611-7. 
442. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C, et al. T cell interleukin-
17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. The 
Journal of experimental medicine. 1996;183(6):2593-603. 
443. Lai T, Wang K, Hou Q, Zhang J, Yuan J, Yuan L, et al. Interleukin 17 induces up-regulation of 
chemokine and cytokine expression via activation of the nuclear factor kappaB and 
extracellular signal-regulated kinase 1/2 pathways in gynecologic cancer cell lines. Int J 
Gynecol Cancer. 2011;21(9):1533-9. 
444. Kawaguchi M, Kokubu F, Kuga H, Matsukura S, Hoshino H, Ieki K, et al. Modulation of 
bronchial epithelial cells by IL-17. J Allergy Clin Immunol. 2001;108(5):804-9. 
445. Kennedy J, Rossi DL, Zurawski SM, Vega F, Jr., Kastelein RA, Wagner JL, et al. Mouse IL-17: a 
cytokine preferentially expressed by alpha beta TCR + CD4-CD8-T cells. Journal of interferon 
& cytokine research : the official journal of the International Society for Interferon and 
Cytokine Research. 1996;16(8):611-7. 
446. Barin JG, Baldeviano GC, Talor MV, Wu L, Ong S, Quader F, et al. Macrophages participate in 
IL-17-mediated inflammation. Eur J Immunol. 2012;42(3):726-36. 
250 
 
447. Wright JF, Bennett F, Li B, Brooks J, Luxenberg DP, Whitters MJ, et al. The human IL-17F/IL-
17A heterodimeric cytokine signals through the IL-17RA/IL-17RC receptor complex. J 
Immunol. 2008;181(4):2799-805. 
448. Holmdahl R, Mo J, Nordling C, Larsson P, Jansson L, Goldschmidt T, et al. Collagen induced 
arthritis: an experimental model for rheumatoid arthritis with involvement of both DTH and 
immune complex mediated mechanisms. Clin Exp Rheumatol. 1989;7 Suppl 3:S51-5. 
449. Trentham DE. Collagen arthritis as a relevant model for rheumatoid arthritis. Arthritis 
Rheum. 1982;25(8):911-6. 
450. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in 
murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 1992;89(20):9784-8. 
451. Kowanko IC, Gordon TP, Rozenbilds MA, Brooks PM, Roberts-Thomson PJ. The subcutaneous 
air pouch model of synovium and the inflammatory response to heat aggregated 
gammaglobulin. Agents Actions. 1986;18(3-4):421-8. 
452. Edwards JC, Sedgwick AD, Willoughby DA. The formation of a structure with the features of 
synovial lining by subcutaneous injection of air: an in vivo tissue culture system. J Pathol. 
1981;134(2):147-56. 
453. Herweijer H, Wolff JA. Gene therapy progress and prospects: hydrodynamic gene delivery. 
Gene Ther. 2007;14(2):99-107. 
454. Maruyama H, Higuchi N, Nishikawa Y, Kameda S, Iino N, Kazama JJ, et al. High-level 
expression of naked DNA delivered to rat liver via tail vein injection. J Gene Med. 
2002;4(3):333-41. 
455. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail 
vein injections of naked plasmid DNA. Hum Gene Ther. 1999;10(10):1735-7. 
456. Reyes-Sandoval A, Ertl HC. CpG methylation of a plasmid vector results in extended 
transgene product expression by circumventing induction of immune responses. Mol Ther. 
2004;9(2):249-61. 
457. Yew NS, Cheng SH. Reducing the immunostimulatory activity of CpG-containing plasmid DNA 
vectors for non-viral gene therapy. Expert Opin Drug Deliv. 2004;1(1):115-25. 
458. Mosher DF, Doyle MJ, Jaffe EA. Synthesis and secretion of thrombospondin by cultured 
human endothelial cells. J Cell Biol. 1982;93(2):343-8. 
459. Hunter NR, Dawes J, MacGregor IR, Pepper DS. Quantitation by radioimmunoassay of 
thrombospondin synthesised and secreted by human endothelial cells. Thromb Haemost. 
1984;52(3):288-91. 
460. Murphy-Ullrich JE, Poczatek M. Activation of latent TGF-beta by thrombospondin-1: 
mechanisms and physiology. Cytokine Growth Factor Rev. 2000;11(1-2):59-69. 
461. van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, Hazes JM, et al. Th17 cells, 
but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix 
metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, 
including autocrine interleukin-17A production. Arthritis Rheum. 2011;63(1):73-83. 
462. Rosu A, Margaritescu C, Stepan A, Musetescu A, Ene M. IL-17 patterns in synovium, serum 
and synovial fluid from treatment-naive, early rheumatoid arthritis patients. Rom J Morphol 
Embryol. 2012;53(1):73-80. 
463. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, et al. Anti-
interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 
2012;366(13):1190-9. 
464. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, et al. Brodalumab, an 
anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181-9. 
465. Mpofu S, Fatima F, Moots RJ. Anti-TNF-alpha therapies: they are all the same (aren't they?). 
Rheumatology (Oxford). 2005;44(3):271-3. 
466. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 
2009;36(6):1118-25. 
251 
 
467. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis: a systematic review. 
J Rheumatol. 2010;37(6):1096-104. 
468. Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of 
certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A 
randomised controlled trial. Ann Rheum Dis. 2009;68(6):797-804. 
469. Zrioual S, Ecochard R, Tournadre A, Lenief V, Cazalis MA, Miossec P. Genome-wide 
comparison between IL-17A- and IL-17F-induced effects in human rheumatoid arthritis 
synoviocytes. J Immunol. 2009;182(5):3112-20. 
470. Hyde SC, Pringle IA, Abdullah S, Lawton AE, Davies LA, Varathalingam A, et al. CpG-free 
plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat 
Biotechnol. 2008;26(5):549-51. 
 
 
 
